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Abstract 
 
In order to harness the therapeutic potential of stem cells, a clear understanding of the 
factors and mechanisms governing their fate is required. Self-renewal, pluripotency and 
proliferation are important cellular functions for maintaining the stem cell state. The class 
IA phosphoinositide 3-kinase (PI3K) family of lipid kinases regulate a variety of 
physiological responses including cell migration, proliferation and survival. Moreover, 
this class of PI3Ks were previously reported to play a role in proliferation and 
maintenance of self-renewal in murine embryonic stem cells (mESCs). Here the 
activation of PI3Ks, the intracellular signalling, including cross-talk between other 
important pathways, and the roles of specific catalytic subunits of the PI3K class I family 
have been investigated.  
 
Despite inhibition of PI3Ks giving rise to differentiated cell types, early lineage 
commitment of mESCs was shown to be regulated by pathways not involving PI3Ks. 
Differentiation towards mesoderm, endoderm and ectoderm were detected upon broad 
selectivity inhibition of PI3Ks with LY294002. Cross-talk between PI3K and MAPK 
pathway signalling was highlighted as a possible mechanism for PI3Ks to regulate self-
renewal. Inhibition of PI3Ks with LY294002 led to an enhancement in MAPK pathway 
activation. On further investigation, activation of MAPK pathway signalling by inducible 
expression of constitutively active Mek brought forth a minimal reduction in self-renewal. 
Furthermore, inhibition of p110β induced an enhancement in Erk phosphorylation akin to 
that induced by LY294002, implicating this isoform in regulating MAPK signalling under 
normal mESC culture conditions. 
 
Insulin was shown to activate PI3Ks in mESCs and could be inhibited by treatment with 
pharmacological inhibitors of the p110α catalytic subunit isoform. Further investigation 
into the role of p110α in mESCs revealed a role in cell proliferation and metabolic 
activity. However, pharmacological or siRNA-mediated interference of this isoform did 
not perturb self-renewal. In contrast, p110β was identified as having a predominant role 
in the maintenance of self-renewal of mESCs. Both specific pharmacological inhibition 
and siRNA targeted knockdown of p110β led to a marked loss in alkaline phosphatase 
staining and a reduction in Nanog and Rex1 expression, indicating a loss of self-
renewal. 
 
 
 
iv 
Thus, independent roles for p110α and p110β in regulating mESC proliferation and self-
renewal were found to be the result of coupling to different PI3K catalytic subunit 
isoforms. Interestingly, reducing proliferation by inhibition of p110α or mTOR led to a 
greater decline in mESC self-renewal when induced by inhibition of p110β. This 
demonstration of cross talk between the pathways that regulate proliferation and self-
renewal suggests a priming effect where the rate of proliferation could sensitise mESCs 
to levels of p110β activation in order to regulate self-renewal and ultimately cell fate. 
v 
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Chapter 1: Introduction 
 2
1.1 Intracellular signalling pathways 
 
Cell signalling is the perception of an extrinsic signal, supplied by the environment of a 
cell, and its interpretation into a cellular response. The underlying mechanism involves 
the detection of an extrinsic signal, often by a cell surface receptor, followed by the 
activation of signalling pathways within the cell. Intracellular signalling comprises a 
complex system of signalling molecules that sequentially activate or inhibit other 
signalling molecules in specific pathways. However, specific pathways are often part of 
multifaceted networks with many divergent branches that exhibit a high level of cross-
talk, as well as positive and negative feedback. A single extrinsic signal or ligand, such 
as a growth factor, hormone or cytokine, may activate a single pathway leading to an 
appropriate cellular response. However, more often a number of pathways are 
activated providing detailed information regarding the environment of a cell. Such 
complicated intracellular signalling appears to be required in order to regulate cellular 
activities such as cell division, migration and apoptosis. Further diversity is provided by 
multiple isoforms of the same protein, arising from different genes or alternative 
splicing of the same gene, which are categorised into families of signalling molecules 
that display similar enzymatic or functional activity. The phosphoinositide 3-kinase 
family of enzymes were discovered in the 1980s and have gained the attention of many 
research groups owing to the increasingly diverse cellular responses that are mediated 
by signalling pathways involving different members of this superfamily. 
 
 
1.2 Phosphoinositide 3-Kinase  
1.2.1 Signalling by intracellular messengers 
 
The actions of phosphoinositides as second messengers were first reported in the early 
1980s. Inositol lipids were described as signal transducers, linking growth factor 
receptors to the activation of oncogenes (Berridge and Irvine, 1984). A few years later 
it was reported that stable complexes of middle T antigen and pp60c-src existed in 
association with an 81kDa protein (Courtneidge and Heber, 1987). This protein was 
reported to be phosphorylated at tyrosine residues and its presence in kinase assays 
correlated with phosphatidylinositol (PI) kinase activity (Courtneidge and Heber, 1987). 
Indeed two PI kinases were identified in fibroblasts, one of which was reported to 
associate with tyrosine kinases (Whitman et al., 1987), consistent with the tyrosine 
phosphorylation previously described (Courtneidge and Heber, 1987). Upon further 
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characterisation, the site of phosphorylation mediated by this kinase was described as 
the D3 hydroxyl group of the inositol headgroup leading to the production of the 
phospholipid, phosphatidylinositol-3-phosphate (PI(3)P) (Whitman et al., 1988). It is 
now widely known that the phosphoinositide 3-kinase (PI3K) family of kinases catalyse 
the transfer of the γ-phosphate of adenosine triphosphate (ATP) to phosphoinositides 
at the D3 position of the inositol ring (Figure 1.1A). Different PI3Ks respond to different 
stimuli and exhibit a preference over certain inositol substrates. Thus a variety of 
second messenger products can be produced by PI3Ks (Figure 1.1B), which leads to 
activation of diverse downstream pathways and effects on a variety of cellular 
responses. 
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Figure 1.1 PI3K catalyses the addition of a phosphate group to the D3 position of 
the inositol ring of phosphatidyl inositols.  
A The fatty acid side chains of phospholipids localise within the lipid bilayer of the cell 
membrane leaving the hydrophilic inositol ring (head group) accessible in the cytosol. 
All kinases catalyse phosphotransferase reactions, typically transferring the γ-
phosphate of ATP to a substrate to produce a phosphorylated substrate and adenosine 
diphosphate (ADP). PI3K, in particular, catalyses the transfer of phosphate to the D3 
hydroxyl position of the inositol ring of phospholipids, to produce phosphoinositide 3-
phosphate (PIP). B Structures of phosphoinositides produced by the actions of PI3Ks. 
Adapted from Vanhaesebroeck and Waterfield 1999, Hawkins et al., 2006. 
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1.2.2 Phosphoinositide 3-kinases: structure and function 
 
Mammalian PI3Ks are divided into three classes (summarised in Table 1.1). PI3Ks are 
categorised according to their catalytic and regulatory subunits, receptor activation and 
lipid substrates. The role of class I PI3Ks are investigated in the present study and will 
therefore be described in more detail (Section 1.2.2.1). Class II PI3Ks contain a C2 
domain for calcium-dependent binding to phospholipids (MacDougall et al., 1985) and 
are typically activated by tyrosine kinases and heterotrimeric GTP-binding proteins (G 
proteins) (reviewed by Vanhaesebroeck and Waterfield, 1999). Class III PI3Ks are 
homologues of the yeast vesicular protein-sorting protein Vps34p. Reports suggest that 
class III PI3Ks may not require activation by extracellular stimuli but may contribute to 
cellular levels of phosphoinositide 3-phosphate (reviewed by Herman et al., 1992). 
Cloning of the catalytic domain of PI3Ks and Vps34p revealed high sequence 
homology (Schu et al., 1993). Indeed sequence alignment of kinase domains has 
furthered the discovery of more PI3K family members, each having a conserved kinase 
core domain (Table 1.1). 
 
 
Table 1.1 Three classes of PI3K have been described in mammalian cells.  
Compiled from Vanhaesebroeck and Waterfield 1999, Wymann and Pirola 1998, 
Domin and Waterfield 1998. 
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1.2.2.1 Class I PI3Ks 
 
Class I PI3Ks are subdivided into two groups; Class IA and Class IB (Table 1.1). Class 
IA PI3Ks consist of a 110kDa catalytic subunit of which there are three isoforms p110α, 
p110β and p110δ encoded by the genes Pik3ca, Pik3cb and Pik3cd respectively (Hiles 
et al., 1992, Hu et al., 1993, Vanhaesebroeck et al., 1997). Following on from earlier 
immunoprecipitation studies, the catalytic subunit was found to be associated with an 
85kDa regulatory subunit, often referred to as an adaptor protein. In fact there are 
several regulatory subunits expressed in mammalian cells; p85α, p85β, p50α, p55α 
and p55γ (Domin and Waterfield, 1997). Pik3r1, Pik3r2, and Pik3r3 encode p85α, p85β 
and p55γ respectively, while alternative splicing of Pik3r1 gives rise to p50α and p55α. 
 
The regulatory subunit consists of an N terminal Src homology 3 (SH3) domain and two 
C terminal Src homology 2 (SH2) domains (Figure 1.2). SH3 domains bind proline rich 
regions of proteins and therefore serve to regulate PI3K activity by protein-protein 
interactions. Additionally, the SH3 domain of p85 can interact with its own proline rich 
region (Kapeller et al., 1994). However, the shorter p55 isoform lacks SH3 domains 
(Antonetti et al., 1996). SH2 domains bind to phosphorylated tyrosine residues within 
consensus motifs on activated receptors or adaptor proteins (Songyang et al., 1993). 
The region between the two SH2 domains of p85 subunits is highly conserved and 
provides a site for phosphorylation by p110α or p110β. Phosphorylation of a conserved 
serine residue within the inter-SH2 domain coincides with an increase in PI3K activity 
(Dhand et al., 1994). Antibodies against the p85 inter-SH2 domain region block the 
binding of p110 to p85 in vitro (Dhand et al., 1994). Thus, interaction of p85 and p110 
subunits and intrinsic protein-serine kinase activity may act as an autoregulatory 
mechanism for PI3K activity. The interaction of p85 with p110 and other proteins is 
shown in Figure 1.2. 
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Figure 1.2 Interaction of p85 and p110 is required for catalytic activity 
The inter-SH2 domain of p85 binds p110 and also provides a site for intrinsic serine 
kinase-mediated phosphorylation for autoregulation. The SH2 domains of p85 have 
affinity for phosphorylated tyrosine residues on the intracellular domains of receptors, 
recruiting the p110/p85 heterodimer to the plasma membrane. At the membrane, 
p85/p110 heterodimers can interact with various proteins to form a protein complex 
capable of kinase activity and production of second messenger phosphatidylinositol 
lipids. Adapted from Vanhaesebroeck et al., 2005. 
 
 
Prior to stimulation, p85 may act to inhibit catalytic activity of p110 since monomers of 
p110α or p110β were shown to exhibit kinase activity, which was reduced by co-
expression with p85 (Yu et al. 1998). Activation of class IA PI3Ks occurs by a number of 
overlapping mechanisms but typically involves initial extracellular stimuli such as 
growth factors, hormones, neurotransmitters or antigens (Wymann and Pirola 1998). 
Activation of receptors following ligand stimulation results in autophosphorylation of the 
intracellular portion of the receptors either by dimerisation or ligand-induced 
conformation change. SH2 domains of p85α bind phosphorylated tyrosine residues 
within the receptor consensus motif pYXXM (where X denotes any amino acid) 
(Carpenter et al., 1993, Rordorf-Nikolic et al., 1995). In insect cells, it was reported that 
the monomeric activity of p110α could be decreased by coexpression of p85 and that 
addition of phosphotyrosyl peptides restored activity to that of monomeric p110α (Yu et 
al., 1998). However, in HEK293 cells, the low monomeric activity of p110 was 
enhanced by coexpression of p85. Therefore, a model was proposed where by, p85 
both stabilises and inhibits p110 by conformational change, and upon binding of p85 to 
phosphorylated tyrosine consensus motifs inhibition of p110 is reversed (Yu et al., 
1998). Nevertheless, SH2 domain binding to phosphotyrosine recruits p85/p110 
complexes to the membrane allowing association with adaptor proteins and receptor 
protein tyrosine kinases, typically growth factor receptors (van der Geer et al., 1994). 
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Class I PI3Ks share Ras as a common binding partner. Ras is a small GTPase, which 
is reported to bind Class I PI3Ks when associated with GTP but not when bound to 
GDP (Rodriguez-Viciana et al., 1994, Rubio et al., 1997). Furthermore, expression of 
constitutively active Ras results in an enhancement of PI(3,4)P2 and PI(3,4,5)P3 levels 
(Rodriguez-Viciana et al., 1994) indicating that PI3Ks are activated downstream of Ras. 
In contrast, others report that Ras is activated by PI3Ks. Expression of mutant PDGF 
receptor lacking PI3K docking sites failed to activate Ras (Satoh et al., 1993) while 
expression of PDGF receptor containing only PI3K docking sites was sufficient to 
mediate Ras activation (Valius and Kazlauskas, 1993). In fact, both receptor-PI3K and 
Ras-PI3K interactions occur to form a ternary complex with cross-talk. In this model, 
p85 recruitment to phosphotyrosine residues and p110 interaction with Ras allows the 
formation of a ternary complex at the plasma membrane. This complex aids allosteric 
cooperativity thereby enhancing the activity of both p110 and Ras (Kaur et al., 2006). 
 
Following recruitment to the receptor signalling complex, class I PI3Ks preferentially 
utilise PI(4,5)P2 as a substrate, by transferring the terminal phosphate of ATP, to yield 
PI(3,4,5)P3. PI3Ks have also been shown to phosphorylate PI, PI(4)P and PI(4,5)P2 in 
vitro (Irvine, 1992). These lipid second messengers serve as an amplification step in 
PI3K signal transduction since once formed, the activated PI3K-receptor complex 
continues to phosphorylate PI substrates until activation ceases. Additionally the 
second messenger products of PI3K are capable of activating multiple effector 
proteins. PI3K effector proteins contain conserved Pleckstrin Homology (PH) domains 
that specifically bind PI3K lipid products inducing recruitment to the plasma membrane 
(Katan and Allen, 1999). For example, PI(3,4)P2 and PI(3,4,5)P3 recruit Protein Kinase 
B (PKB, also referred to as Akt) to the plasma membrane by binding the PH domain of 
PKB (Burgering and Coffer, 1995). PKB is a serine/threonine protein kinase which is 
activated by a number of extrinsic stimuli including insulin, platelet-derived growth 
factor (PDGF), epidermal growth factor (EGF) and basic fibroblast growth factor 
(bFGF) (reviewed by Hanada et al., 2004). Activation of PKB by these factors can be 
prevented by pharmacological inhibition of PI3Ks or by the expression of a dominant 
negative form of PI3K, either of which reduce levels of PIP3 and therefore reduce PKB 
activation (Burgering and Coffer, 1995). In addition to PH domains, other domains that 
bind phosphoinositides include phox homology (PX) and Fab1p YOPB Vps27p EEA1 
(FYVE) domains, which typically bind the phosphoinositide products of class II and III 
PI3Ks (reviewed by Sasaki et al., 2007). 
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At the membrane, PKB is brought into close proximity with phosphoinositide-dependent 
protein kinase (PDK1). PDK1 also contains a PH domain at the C terminal end of the 
protein, which anchors PDK1 to the plasma membrane allowing interaction with other 
proteins (Komander et al., 1994). For example, PDK1 acts to phosphorylate Thr308 of 
PKB (Alessi et al., 1997) (Figure 1.3). Additionally, phosphorylation at Ser473 of PKB 
occurs when PDK1 is bound to Protein Kinase C-related kinase-2 (PRK2) (also 
referred to as PDK1-interacting fragment (PIF)) in the presence of PI(3,4,5)P3 
(Balendran et al., 1999). Others report that PDK1 is not necessary for Ser473 
phosphorylation of PKB, but that the presence of PDK1 may enhance phosphorylation 
at this site (Williams et al., 2000). Once activated, by phosphorylation at both Ser473 
and Thr308, PKB can signal downstream to mediate a number of cellular functions 
including metabolism, cell growth and apoptosis. In addition, activity of PI3K and PKB 
resulting from stimulation of cells with insulin, Wnt or growth factors such as PDGF or 
EGF can inhibit glycogen synthase kinase-3 (Gsk-3) (Bardy et al., 1998, Cross et al., 
1995, Doble and Woodgett, 2003, van Noot et al., 2002). 
 
PDK1 has also been implicated in the activation of AGC family kinases, named after 
the well characterised protein kinases A, G and C (PKA, PKG and PKC) but also 
including p70 ribosomal S6 Kinase (p70S6K), serum and glucocorticoid-induced 
protein kinase (SGK) and PKB (Mora et al., 2004, Williams et al., 2000). Unlike PKB, 
S6K and SGK do not interact with PI(3,4)P2 or PI(3,4,5)P3. Activation by PDK1 occurs 
when S6K or SGK directly bind to a hydrophobic pocket adjacent to the kinase domain 
of PDK1, termed the PIF pocket (Biondi, 2001). In PDK1 knock-out cells activation of 
PKB and p70S6K is inhibited and PDK1 substrates lack phosphorylation at the 
conserved threonine residue (Williams et al., 2000). PDK1 orchestrates a variety of 
cellular functions including regulation of metabolism, cell cycle, apoptosis and 
transcription factors (Hanada et al., 2004, Hennessy et al., 2005). 
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Figure 1.3 Activation of PI3K and downstream signalling 
Activation of PI3K occurs via interaction of p85/p110 dimers with phosphorylated 
tyrosine residues of receptors or adaptor molecules and interaction with Ras. PI3Ks 
catalyse the addition of a phosphate group from ATP to PI(4,5)P2 to form PI(3,4,5)P3 
and ADP. Activation of downstream effectors occurs by recruitment of effector PH 
domains to PI(3,4,5)P3 in close proximity to PDK1. PKB is activated by phosphorylation 
at two key sites, threonine 308 (Thr308) and serine 473 (Ser473). Downstream 
effectors of PI3K mediate an array of cellular events. 
 
 
Currently there is only one member of the Class IB PI3Ks, PI3Kγ. The p110γ catalytic 
subunit, encoded by the gene Pik3cg, associates with a 101kDa regulatory protein 
(p101) encoded by the gene Pik3r5. Incidentally, p101 has little sequence homology to 
the class IA regulatory subunits but p87PIKAP (PI3K adaptor protein of 87kDa), a recently 
described novel regulatory subunit of p110γ shared sequence homology with p101 
(Voigt et al., 2006). High sequence homology was found between p87PIKAP and p101 
particularly in regions known to participate in p110γ binding. Expression of p87PIKAP 
was detectable in dendritic cells, macrophages, and neutrophils but expression was 
notably high in the heart (Voigt et al., 2006).  
 
The p110/p101 heterodimer is activated by G protein interaction following stimulation of 
G protein coupled receptors (GPCRs) (Figure 1.4) (Stephens et al., 1997). More 
specifically, the Gβγ subunit was reported to mediate the activation of p110/p101 via the 
N terminus of p110γ (Krugmann et al., 1999). In an alternative study, p101 was 
reportedly not required for Gβγ-mediated activation of p110γ kinase activity but found to 
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sensitise p110γ for Gβγ activation in the presence of PI(4,5)P2 thereby determining 
substrate specificity (Maier et al., 1999). However, in vivo, p101 is required for Gβγ-
mediated activation of p110γ since p101 acts to recruit the p110/p101 heterodimer to 
the plasma membrane via interaction of p101 and Gβγ (Brock et al., 2003). Additionally, 
p87PIKAP was reported to have sequence similarity to p101 in the same region used for 
Gβγ association (Voigt et al., 2006). 
 
A number of research papers have been published reporting that p110β of the class IA 
PI3Ks can be alternatively activated by G proteins (Figure 1.4). In an in vitro kinase 
assay, purified Gβγ subunits were shown to activate p110β leading to an increase in 
PI(3,4,5)P3. This activation was substantially enhanced in the presence of tyrosine 
phosphorylated peptides (Maier et al., 1999). In immunoprecipitates, lysophosphatidic 
acid (LPA), a GPCR ligand that utilises Gi, was shown to activate PI3Kβ (Roche et al., 
1998). However, in an NIH3T3-derived cell line lacking p110β expression, LPA 
stimulation failed to activate PKB (Murga et al., 2000). Furthermore, in Chinese 
hamster ovary (CHO) cells expressing the GPCR adenosine receptor (A1R), stimulation 
with the A1R ligand PIA [N6-(2-phenylisopropyl)adenosine] induced PKB 
phosphorylation, which could be inhibited by the introduction of a vector producing 
p110β-targeting short hairpin RNA (shRNA) (Kubo et al., 2005). Recently a mouse line 
was created with a conditional genetic inactivation of p110β that induces the 
expression of a truncated, catalytically inactive form of p110β (Guillermet-Guibert et al., 
2008). Crossed heterozygous mice produced fewer viable mice than predicted 
however, mouse embryonic fibroblasts (MEFs) and bone marrow-derived macrophages 
(BMMs) could be isolated from viable mice. These cells were used to demonstrate G 
protein activation of p110β. In BMMs, stimulation with complement 5a, a GPCR 
agonist, resulted in PKB phosphorylation by both p110β and the class IB catalytic 
isoform p110γ. In MEFs, which express p110β but not p110γ, p110β-mediated 
activation of PKB was induced following stimulation with the GPCR agonists LPA and 
sphingosine-1-phosphate (S1P) (Guillermet-Guibert et al., 2008). Thus, depending on 
cell type or stimulating factor, activation of GPCRs may result in activation of either 
p110γ or p110β. 
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Figure 1.4 GPCR-mediated activation of p110β and p110γ 
The G protein coupled receptors (GPCRs) are 7 transmembrane domain containing 
receptors which can mediate the activation of p110γ, and more recently reported 
p110β, via a heterotrimeric G protein subunit complex. Activated G proteins are 
guanosine triphosphate (GTP) coupled. In general, dissociation of GTP-bound Gα from 
the heterotrimeric complex results in activation of the remaining dimer Gβγ, of the other 
two G proteins, Gβ and Gγ. Gβγ is reported to activate p110β and p110γ in certain cell 
types given the appropriate extracellular stimuli. When Gα hydrolyses GTP to 
guanosine diphosphate (GDP), Gα regains its affinity for Gβγ and the heterotrimeric 
complex re-associates. Adapted from Yart et al., 2002. 
 
 
1.2.2.2 Regulation of PI3K activity 
 
With a variety of receptors capable of activating PI3Ks, it follows that strict regulation of 
activity is required. This is primarily mediated by the actions of two phosphatases; SH2-
containing inositol 5-phosphatase (SHIP) and phosphatase and tensin homolog 
(PTEN). SHIP dephosphorylates the D5 position of phosphoinositol lipids 
(Rohrschneider et al., 2000) and PTEN dephosphorylates the D3 position (Cantley and 
Neel, 1999, Stambolic et al., 1998) (Figure 1.5). The actions of either of these 
phosphatases reduce the levels of PI(3,4,5)P3 present and therefore reduce the 
recruitment of PH domain containing effectors to the plasma membrane. However, 
since PTEN removes the phosphate group at the D3 position it reverts PI3K products 
to PI3K substrates. PI3Ks are known to promote growth due to activation by growth 
factor receptors. Thus, PTEN is a tumour suppressor since it reduces levels of 
PI(3,4)P2 and PI(3,4,5)P3 in cells and therefore reduces growth promoting signals 
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(Cantley and Neel, 1999). Indeed PTEN-null cells exhibit constitutively active PKB due 
to high levels of PI(3,4,5)P3 (Stambolic et al., 1998).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Regulation of PI3K activity 
SHIP removes the D5 phosphate from inositol phosphate products of PI3K. PTEN 
removes the D3 phosphate from inositol phosphate products of PI3Ks. Therefore, the 
activity of either SHIP or PTEN reduces the amount of PI(3,4,5)P3 in cells and 
counteracts the activity of PI3Ks. PI3K-interacting protein, PIK3IP1 is a novel regulator 
of PI3K activity with similarities to p85. However, instead of aiding activation and 
recruitment of PI3Ks to the plasma membrane, PIK3IP1 negatively regulates PI3K 
activity. 
 
 
More recently, a novel PI3K interacting protein (PIK3IP1) has been reported. PIK3IP1 
is a transmembrane protein and shares sequence homology with the p85 regulatory 
subunit. It is this homologous region of PIK3IP1 that binds to p110 resulting in reduced 
PI3K activity and limiting PKB activation (Zhu et al., 2007) (Figure 1.5). Indeed, further 
investigation has highlighted a role for this protein in preventing the development of 
hepatocellular carcinoma in both human disease and in a mouse model. Isolated 
hepatic cells from PIK3IP1 transgenic mice exhibited reduced PI3K signalling and 
suppressed hepatic cell growth (He et al., 2008). Furthermore, these mice had a 
diminished rate of spontaneous hepatocellular carcinoma development. Consistent with 
this, tissue from human liver tumours displayed reduced expression of PIK3IP1 (He et 
al., 2008). 
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Classically, p85 is reported to regulate the activation of p110 isoforms with associated 
interaction of receptor-tyrosine kinases (Dhand et al., 1994). However, it became 
apparent that monomeric p85 subunits could act as inhibitors of PI3K activation. In this 
model, free p85, not bound to p110, competes with heterodimeric p85-p110 for 
phosphorylated tyrosine residues. Binding of free p85 to phosphorylated tyrosine 
residues of activated receptors prevents the binding of p85-p110, thereby reducing 
PI3K activity (Geering et al., 2007). Thus, p85 not only positively regulates p110 
catalytic activity via p110 interaction at the plasma membrane but also negatively 
regulates kinase activity by competitive binding depending on the balance of p85 and 
p110 subunits (Brachmann et al., 2005). In addition, the expression of p85 and p110 
subunits can be interlinked. Given these two factors, targeted deletion of individual 
regulatory subunits could lead to altered expression of other subunits and 
unpredictable signalling outcomes. For example, in cells isolated from p85α knock-out 
mice, the expression of p85β is elevated, while the expression of p110α, p110β and 
p110δ is reduced compared to cells from wild-type mice (Fruman et al, 1999,Suzuki et 
al., 1999, Lu-Kuo et al., 2000). Knock-out mice lacking the p85 regulatory subunit tend 
to have increased insulin sensitivity and accordingly, cells isolated from these mice 
show increased PI(3,4,5)P3 levels and enhanced PKB phosphorylation at Ser473 
(Vanhaesebroeck et al., 2005, Foukas et al., 2006). A comprehensive study compared 
the kinase activity and insulin signal transduction of various PI3K regulatory subunits 
with the p110α catalytic subunit. Increasing the expression of p85α had a negative 
effect on PI3K activity. Furthermore, expression of p85α lacking the p110 binding 
domain also inhibited phosphotyrosine associated PI3K activity (Ueki et al., 2000). 
 
 
1.2.2.3 Class I PI3Ks: Functional roles and disease states 
 
The variety and combination of regulatory and catalytic subunits of PI3Ks allows cells 
to mediate cellular functions in an isoform selective manner, thus roles for individual 
isoforms are emerging.  
 
A major role for p110α in regulating growth and metabolic regulation has been 
reported. Growth and metabolic activity via p110α appears to be induced following 
insulin or growth factor stimulation (Roche et al., 1998). Knock in of kinase dead p110α 
produced viable heterozygous mice with stunted growth and hyperinsulinaemia 
(Foukas et al., 2006) where as homozygous p110α knock out mice were embryonic 
lethal, reportedly due to proliferative defects (Bi et al., 1999). Mouse PI3K catalytic 
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gene knock out and knock in studies are compared and discussed in further detail in 
Section 1.3.6.3. Of relevance, p110α was shown to be selectively recruited to the 
insulin receptor substrate (IRS) complex for signal transduction following insulin or 
insulin-like growth factor stimulation (Foukas et al., 2006). Furthermore, selective 
inhibitors of p110α blocked insulin-stimulated PI(3,4,5)P3 production, inhibited insulin-
induced PKB phosphorylation and reduced glucose uptake in adipocytes and myotubes 
(Knight et al., 2006). Perhaps unsurprisingly, given the regulation of cell growth by 
p110α, activating mutations of p110α or enhancements in copy number of PIK3CA, 
which encodes human p110α, are found in cancerous tissues (Shayesteh et al., 1999, 
Levine et al., 2005, Wu et al., 2005) highlighting an oncogenic role for p110α. Although 
p110α is implicated in many cancerous tissue types mutations and increased copy 
numbers of p110α are commonly found in ovarian and breast tumours (Shayesteh et 
al., 1999, Bachman et al., 2004, Levine et al., 2005) and colorectal tumours (Samuels 
et al., 2004). Furthermore, mutations of p110α are reportedly located in the kinase and 
helical domains inducing enhanced activity (Samuels et al., 2004). Additionally, 
amplifications or mutations of the genes encoding PKB isoforms, a major effector of 
PI3Kα, are also reported in human tumours in particular ovarian cancer (Cheng et al., 
1992, Liu et al., 1998). Consistent with this, inhibitory mutations of the phosphatases, 
PTEN and SHIP, endogenous antagonists of PI3K activity, result in excess cellular 
PI(3,4,5)P3 which can lead to cancerous phenotypes (Hennessy et al., 2005). 
Additionally a germline mutation of PTEN has been implicated in Cowden’s Disease, 
an inheritable syndrome that enhances the risk of breast, thyroid and skin tumour 
development (Liaw et al., 1997). 
 
Despite both p110α and p110β being ubiquitously expressed, much less is known 
about the functional role of p110β. Initially, p110β was implicated in stabilising platelet 
integrin αIIbβ3 and subsequent formation of adhesion bonds, a step in platelet activation 
and thrombus formation. Selective pharmacological inhibition of p110β prevented 
sustained platelet aggregation in response to weak agonist stimulation but was not 
necessary for initial platelet aggregation (Jackson et al., 2005). Other reports point 
towards a functionally redundant role for p110β in cell growth. LPA or insulin were 
demonstrated to stimulate p110β-mediated signalling (Roche et al., 1998). In most cell 
types, p110α is the only mediator of insulin signalling. However, in certain cell types, for 
example HepG2 cells, inhibition of p110β alone did not alter insulin-induced PKB 
phosphorylation whereas inhibition of p110β in combination with inhibition of p110α 
reduced PKB phosphorylation. Additionally in J774.2 macrophages, p110α, p110β and 
p110δ all contribute to insulin signalling in a functionally redundant manner 
(Chaussade et al., 2007). Additionally, both p110β and p110γ contribute to GPCR-
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mediated signalling in macrophages but p110β was reported to be dispensable 
(Guillermet-Guibert et al., 2008).  
 
The broad expression profiles of p110α and p110β are in stark contrast to the largely 
restricted expression of p110δ to cells of the immune system (Vanhaesebroeck et al., 
1997). This is exemplified by a major role for p110δ in the lymphohaemopoietic system. 
Gene knock in mice expressing catalytically inactive p110δ are reported to have 
impaired B and T cell immune responses (Okkenhaug et al., 2002). Furthermore, 
p110δ was found to be essential for B cell development, activation and function 
(Clayton et al., 2002, Jou et al., 2002). Selective inhibition of p110δ in neutrophils 
prevented N-formyl-methyl-leucyl-phenylalanine (fMLP)–induced PI(3,4,5)P3 production 
and chemotaxis, an essential stage in innate immunity (Sadhu et al., 2003). However, a 
redundant role for p110δ in insulin signalling in HepG2 cells and J774.2 macrophages 
was identified. Although p110α is the major PI3K involved in insulin signal transduction, 
co-inhibition of p110α and p110δ further reduced insulin-stimulated PKB 
phosphorylation compared to inhibition of p110α alone in HepG2 cells (Chaussade et 
al., 2007). 
 
The class IB PI3K p110γ exhibits expression restricted to the haematopoietic system, 
endothelium, heart and brain. Accordingly, knock out and catalytically inactive knock in 
studies in mice report a viable and fertile phenotype with normal growth rates 
(Crackower et al., 2002, Hirsch et al., 2000, Patrucco et al., 2004). However, p110γ 
has been implicated in mediating inflammatory processes and in the cardiovascular 
system using anti-p110γ antibodies and selective pharmacological inhibitors (reviewed 
by Rückle et al., 2006).  
 
 
1.2.2.4 Functional roles of other classes of PI3K  
 
A great deal of focus has been placed on defining the physiological roles of class I 
PI3Ks, however, the importance of other PI3K classes are beginning to emerge. The 
class II PI3K PI3K-C2β has been implicated in the migration of ovarian and cervical 
cancer cells (Maffucci et al., 2005) and recombinant expression of this isoform in 
HEK293 cells enhanced migration and decreased cell adhesion (Domin et al., 2005). In 
contrast, PI3K-C2α has been implicated in both the formation of clathrin-coated 
structures and clathrin-mediated trafficking (Gaidarov et al., 2001, Gaidarov et al., 
2005). Consistent with this PI3K-C2α was found to be involved in an ATP-dependent 
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priming phase of regulated exocytosis in neuroendocrine cells (Meunier et al., 2005). In 
contrast, down-regulation of PI3K-C2α expression is reported to inhibit noradrenaline-
induced contraction, defining a role for this isoform in vascular smooth muscle 
contraction (Wang et al., 2006). 
 
The class III PI3K is primarily involved in trafficking of protein and vesicles. Within the 
endocytic system, hVps34, the mammalian homologue of Vps34 in Saccharomyces 
cerevisiae, mediates the internalisation of PDGF receptors (Siddhanta et al., 1998) and 
is required for the formation of internal vesicles within multivesicular endosomes (Futter 
et al., 2001). 
 
 
1.2.3 Pharmacological inhibitors of PI3Ks 
 
Dysregulation of PI3Ks or proteins that regulate PI3Ks often leads to inflammatory 
disorders, autoimmune diseases and, most widely reported, cancer development and 
progression (Rommel et al., 2007, Hennessy et al., 2005). Therefore, inhibition of 
PI3Ks became a desirable target for therapeutic intervention of such disease states. 
 
Early pharmacological inhibitors of PI3Ks exhibited broad selectivity. The Penicillium 
funiculosum metabolite, wortmannin, was first described for its anti-inflammatory 
actions on acute oedema and inhibition of the respiratory burst in neutrophils and 
mononuclear phagocytes (Wiesinger et al., 1974, Baggiolini et al., 1987). Authors 
proposed that this compound interfered in some way with the signal transduction 
system mediating the activation of the respiratory burst oxidase response to a stimulus. 
Indeed, PI3K was later identified as a target of wortmannin. In neutrophils, treatment 
with wortmannin prevented fMLP-induced PI(3,4,5)P3 production and direct inhibition of 
PI3Ks was confirmed in vitro (Arcaro and Wymann, 1993). The irreversible actions of 
wortmannin are the result of covalent bonding to a catalytic lysine residue within the 
ATP-binding pocket of PI3Ks. Mutation of this amino acid residue to an arginine 
residue impairs wortmannin binding to PI3Ks (Wymann et al., 1996).  
 
LY294002, another early PI3K inhibitor, also targets the ATP-binding pocket of PI3Ks 
but, in contrast to wortmannin, LY294002 is a reversible competitive inhibitor of PI3Ks 
(Vlahos et al., 1994). With the exception of Class II PI3K-C2α that is wortmannin-
resistant (Domin et al., 1997), both wortmannin and LY294002 exhibit no selectivity for 
individual classes or isoforms of the PI3K family, what is more, their therapeutic use is 
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limited due to toxic effects in vivo (Hennessy et al., 2005). Unwanted side-effects are 
often the result of inhibition of PI3K-related kinases which share sequence similarity 
and structurally comparable kinase and ATP-binding domains, leaving them open 
targets for wortmannin and LY294002 (Abraham et al., 1996). 
 
Two newer, Class I PI3K inhibitors have been described. ZSTK474 is an s-triazine 
derivative. ZSTK474 was identified in a screen for potential compounds exhibiting 
strong inhibition of tumour cell proliferation (Yaguchi et al., 2006). Further investigation 
revealed that ZSTK474 was more potent than wortmannin or LY294002 at inhibiting 
growth and an effective anti-tumour compound. Indeed, ZSTK474 was shown to induce 
a reduced level of cell proliferation by cell cycle arrest at G0/G1, without indication of 
enhanced apoptosis (Dan et al., 2008). Inhibition of PI3Ks by ZSTK474 is achieved by 
binding the ATP-binding site in a similar manner to that previously described for 
LY294002 and wortmannin. Reversible inhibition of class IA PI3Ks was in the nM range 
when tested using a recombinant protein assay, while other protein kinases tested, 
including MEK, p70S6K, Pim1, protein kinases A, B and C, were not appreciably 
inhibited by ZSTK474 at µM concentrations (Yaguchi et al., 2006). In a more detailed 
study on individual class I
 
PI3K isoforms, ZSTK474 was found to inhibit all isoforms of 
this class with similar selectivity (Kong and Yamori, 2007). The mammalian target of 
rapamycin (mTOR), a serine/threonine kinase and member of the PIKK subfamily of 
kinases, contains a conserved kinase domain and acts downstream of PI3Ks to 
regulate cell growth via p70S6K (Abraham et al., 1996). Both LY294002 and 
wortmannin exhibit inhibition of mTOR which contributes to the toxicity of these 
inhibitors and makes them unlikely therapeutic agents (Knight et al., 2006, Brunn et al., 
1996). ZSTK474 is reported to weakly inhibit mTOR, but at concentrations higher than 
those needed to inhibit class I PI3Ks (Kong and Yamori, 2007). 
 
PI-103 is described as a dual inhibitor of p110α and mTOR. Unlike other PI3K 
inhibitors, PI-103 was shown to inhibit both rapamycin-sensitive mTORC1 and 
rapamycin-insensitive mTORC2 (Knight et al., 2006). Effective inhibition of glioma cell 
proliferation without inducing DNA damage was achieved by treatment with PI-103 
(Fan et al., 2006). In addition, an in vivo mouse model indicated that PI-103 could 
reduce xenograft size without the complications of toxicity associated with other PI3K 
inhibitors (Fan et al., 2006). Furthermore, the usefulness of PI-103 as a therapeutic 
agent was compounded by a report describing an enhanced sensitivity of tumour cells 
to radiotherapy following incubation with PI-103 (Prevo et al., 2008). However, in an in 
vitro screen of small molecule inhibitors of PI3Ks, PI-103 was only slightly more 
selective for p110α than for other p110 isoforms, limiting its use for the investigation of 
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the specific physiological roles mediated by individual PI3K isoforms (Knight et al., 
2006). 
 
1.2.3.1 Selective class I PI3K inhibitors 
 
Class I PI3Ks have been implicated in cellular processes such as migration, survival 
and proliferation and their deregulation results in diseases such as cancer and 
inflammatory disorders (discussed in section 1.2.2.3). Subsequently, the therapeutic 
potential of inhibiting PI3Ks was realised but such broad inhibition of the PI3K family 
and PI3K-related kinases by LY294002 or wortmannin contributed to unwanted side-
effects during drug discovery screens, restricting their use medicinally. Furthermore, a 
lack of selectivity for individual kinases impedes the investigation of the role of 
particular isoforms in cellular functions. The crystallisation of broad selectivity inhibitors 
bound to the ATP-binding site of PI3K catalytic subunits and the elucidation of crystal 
structures led to the possibility of developing isoform selective inhibitors by exploiting 
subtle differences in ATP-binding pockets (Knight et al., 2006, Walker et al., 2000). 
Therefore, these selective isoform inhibitors provide new hope for targeting isoforms 
implicated in specific diseases whilst limiting toxic effects and have aided investigation 
into the functional and physiological roles of individual isoforms in specific systems 
(reviewed by Crabbe et al., 2007). 
 
The ATP binding pockets of PI3Ks have similar amino acid sequences in each isoform, 
thus selective inhibitors must exploit subtle conformational differences in order to 
achieve selectivity (Knight et al., 2004). Modelling based on the structure of LY294002 
and the crystal structure of p110γ indicated that selectivity arises due to an induced 
conformational change resulting from inhibitor occupancy of the entrance to the ATP 
binding pocket (Walker et al., 2000, Knight et al., 2006). At this site, hydrogen bonds 
form between PI3K and the inhibitor in much the same orientation as hydrogen bonds 
formed with ATP. Furthermore, affinity arises by accessing deeper within the ATP 
binding pocket; co-crystallisation of p110γ and highly selective inhibitors confirmed that 
this deep hydrophobic pocket was occupied (Knight et al., 2006). The chemical 
structures of all PI3K inhibitors used in this study are shown in Table 2.3. 
 
The synthesis of IC87114 (Sadhu et al., 2001), one of the earliest isoform selective 
inhibitors, led to the confirmation that p110δ has an essential role in neutrophil 
polarisation and specific directional movement (Sadhu et al., 2003). In the same screen 
used to assess PI-103 selectivity, the IC50 value for IC87114 against p110δ was 
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0.13µM while the IC50 values for p110β and p110γ were 16µM and 61µM respectively 
(Knight et al., 2006). Of the Thrombogenix series of compounds, TGX-121 (Robertson 
et al., 2001) and TGX-221 (Jackson et al., 2004) preferentially inhibit p110β. TGX-221 
is more potent than TGX-121, and aided the investigation of the role of p110β in 
platelet activation in response to fluid sheer stress (Jackson et al., 2005). Two 
structurally distinct p110α inhibitors have been used in the present study, PIK-75 and 
compound 15e. PIK-75 was also screened for kinase selectivity and found to inhibit 
p110α with an IC50 of 5.8nM, approximately 10 fold, 100 fold and 200 fold more potent 
at inhibiting p110α than p110γ, p110δ and p110β respectively (Knight et al., 2006). 
However, PIK-75 displays inhibition of DNA-PK in the nM range and inhibition of 
mTORC1 and mTORC2 in the µM range (Knight et al., 2006). In comparison, little 
information is available regarding compound 15e other than synthesis information and 
preliminary studies indicating that compound 15e is effective at inhibiting A375 cell 
proliferation with an IC50 of 580nM (Hayakawa et al., 2006). As yet, no reports exist 
which assess the effects of compound 15e on mTOR or other PI3K related kinases. 
The class IB PI3K inhibitor AS605240 has been used to effectively inhibit joint 
inflammation in a mouse model of rheumatoid arthritis (Camps et al., 2005) and to 
prolong survival in a mouse model of systemic lupus erythematosus (Barber et al., 
2005). Thus, both broad selectivity and class I PI3K selective inhibitors have 
contributed to investigations into the roles of PI3K class I isoforms in healthy and 
disease states, and may provide future therapies (Crabbe et al., 2007). 
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1.3 Stem Cells 
1.3.1 Stem cells: A brief history 
 
In the 1960s researchers discovered that cells of the bone marrow were capable of 
forming more than one type of specialised blood cell (Till and McCullock, 1961). 
Consequently the idea of a common, ‘stem’ cell population giving rise to other cell 
types came to be. The first known stem cells to be isolated and grown in culture were 
those from mouse teratocarcinomas. These gonadal tumours comprised both 
undifferentiated cells and differentiated cells from each of the three embryonic germ 
layers; endoderm, mesoderm and ectoderm (Martin and Evans, 1975). The 
undifferentiated cells, named Embryonic Carcinoma Cells (ECCs), were shown to be 
capable of differentiation into any cell type of the three germ layers when co-cultured 
with mitotically inactivated embryonic fibroblast cells. This feeder layer of cells provided 
ECCs with factors thought to be important for growth and differentiation (Martin, 1980). 
Investigation into ECC culture requirements and characterisation of these cells led to 
the subsequent isolation of embryonic stem cells (Evans and Kaufman, 1981). 
 
 
1.3.1.1 Fertilisation and pre-implantation development 
 
Following fertilisation, the pre-implantation embryo is dependent on autocrine factors 
for survival and growth. The embryo undergoes sequential mitotic cell divisions, 
establishes polarity and undergoes compaction, where cell outlines cease to be visible, 
to form the morula. The blastocyst stage of embryonic development starts at three to 
four days post-fertilisation in mice. At this stage, the earliest differentiation steps have 
already taken place. The blastocyst comprises of an outer trophectoderm layer, a 
cavity, known as the blastocoel, and an inner cell mass (ICM) that gives rise to the 
embryo proper (Figure 1.6). Isolated pluripotent cells of the ICM of blastocyst stage 
embryos generate all cell types of the adult organism in vitro but do not generate 
extraembryonic lineage cells of the trophoblast or primitive endoderm (Rossant, 2008). 
 
During the late blastocyst stage, the outer trophectoderm attaches to the uterine lining 
to commence implantation. Additionally, trophectoderm develops into extraembryonic 
ectoderm followed by the placenta and chorion or terminal differentiation into primary 
trophoblast cells (Rossant and Cross, 2001). At the blastocyst stage the ICM 
delaminates and gives rise to primitive ectoderm and a layer of primitive endoderm 
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(Figure 1.7). Primitive ectoderm develops into the epiblast, from which all of the embryo 
cell types (three germ layers) are derived as well as extraembryonic mesoderm. 
Primitive endoderm, at the surface of the ICM, forms parietal endoderm and visceral 
endoderm, contributing to the yolk sac (Lu et al., 2001). Development of the implanted 
embryo ensues. At embryonic day 10.5 (E10.5, days post-fertilisation) in mice, the 
embryo is termed a foetus and the gestation period for mice is generally 19-21 days. 
(Boiani and Scholer, 2005, Wang and Dey, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Pre-implantation development in the mouse 
Following fertilisation, the embryo undergoes multiple rounds of mitotic cell division. 
Cells flatten and their outlines are not easily distinguishable at compaction. On 
embryonic day 3.5 (E3.5) a blastocyst forms consisting of an inner cell mass (ICM) and 
a blastocoel cavity. The blastocyst is surrounded by trophectoderm cells. When the 
embryo implants, cells of the trophectoderm develop into the trophoblast cells, while 
the cells of the ICM contribute to the epiblast and primitive ectoderm. Adapted from 
Boiani and Scholer, 2005, Wang and Dey, 2006. 
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Figure 1.7 Early lineage commitment 
Cells of the ICM differentiate into two distinct lineages; Primitive endoderm and 
Primitive ectoderm. Primitive ectoderm gives rise to the epiblast, from which all cell 
types of the embryo are derived by differentiation into cells representing the three germ 
layers. Additionally, the epiblast forms extraembryonic mesoderm and germ cells. 
 
 
1.3.2 Derivation, sources and properties of stem cells 
 
Pluripotency describes the ability of stem cells to form any differentiated cell type of the 
adult organism. The inner cell mass contains pluripotent cells from which murine 
embryonic stem cell (mESC) lines can be derived (Evans and Kaufman, 1981). 
Isolation of these cells from blastocyst stage embryos can be achieved at E3.5 (Figure 
1.8). 
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Figure 1.8 Isolation of murine ESC lines 
At E3.5 cells of the ICM are pluripotent. ESC lines can be isolated from blastocyst 
stage embryos and grown in culture in a pluripotent, self-renewing manner. ESCs 
characteristically have large nuclei compared to cytosol volume. Given the right growth 
conditions, these ESC lines can be cultured long-term whilst retaining their 
pluripotency.  
 
 
1.3.2.1 The properties of self-renewal and pluripotency 
 
Stem cells have the unique properties of self-renewal and pluripotency. The term self-
renewal encompasses a number of cellular events; maintenance of pluripotency, 
continuous proliferation, inhibition of apoptosis and prevention of differentiation. Thus, 
self-renewal is defined as proliferation with the suppression of differentiation (Smith, 
2001, Burdon et al., 2002). Differentiation describes the process of a cell, such as a 
stem cell, becoming a more specialised cell type whereas self-renewal maintains the 
less specialised cell type but retains the ability to differentiate. Therefore self-renewal is 
necessary to maintain pluripotency (Figure 1.9).  
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Figure 1.9 Self-renewal and pluripotency 
Self-renewal of ESCs maintains a population of undifferentiated, pluripotent, 
proliferating cells. However, spontaneous differentiation is a feature of ESCs in culture. 
Differentiation into any cell type is a unique property of embryonic stem cells and 
demonstrates their pluripotency. Embryonic stem cells form progenitor cells that 
undergo further differentiation along a particular lineage toward specialised cell types 
(Evans and Kaufman, 1981, Smith, 2001, Keller, 2005). Embryonic stem cells can give 
rise to any cell type of the adult organism by differentiation to any of the three germ 
layers (Evans and Kaufman, 1981). Embryonic stem cells in vivo and in vitro primarily 
differentiate into multipotent progenitor cells. Unlike embryonic stem cells, progenitor 
cells are already specialised to a certain degree, thus further differentiation and 
specialisation is limited to a particular lineage.  
 
 
1.3.2.2 Human embryonic stem cells 
 
Human ESC (hESC) lines were first established in 1998 (Thomson et al., 1998) 
following previous success in the isolation of ESC from other primate species 
(Thomson et al., 1995, Thomson and Marshall, 1998). Despite ethical concerns and 
controversy, the isolation of hESCs was conducted with a view to researching potential 
cell-based therapies and for the study of early human embryo development. In vivo 
hESCs can divide indefinitely maintaining an undifferentiated, pluripotent state (Hwang 
et al., 2004, Park et al., 2003a) much the same as mESCs. Additionally the pluripotent 
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nature of hESCs allows differentiation to produce cells representative of all lineages of 
the adult organism (Amit et al., 2000, Itskovitz-Eldor et al., 2000, Reubinoff et al., 2000, 
Schuldiner et al., 2000, Pera et al., 2004, Draper and Fox, 2003). The similarities and 
differences in the underlying mechanisms that regulate maintenance of 
undifferentiated, pluripotent ESCs from humans and mice are described in section 
1.3.7. 
 
1.3.2.3 Other sources of stem cells 
 
Unlike embryonic stems cells which are pluripotent, the ability of adult stem cells to 
differentiate is restricted. Thus, adult stem cells are described as multipotent or 
unipotent since their differentiation potential is limited to several distinct specialised cell 
types or a single mature cell type. Adult stem cells also have limited self-renewal 
potential compared to ESCs but serve to generate new tissue to replace lost or 
damaged tissue through homeostasis or injury. Examples of adult stem cells include 
haematopoietic stem cells which give rise to all myeloid and lymphoid blood lineages, 
mesenchymal stem cells, derived from bone marrow that produce bone, cartilage and 
tendons, and gut crypt cells that form enterocytes, enteroendocrine cells and Paneth 
cells (Ogawa, 1993, Eckfeldt et al., 2005). Aside from ESCs and adult stem cell 
populations, other stem cell sources include fetal and umbilical cord stem cells. These 
are reported to be multipotent but researchers hold hopes that these may also be used 
to derive specialised cell types for transplantation (Mimeault et al., 2007). 
 
1.3.3 Potential uses of ESCs 
 
ESCs are a good model system for early embryonic development. Much research has 
involved gene targeting in ESCs, or the isolation of ESCs from embryos following gene 
targeting, providing evidence for the role of particular genes in development and 
differentiation (Williams et al., 2000, Winnier et al., 1995, Anton et al., 2007, Lin et al., 
2005, Sun et al., 1999, Stiles et al., 2002, Stambolic et al., 1998, Suzuki et al., 1998). 
In addition ESCs undergo both spontaneous and induced differentiation when cultured 
in vitro allowing research into the field of lineage commitment (Cheng et al., 1998, Ying 
et al., 2003a, Ying et al., 2003b). Using ESCs as a model of early embryo 
development, populations of cells have been identified that are examples of early 
progenitors gaining insights into lineage commitment and the induction of 
differentiation. For example, the culture conditions necessary to induce mESCs to 
differentiate into early primitive ectoderm-like cells, similar to primitive ectoderm cells of 
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an E4.75 mouse embryo, have been described (Rathjen et al., 1999). The proliferation 
capacity and cell cycle characteristics of ESCs resembles that of cancerous cells which 
has furthered knowledge of tumour growth and allowed more specific treatments to be 
investigated (Cheng et al., 1998, Sun et al., 1999, Savatier et al., 1994). 
 
The limited supply of adult stem cells, the isolation of which is often difficult and painful 
for the donor, is compounded by their limited capacity for self-renewal, reducing the 
ability of adult stem cells to be expanded in culture in vitro for investigation. The 
pluripotent nature of ESCs means that these cells have the ability to become a broad 
array of cell types, while adult stem cell differentiation is somewhat restricted. 
Therefore, ESCs having undergone expansion and directed differentiation have the 
potential to treat more diverse pathological disorders. The use of ESCs in the field of 
regenerative medicine, the use of live cells or tissue structures to repair or replace cells 
or tissue that is damaged or dysfunctional, is rapidly expanding. Much research 
focuses on both the expansion of ESCs and directed differentiation into homogenous 
cultures ex vivo, followed by transplantation (Figure 1.10). Notably, the formation of 
insulin-secreting cells derived from ESCs provides new hope for diabetes treatment 
(Soria et al., 2000, Segev et al., 2004). Myocardial infarction causes ischemic damage 
to cardiac cells which could be replaced with cardiomyocytes derived from ESCs 
(Kolossov et al., 2006). In the field of neurodegeneration research, ESC-derived neural 
precursor cells have already been described (Lang et al., 2004) and used to effectively 
relieve motor dysfunction in a rat model of Parkinson’s disease (Bjorklund et al., 2002). 
Furthermore, the concept of regenerative medicine has been expanded beyond purely 
the use of ESC-derived cell types and tissue structures. Genetic manipulation prior to 
transplantation may not only reduce the risk of rejection but ESC-derived cells may 
also be a novel vehicle for gene therapy to treat genetic diseases and cancer 
(Mimeault et al., 2007). 
 
An important area of investigation regarding the use of ESC-derived cells for 
transplantation is how to avoid the transplantation of undifferentiated ESCs, which has 
been shown to produce teratocarcinomas (Thomson et al., 1998, Fujikawa et al., 
2005). Specific lineage selection, elimination of undifferentiated cells and 
transplantation of precursor cells versus mature, terminally differentiated cells may all 
avoid unwanted teratocarcinoma formation and enhance the establishment of 
transplanted cells (Keller, 2005). Additionally, the intraspecies and interspecies transfer 
of pathogens, a risk of growing human stem cells on feeder layers prior to 
transplantation, might be overcome by using ESC-derived feeder cells too. Both mouse 
and human ESC-derived embryonic fibroblast cells have been isolated and 
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characterised for use as feeder cells for culturing undifferentiated, pluripotent ESCs 
(Shi et al., 2006b, Wang et al., 2005). 
 
ESCs and ESC-derived cell types may provide researchers with an unlimited supply of 
cells on which to test new candidate drugs. The area of drug discovery and 
development currently relies on animal models, limited human cell lines and human 
volunteers. It is hoped that drug toxicity testing on ESC-derived cell types will benefit 
this area of research (Keller, 2005). Furthermore, given that ESCs are, in themselves, 
a model of early embryo development, they could be used to predict the toxicological 
effects of new drugs on embryos in a more ethically sound manner (Figure 1.10). 
 
Recent research has led to a unique method of inducing differentiated cells towards a 
pluripotent state. Mouse skin cells were reverted to ESC-like cells by the expression of 
four mESC-specific genes (Takahashi and Yamanaka, 2006, Okita et al., 2007). More 
recently, adult human fibroblasts have been genetically manipulated to form these 
induced pluripotent stem cells (iPSCs) (Takahashi et al., 2007) and although less 
efficient, only three genes were required to create iPSCs from both mouse and human 
fibroblasts (Nakagawa et al., 2008) (iPSCs are described in more detail in Section 
1.3.4.8). Indeed a number of strategies have been taken to achieve reprogramming of 
somatic cells including nuclear transfer, cell fusion, cell explantation and virus infection 
(Jaenisch and Young, 2008). Currently, the efficiency of generating iPSCs is extremely 
low due to multiple transfection requirements, the slow formation of iPSCs from 
somatic cell types and subsequent selection of iPSCs from the population. It is 
therefore important that iPSCs continue to be investigated alongside ESCs since if the 
differences between iPSCs and ESCs are not detrimental to their therapeutic potential, 
iPSCs could be used to generate patient-specific regenerated tissues for therapy 
(Condic and Rao, 2008). Furthermore, the use of patient-specific iPSCs would negate 
immune-rejection issues that would be associated by using even best-match ESC-
derived cells (Figure 1.10). Avoiding the use of immunosuppressants would also 
overcome a challenge in the fields of cell replacement therapy and regenerative 
medicine. 
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Figure 1.10 Potential and current uses of ESCs and iPSCs 
ESCs not only have great potential for use in the fields of regenerative medicine and 
cell replacement therapy but also provide a model system for the study of 
developmental biology and for drug development (Keller, 2005). In addition, ESC-
derived cells might be used for cell replacement therapy, drug development and as a 
source of progenitor or differentiated cell lines for research. More recently, iPSCs, 
which are derived from differentiated cell types and forced towards a pluripotent state, 
exhibiting properties similar to ESCs have been described (Takahashi et al., 2007, 
Nakagawa et al., 2008). Investigations into iPSCs are still in the early stages but they 
might provide patient-specific cells for replacement therapy or be used as disease 
model cell lines. 
 
 
In order to realise the therapeutic potential of ESCs or iPSCs, a thorough 
understanding of the underlying mechanisms regulating self-renewal and differentiation 
is required. Murine ESCs were the first to be isolated and show some similarities to 
human ESCs, thus make an ideal replacement with fewer ethical concerns 
(Koestenbauer et al., 2006, Evans and Kaufman, 1981). Much research has focused 
on identifying master regulators of self-renewal but as with other important cellular 
functions, multiple pathways exist to maintain, regulate, direct and modify cell fate. 
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1.3.4 Murine embryonic stem cell self-renewal 
1.3.4.1 Markers of mESC self-renewal  
 
In order to effectively research and assess self-renewal of mESCs, a number of 
markers are used. It is important to note that the presence of self-renewal markers 
indicates that ESCs are in an undifferentiated state but does not indicate that ESCs are 
pluripotent. To assess pluripotency, cells must be induced to differentiate or allowed to 
freely differentiate before detection of a panel of markers representing early lineages 
are used to confirm pluripotency.  
 
Alkaline phosphatase is a hydrolase enzyme responsible for dephosphorylating 
molecules such as nucleotides, proteins, and alkaloids under alkaline conditions. It is 
present within all tissues of the body but is elevated in cells under specific diseased 
states and in cells of the liver, kidney, bone, placenta and embryo (Scutt and Bertram, 
1999). Dense staining of alkaline phosphatase was demonstrated in the ICM of murine 
blastocysts (Johnson et al., 1977). Consistent with this, alkaline phosphatase activity is 
detectable on the cell surface of undifferentiated, self-renewing ESCs but expression is 
lost upon differentiation (Pease et al., 1990). Enzymatic assay for alkaline phosphatase 
activity is frequently used as a measure of self-renewal and, due to cell surface 
expression in undifferentiated cells, positive staining correlates with alkaline 
phosphatase activity at the cell surface of self-renewing ESCs (Pease et al., 1990).  
 
A number of transcription factors are known to have higher expression in self-renewing 
ESCs compared to differentiated cell types. Oct4 was first identified as an ESC and 
germ line specific transcription factor (Okamoto et al., 1990). Oct4 is encoded by the 
gene Pou5f1 and is a member of the Octamer transcription factor family, which contain 
a POU (Pit Oct Unc) domain. POU domains share sequence homology with the 
mammalian genes Oct1, Oct2 and Pit1, and the Caenorhabditis elegans gene Unc-86 
(Ryan and Rosenfeld, 1997). Oct4 interacts with the octamer DNA motif (5’-
ATGCAAAT-3’) via its POU domain to regulate transcription. Oct4 is expressed in pre-
implantation embryos, undifferentiated mESCs, epiblast cells and germ cells and Oct4 
expression is essential for the formation of pluripotent founder cells within the 
mammalian embryo (Okamoto et al., 1990, Schöler et al., 1990). Consistent with this, 
cells isolated from blastocyst stage embryos lacking Oct4 expression are not 
pluripotent (Nichols et al., 1998) and induction of mESC differentiation with retinoic acid 
results in a reduction in Oct4 expression (Okamoto et al., 1990). Oct4 regulates mESC 
fate by the level of Oct4 expression in that a less than two-fold increase in Oct4 
Chapter 1: Introduction 
 31
expression was reported to result in differentiation towards primitive endodermal and 
mesodermal lineages (Niwa et al., 2000) Conversely, the same study reported that 
reduced expression of Oct4, to levels less than half that of normal expression, led to a 
loss of pluripotency and the expression of trophectodermal markers (Niwa et al., 2000). 
Therefore, Oct4 is thought to maintain self-renewal at a critical level of expression, 
deviations from this level of expression determine both cell fate and lineage 
commitment (Niwa, 2001). 
 
Another important regulator of self-renewal is Sox2, a Sox (SRY-related HMG box) 
gene family transcription factor with notable expression in pluripotent and multipotent 
cell types such as the ICM, epiblast cells, germ cells and extraembryonic ectoderm. In 
the absence of Sox2, blastocysts form, but embryos fail to survive after implantation 
(Avilion et al., 2003). Around the same time, a report was published detailing an in 
silico screen for genes that maintain pluripotency and are expressed exclusively in the 
ICM and in ESCs. This screen highlighted nine genes but for one particular gene, 
expression was not detected in twelve somatic tissues (Mitsui et al., 2003). 
Furthermore, expression of this gene in ESCs was reportedly reduced by retinoic acid-
induced differentiation (Mitsui et al., 2003). Following functional expression cloning, this 
gene was demonstrated to express a transcription factor, which was subsequently 
named Nanog after Tír na nÓg (an island in Celtic mythology which, translated to 
English, means ‘land of the ever young’) (Chambers et al., 2003). Nanog is a 
homeodomain-containing transcription factor and is necessary for pluripotency of the 
ICM and ESCs (Mitsui et al., 2003), thus it is often referred to as a master regulator of 
self-renewal, although Oct4 and Sox2 are also required for maintaining self-renewal. A 
5 fold enhancement in the expression of Nanog is reported to maintain mESC self-
renewal even in the absence of LIF, a major promoter of mESC self-renewal, whereas 
reduced Nanog expression leads to extraembryonic endoderm differentiation (Mitsui et 
al., 2003, Chambers et al., 2003). 
 
The zinc finger protein Reduced Expression-1, Rex1 (also referred to as Zfp42) was 
initially identified in ECCs and noted for its expression, which was down-regulated 
following retinoic acid-induced differentiation (Hosler et al., 1989). Rex1 was 
demonstrated to be specifically expressed in ESCs, pre-implantation embryos, 
trophoblast and spermatocytes. Furthermore, it it a suitable marker for self-renewing 
mESCs since expression is reduced following induction of differentiation (Rogers et al., 
1991). Although Rex1 is used as a marker of self-renewing mESCs, unlike Nanog and 
Oct4, Rex1 expression is dispensable for the maintenance of self-renewal of mESCs 
and is not required for the normal development of mouse embryos (Masui et al., 2008). 
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Detection of one or more of these markers is frequently used to assess self-renewal of 
ESCs and forms the basis of investigations into the signalling underlying the 
maintenance of self-renewal. 
 
1.3.4.2 Leukaemia inhibitory factor-mediated intracellular signalling 
 
Murine ESCs can be cultured on a feeder layer of mouse embryonic fibroblast cells 
(MEFs) which produce the cytokine Leukaemia Inhibitory Factor (LIF). LIF supports 
mESC growth and maintenance of self-renewal (Smith et al., 1988, Bard and Ross, 
1991, Gough et al., 1989, Williams et al., 1988) and must be supplemented in the 
medium for mESCs to be grown in feeder-free conditions.  
 
LIF binds to a heteromeric complex of the LIF recetor (LIFR) and the common cytokine 
receptor gp130 (Ernst and Jenkins, 2004). Janus-associated tyrosine kinase (JAK) 
remains associated with gp130 but phosphorylates tyrosine residues of gp130 and 
LIFR upon LIF binding. This phosphorylation prompts the recruitment of signal 
transducer and activator of transcription 3 (Stat3), the SH2 domains of which bind 
tyrosine phosphorylated residues on the intracellular regions of these receptors 
(Burdon et al., 1999, Stahl et al., 1995). Recruitment allows the phosphorylation of 
Stat3 by JAK. Phosphorylated Stat3 homodimerises and translocates to the nucleus 
where it regulates transcription of target genes (Figure 1.11). 
 
LIF-induced activation of the Jak/Stat3 pathway is important for the maintenance of 
pluripotency and self-renewal of mESCs (Boeuf et al., 1997, Burdon et al., 2002, Niwa 
et al., 1998, Matsuda et al., 1999, Smith, 2001). In fact, LIF withdrawal causes a 
reduction in Nanog protein expression, coinciding with a loss of self-renewal (Storm et 
al., 2007). Artificial induction of Stat3 activation was sufficient to maintain self-renewal 
without the requirement for LIF (Matsuda et al., 1999). Inhibition of Stat3 activation, by 
the expression of a mutated form of Stat3 lacking the ability to dimerise, induced 
differentiation of mESCs (Niwa et al., 1998). It was observed by Raz et al., 1999 that 
different mESC lines exhibit varying dependency on LIF but a strong correlation existed 
between nuclear Stat3 binding activity and the formation of pluripotent mESC colonies 
of cells plated at clonal density (Raz et al., 1999). Moreover, over-expression of Stat3 
removes the requirement for LIF in order to support self-renewal in the presence of 
serum (Boeuf et al., 1997). The key effector and transcriptional target of the LIF/Stat3 
pathway has been reported to be the proto-oncogene c-myc, which, in other cell types 
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regulates cell proliferation, growth and apoptosis. The activity c-myc in mESCs has 
been reported to be necessary for self-renewal maintenance (Cartwright et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 LIF-dependent regulation of self-renewal 
LIF promotes the self-renewal of mESCs via the activation of Stat3. Phosphorylated 
Stat3 dimerises and translocates to the nucleus where it regulates the expression of c-
myc. LIF can also activate PI3K and Ras/Erk signalling by a Stat3-independent route. 
 
 
The Mitogen Activated Protein Kinase (MAPK) and PI3K signalling pathways are also 
reported to be activated by LIF (Figure 1.11) indicating that LIF is capable of regulating 
Stat3-independent pathways in mESCs (Burdon et al., 1999, Qu and Feng, 1998). The 
mechanism of activation of the MAPK pathway by LIF is thought to be via SH2 domain-
containing tyrosine phosphatase-2 (Shp-2). Shp-2 is recruited to the plasma 
membrane, via its SH2 domains binding to phosphorylated tyrosine residues, where it 
binds the adaptor protein growth factor receptor binding protein (Grb2). By binding 
Grb2, which is itself bound to the guanine nucleotide exchange factor for Ras (Sos1), 
Shp-2 is capable of activating MAPK signalling via Ras following LIF receptor 
stimulation (Figure 1.11) (Fukada et al., 1996, Ernst et al., 1996). The mechanism of 
LIF-induced activation of the PI3K pathway in mESCs is yet to be defined although, in 
Hep-G2 cells, Shp-2 was reported to associate with Grb2-associated binder (Gab), to 
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activate the PI3K pathway following activation of the cytokine receptor gp130 
(Takahashi-Tezuka et al., 1998), which is a component of the LIF receptor heterodimer 
(Ernst and Jenkins, 2004). The activation of MAPK and PI3K signalling and their role in 
regulating mESC fate are described in detail in Sections 1.3.4.6 and 1.3.6 respectively. 
 
With regards to the maintenance of self-renewal, LIF activation of Stat3 is reported to 
prevent mesoderm and endoderm differentiation (Ying et al., 2003a) while in serum-
free conditions LIF induces neural differentiation (Ying et al., 2003a, Ying et al., 2003b). 
In such serum-free culture conditions, BMP4 is required in addition to LIF, in order to 
maintain self-renewal of mESCs (see Sections 1.3.4.3 and 1.3.4.4). 
 
LIF has also been reported to activate Src family non-receptor tyrosine kinases. In 
particular c-Yes and Hck were shown to be activated by LIF in mESCs (Annerén et al., 
2004, Meyn et al., 2005). Introduction of an activated mutant of Hck into mESCs 
reduced the concentration of LIF required to maintain self-renewal (Annerén et al., 
2004). Furthermore, Hck was found to be associated with gp130 of the LIF receptor 
heterodimer (Ernst et al., 1994). Activity of c-Yes could be stimulated by LIF or by 
factors present in serum and activity was down-regulated upon LIF withdrawal or 
following the induction of differentiation, although protein levels remained the same. 
Differentiation of mESCs was induced following treatment with a selective Src family 
kinase inhibitor or expression of c-Yes short interfering RNA (siRNA). Furthermore, c-
Yes activity was found to be independent of the Jak/Stat and MAPK pathways and 
represents an alternative pathway for LIF to maintain self-renewal (Annerén et al., 
2004). To date seven of the eight known Src family kinases have been shown to be 
expressed in self-renewing mESCs (Thomas and Brugge, 1997). Expression of Lyn, 
Fyn, Src and Yes remains constant during embryoid body differentiation but Fgr, Hck 
and Lck expression decreases upon differentiation. Intriguingly, partial inhibition with 
low doses of inhibitors or inhibitors that target only selective Src family kinases induced 
differentiation even in the presence of LIF, while higher doses or more potent inhibitors 
maintained the undifferentiated state even in the absence of LIF. In-depth analysis of 
the expression profiles of Src family kinase members in mESCs alongside the inhibition 
profiles of the inhibitors used led to a model of two opposing pathways for Src family 
members. The authors suggested Hck and Yes promote self-renewal in the presence 
of LIF. Upon LIF removal when Hck expression is decreased, or in the presence of Hck 
and Yes selective inhibition, this pro-self-renewal signal is reduced allowing Src and 
Fyn to promote differentiation (Figure 1.12) (Meyn et al., 2005). 
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Figure 1.12 Non-receptor tyrosine kinase regulation of self-renewal 
The Src family of non-receptor tyrosine kinases have been shown to be activated by 
LIF, independent of the Jak/Stat pathway. Src and Fyn are expressed in self-renewing 
mESCs and throughout differentiation. Hck and Yes promote self-renewal via a 
predominant pathway. When Hck expression is reduced upon the initiation of 
differentiation, Src and Fyn act to promote differentiation. Adapted from Meyn et al., 
2005. 
 
 
1.3.4.3 Bone morphogenic proteins contribute to mESC self-renewal 
maintenance 
 
Bone morphogenic proteins (BMPs) are growth factors belonging to the transforming 
growth factor beta (TGFβ) superfamiy. BMPs have two types of receptors, all of which 
are transmembrane serine/threonine kinases; Type I receptors, Alk2, Alk3 (BmprIa) 
and Alk6 (BmprIb) and type II receptor, BmprII. Undifferentiated mESCs express 
BmprIa and BmprII (Qi et al., 2004). Binding of BMP to a dimer of type I and type II 
receptors initiates the canonical BMP signalling pathway (Figure 1.13). Ligand binding 
activates intracellular mediators, Smad proteins. The nomenclature of Smad proteins is 
derived from BMP-like signalling pathways in Caenorhabditis elegans (Sma) and 
Drosophila mothers against decapentaplegic (Mad) (Attisano and Wrana, 2002). In 
vertebrates there are eight members of the Smad family which are divided into three 
subgroups; receptor R-Smads, inhibitory I-Smads and a common-partner co-Smad. R-
Smads Smad2 and Smad3 are activated via TGFβ and activin receptors, where as R-
Smads Smad1, Smad5 and Smad8 are phosphorylated by type I BMP receptors (Itoh 
et al., 2000). Activation of Smad1, Smad5 or Smad8 results in homodimerisation 
followed by the formation of a heterotrimeric complex with co-Smad, Smad4 (Figure 
1.13). In contrast, I-Smads are inhibitory, thus Smad6 and Smad7 inhibit TGFβ family 
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signalling and prevent the activation of R-Smads and co-Smads (Hata et al., 1998, 
Nakao et al., 1997). TGFβ signalling can induce the expression of Smad6 and Smad7 
thereby initiating a negative feedback loop in order to regulate R-Smad and co-Smad 
signalling (Whitman, 1997). In the absence of I-Smads, the heterotrimeric complexes of 
R-Smads and co-Smads translocate and accumulate in the nucleus where, in 
conjunction with other transcription factors, they function to regulate the expression of 
target genes dependant on cell type (Itoh et al., 2000, Derynck and Zhang, 2003). In 
mESCs, Smad complexes are reported to regulate the transcription of members of the 
Id (inhibitor of differentiation) gene family, expression of which inhibits basic helix-loop-
helix transcription factors required for differentiation (Ruzinova and Benezra, 2003). 
 
Cross-talk exists between BMP-induced signalling and that mediated by other growth 
factors and cytokines. For example, reciprocal inhibition exists between Smad activity 
and the MAPK pathway (Figure 1.13). FGF or Ras activated Erk inhibits Smad 
translocation to the nucleus via phosphorylation of a linker region between the two 
globular domains of Smad1 (Kretzschmar et al., 1997). Further to the prevention of 
nuclear accumulation, phosphorylation by Erk allows additional phosphorylation of the 
linker region by Gsk-3 (Fuentealba et al., 2007). This double phosphorylation results in 
selective binding of Smurf1, an E3 ubiquitin ligase, followed by polyubquitinisation of 
phosphorylated Smad1 and subsequent degradation (Sapkota et al., 2007). Thus BMP-
induced Smad signalling and degradation is regulated by other pathways which are of 
importance in stem cell fate. 
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Figure 1.13 The canonical BMP signalling pathway 
Following the binding of BMP4 to BMP receptors type I and type II, type I receptor-
mediated Smad1/5/8 phosphorylation occurs. Phosphorylated Smad1 dimerises and 
binds to co-Smad, Smad4. This heterotrimeric complex translocates to the nucleus 
where it regulates transcription of Id genes. Expression of particular Id genes inhibits 
differentiation of mESCs. Phosphorylation of Smad1 at specific sites by FGF-induced 
Erk activity or inhibition of Gsk-3 by Wnt signalling prevents nuclear accumulation of 
the Smad1-Smad4 complex. 
 
 
Over-expression of Smad1/4 or expression of constitutively active BMP receptor in 
mESCs relieves the requirement for LIF (Ying et al., 2003b). Moreover, mESCs can not 
be derived from blastocysts lacking Bmpr1a or Smad4 (Qi et al., 2004). Thus BMP 
signalling appears to be an important contributor, not only to the maintenance of self-
renewal of mESCs in culture, but also for the establishment of ESC lines. 
 
1.3.4.4 Serum-free chemically defined culture of mESCs 
 
LIF can only maintain self-renewal in the presence of serum-containing media. In 
serum-free culture conditions, LIF alone induces neural differentiation (Wilson and 
Edlund, 2001, Ying et al., 2003a, Ying et al., 2003b). In conjunction with LIF, BMP4 is 
required to completely eliminate the requirement for serum. Such serum-free media is 
supplemented with N2 (Bottenstein and Sato, 1979) and B27 (Brewer and Cotman, 
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1989, Brewer et al., 1993) supplements of known components (listed in Table 2.1), 
thus can also be described as chemically-defined media. In the absence of LIF, BMP 
was reported to prevent the differentiation of mESCs and embryoid bodies towards 
neural lineages (Ying et al., 2003b, Wiles and Johansson, 1999) and to promote 
mesodermal differentiation (Nakayama et al., 2000). Consistent with this, treatment of 
hESCs with BMP alone was reported to promote differentiation towards mesoderm, 
endoderm and trophoblast cell types (Schuldiner et al., 2000, Xu et al., 2002, Pera et 
al., 2004). In mESCs, BMP is known to mediate its effects on maintaining a balance of 
self-renewal via Smad-mediated transcriptional regulation of Id2 gene expression 
(Hollnagel et al., 1999, Ying et al., 2003b). Moreover, Id2 over-expression can 
suppress neural differentiation in the absence of BMP (Ying et al., 2003b). Additionally, 
Nanog was reported to bind to Smad1 to prevent the binding to co-Smad (Smad4). 
This negative regulation of the BMP/Smad pathway by Nanog was suggested by 
authors to be a control mechanism for inhibiting BMP-induced mesoderm differentiation 
(Suzuki et al., 2006). Further to this, embryos with a homozygous Bmp4-null mutation 
fail to undergo mesoderm differentiation (Winnier et al., 1995). Thus, BMP4 and LIF act 
in synergy in serum-free media to maintain mESC pluripotency by balanced inhibition 
of lineage commitment towards neural and non-neural fates respectively (Figure 1.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14 Cross-talk of BMP4 and LIF signalling maintains pluripotency 
A balance of LIF and BMP-induced signalling is required to maintain self-renewing 
pluripotent mESCs in serum-free culture conditions. LIF promotes neural differentiation 
via the activation of Erk and inhibits non-neural differentiation via Stat3. Conversely 
BMP4 inhibits neural differentiation via the expression of Id2 and promotes non-neural 
differentiation. 
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1.3.4.5 Autocrine and paracrine signalling in ESCs 
 
Although chemically defined media allows the effects of individual factors to be 
assessed, ESCs are known to secrete their own survival enhancing factors into culture 
media. In a screen for proteins secreted by undifferentiated ESCs, a variety of 
chemokines, growth factors and colony stimulating factors were detected at higher 
levels in ESC-conditioned media compared to background levels in serum-containing 
media (Guo et al., 2006). Conditioned media from mESCs was used to demonstrate an 
anti-apoptotic effect on H9c2 cardiac myoblast cells (Singla et al., 2008). An increase in 
cell survival was observed for H9c2 cells cultured in mESC conditioned media following 
H2O2 treatment to induce apoptosis. Furthermore, this reduction in apoptosis was found 
to be mediated by PI3K/PKB signalling (Singla et al., 2008). Additionally, mESC-
conditioned media is reported to enhance the survival and colony formation of murine 
bone marrow myeloid progenitor cells (Guo et al., 2006). Murine ESC-conditioned 
media containing LIF, when applied to fresh mESCs, induces enhanced Nanog mRNA 
expression compared to expression levels found in mESCs cultured in unconditioned 
media and LIF (Welham et al., 2007). Even conditioned media made in the absence of 
LIF, leads to a small increase in Nanog expression when used to culture fresh mESCs 
and a significant increase when LIF is added after conditioning (Welham et al., 2007).  
 
Human ESCs have also been reported to exhibit paracrine signalling, necessary for 
survival and maintenance of self-renewal (reviewed by Stewart et al., 2008). FGF2, 
known to promote self-renewal of hESCs, was reported to induce the expression of 
TGFβ family members, notably BMP4, by MEFs (Greber et al., 2007). This report 
suggests that MEF’s support hESC self-renewal by expressing self-renewal promoting 
factors in response to FGF2. Furthermore, hESC-derived fibroblast-like cells were 
demonstrated to express insulin-like growth factor 2 (IGF-2), to maintain the survival of 
hESCs, in response to FGF (Bendall et al., 2007). This reciprocal paracrine signalling 
of IGF-2 and FGF between hESCs and hESC-derived fibroblast-like cells was reported 
to maintain hESCs in an undifferentiated state (Bendall et al., 2007). Therefore, it is 
likely that ESCs secrete factors that aid survival and maintain self-renewal via 
autocrine and paracrine signalling.  
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1.3.4.6 MAPK pathway signalling promotes differentiation 
 
Six distinct classes of mitogen activated protein kinases (MAPKs) exist and all respond 
to extracellular stimuli, mitogens. In mESC signalling, the classical MAPKs, 
Extracellular signal-regulated kinases Erk1 and Erk2 along with p38 isoforms have 
been reported to be active. Erk and p38 MAPK signalling is important for proliferation in 
many other cell types (reviewed by Roux and Blenis, 2004). However, Burdon et al., 
demonstrated that pharmacological inhibition of Mek (MAPK Erk Kinase) with 
PD098059 in mESCs did not affect the propagation of cells, in fact, inhibition of Erk 
activation enhanced self-renewal (Burdon et al., 1999).  
 
Erk1/2 activity can be stimulated by fibroblast growth factor 4 (FGF4) in mESCs 
(Kunath et al., 2007) and, interestingly, FGF4 is secreted by undifferentiated cells (Ma 
et al., 1992, Rathjen et al., 1999). However, mESCs lacking FGF4 do not form neural 
or mesodermal lineages, thus FGF4 and Erk signalling is required for complete lineage 
commitment (Kunath et al., 2007). In agreement with this research, Stavridis et al., 
2007 demonstrated that FGF-induced Erk1/2 signalling is required during neural 
specification, albeit for a discrete stage-dependent period. Activation of Ras/Erk 
signalling via Grb2 and SHP-2 is also necessary for lineage commitment (Fukada et 
al., 1996, Ernst et al., 1996). Grb2-null ESCs lack the ability to differentiate into 
endoderm (Cheng et al., 1998). Consistent with this, transfection with constitutively 
active Mek induced primitive endoderm differentiation. What is more, the Grb2/Mek 
pathway was shown to repress Nanog expression following induction of MAPK 
signalling by sodium vanadate or by cell aggregation (Hamazaki et al., 2006). 
 
Early embryogenesis can be modelled using pluripotent, self-renewing ESCs. To form 
embroyid bodies, ESCs are allowed to aggregate and are provided with vital 
differentiation inducing factors. Embryoid bodies have significant morphological and 
gene expression pattern similarities with early embryos (Desbaillets et al., 2000). 
Retrospectively, the formation of embryoid bodies and the expression of marker genes 
from each of the three primitive layers can be used to confirm the pluripotency of 
ESCs. Embryoid body formation using ESCs expressing a truncated FGF receptor 2 
mutant failed to yield epithelial differentiation (Chen et al., 2006). In accordance, the 
inhibition of Mek following embryoid body formation was shown to prevent 
differentiation (Burdon et al., 1999). Expression of a mutant activated form of Ras in 
mESCs results in reduced self-renewal marker expression. Consistent with this, Ras 
was found to be activated in embryoid body differentiation. The Raf/Mek/Erk pathway 
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was shown to mediate Ras-activated differentiation towards extraembryonic endoderm 
(Yoshida-Koide et al., 2004). 
 
A peak in p38 MAPK activity was noted between 3 and 4 days after LIF withdrawal and 
at day 5 of embryoid body formation (Aouadi et al., 2006). Additionally, ESCs lacking 
p38α, a member of the p38 MAPK family, exhibited decreased cardiomyogenesis but 
enhanced differentiation towards neural cell types in vitro. In vivo, deletion of p38α was 
embryonic lethal at E11.5-12.5 (Tamura et al., 2000) indicating that p38α is required for 
normal embryo development and maintenance of pluripotency. Consistent with p38 
activity being associated with a loss of self-renewal, inhibition of p38 MAPK allowed an 
ESC line to be derived from blastocysts lacking the type I BMP receptor BmprIa (Qi et 
al., 2004). Thus, activation of MAPKs promotes differentiation by a number of 
mechanisms, including cross-talk with signalling pathways that promote self-renewal. 
MAPK signalling in mESCs is summarised in (Figure 1.15). 
 
Given that MAPK signalling is activated by secreted factors and even by LIF, the major 
promoter of mESC self-renewal, and activation of MAPK signalling promotes 
differentiation, it follows that this pathway is tightly regulated by cross-talk with self-
renewal promoting pathways. Consistent with this notion, it was proposed that mESC 
fate is determined by a fine balance between Stat3 and Erk signalling, positive and 
negative regulators of self-renewal respectively (Burdon et al., 1999, Niwa et al., 1998). 
BMP4 exerts its self-renewal-promoting effects in part by inhibiting both Erk and p38 
MAPK via XIAP (X-linked inhibitor of apoptosis) (Figure 1.15) (Qi et al., 2004). XIAP 
expression is enhanced when BMP4 is added to culture media and links BMP type 1 
receptors to p38 MAPK (Yamaguchi et al., 1999). Additionally inhibition of PI3Ks 
enhances basal Erk activity suggesting a dampening effect on the MAPK pathway by 
PI3K activity may exist in mESCs (Paling et al., 2004). Therefore, LIF and cytokine-
induced activation of Erk is regulated by other signalling pathways in order to maintain 
a balance of self-renewal promoting signalling. 
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Figure 1.15 MAPK signalling and regulation in mESCs 
MAPK signalling via the classical Erk1 and Erk2 MAPKs or via p38, promotes 
differentiation in a number of ways. BMP mediates its effects on self-renewal via Smad 
activation (described fully in the text, Section 1.3.4.3 and Figure 1.13). Smad pathway 
activity is inhibited by Erk, and p38 may also exhibit cross talk with the BMP/Smad 
pathway. Reciprocally, MAPKs can be inhibited by XIAP (X-linked inhibitor of 
apoptosis) following stimulation of the BMP receptor. 
 
 
1.3.4.7 Glycogen synthase kinase-3β and mESC fate 
 
Glycogen Synthase Kinase-3β (Gsk-3β) is part of the canonical Wnt pathway, in which 
the transcription factor β-catenin regulates the expression of Wnt target genes (Figure 
1.16). Briefly, the canonical Wnt pathway involves the stabilisation of β-catenin present 
in the cytoplasm. β-catenin uses the scaffold proteins adenomatous polyposis coli 
(APC) and Axin to complex with casein kinase Iα (CKIα) and Gsk-3β. These kinases 
phosphorylate β-catenin, marking it for ubiquitination and proteasomal degradation. 
When Wnt ligands bind to a Frizzled family receptor and low-density lipoprotein 
receptor-related protein LRP-5/6/arrow family co-receptor, a signalling cascade 
involving over 50 known components is initiated. Of these known components, the 
functions of those contributing to the canonical Wnt signalling pathway are best 
characterised. LRP is phosphorylated by CKIγ and Gsk-3β at the membrane. 
Phosphorylation of LRP provides a binding site for Axin which subsequently docks at 
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the membrane. Dishevelled protein associates with the Frizzled receptor and Axin, 
increasing the affinity of Dishevelled for Gsk-3β. Thus, the APC/Axin/CKIα/Gsk-3β 
destruction complex dissociates leading to the accumulation of cytoplasmic β-Catenin. 
Interaction with T-cell factor and Lymphoid enhancer factor (TCF/LEF) family of 
transcription factors allows β-catenin to bind to Wnt-responsive genes. Interaction with 
β-catenin removes transcriptional repression applied by TCF/LEF transcription factors 
and allows the transcription of genes such as c-Myc and CyclinD1 (Eisenmann, 2005, 
Kestler and Kühl, 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16 The cannonical Wnt pathway 
Prior to a Wnt signal (left panel), a destruction complex of APC, Axin, CKIα, Gsk-3β 
forms and phosphorylates β-catenin for ubiquitination. TCF and LEF family 
transcription factors inhibit the transcription of Wnt target genes. Upon Wnt ligand 
binding (right panel) to the Frizzled receptor, the destruction complex dissociates and 
components associate with Dishevelled and Frizzled at the plasma membrane. 
Accumulation of β-catenin induces translocation to the nucleus, where β-catenin 
interacts with target genes to allow transcription. Adapted from Eisenmann, 2005, 
Kestler and Kühl, 2008.  
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Conditioned medium from cells expressing Wnt3a applied to mESCs supported the 
growth, maintenance of pluripotency and maintenance of self-renewal in the absence 
of LIF (Singla et al., 2006). Wnt5a and Wnt6 are also reported to promote self-renewal 
of cultured mESCs (Hao et al., 2006). Additionally, the canonical Wnt pathway was 
reported to be fully functional in mESCs and found to induce the expression of the self-
renewal marker Rex1 (Sato et al., 2004). In mESCs deficient for β-catenin, the 
expression of Rex1 is reduced but negligible changes in the expression of Nanog, 
Sox2 and Id genes were reported (Anton et al., 2007). Consistent with a lack of change 
in the expression of transcription factors important for maintaining the undifferentiated 
state, β-catenin-null mESCs maintained self-renewal and pluripotency in culture (Anton 
et al., 2007). However, a conditional activation mutant of β-catenin, that allows 
translocation to the nucleus, was sufficient to support mESC self-renewal in the 
absence of LIF (Hao et al., 2006). In the same investigation, Wnt3a treatment of 
mESCs induced enhanced Stat3 mRNA and protein levels, which were shown to be 
the result of activated β-catenin. These results suggest that Wnt and LIF-induced 
signalling promote self-renewal and converge on Stat3 in order to do so (Hao et al., 
2006). Withdrawal of LIF induces a down-regulation of Nanog and β-catenin within 3 
days, however Oct-4 down-regulation does not occur until day 6. Oct4 and β-catenin 
have been shown to associate and sustain Nanog expression in order to contribute to 
the maintenance of self-renewal (Takao et al., 2007). 
 
β-catenin is not the only substrate of Gsk-3, others have been identified such as 
glycogen synthase (GS) and eukaryotic protein synthesis initiation factor-2B (eIF-2B). 
Stimulation of cells with growth factors results in the phosphorylation and inactivation of 
Gsk-3 via PI3K/PKB (Cross et al., 1995). In the absence of growth factor stimulation, 
when Gsk-3 is active, Gsk-3 phosphorylates and inactivates GS and eIF-2B to inhibit 
glycogen and protein synthesis (Cohen et al., 1997, Doble and Woodgett, 2003). Gsk-3 
has been shown to phosphorylate Smad1 in mESCs thereby preventing the nuclear 
accumulation of Smad complexes (Fuentealba et al., 2007). Further to this, others have 
reported Wnt signalling in differentiation processes. APC-deficient mESCs, or 
expression of a dominant negative form of β-catenin in mESCs, prevents differentiation 
towards neural lineages. Consistent with this, a reduction in the expression of BMP-4 in 
APC-deficient mESCs compared to wild-type mESCs is observed (Haegele et al., 
2003). An endogenous antagonist of Wnt signalling, Dickkopf-1, was shown to be 
necessary for the induction of neural differentiation. Dickkopf-1 is a secreted 
glycoprotein that interacts with LRP-5/6 inducing endocytosis of the co-receptor of Wnt 
signalling (Mao et al., 2002). Dickkopf-1 is induced in embryoid body formation 
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following exposure of embryoid bodies to retinoic acid, a method of inducing neural 
differentiation (Verani et al., 2000).  
 
In the regulation of mESCs, both the canonical and alternative pathways involving  
Gsk-3 and Wnt signalling have been identified. Alternative pathways involving Gsk-3 in 
mESCs are discussed in Section 1.3.6.1. 
 
 
It is widely accepted in the stem cell field that multiple pathways contribute to the 
maintenance of self-renewal and pluripotency of ESCs. Much emphasis is placed on 
balancing signalling promoting self-renewal with signalling promoting differentiation in 
order that self-renewal is maintained. Consequently, a “ground state” of pluripotency 
was hypothesised (Ying et al., 2008). Smith and co workers sought to investigate the 
default fate of mESCs if self-renewal promoting signals (FGF4, Stat3 and Gsk3) and 
differentiation promoting signals (Erk) were removed. In a serum and LIF-free media 
containing the FGF receptor inhibitors PD184352 and SU5402, plus the Gsk-3 inhibitor, 
CHIR99021, it was reported that undifferentiated mESCs could be continually cultured 
and expanded. Additionally, this media was reported to sufficiently support the 
derivation of mESCs from blastocyst stage embryos (Ying et al., 2008). Thus, authors 
demonstrated that in the absence of Stat3, Erk and Gsk-3 signalling and in the 
absence of autocrine FGF4 signalling, mESCs adopt a self-renewing, pluripotent 
ground state. This observation was suggested to be an intrinsic self-maintaining 
mechanism and a feature of mESCs in culture. Furthermore, the same group reported 
that the dual inhibition of Mek, upstream of Erk, and Gsk-3 with PD0325901 and 
CHIR99021 respectively supported efficient reprogramming of brain-derived neural 
stem cells into iPSCs following transfection with Klf4 and Oct4 (Silva et al., 2008). 
However, LIF was required, in conjunction with these two inhibitors, in order to 
establish fully reprogrammed iPCSs, suggesting that Stat3 signalling is not entirely 
dispensable particularly for reprogramming. These observations indicate that the 
pluripotent ground state, observed in ESCs in the absence of fate-determining 
signalling, can be recaptured following induction of differentiated cells towards induced 
pluripotent cells. 
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1.3.4.8 Transcriptional regulation of self-renewal 
 
Extrinsic factors present in culture media and secreted by ESCs activate an array of 
intracellular signalling pathways. These pathways have been shown to maintain self-
renewal by; balancing signals that promote differentiation to particular lineages, 
inhibition of differentiation, promotion of proliferation and promotion of cell survival. 
Together these signalling pathways regulate a transcriptional network of core 
regulators, namely transcription factors, some of which are used as markers of self-
renewal (discussed in Section 1.3.4.1).  
 
In ESCs, the level of Oct4 expression controls lineage commitment rather than self-
renewal directly. Cells isolated from the blastocyst stage of Oct4-null embryos are not 
pluripotent, instead these cells represent those of extraembryonic trophectoderm 
(Nichols et al., 1998). Over-expression of Oct4 induces primitive endoderm and 
mesoderm differentiation while suppressed expression induces trophectoderm 
production (Niwa et al., 2000). Thus, up-regulated expression of Oct4 alone can not 
relieve the requirement for LIF and therefore does not support self-renewal. 
 
Nanog appears to be a master regulator of self-renewal. Unlike Oct4, over-expression 
of Nanog in mESCs, allows self-renewal to be maintained even in the absence of LIF 
(Mitsui et al., 2003, Chambers et al., 2003). Moreover, over-expression of Nanog can 
delay retinoic acid-induced differentiation. In the absence of Nanog, ESCs differentiate 
towards extraembryonic endodermal lineages (Mitsui et al., 2003). Nanog was 
identified in a screen for genes expressed exclusively in ESCs that acted 
independently of the LIF/Jak/Stat pathway. Each of the nine genes identified were 
expressed constitutively in ESCs but only Nanog could maintain self-renewal in the 
absence of LIF (Mitsui et al., 2003). Nanog is reported to form homodimers by self-
association of a region of Nanog protein that displays a tryptophan repeat every fifth 
residue (Mullin et al., 2008). Furthermore, this region of Nanog protein was 
demonstrated to be functionally critical for Nanog transcriptional activity, required for 
the maintenance of mESC self-renewal (Mullin et al., 2008). In an independent study, 
Nanog was reported to both positively and negatively regulate expression of target 
genes by the formation of a homodimer (Wang et al., 2008). Indeed forced expression 
of dimerised Nanog, connected via C-terminal domains, maintained self-renewal in the 
absence of endogenous Nanog and in the absence of LIF (Wang et al., 2008). 
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Nanog and Oct4 have been reported to form a weak or transient complex to allow co-
binding to numerous sites within the mESC genome for both activation and 
suppression of transcription (Zhang et al., 2007). The products of some genes bound 
by Nanog and Oct4 are down-regulated upon induced differentiation, consistent with a 
decrease in expression of Nanog and Oct4 themselves (Loh et al., 2006). Inducible 
Sox2-null ESCs exhibit a loss of self-renewal coupled with the expression of 
trophectoderm markers. It was noted that forced expression of Oct4, rescued Sox2-null 
ESC pluripotency. Furthermore, Oct4 and Sox2 were shown to cooperatively activate 
enhancers of ESC-specific genes, including Nanog, Oct4 and Sox2 (Masui et al., 
2007). Consistent with this, Oct4 and Sox2 were found to co-bind the Nanog promoter 
in both mouse and human ESCs, to enhance Nanog mRNA expression (Rodda et al., 
2005).  
 
Kruppel-like factor 4 (Klf4) was shown to cooperate with both Oct4 and Sox2 to activate 
the core promoter of Lefty1, a target gene of Oct4 (Nakatake et al., 2006). Interestingly, 
although Klf4 was reported to be dispensable for maintaining the undifferentiated state 
of mESCs (Nakatake et al., 2006), the importance of Klf4 in inducing pluripotency in 
somatic cells is increasingly apparent (Lin et al., 2005, Takahashi and Yamanaka, 
2006, Takahashi et al., 2007, Silva et al., 2008). Consistent with this, Klf2, Klf4 and Klf5 
were demonstrated to be functionally redundant but simultaneous knockdown of all 
three of these Klf family members resulted in the differentiation of ESCs (Jiang et al., 
2008). Furthermore, Klf4 was reported to not only share common targets with Nanog 
but also to bind genes encoding transcription factors important for maintaining self-
renewal, including Pou5f1, Nanog and Sox2 (Jiang et al., 2008). Interestingly, Nanog 
and Sox2 appear to regulate Rex1 transcription by binding to the Rex1 promoter. 
Indeed, Nanog was shown to promote Rex1 expression in differentiated cells as well as 
ESCs by co-transfection of Rex1 and Nanog genes (Shi et al., 2006a). Additionally, 
Oct4 is also reported to promote Rex1 expression in ESCs (Ben-Shushan et al., 1998). 
 
Alongside promoting the expression of pluripotency genes, Oct4 also acts to repress 
differentiation. FoxD3, a member of the forkhead box (Fox) family of transcription 
factors is implicated in early linage commitment, particularly endodermal differentiation 
(Hromas and Costa, 1995). Oct4 was shown to interact with the DNA-binding domain 
of FoxD3 thereby preventing FoxD3 from binding lineage-specific gene promoters (Guo 
et al., 2002). Additionally, Nanog is known to repress differentiation and early lineage 
commitment genes GATA1 and GATA6 (Chambers et al., 2003, Mitsui et al., 2003).  
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Further genes that contribute to maintaining self-renewal have also been identified. 
These genes, Esrrb, Tbx3 and Tcl1, were down-regulated following induced 
differentiation (Ivanova et al., 2006). Interference of these three genes with short-
hairpin RNA (shRNA) was used to ascertain their roles in maintaining self-renewal and 
knock-down of Esrrb was found to prevent differentiation of embryoid bodies towards 
neuroectodermal and mesodermal lineages. In contrast, forced expression of Sox2 and 
Tbx3 prevented mesodermal differentiation, while Tcl1 was shown to prevent the 
expression of certain neural crest genes. However, over-expression of Nanog could 
overcome the effects of reduced Esrrb, Tbx3 and Tcl1 expression, further confirming 
Nanog as one of the master regulators of self-renewal (Ivanova et al., 2006).  
 
Much evidence exists to support the fact that the major pluripotency-maintaining 
transcription factors act as a gene regulatory network to control pluripotency at a 
transcriptional level (reviewed by Niwa, 2007). Furthermore, extrinsic factors present in 
culture medium and secreted by ESCs activate a network of signalling pathways that 
converge in the nucleus at a seemingly minimal number of transcription factors. The 
activity of the main transcription factors, Nanog, Sox2 and Oct4, appear to regulate 
both their own expression and expression of genes for self-renewal and lineage 
directed differentiation. This observation was incorporated into a model by Niwa et al., 
which encompasses self-renewal and proliferation governed by epigenetic processes, 
which in turn are under the control of a transcription factor network found in pluripotent 
cells (Niwa, 2007). In light of this, Yamanaka et al., sought to identify the fewest 
number of genes that could be used to revert differentiated somatic cells into cells with 
stem cell-like properties. Forced expression using viral-mediated transduction of Oct4, 
Sox2, Klf4 and c-Myc reprogrammed a subpopulation of mouse and human fibroblasts 
to ESC-like cells known as induced pluripotent stem cells (iPSCs) (Takahashi and 
Yamanaka, 2006, Takahashi et al., 2007) Of interest, Nanog appears to be 
dispensable in this reprogramming cocktail of genes. Although, it was suggested that 
Nanog expression in iPSCs might arise by the suppression of p53 by Klf4, since Nanog 
expression is repressed by p53 following DNA damage (Lin et al., 2005). Interestingly, 
c-Myc activation is reported to result in the differentiation of hESCs (Sumi et al., 2007) 
and reprogramming without c-Myc proved to be possible but less efficient (Nakagawa 
et al., 2008). In a separate study, Oct4, Sox2, Nanog and Lin28 were demonstrated to 
be sufficient to reprogram human fetal and postnatal fibroblasts, and human ESC-
derived somatic cells towards pluripotent cells with ESC morphology, hESC marker 
expression and normal karyotypes (Yu et al., 2007). Lin28 was included by this group 
since it encodes a DNA modifying protein which is expressed in undifferentiated hESCs 
but upon differentiation Lin28 expression is decreased (Richards et al., 2004). 
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However, it was observed that Lin28 was absent in some of the iPSC clones generated 
by retroviral transduction, indicating that Lin28 is not essential for reprogramming 
human somatic cells (Yu et al., 2007). 
 
Selection of iPSCs from the total population by detection of endogenous Oct4 or Nanog 
is reported to be the most efficient way of selecting iPSCs. Following selection, iPSCs 
are demonstrated to display properties that are thus far indistinguishable from ESCs 
(Okita et al., 2007). Pluripotency markers such as alkaline phosphatase, endogenous 
Oct4 and Nanog are sequentially activated in mouse somatic cells following induction 
towards iPSCs. The time course for these pluripotency markers to be detected, 10-30 
days after transfection, indicates that reprogramming is a slow and complex process for 
cells to undergo and one that requires forced conditions (Brambrink et al., 2008). 
Nevertheless, iPSCs demonstrate the ultimate control over cell fate that core 
pluripotency regulating transcription factors have in ESCs. 
 
 
1.3.5 Murine embryonic stem cell proliferation 
 
ESCs have the capacity to undergo continuous division with great proliferation 
potential. Indeed the transplanting of self-renewing ESCs into adult mice produces the 
formation of tumours, containing all three germ layers called teratomas (Martin and 
Evans, 1975, Martin, 1980). Unsurprisingly, this perpetual proliferation has been 
likened to the aggressive growth of cancerous tumours resulting from uncontrolled 
proliferation of tumour cells. However, ECCs, isolated from teratomas, contain 
chromosome abnormalities but ESCs, derived from the ICM of a blastocyst, have no 
genetic abnormalities.  
 
Mammalian cells require cues from growth factors to pass the G1 phase of the cell 
cycle. In the absence of growth factors, mammalian cells exit G1 phase and enter G0 
quiescence (Pardee, 1989). However, ESCs are unlike other mammalian cell types in 
that they have a short G1 phase and do not enter quiescence. ESCs rapidly proliferate, 
with a cell cycle time of 10 hours, and an observed 70% of ESCs are in S-phase of the 
cell cycle at any given time (Sun et al., 1999, Savatier et al., 1994). In differentiated cell 
types, retinoblastoma protein (RP) is reported to be important for G1/S transition, in that 
hypophosphorylated RP, found in G1 phase cells, sequesters E2F transcription factors 
and, as a result, inhibits the expression of genes required for entry into S phase 
(Harbour et al., 1999). Phosphorylation of RP by complexes of cyclins and cyclin-
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dependent kinases (CDKs) allows the release of some E2F transcription factors and 
subsequent transcription of cyclin E and cdc25A genes. Inhibitory phosphatases are 
removed from CDK2 by the cdc25A phosphatase allowing CDK2 to form a complex 
with Cyclin E, which further phosphorylates RP. The remaining sequestered E2F is 
released prompting transcription of target genes and entry of cells into S phase 
(reviewed by Bartek and Lukas, 2001, Harbour and Dean, 2000). However, in ESCs 
hypophosphorylated RP was reported to be undetectable with RP seemingly 
constitutively phosphorylated, leading authors to suggest that either RP was 
rephosphorylated immediately after mitosis in ESCs or that ESC cell cycle regulation 
was RP-independent (Savatier et al., 1994, Burdon et al., 2002). It is likely that ESCs 
do not depend on RP regulation for cell cycle control since disruption of RP or two RP-
related genes did not significantly affect mESC proliferation (Dannenberg et al., 2000, 
Sage et al., 2000). Additionally, in contrast to differentiated cell types, ESCs display low 
expression of cyclin D1, which may explain the observed constitutive phosphorylation 
of RP in ESCs. Furthermore, cyclin D1 protein levels are reported to be independent of 
regulation by Ras/Erk signalling but dependent on PI3K activity, and to be uncoupled 
from specific mitogen activation (Jirmanova et al., 2002).  
 
Uniquely, serum withdrawal does not substantially alter ESC proliferation (Schratt et 
al., 2001) but does down-regulate Erk activity (Lianguzova et al., 2007). However, 
activation of the classical MAPK pathway is not required for G1 to S phase progression 
in ESCs. In fact, inhibition of Mek does not alter the proliferation rate of ESCs 
(Jirmanova et al., 2002), while inhibition of Mek or p38 was not sufficient to change the 
proportion of cells in G1 or S phases (Lianguzova et al., 2007, Fluckiger et al., 2006). 
Consistent with this, expression of inactive Grb2 in ESCs does not affect proliferation 
(Cheng et al., 1998). Mitogenic stimuli are not required for S-phase entry, explaining 
the shortened G1 phase characteristic of ESCs. Uncoupling of cell cycle control from 
the MAPK pathway, a usual activator of proliferation in other cell types, explains the 
ability of mESCs to proliferate in the absence of serum or growth factors (Lianguzova 
et al., 2007, Burdon et al., 1999). Furthermore, mouse embryos deficient for serum 
response factor (SRF), which regulates gene activation depending on the stage of the 
cell cycle, grow and develop normally until E6, and ESCs derived from these embryos 
exhibit normal proliferation rates and unaltered cell cycle progression (Schratt et al., 
2001). 
 
Having ascertained that typical mitogen-activated Ras/Erk signalling did not regulate 
mESC proliferation, research focus turned to mTOR, which activates S6K and S6, a 
pathway known to be important for protein synthesis and cell growth (Abraham, 1996). 
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It was demonstrated that the expression of mTOR was greatest in ESCs, testis and 
kidneys (Murakami et al., 2004). Induced inactivation of mTOR in ESCs or inhibition 
with rapamycin resulted in severely limited proliferation (Murakami et al., 2004). 
Consistent with the findings in ESCs, studies on mTOR deficient mouse embryos 
revealed embryonic lethality due to impaired cell proliferation and a failure of cells of 
the ICM to proliferate (Murakami et al., 2004, Gangloff et al., 2004). 
 
1.3.6 The role of PI3K in mESC fate 
 
During the pre-implantation stage of embryo development, the cells comprising the 
embryo depend on both autocrine and paracrine factors for growth and development. 
p85 and p110 PI3K isoforms are expressed and localised to the plasma membrane of 
embryos from the one-cell stage to the blastocyst stage of development (Riley et al., 
2005). More importantly, using GFP-tagged PH domains to monitor PI(3,4,5)P3 
synthesis, PI3Ks were demonstrated to be functionally active in one-cell embryos 
through to early blastocyst stage embryos (Halet et al., 2008). To date, two roles for 
PI3K in mESCs have been described: the maintenance of self-renewal and the 
regulation of proliferation. 
 
1.3.6.1 The contribution of PI3K to self-renewal 
 
Accruing evidence defining the role of PI3Ks in self-renewal comes from the use of a 
number of techniques (summarised in Figure 1.17). Treatment of mESCs with 5µM 
LY294002 led to a reduction in alkaline phosphatase staining and a change in ESC 
morphology to that resembling differentiated cells (Paling et al., 2004). Consistent with 
these findings, embryoid body formation can be inhibited by the presence of LY294002 
(Chen et al., 2000). Treatment with LY294002 was also shown to decrease Nanog 
RNA levels in mESCs after 48 hours and protein levels within 8 hours (Storm et al., 
2007). LIF was shown to activate signalling downstream of PI3Ks, namely PKB, Gsk-3 
and S6. Activation of these signalling molecules down stream of PI3Ks by LIF was 
shown to be inhibited by pre-treatment with LY294002 (Paling et al., 2004). Consistent 
with the involvement of PI3Ks in self-renewal, a gain-of-function screen for genes that 
when over-expressed could maintain self-renewal in the absence of LIF, highlighted 
PKB as one such gene (Pritsker et al., 2006). Adding weight to this, expression of a 
myristolated, active form of PKB was reported to promote self-renewal in the absence 
of LIF (Watanabe et al., 2006). 
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Gsk-3 is known to participate in signalling networks other than the canonical Wnt 
pathway. For example, Gsk-3 is negatively regulated by PI3K-induced PKB activity 
following insulin stimulation (Cross et al., 1995). Negative regulation of Gsk-3 requires 
phosphorylation at serine 21 (Ser21) for Gsk-3α and serine 9 (Ser9) for Gsk-3β. In 
PDK1-null ESCs, Gsk-3 is not phosphorylated and thus remains active (Williams et al., 
2000). An inhibitor of Gsk-3, 6-bromoindirubin 3’-oxime (BIO), which is derived from 
mollusc Tyrian Purple (Meijer et al., 2003), mimics the actions of PKB on Gsk-3. 
Treatment with BIO results in the up-regulation of Rex1 expression and activation of 
Wnt signalling and has been reported to enhance self-renewal of mESCs in the 
absence of LIF (Sato et al., 2004). Additionally, BIO treatment reverses the effects of 
LY294002 on Nanog protein expression levels (Storm et al., 2007) (Figure 1.17). A 
series of bisindolylmaleimides, which inhibit Gsk-3, were analysed alongside BIO and 
were also shown to enhance self-renewal of mESCs (Bone et al., 2009). Expression of 
an activated form of Gsk-3β in mESCs reduced Nanog expression, consistent with the 
non-phosphorylated form being in an active state. Expression of a dominant negative 
form of Gsk-3β, which imitates the effects of Gsk-3 inhibitors, enhanced Nanog 
expression (Storm et al., 2007). The link between Nanog and PI3K was strengthened 
by the findings that LY294002 reduced the expression of Nanog target genes. 
Conversely, induced expression of Nanog rescued the effect of LY294002 on self-
renewal (Storm et al., 2007).  
 
The tumour suppressor p53 responds to cell stress and induces pro-apoptotic 
signalling. Gsk-3 is reported to phosphorylate and interact with p53 in the nucleus, 
leading to cytoplasmic localisation and the prevention of p53-induced apoptosis (Qu et 
al., 2004). However, in mESCs, DNA damage results in enhanced p53 protein levels 
and decreased Nanog mRNA expression after just 4 hours, a feature not observed in 
p53 null ESCs. Furthermore, p53 was found to bind the Nanog promoter and inhibit 
expression of Nanog following induced DNA damage or retinoic acid-induced 
differentiation (Lin et al., 2005). Taken together, these reports indicate that PI3Ks 
maintain self-renewal via PKB and possibly via Gsk-3, although Gsk-3 is also regulated 
by other signalling pathways.  
 
Inhibition of PI3Ks with LY294002 was also found to lead to an enhancement in Erk 
phosphorylation in mESCs (Paling et al., 2004). Activation of this pathway is reported 
to induce differentiation (Burdon et al., 1999). Treatment with both LY294002 and 
U0126, an inhibitor of Mek, reversed the effect of reduced alkaline phosphatase 
staining observed with LY294002 alone (Paling et al., 2004). However, U0126 was not 
sufficient to reverse the effect of LY294002 on Nanog expression (Storm et al., 2007). 
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Nevertheless, these results suggest that PI3Ks may promote self-renewal, at least in 
part, by regulation of the MAPK pathway.  
 
The class IA PI3Ks were implicated in regulating mESC self-renewal by the expression 
of an inducible dominant negative form of p85, which lacks the p110 binding site (Hara 
et al., 1994). This dominant negative mutant, ∆p85, acts as a competitive inhibitor of 
p110 isoforms. Induced expression of ∆p85 in mESCs reduces PKB, Gsk-3 and S6 
phosphorylation and results in a reduction in the percentage of alkaline phosphatase 
positive colonies, consistent with a loss of self-renewal (Paling et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.17 Evidence of a role for PI3Ks in maintaining mESC self-renewal 
PI3Ks have been shown to participate in maintaining the undifferentiated state of 
mESCs. The approaches taken to reveal this role for PI3K are shown in grey boxes 
and referred to in the text. PI3K appears to maintain self-renewal via PKB and Gsk-3 
and may prevent differentiation by exerting an inhibitory effect on MAPK signalling. 
 
 
1.3.6.2 The role of PI3K in mESC proliferation 
 
The tumour-like growth properties observed in ESCs might be partly attributed to the 
activity of PI3Ks (summarised in Figure 1.18). Unconvincing evidence of a role for 
PI3Ks in mESC proliferation came from the use of 20-40µM LY294002 which yielded 
only a small increase in the proportion of cells in G1 phase and a reduction in cell 
growth following 48 hours treatment (Lianguzova et al., 2007). Additionally, an increase 
in mESCs in G1 phase following 24-hour treatment and a dramatic reduction in cell 
growth after 4 days treatment was reported using 25µM LY294002 (Jirmanova et al., 
2002). Such concentrations of LY294002 are likely to have strong off-target effects 
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which could be toxic to cells, explaining the results obtained. Notably, inhibition of 
mTOR is evident at 1-30µM LY294002 (Brunn et al., 1996) and mTOR has been 
demonstrated to be essential for the proliferation of mESCs (Murakami et al., 2004). 
 
Paling et al., demonstrated that the metabolic activity of mESCs was unchanged using 
modest doses of LY294002 (less than 10µM) and that growth rates were unaffected by 
5µM LY294002 (Paling et al., 2004). Additionally, 5µM is close to the published IC50 
value for PI3Ks (Knight et al., 2006, Vlahos et al., 1994) and effects on PI3K effector 
phosphorylation are visible at this concentration in mESCs (Paling et al., 2004, Storm 
et al., 2007). Furthermore, LIF is important to maintain self-renewal and is reported to 
activate PI3Ks in ESCs. However, LIF concentration had little or no effect on the 
proliferation rate of a number of mESC lines (Raz et al., 1999). Interestingly, 10µM 
LY294002 treatment of embryos from the one-cell stage resulted in only 40% of 
embryos surviving to the 8-cell stage and only 10% surviving to the blastocyst stage of 
development. Importantly, this developmental restriction imposed by PI3K inhibition 
with LY294002 was not attributable to apoptosis (Halet et al., 2008).  
 
More convincing evidence of a role for PI3Ks in mESC proliferation can be drawn from 
the characteristics of the tumour suppressor PTEN, a regulator of cellular PI(3,4,5)P3 
levels and thus a negative regulator of PI3K activity (Figure 1.5). Mutations or deletions 
of PTEN are often associated with human cancers (Li et al., 1997, Cantley and Neel, 
1999). PTEN-deficient ESCs exhibit a faster growth rate and maintained growth even in 
the absence of serum. The mechanism of enhanced growth rate is attributed to 
reduced levels of p27KIP1, a cyclin-dependent kinase inhibitor which inhibits G1 cell cycle 
kinases that promote S-phase entry (Sun et al., 1999). Reduced expression of p27KIP1 
can arise due to phosphorylation and inhibition of forkhead transcription factors of the 
FOXO family by PKB (Stahl et al., 2002). In particular, FoxO3 has been implicated in 
interleukin-2 induced phosphorylation and subsequent regulation of p27KIP1 expression 
(Stahl et al., 2002). Although, activated PKB is reported induce phosphorylation of 
p27KIP1 leading to cytosolic sequestration, prevention of nuclear localisation and 
attenuating the cell-cycle inhibitory effects of p27KIP1 (Liang et al., 2002, Shin et al., 
2002, Viglietto et al., 2002). Furthermore, PKB activity is implicated in maintaining cell 
survival by negative regulation of the Bcl-2 family of pro-apoptotic proteins. For 
example, PKB-mediated phosphorylation of the Bcl-2 family member, BAD, induces 
binding of 14-3-3 proteins to BAD, releasing BAD from its target proteins (Datta et al., 
2000). Constitutive expression of Bcl-2 in a transgenic mESC line reportedly supported 
the proliferation of mESCs in the absence of feeder cells or serum, however LIF was 
still required to maintain self-renewal and pluripotency (Yamane et al., 2005). 
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The activity of PI3Ks and subsequent downstream effectors such as PKB are 
enhanced in PTEN-null ESCs (Williams et al., 2000, Sun et al., 1999). In mESCs 
deficient in both PTEN and PKB, phosphorylation of Gsk-3β and S6K was reduced and 
cell growth was slower than either wild-type or PTEN-null cells. Unlike PTEN knockout 
ESCs, that form rapidly proliferating teratomas when injected into adult mice, 
PTEN/PKB double knockout ESCs formed teratomas with slower growth rates. 
However, these teratomas contained more differentiated cell types compared to 
teratomas formed from wild-type ESCs (Stiles et al., 2002).  
 
If PTEN is important for regulating PI3K-induced proliferation in ESCs but serum or 
growth factors are not essential for ESC proliferation, how is PI3K activated? In a 
screen for genes expressed exclusively in ESCs, but not in differentiated cells, a Ras-
like gene with 40-50% homology to Ras isoforms (HRas, KRas and NRas) was 
identified. This Ras-like gene, termed ERas (Takahashi et al., 2003), contains amino 
acid residues akin to those in activated, oncogenic HRas mutants, commonly found in 
human tumours (Fasano et al., 1984). ERas was confirmed to be predominantly GTP-
bound and therefore active in both human and mouse ESCs. Over-expression of ERas 
in ESCs further enhances growth rates and transfection with antisense ERas cDNA 
significantly suppresses cell growth (Takahashi, 2003). ERas localises to the plasma 
membrane where it interacts with PI3Ks to promote PKB phosphorylation (Takahashi et 
al., 2005). In ERas-null ESCs, the level of PKB phosphorylation was reduced 
compared to wild-type ESCs. Both the reduced levels of PKB phosphorylation and the 
proliferative defects observed in ERas-null ESCs could be rescued by the forced 
expression of a myristolated, active form of p110 (Takahashi et al., 2003).  
 
ESCs were found to express very low levels of p85α and targeted deletion of p85α in 
ESCs resulted in no change in PI3K activation (Hallmann et al., 2003). It was 
suggested that this effect was the result of compensation by utilisation of p85β instead. 
Despite this compensation, in order to maintain PI3K activation, PKB phosphorylation 
was lowered and cell growth rates were reduced (Hallmann et al., 2003). 
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Figure 1.18 Evidence of a role for PI3Ks in mESC proliferation 
Much research has been done to investigate the unique proliferation, growth and cell 
cycle characteristics of mESCs. The approaches used to implicate PI3Ks in mESC 
proliferation are shown in grey boxes.  
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1.3.6.3 Knockout studies in mice and ESCs 
 
Knocking out a gene provides valuable information regarding the normal physiological 
function of the protein products encoded by that gene. Since ESCs provide an in vitro 
model of cells of the early embryo, much can be learned by investigating knockout 
mice as well as knockout studies using ESCs. In the present study, the roles of the 
PI3K class I catalytic isoforms p110α, p110β, p110γ and p110δ in regulating mESC 
fate were of particular interest. Some clues could be drawn from previous work using 
knock-out mice (summarised in Table 1.2). 
 
A profound proliferative defect was observed in embryos with a homozygous deletion 
of Pik3ca, the gene encoding p110α. Pik3cadel/del embryos were not viable and did not 
survive beyond E9.5. Furthermore, cells isolated from Pik3cadel/del embryos could not be 
expanded in culture, even with the addition of serum or growth factors (Bi et al., 1999). 
Thus, functional p110α is required for growth and development of the embryo. 
However, two drawbacks with this knockout exist. Firstly, the technique used to 
produce this knockout involved replacing the p110α start codon and p85-binding 
domain with a neomycin selection cassette, giving rise to a hybrid p110α mRNA, which 
contains a downstream start codon and an open reading frame. It is unknown if this 
truncated p110α mRNA is translated in these cells but, theoretically, expressed 
truncated hybrid p110α protein could display Ras-binding and catalytic activity. 
Secondly, the expression of p85 was enhanced in Pik3cadel/del embryos. This excess of 
free p85 may act as a negative regulator of PI3K activity by competing for 
phosphorylated tyrosine residues with p85 bound to other isoforms of p110. To avoid 
these complications, transgenic knock-in mice were generated expressing p110α with a 
single mutated amino acid residue rendering this isoform catalytically inactive (Foukas 
et al., 2006). Mice homozygous for this mutation exhibit embryonic lethality whereas 
heterozygous mice, with reduced p110α activity demonstrate impaired insulin 
signalling, implying a major role for p110α in insulin signal transduction (Foukas et al., 
2006). 
 
Mice in which Pik3cb, the gene encoding p110β, had been knocked out were reported 
to be embryonic lethal with Pik3cbdel/del embryos not surviving past E3.5 (Bi et al., 
2001). Interestingly, E3.5 pre-implantation embryos, at the blastocyst stage, are used 
to derive self-renewing, pluripotent mESC lines for culture (Evans and Kaufman, 1981). 
In comparison, mice generated to express a catalytically inactive form of p110β were 
demonstrated to exhibit lethality but with incomplete penetrance (Ciraolo et al., 2008, 
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Guillermet-Guibert et al., 2008). Authors explained the disparate results observed with 
knock-in mice compared to knock-out mice (Bi et al., 2001) on the non-catalytic 
functions mediated by p110β. A non-catalytic, structural or association role for p110β 
has been described for epidermal growth factor receptor endocytosis, which is reported 
to be impaired when the expression of p110β is reduced (Ciraolo et al., 2008). 
Moreover, the small GTPase Rab5, which is mainly located on endosomes, associates 
with p110β (Christoforidis et al., 1999).  
 
Both knock-in and knock-out approaches were adopted to investigate p110δ, encoded 
by Pik3cd. Two Pik3cd knockout lines and a catalytically inactive p110δ knock-in line 
all displayed similar phenotypes. KO mice were reported to have defective lymphocyte, 
mast cell and neutrophil function (Clayton et al., 2002, Jou et al., 2002). Interestingly 
knocking out p110δ resulted in a reduction in the expression of p85α, p55α and p50α 
regulatory subunits in B cells. Using an alternative approach, a catalytically inactive 
p110δ knock-in was created producing mice that were viable but developed 
inflammatory bowel disease and had impairment of antigen receptor signalling in B and 
T cells. In cells expressing inactive p110δ, the expression and activity of other PI3K 
subunits was similar to that of wild-type cells (Okkenhaug et al., 2002). This role for 
p110δ is consistent with expression of this isoform being greatest in haematopoietic 
cells. 
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Table 1.2 PI3K catalytic and regulatory subunit gene-targeting studies in mice 
PI3K 
Isoform 
Embryonic 
Lethality 
Other Effects 
p110α KO E9.5 Proliferative defects. 
Elevated expression of p85 in embryo. 
(Bi et al., 1999) 
p110α KI  Homozygotes – embryonic lethal. 
Heterozygotes - impaired insulin signalling. 
(Foukas et al., 2006) 
p110β KO E3.5 
(Blastocyst 
stage) 
Homozygotes – embryonic lethal. 
Heterozygotes – live born. 
(Bi et al., 2001) 
p110β KI Embryonic 
lethal with 
incomplete 
penetrance 
Growth retardation of a proportion of surviving mice with 
low expression of p110β. 
Indication that kinase-independent functions are sufficient 
to allow embryonic development leading to viable adult 
mice. 
(Ciraolo et al., 2008) 
p110δ KO Viable Impaired neutrophil function. 
Decreased T-cell dependent antibody production. 
Reduced expression of p85α, p55α and p50α in B cells. 
(Clayton et al., 2002, Jou et al., 2002) 
p110δ KI Viable Impaired antigen signalling in B and T cells. 
Develop intestinal inflammation. 
No alteration in p110 isoforms. 
(Okkenhaug et al., 2002) 
p110γ KO Viable Impaired neutrophil and macrophage inflammatory 
reactions. 
Increased cardiac contractility. 
No alteration in p110 isoforms. 
(Hirsch et al., 2000) 
p110γ KI Viable Impaired neutrophil and macrophage inflammatory 
reactions. 
No alteration in p110β expression in macrophages. 
(Patrucco et al., 2004) 
p85α only Viable Increased insulin sensitivity. 
Elevated expression of p55α and p50α, p50α. 
(Terauchi et al., 1999) 
pan-p85α Perinatal 
lethality 
Reduced insulin sensitivity. 
Elevated expression of p85β. 
Reduced expression of p110α and p110β. 
(Fruman et al., 1999) 
 
 
The knock-out and kinase-dead knock-in approach was also used to investigate p110γ. 
Both techniques exhibited impaired neutrophil and macrophage inflammatory reactions 
(Hirsch et al., 2000, Patrucco et al., 2004). Only p110γ knockout mice displayed 
increased cardiac contractility and enhanced cAMP levels in cardiac cells. This was 
attributed to the kinase activity-independent coupling of p110γ to phosphodiesterase 
3B in order to degrade cAMP in cardiac cells and reduce contraction. Therefore, in 
p110γ kinase-dead knock-in mice, p110γ expression allows coupling to 
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phosphodiesterase 3B and is unaffected by the lack of kinase activity (Hirsch et al., 
2000, Crackower et al., 2002). 
 
Knock-outs of the p85 regulatory subunit tend to have increased insulin sensitivity 
coupled to increased cellular PI(3,4,5)P3 levels and enhanced PKB phosphorylation at 
Ser473 (Vanhaesebroeck et al., 2005). Mice lacking p85α only (expression of splice 
variants is intact) are viable but display hypoglycaemia and increased insulin 
sensitivity. This enhanced insulin sensitivity is explained by an increase in the 
expression of p55α and p50α. Additionally, p50α is capable of coupling to p110α to 
mediate insulin signal transduction in adipocytes and skeletal muscle (Terauchi et al., 
1999). Furthermore, p50α-associated PI3K activity was shown to be greater than that 
for p55α or p85α (Ueki et al., 2000). Consistent with this, pan-p85α knock-out mice (no 
expression of splice variants) are perinatal lethal and have reduced sensitivity to 
insulin. Moreover, expression of p85β was elevated, while p110α and p110β 
expression were reduced in pan-p85α knock-out mice (Fruman et al., 1999). 
 
Further information is provided from knockouts of effectors of PI3K signalling and 
phosphatases which regulate the cellular levels of PI3K inositol lipid products. PDK1 
knock-out mice die at E9.5 resulting from underdevelopment of somite, forebrain and 
neural crest tissues. PDK1-/- mice are also smaller than wild-types but this is reported 
to be the result of a developmental block rather than a direct effect on cell proliferation. 
Therefore, PDK1 is important for mouse embryonic development (Lawlor et al., 2002). 
In contrast, embryonic lethality occurs at E6.5 in mice lacking mTOR as a direct result 
of reduced growth and proliferation (Murakami et al., 2004). PTEN deficient mice die at 
E9.5, while heterozygotes exhibit reduced survival rates and enhanced occurrence of 
tumours (Suzuki et al., 1998, Stambolic et al., 1998), suggesting a role for PTEN in 
growth and development. 
 
Knock-out studies of individual p110 and p85 isoforms provide useful clues as to the 
necessity of PI3K isoforms for embryonic development and in ESC fate. Nonetheless, 
these studies have been hampered by compensatory expression of other catalytic and 
regulatory PI3K subunit isoforms. Additionally embryonic lethality clearly highlights an 
essential role for p110α and p110β in embryonic development. However, due to this 
lethality further investigation and clarification of p110α and p110β functions in embryo 
development, ESC self-renewal, proliferation and differentiation is restricted. Moreover, 
insights gained from knock-outs of PI3K effectors and regulatory phosphatases lack the 
details of PI3K isoform coupling to a specific functional role. 
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1.3.7 Human ESCs: similarities and differences to mESCs 
 
While human and mouse ESCs share common properties of perpetual self-renewal, 
pluripotency and the ability to differentiate into more specialised cell types, they differ 
somewhat in their cell-surface markers of self-renewal, in the extrinsic factors required 
to maintain pluripotent self-renewal and in the response to these factors.  
 
Human ESCs are reported to express the self-renewal markers alkaline phosphatase 
and Rex1 (Draper and Fox, 2003, Eiges et al., 2001). Furthermore, human and murine 
ESCs share similar transcription factors that regulate self-renewal such as Nanog, Oct4 
and Sox2 (Richards et al., 2004, Boyer et al., 2005). Indeed, forced expression of Oct4, 
Sox2, Klf4 and c-Myc, the same set of four genes used for mouse cells, induces 
reprogramming of human fibroblasts to iPSCs (Takahashi et al., 2007) although more 
efficient reprogramming was achieved when Klf4 and c-Myc were replaced with Nanog 
and the hESC-specific gene Lin28 (Yu et al., 2007). Further evidence of the conserved 
function of Oct4 in mouse and human ESCs comes from a report indicating that RNAi-
mediated knockdown of Oct4 induced the expression of endoderm markers in ESCs 
from both species (Hay et al., 2004).  
 
One notable difference in cell surface marker expression of human and mouse ESCs is 
that of the stage-specific embryonic antigens (SSEAs). Three forms of SSEA exist and 
each have different expression patterns throughout development. Self-renewing, 
pluripotent hESCs express SSEA-3 and SSEA-4. This expression is lost upon 
differentiation when hESCs begin to express SSEA-1 (Thomson and Marshall, 1998, 
Thomson et al., 1998). Conversely, undifferentiated mESCs and the ICM of mouse pre-
implantation embryos express SSEA-1 (Solter and Knowles, 1978). 
 
Unlike mESCs, hESC self-renewal is not maintained by LIF (Thomson et al., 1998, 
Dahéron et al., 2004, Humphrey et al., 2004). In fact, hESCs exhibit low expression of 
LIFR, Jak and Stat3 and high expression of suppressor of cytokine signalling (SOCS) 
which negatively regulates LIF signalling (Wei et al., 2005). Basic fibroblast growth 
factor (bFGF) is required to maintain hESC self-renewal, this, as with LIF for mESCs, 
can be provided by a layer of feeder cells on which ESCs can be cultured, or by 
addition to ESC optimised culture media (Thomson et al., 1998, Amit et al., 2004). 
BMP4 treatment of hESCs is reported to stimulate mesoderm, trophoblast and 
extraembryonic endoderm differentiation (Schuldiner et al., 2000, Xu et al., 2002, Pera 
et al., 2004). This is consistent with BMP-induced differentiation towards non-neural 
cell types in mESCs (Nakayama et al., 2000, Ying et al., 2003b, Wiles and Johansson, 
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1999). BMP-induced signalling activity and loss of self-renewal in hESCs can be 
counteracted by higher doses of bFGF or by the expression of Noggin, a BMP 
antagonist (Xu et al., 2005). 
 
As in mESCs, a role for PI3Ks in regulating hESC fate is emerging. Pharmacological 
inhibition of PI3Ks in hESCs is reported to result in a reduction in the percentage of 
alkaline phosphatase positive colonies (Pyle et al., 2006). A large scale transcriptional 
comparison of hESC lines revealed that a high proportion of transcripts belonged to 
signalling pathways, notably the Ras/MAPK, PI3K/PKB and NFκβ pathways (Armstrong 
et al., 2006). Furthermore, treatment of hESCs with LY294002 led to differentiated 
colony morphologies and reduced expression of the self-renewal markers Nanog, Sox2 
and Oct4 (Armstrong et al., 2006). For the feeder-free culture of hESCs, proliferation 
and pluripotency maintenance were shown to be dependent upon extracellular matrix 
molecules (Xu et al., 2001). Expression of tropomyosin-related kinase (TRK) receptors 
was detected in hESCs. What is more, three neurotrophin ligands of TRK receptors 
were shown to enhance clonal survival, maintain pluripotency and suppress apoptosis 
of hESCs, mediated via TRK, PI3K and PKB activation (Pyle et al., 2006).  
 
In mESCs, c-Yes, a Src family non-receptor tyrosine kinase, was found to be activated 
by LIF and to partially contribute to mESC self-renewal independently from the Jak/Stat 
pathway (Annerén et al., 2004). Although hESC self-renewal is independent from LIF, 
higher levels of c-Yes were detected in hESCs compared to differentiated somatic cell 
types (Annerén et al., 2004), however, a role for non-receptor tyrosine kinases in 
hESCs is yet to be established. S1P, a GPCR agonist, has been shown to maintain the 
undifferentiated state of hESCs (Pébay et al., 2005). In contrast, lysophospholipids 
have been shown to promote the differentiation of mESCs. Indeed, S1P is reported to 
promote cardiac differentiation in embryoid bodies formed from mESCs (Sachinidis et 
al., 2003) and sphingosylphosphorylcholine was shown to induce cardiac and neural 
differentiation of self-renewing mESCs (Kleger et al., 2007). 
 
Although mESCs and hESCs share mechanisms that maintain self-renewal and 
pluripotency, not all mechanisms are present in both cells. Using mESCs to investigate 
self-renewal, pluripotency and survival has led to many discoveries regarding extrinsic 
stimuli, signalling pathways and transcriptional control. Investigation into whether these 
same mechanisms are conserved in hESCs is a rapidly advancing area of research. 
Thus, gaining knowledge from mESCs is leading to the faster advancement in hESC 
knowledge and making the ideal of ESCs as a regenerative medicine more feasible. 
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1.4 Aims 
 
Expansion of undifferentiated ESCs to sufficient numbers that would be of use for 
regenerative medicine is required if the therapeutic potential of ESCs is to be realised. 
Such expansion requires the maintenance of self-renewal and pluripotency prior to 
directed differentiation. PI3K function in the survival and self-renewal of hESCs is 
beginning to be unravelled. Separate roles for PI3Ks in proliferation and maintenance 
of self-renewal of mESCs have already been described. However, the contribution to 
proliferation and the maintenance of self-renewal by PI3Ks are largely addressed as 
individual issues. Thus, the present study endeavours to further characterise the role of 
PI3Ks in mESC fate. This was tackled by addressing the following aims: 
 
 
●   To determine if inhibition of PI3Ks influence differentiation towards a particular 
lineage. PI3Ks have been shown to induce differentiation in mESCs, observed by a 
reduction in alkaline phosphatase staining, a decrease in Nanog expression and a 
change in the morphology of mESC colonies formed in the presence of the broad 
spectrum PI3K inhibitor LY294002 (Paling et al., 2004, Storm et al., 2007). The 
contribution of PI3Ks to early lineage commitment of 2D cultured mESCs has not been 
reported. 
 
 
●   To elucidate which factors, present in culture media or secreted by mESCs, 
contribute to the activation of PI3Ks. LIF is known to activate signalling downstream of 
PI3Ks in mESCs. ESCs are routinely cultured in media containing a serum-
replacement product of undefined components in order to maintain self-renewal 
(Burdon et al., 1999) and ESCs are known to secrete factors into culture media that 
aids their survival and dictates their fate (Guo et al., 2006, Singla et al., 2008). 
Consequently factors present in culture media, other than LIF, or those secreted by 
mESCs, may contribute to the activation of PI3Ks. 
 
 
●   To investigate upstream regulators and downstream effectors of PI3Ks in mESCs. 
The signalling pathways downstream of PI3Ks in other cell types are varied and exhibit 
a high degree of cross-talk (Vanhaesebroeck and Waterfield, 1999). Signalling 
pathways involving PI3Ks will be investigated using identified activators of PI3Ks in 
mESCs. 
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●   To analyse the roles of PI3K subunit isoforms in mESC fate. PI3Ks have been 
investigated as a whole with regards to self-renewal and survival using the broad 
spectrum PI3K inhibitor LY294002. However Paling et al., identified the class IA PI3Ks 
as regulators of self-renewal in mESCs. Additionally, gene knockout studies in mice 
indicate that the class I isoforms may have distinct, redundant or overlapping roles 
(Vanhaesebroeck et al., 2005). The individual contribution of class I PI3K isoforms to 
mESC fate will be addressed in the present study. Of particular interest is p110β given 
that the embryonic lethality of catalytically inactive p110β knockout mice at E3.5 (Bi et 
al., 2001) coincides with the isolation of mESCs from blastocysts at the same stage of 
development (Evans and Kaufman, 1981). 
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2.  MATERIALS AND METHODS 
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2.1 Cell lines, culture and storage 
 
All cells were incubated in humidified incubators at 37oC with 5% (v/v) CO2. 
 
2.1.1 E14tg2A murine embryonic stem cell (mESC) line 
 
E14tg2A murine embryonic stem cell (mESC) line (Clone R63) was a kind gift of Dr 
Owen Witte, UCLA, California (Era and Witte, 2000). E14tg2A cells are stably 
transfected with a tetracycline-regulated transactivator construct pCAG20-1. 
 
2.1.2 Mek* mESC clones 
 
Cloned E14tg2A mESCs expressing an inducible version of constitutively activated, 
histidine-tagged Mek1 (mitogen-activated extracellular signal-regulated kinase) were 
generated by Professor Welham (unpublished data). Constitutively active Mek1 was 
constructed by substitution mutations of serines 218 and 222, within the catalytic 
domain, to glutamic acid residues, mimicking activating phosphorylation (Treinies et al., 
1999). This activated form of Mek (Mek*) was inserted into a gene expression vector 
under the control of a tetracycline-off expression system. Tetracycline binds the 
tetracycline-sensitive transactivator (tTA) to suppress expression. In the absence of 
tetracycline, tTA is expressed from the regulator plasmid which acts via the tTA-
dependent promoter to drive expression of exogenous Mek*. 
 
Cloned cells were routinely cultured in KO complete media supplemented with LIF and 
500ng/ml tetracycline to suppress Mek* expression. 
 
2.1.3  Murine embryonic stem cell culture 
 
E14tg2A and Mek* mESCs were routinely cultured on 92 x 17mm NUNC dishes coated 
with 0.1% (w/v) porcine gelatine. Cells were grown in Knockout Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 15% (v/v) knockout serum replacement, 
2mM Glutamine, 50µM 2-mercaptoethanol, 1% non-essential amino acids. Knockout 
DMEM plus supplements is referred to as KO complete media from here on in. For 
culture, KO complete media was supplemented with 1000U/ml Leukaemia inhibitory 
factor (LIF), or 4µl/ml recombinant LIF conditioned media to maintain self-renewal. 
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To passage, cells were washed with phosphate buffered saline (PBS) and 0.5ml of 
trypsin/Ethylenediaminetetraacetic acid (EDTA) applied. Dishes were incubated for 5 
minutes at 37oC with 5% (v/v) CO2. Cells were resuspended in KO complete media and 
pelleted at 1000rpm. The supernatant was removed and cells resuspended in fresh KO 
complete media. Cells were plated at 0.5x106 cells per dish and routinely cultured every 
two days to maintain a sub-confluent density ( <1.5x106 cells per dish) and to limit 
differentiation. Cultures were passaged for no longer than 3 weeks (Paling et al., 2004). 
 
2.1.3.1  LIF-conditioned media 
 
Conditioned media was collected from the HEK293LIFV5 cell line (Park et al., 2003b) 
generated by stable expression of a V5 epitope-tagged LIF gene in HEK293 cells. (a 
kind gift from Dr. Konstantinos Anastassiadis, University of Technology, Dresden). 
Media was sterilised by filtration and batch tested in-house for the capacity to maintain 
self-renewal and stimulate LIF-mediated signalling.  
 
2.1.3.2  N2B27 chemically defined serum-free media 
 
E14tg2A cells were cultured in N2B27-defined media containing 1:1 Neurobasal media 
to DMEM F12 media supplemented with N2 and B27 supplements (Bottenstein and 
Sato, 1979, Brewer and Cotman, 1989, Brewer et al., 1993)) (Table 2.1), 2mM 
glutamine, 50µM Bovine Serum Albumin (BSA) fraction V, 0.0125% (v/v) 
Monothioglycerol (MTG), 1000U/ml LIF and 10ng/ml recombinant BMP4. To maintain a 
high cell density, cells were plated at no fewer than 0.5x106 cells/92cm NUNC-tissue 
culture dish coated with 0.1% (w/v) porcine gelatine. Stimulation experiments were 
conducted using cells cultured for at least 2 days in N2B27-defined media. 
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Table 2.1 Composition of N2 and B27 supplements 
N2 SUPPLEMENT B27 SUPPLEMENT 
25µg/ml Insulin 
100µ/ml Apo-transferrin 
30ng/ml Sodium Selenite 
16µg/ml Putrescine 
6ng/ml Progesterone 
Biotin 
L-camitine 
Corticosterone 
Ethanolamine 
D(+)-galactose 
Glutathione (reduced) 
Linoleic acid 
Linolenic acid 
Progesterone 
Putrescine 
Retinyl acetate 
Selenium 
T3 (triodo-1-thyronine) 
DL-α-tocopherol (Vitamin E) 
DL-α-tocopherol acetate 
Albumin (bovine) 
Catalase 
Insulin 
Superoxide dismutase 
Transferrin 
 
2.1.3.3  Murine ESC freezing and thawing 
 
Freezing media consisted of Glasgow Modified Eagle Medium (GMEM) supplemented 
with 2mM glutamine, 50µM 2-mercaptoethanol, 1% (v/v) non-essential amino acids, 
1mM sodium pyruvate. E14tg2A cells were suspended at 2x106 cells/ml in freezing 
media plus 10% ES screened Fetal Bovine Serum (FBS). Cold freezing media plus 10% 
(v/v) DMSO was added drop wise to give a final suspension of 1x106 cells/ml. Aliquots of 
1ml were added to NUNC cryovials and stored at -80oC for 24 hours. Cryovials were 
transferred to liquid nitrogen for long-term storage. 
 
Cells were thawed rapidly and resuspended drop wise in 10ml KO complete media to 
wash. Pelleted cells were resuspended and plated onto gelatine coated, 92 x 17mm 
NUNC dishes. After 24 hours media was replaced and cells routinely cultured as 
previously described. 
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2.1.4 BaF/3 cell line 
 
BaF/3 cells are an immortalised murine bone marrow derived pro-B cell line with 
interleukin-3 (IL-3)-dependent proliferation (Palacios and Steinmetz, 1985). 
 
BaF/3 cells were cultured in non-tissue culture treated plastic in RPMI 1640 medium 
supplemented with 10% (v/v) Fetal Calf Serum (FCS), 20µM 2-mercaptoethanol, 100U 
penicillin/streptomycin, 2mM glutamine and 5-10% JWW3 conditioned media, as a 
source of IL-3. Cells were passaged regularly by serial dilution. 
 
2.1.4.1  JWW3 conditioned media 
 
JWW3 cells expressing murine IL-3 (mIL-3) were cultured in 175 cm2 tissue culture 
flasks for 1 week. Media was collected and filtered to remove cells and cell debris then 
sterilised using 0.2µm bottle top filter (Nalgene). JWW3 conditioned media was tested 
using an XTT dye reduction assay (section 2.4.1) with BaF/3 cells to determine the 
optimum concentration of conditioned media for maximum BaF/3 cell growth (typically 5-
10% JWW3). JWW3 conditioned media was stored at -20oC. 
 
2.1.4.2  BaF/3 freezing and thawing 
 
BaF/3 cells were suspended at 2x106/ml in 90% FCS and 10% DMSO. Aliquots of 1ml 
were added to NUNC cryovials and stored at -80oC for 24 hours. Cryovials were 
transferred to liquid nitrogen for long-term storage. 
 
BaF/3 cells were thawed rapidly, resuspended in supplemented RPMI 1640 medium and 
pelleted. The pelleted cells were resuspended in supplemented RPMI 1640 culture 
media for expansion. 
 
Chapter 2: Materials and Methods 
70 
Table 2.2 Tissue culture consumables 
PRODUCT SUPPLIER CATALOG # 
GROWTH MEDIUM 
Glasgow’s Modified Eagle Medium 
(GMEM) Invitrogen, Paisley, UK 21710-025 
Knockout Dulbecco’s Modified Eagle 
Medium (DMEM) Invitrogen 10829-018 
RPMI 1640 Invitrogen 21875-059 
SERUM 
Knockout Serum Replacement Invitrogen 10828-028 
Bovine Serum Albumin (BSA) Fraction V 
(for N2B27-defined medium)   
Fetal Calf Serum (for BaF/3 cell line) Sigma, Dorset, UK  
ES Screened Fetal Bovine Serum (FBS) 
(Hyclone) Perbio, Hyclone, UK SH30070.03E 
ES Screened Fetal Bovine Serum (FBS) 
(Biosera, South America origin) 
Biosera, Ringmer, East 
Sussex, UK 
S181S 
MEDIUM SUPPLEMENTS 
ESGRO LIF 
Chemicon, Hampshire, 
UK 
ESG1106 
N2 Supplement (100X) Fisher Scientific, 
Leicestershire, UK  
07152 
B27 Supplement (50x) Fisher Scientific 07153 
Glutamine Invitrogen 25030-024 
2-mercaptoethanol 
Bio-Rad, Hemel 
Hempstead, Hertfordshire 
161-0710 
100x Non-essential amino acids (NEAA) Invitrogen 11140-050 
Monothioglycerol Sigma M6145 
Recombinant Human BMP4 
R&D Systems, Abingdon, 
UK 
314-BP 
Sodium Pyruvate Fisher Scientific 11360 
Tetracycline Hydrochloride Sigma T7660 
Penicillin/streptomycin Invitrogen 15140-122 
OTHER 
Porcine Gelatine Sigma G1890-110G 
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Trypsin-Ethylenediaminetetraacetic acid 
(EDTA) Fisher Scientific 25300-062 
DMSO Sigma D2650 
Phosphate Buffered Saline (PBS) Invitrogen 14200-067 
10x Hank’s Balanced Salt Solution 
(HBSS) Invitrogen 14060-040 
TISSUE CULTURE PLASTIC WARE 
15ml Centrifuge Tubes 
Greiner Bio-one (GBO) 
Gloucestershire, UK 
188271 
50ml Centrifuge Tubes GBO 227261 
NUNC Cryovials Fisher Scientific CRY-960-070B 
NUNC Tissue Culture dish 60x15mm Fisher Scientific TKT-110-010S 
NUNC Tissue Culture dish 92x17mm Fisher Scientific TKT-110-070A 
NUNC T75 Tissue Culture Flasks Fisher Scientific TKT-130-130R 
3ml Pasteur Pipettes GBO 612398 
Petri (non-tissue culture treated) dishes 
60x15mm 
GBO 628160 
10ml Single-wrapped Sterile Pipettes GBO 607180 
25ml Single-Wrapped Sterile Pipettes GBO 760180 
150mm unplugged glass pipettes Fisher Scientific FB50251 
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2.2 Inhibitors 
 
A variety of inhibitors were used in this study to assess the role of PI3Ks in mESC fate 
(Table 2.3). 
 
Table 2.3 Pharmacological Inhibitors 
INHIBITOR STRUCTURE INFORMATION SUPPLIER 
BROAD SPECTRUM PI3K INHIBITORS 
LY294002 
 
 IC50 
PI3K 1.4 µM 
p110α 9.3 µM  
p110β 2.9 µM  
p110δ 6.0 µM  
p110γ 38 µM 
mTOR 8.9 µM 
 
Inhibition of PIP2 production 
in platelets IC50 2.5-5 µM 
 
(Vlahos et al., 1994, Walker 
et al., 2000, Jackson et al., 
2005) 
Calbiochem 
Wortmannin 
 
 
IC50 
PI3K 2-4 nM 
Class IA 4.2nM 
 
Inhibition of agonist-mediated 
respiratory-burst activation 
IC50  12nM 
 
(Arcaro and Wymann 1993, 
Knight et al., 2004, Powis et 
al., 1994, Walker et al., 2000, 
Wymann et al., 1996) 
Calbiochem 
ZSTK474 
 
 
 
IC50 
PI3K 37 nM 
p110β 17 nM  
p110δ 6 µM  
p110γ 53 µM 
 
Inhibition of growth of 
HUVECs 0.146 µM 
 
(Dan et al., 2008, Kong and 
Yamori, 2007, Yaguchi et al., 
2006, Kong et al., 2009) 
Zenyaku Kogyo 
Co, Tokyo, 
Japan.  
Generous gift 
from Tom 
Crabbe, UCB, 
Slough UK 
N
N
N
O
N
N
N
N
O
F
F
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DUAL PI3K/mTOR INHIBITOR 
PI-103 
 IC50  
p110α 0.008 µM  
p110β 0.088 µM  
p110δ 0.048 µM  
p110γ 0.15 µM 
mTORC1 0.02 µM 
mTORC2 0.083 µM 
 
(Fan et al., 2006, Hayakawa 
et al, 2001b, Knight et al., 
2004, Knight et al., 2006) 
Generous gift 
from Tom 
Crabbe, UCB, 
Slough, UK 
 
 
Patent 
WO01083456 
PI3K p110 CATALYTIC SUBUNIT ISOFORM INHIBITORS 
p110α Selective 
Compound 
15e 
 
 
 
 
Inhibition of A375 cell 
proliferation IC50 580nM 
 
 
(Hayakawa et al., 2006) 
Alexis 
Biochemicals, 
Nottingham, UK 
PIK-75 
 
IC50  
p110α 0.0058 µM  
p110β 1.3 µM  
p110δ 0.51 µM  
p110γ 0.076 µM 
mTORC1 1 µM 
mTORC2 10 µM 
 
(Hayakawa et al., 2001a, 
Knight et al., 2001) 
Generous gift 
from Peter 
Shepherd, 
University of 
Auckland, New 
Zealand 
 
Patent 
WO2001083481 
p110β Selective 
TGX-221 
 
IC50  
p110α 5 µM  
p110β 5-50 nM  
           (for ATP 50 µM-1 mM) 
p110γ 10 µM 
 
Inhibition of PIP2 production 
in platelets 50nM 
 
(Condliffe et al., 2005, 
Hennessy et al., 2005, 
Jackson et al., 2004, Jackson 
et al., 2005) 
Generous gift 
from Peter 
Shepherd 
Patent 
WO2004016607 
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TGX-121 
 
IC50  
PI3K 0.05 µM 
p110β 0.05 µM  
p110γ 5 µM 
 
 
(Robertson et al., 2001, 
Kuang et al., 2006) 
Generous gift 
from Tom 
Crabbe 
 
Patent 
WO0153266 
p110δ Selective 
IC87114 
 
IC50  
p110α >200 µM  
p110β 16 µM  
p110δ 0.13 µM  
p110γ 61 µM 
 
(Knight et al., 2006, Sadhu et 
al., 2001, Sadhu et al., 2003) 
Generous gift 
from Tom 
Crabbe 
 
Patent 
WO0181346 
p110γ Selective 
AS605240 
 
IC50 
p110γ 0.008 µM 
 
Inhibition of C5a mediated 
PKB phosphorylation in 
RAW264 mouse 
macrophages IC50  0.09 µM 
 
(Barber et al., 2005, Camps 
et al., 2005) 
Generous gift 
from Tom 
Crabbe 
 
Patent 
WO2004007491 
mTOR INHIBITOR 
Rapamycin 
 
Inhibition of p70 S6K activity 
in 3T3 cells IC50 50 ρM 
 
(Kuo et al., 1992) 
Calbiochem 
N
N
N
N
N
N
NH2
O
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G PROTEIN INHIBITOR 
Pertussis 
toxin  
(PTX) 
AB5-type exotoxin 
produced by the 
bacterium 
Bordetella 
pertussis 
PTX inhibition of 
norepinephrine-induced  
inositol phosphate 
production in primary 
cultures of neuronal and 
glial cells, IC50 7 ng/ml 
 
(Burns, 1988, Wilson and 
Minneman 1990) 
Calbiochem 
IC50 values represent the concentration of an inhibitor that is required for 50% 
inhibition. However, it is difficult to compare IC50 values since they are derived in 
different ways. Assays can be cell based or cell-free but can also differ in the 
conditions used to derive this value. For example, variations in the concentration 
of ATP between assays can alter the IC50 value obtained for an ATP-competitive 
inhibitor in a kinase assay. Furthermore, cell type, relative expression of target 
proteins and off-target proteins, cell permeability and stability of inhibitors under 
tissue culture conditions and the measurement of a biological process can all 
cause additional variability. 
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2.3 Biochemical analysis techniques 
2.3.1 Cell stimulations 
2.3.1.1  mESC stimulations 
 
A number of different media were used to assess intracellular signalling in mESCs 
relating to PI3K activation, inhibition of specific PI3K isoforms and siRNA-mediated 
knockdown of PI3K catalytic isoforms. Figure 2.1 details the different media used for 
mESC stimulation experiments. 
 
E14tg2A mESCs or Mek* transfected mESCs were plated at 3x105 cells per 60mm 
gelatin coated NUNC-tissue culture dish and incubated for 24-48 hours. Prior to 
stimulation, cells were washed three times with PBS and serum starved by incubating 
for 4 hours in GMEM supplemented with 2mM glutamine, 50µM 2-mercaptoethanol, 1% 
(v/v) non-essential amino acids and 1mM sodium pyruvate. No serum starvation period 
was required for cells cultured in N2B27-defined media since it is serum-free. Instead, 
cells were incubated for 4 hours in 1:1 Neurobasal media to DMEM F-12 media for 4 
hours. Where stated, cells were pre-treated with inhibitors for 30 minutes. The stated 
dose of cytokine was diluted in GMEM and 1:1 Neurobasal media to DMEM F-12 media 
and applied to cells. During the stimulation period, dishes were incubated at 37oC and 
5% (v/v) CO2.  
 
For stimulation of GPCRs, 10% (v/v) KO SR in GMEM was boiled for 5 minutes and 
allowed to cool to room temperature prior to stimulations. Murine ESCs were stimulated 
for 5 minutes with boiled 10% (v/v) KO SR in GMEM and washed thoroughly with ice 
cold PBS to ensure all serum was removed from cells prior to lysing. Where pertussis 
toxin was used, mESCs were incubated with 10ng/ml pertussis toxin over-night. A 4 
hour serum starvation period was carried out prior to stimulation. 
 
For long-term stimulations (1-5 days) and analysis of basal signalling, cells were plated 
at 1x105 cells per 60mm gelatin coated NUNC-tissue culture dish in KO complete media 
supplemented with 1000U/ml LIF or N2B27-defined media supplemented with 1000U/ml 
LIF and 10ng/ml BMP4. Inhibitors were added after 4 hours, which allowed cells to 
adhere to the tissue culture dish.  
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Figure 2.1 Experimental design and medium used for mESC stimulations 
Different media were used for the culture and stimulation of mESCs depending on the 
aim of a particular experiment. The culture media and pre-incubation media, where 
appropriate, are indicated in boxes. 
 
Following stimulations, dishes were washed twice with ice-cold PBS and cells 
solubilised in 30µl/106 cells of ice-cold lysis buffer (50mM Tris-HCl pH 7.5, 150mM 
sodium chloride, 1% (v/v) Nonidet P40, 10% (v/v) glycerol, 5mM EDTA, 1mM sodium 
vanadate, 1mM sodium molybdate, 10mM sodium fluoride, 0.7µg/ml Pepstatin A, 
40µg/ml phenylmethylsulphonyfluoride (PMSF), 10µg/ml Aprotinin and 10µg/ml 
soyabean trypsin inhibitor). Dishes were scraped using a cell scraper and cell extracts 
transferred to 1.5ml tubes. Samples were spun at 14000rpm at 4 oC for 1 minute in a 
microfuge to remove cell debris. Supernatants were transferred to clean tubes for 
storage at -20 oC. 
Intracellular Signalling
Basal signalling? Ligand-induced 
signalling?
Identification of 
factors stimulating 
PI3Ks
Stimulation with 
BMP4, insulin or LIF
Stimulation of 
GPCRs with serum, 
LPA or S1P
Long-term incubation 
with inhibitors (>24hrs) 
or siRNA experiments
Signalling 
downstream of 
specific PI3K 
isoforms
Culture: serum-free N2B27 Media
Pre-incubation in absence of LIF, 
BMP4, N2 and B27 supplements
Figures 3.1, 3.2, 3.3, 3.5
Culture: complete KO SR media
Pre-incubation: absence of serum 
replacement and LIF
Figures 3.4, 3.8B, 3.9, 4.3, 4.12, 
4.13, 4.14, 5.5, 5.6, 5.7
Culture and incubation: 
complete KO SR media
Figures  3.7, 3.8A, 4.2, 4.8, 
4.10, 4.11, 4.17, 4.18, 4.22, 
4.23, 5.13, 5.16
In parallel with alkaline 
phosphatase assay
Alkaline posphatase
assay media (GMEM 
plus 10% serum)
Figures  3.10, 4.1, 4.5, 
4.24, 5.12
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2.3.1.2  BaF/3 cell stimulations 
 
BaF/3 cells were washed three times with Hanks buffered saline containing 20mM 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and resuspended at 1x107 
cells/ml in RPMI 1640 and 20mM HEPES lacking serum and IL-3 (JWW3 conditioned 
media). Cells were serum starved for 45 minutes in a 37oC water bath. Cells were pre-
treated with inhibitors for 30 minutes prior to stimulation. Following stimulation with 
20ng/ml IL-3 for 10 minutes, cells were spun briefly. The supernatant was aspirated and 
the cell pellet lysed with ice-cold lysis buffer at 2x107 cells/ml. Samples were spun at 
14000 rpm at 4oC for 1 minute to remove cell debris. Supernatants were transferred to 
clean tubes for storage at -20oC. 
 
2.3.1.3  Bradford assay 
 
A Bradford assay (Bradford, 1976) was performed to determine lysate protein 
concentrations. This colorimetric assay relies on a directly proportional relationship 
between the absorbance of Coomassie brilliant blue dye at 595nm and the amount of 
protein present. Absorbance of the dye increases according to the amount of dye bound 
to arginine and hydrophobic residues of proteins. 
 
Bradford reagent was diluted 1:10 in milli-Q® H2O. To derive a standard curve, 0, 2, 4, 
6, 8, 10 or 12µg/ml Bovine Serum Albumin (BSA) were added to 1ml aliquots of 1:10 
diluted Bradford reagent. In separate tubes, 3-5µl of cell extract samples were added to 
1ml aliquots of 1:10 diluted Bradford reagent. Standard and sample tubes were vortexed 
briefly and 200µl per well plated in triplicate on flat-bottomed 96 well plates. The 
absorbance at 595nm of each well was measured using a Versamax plate reader 
(Molecular Devices). Sample protein concentrations were extrapolated from the 
standard curve established from known BSA dilutions. 
 
The same amount of protein (10-20µg) was taken from each sample and diluted with 
lysis buffer to a maximum volume of 20µl. SDS-sample buffer (5X sample buffer: 10% 
SDS (w/v), 50% glycerol (v/v), 200mM Tris-HCl pH 6.8, 5% 2-mercaptoethanol and 2% 
bromophenol blue) was added to each sample and tubes were boiled for 5 minutes at 
95oC to denature proteins. 
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2.3.2 Protein resolution and immunoblotting 
2.3.2.1  Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
Sample proteins were separated according to molecular size by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Boiling of protein samples in 
reducing conditions (containing 2-mercaptoethanol) denatures protein structure and 
breaks disulphide bonds. SDS binds linear protein at approximately 1.4g per 1g protein 
to give all denatured polypeptide chains an equal mass to charge ratio. Subsequent 
separation by SDS-PAGE is therefore independent of intrinsic electrical charge and 
dependent on polypeptide relative molecular mass alone. 
 
Samples were loaded into individual lanes of a stacking gel of large pore size and pH 
6.8. At this pH, glycine, a component of the running buffer, is weakly ionised with a low 
mobility but NaCl is highly ionised and has a greater mobility through the gel. When a 
constant voltage is applied, current passes through the gel and protein polypeptides are 
trapped between the glycine and NaCl phases within the stacking gel. This arrangement 
allows sample polypeptides to be collected between the NaCl/glycine moving 
boundaries and focused into a thin band of migration. Thus, all polypeptides within the 
samples enter the resolving gel at approximately the same time. The resolving gel has 
smaller pore sizes to allow polypeptides to separate according to relative molecular 
mass. The resolving gel of pH 8.8 causes glycine to become highly ionised and allows it 
to migrate much faster through the gel without restricting the migration of polypeptides 
(Laemmli, 1970). 
 
A broad range molecular weight marker, diluted in 1x SDS sample buffer and boiled, 
was loaded into one lane of each gel and run in parallel to the samples. This was used 
to identify proteins of interest, and known molecular weight, following immunoblotting. 
 
SDS-PAGE gels were prepared using Mini Protean III Gel Electrophoresis Apparatus 
(Bio-Rad). The percentage of acrylamide used in the resolving gel was determined 
according to the size of the proteins to be resolved (Table 2.4). 
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Table 2.4 Proteins resolved according to acrylamide Content 
RESOLVING GEL ACRYLAMIDE % RESOLVED PROTEIN SIZE (kDa) 
7.5 40-200 
10 30-200 
12 15-100 
 
 
The resolving gel solution (Table 2.5) was made according to the required acrylamide 
percentage (Table 2.4). TEMED (Tetramethylethylenediamine) was added last and just 
prior to pouring to initiate the cross-linking reaction. The resolving gel solution was 
poured into the gel casting apparatus (4.5ml per gel) and overlaid with milliQ® H2O. 
 
Table 2.5 Resolving gel solution 
ACRYLAMIDE %: 7.5 10 12 
Acrylamide/bisacrylamide 30% (w/v)/ 0.8% (w/v) (ml) 3.75 5.0 6.0 
milliQ H2O (ml) 5.6 4.35 3.35 
1M Tris-HCl pH 8.8 (ml) 5.6 5.6 5.6 
10% (w/v) SDS (ml) 0.25 0.25 0.25 
10% (w/v) Ammonium persulphate (APS) (µl) 50 50 50 
Tetramethylethylenediamine (TEMED) (µl) 20 20 20 
 
 
The upper stacking gel solution consisted of 1.67ml acrylamide/bisacrylamide, 6ml 
milliQ® H2O, 1.25 1M Tris-HCl, 150µl 10% (w/v) SDS, 50µl 10% (w/v) APS and 20µl 
TEMED. When the resolving gel had set, the overlaying milliQ® H2O was aspirated and 
the stacking gel solution poured onto the resolving gel. Combs were inserted to form 
wells until the stacking gel had set. The wells were washed briefly with milliQ® H2O and 
aspirated. The gel running apparatus was assembled and the reservoir filled with 1x 
SDS-PAGE running buffer (10x 3% (w/v) Tris, 0.1% (w/v) SDS, 14.4% (w/v) glycine). 
 
Samples were loaded into individual wells and a molecular weight marker into a 
separate well. A constant voltage of 80mV was applied during stacking and 180mV to 
resolve. 
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2.3.2.2  Immunoblotting 
 
The process of immunoblotting transfers resolved proteins from SDS-PAGE gels onto 
nitrocellulose paper to allow antibody detection of proteins. Proteins from SDS-PAGE 
gels were transferred onto nitrocellulose paper by semi-dry transfer. Graphite electrodes 
of Pharmacia LKB Novoblot electroblotting apparatus were dampened with semi-dry 
transfer buffer (39mM glycine, 48mM Tris base, 0.0375% (w/v) SDS, 20% (v/v) 
methanol). Nitrocellulose blotting membrane and 3MM Whatman chromatography paper 
were cut to the same size as the resolving gel (8.5x5.5cm) and soaked in semi-dry 
transfer buffer. Four dampened sheets of Whatman paper, a sheet of nitrocellulose 
blotting membrane, an SDS-PAGE gel and four sheets of dampened Whatman paper 
were sandwiched between the upper and lower graphite electrode transfer apparatus. 
Immunoblotting was performed with a current of 0.8mA per cm2 nitrocellulose paper for 
1 hour. 
 
After transfer, nitrocellulose membranes were rinsed briefly in dH2O. Ponceau S solution 
was used to stain nitrocellulose-bound protein to assess transfer, equal loading of 
samples and to visualise the broad range molecular markers. Ponceau stain was 
washed off with Tris-buffered Saline (TBS) (150mM NaCl, 20mM Tris-HCl pH 7.5). 
Nitrocellulose membrane blots were blocked for 1 hour in either 5% BSA block (5% (w/v) 
BSA, 1% (w/v) ovalbumin, 0.05% (w/v) sodium azide in TBS) or 2% ECL (Enhanced 
chemiluminescence) Advance blocking solution (200mg ECL advance blocking 
agent/10ml TBS) at room temperature. Nitrocellulose blots were incubated with primary 
antibodies (Table 2.6) at 4oC for 16 hours with gentle agitation. 
 
Blots were washed once in TBS, three times with TBST (TBS with 0.05% (v/v) Tween) 
for 15 minutes then once again with TBS wash. Blots were incubated with an 
appropriate horse radish peroxidase (HRP) conjugated secondary antibody diluted in 
TBST with gentle agitation. After 1-2 hours, blots were washed as before with an 
additional final TBS wash. ECL Western blotting detection reagent or ECL Advanced 
was applied for 1 minute. Blots were wrapped in Clingfilm and placed in an 
autoradiography cassette. In a dark room, blots were exposed to autoradiography film 
for 1-10 minutes, and developed with an RGII Fuji X-Ray film developer. 
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Table 2.6 Primary antibodies for immunoblotting 
ANTIBODY SOURCE BLOCK DILUTION DILUENT SIZE kDa SUPPLIER 
Primary Antibodies 
α-p110α Rabbit 5% BSA 1:3000 1% BSA 110 SCB 7174 
α-p110β Rabbit 5% BSA 1:1000 1% BSA 110 SCB 602 
α-p85 Rabbit 5% BSA 1:5000 1% BSA 85 UBI 06-195 
α-Nanog Rabbit ECL Adv. 1:5000 ECL Adv. 34/39 AC 21603 
α-Oct4 Rabbit ECL Adv. 1:1000 ECL Adv. 43 SCB 9081 
α-phospho-
p44/42 MAPK 
(Thr202/Tyr204) 
(referred to as 
pErk-1/2) 
Rabbit 5% BSA 1:1000 1% BSA 42/44 SCB 93 
α-phospho-Mek 1 
(Ser217/221) Rabbit 5% BSA 1:1000 1% BSA 45 CST 9121 
α-His Tag (27E8)  Mouse 5% BSA 1:1000 1% BSA  CST 2366 
α-pStat3 (Tyr 
705) Rabbit 5% BSA 1:1000 1% BSA 79 SCB 9131 
α-pStat3 (Ser 
668) Mouse 5% Milk 1:1000 PBS 79 BL 
α-pStat3 (Ser 
727) Rabbit 5% BSA 1:2500 1% BSA 79 BL 
α-phospho-
ribosomal S6 
protein 
(Ser235/236) 
(referred to as 
pS6) 
Rabbit 5% BSA 1:2000 1% BSA 32 CST 2211 
α-pPKB (Ser 473) Rabbit 5% BSA 1:1000 1% BSA 60 CST 4058 
α-pPKB (Thr 308) Rabbit ECL Adv. 1:2000 ECL Adv. 60 CST 4056 
α-pGSK-3 α/β 
(Ser21/9) Rabbit ECL Adv. 1:2000 ECL Adv. 49/51 CST 9331 
α-pSmad1 (Ser 
463/465) Rabbit 5% BSA 1:1000 1% BSA 60-65 UBI 06-702 
Primary Antibodies used for Reprobing 
α-p44/42 MAPK 
(referred to as 
Erk-1/2) 
Rabbit 5% BSA 1:1000 1% BSA 42/44 
 
CST 9102 
α-Stat3 Rabbit 5% BSA 1:2000 1% BSA 79 SCB 482 
α-PKB Rabbit 5% BSA 1:1000 1% BSA 60 CST 9272 
α-GSK-3 β Rabbit 5% BSA 1:1000 1% BSA 46 CST 9315 
α-SH2 domain 
tyrosine 
phosphatase 
(referred to as 
Shp-2) 
Rabbit 5% BSA 1:2000 1% BSA 70 SCB 280 
α-Mek 1 (N-
terminus) Mouse 5% BSA 1:1000 1% BSA 45  
α-Mek 1 Rabbit 5% BSA 1:1000 1% BSA 45 CST 9122 
Suppliers 
AC AbCam, Cambridge, UK 
BL H Boeuf Laboratory, CNRS, Bordeaux, France 
CST Cell Signaling Technologies, New England Biolabs (NEB), Hitchin, UK 
SCB Santa Cruz Biotechnology, Autogen Bioclear, Calne UK 
UBI Upstate Biotechnology Incorporated (Millipore), UK 
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Table 2.7 Secondary antibodies for immunoblotting 
ANTIBODY SOURCE DILUTION DILUENT SUPPLIER 
Mouse-HRP Goat 1:10000 TBST Dako Cytomation #P0447 
Rabbit-HRP Goat 1:20000 TBST Dako Cytomation #P0778 
 
 
2.3.2.3 Stripping and reprobing nitrocellulose membranes 
 
Blots were stripped of initial probing reagents in stripping buffer (6.25% (v/v) 1M Tris-
HCl pH 7.5, 2% (w/v) SDS, 0.77% (v/v) 2-mercaptoethanol) at 55oC for 45 minutes. 
Blots were washed thoroughly in TBST (2-mercaptoethanol waste was disposed of 
appropriately) and incubated in 5% blocking buffer for 1 hour. Appropriate primary and 
secondary antibodies were used to re-probe bound proteins, as before. 
 
2.3.3 Immunochemistry 
 
2.3.3.1  Cytospin preparation of slides 
 
Mek* transfected mESCs were washed twice with PBS, dissociated and resuspended at 
1x105 cells/ml in GMEM plus 5% ESC screened FBS. After securing a glass slide, filter 
paper and cuvette in a metal holder, 100µl of resuspended cells were loaded per slide. 
This was spun at 500rpm for 10 minutes under slow acceleration in a Cytospin 3 
(Shandon). The glass slide was carefully retrieved and the area around the 
cytocentrifuged cells marked with a PAP hydrophobic barrier pen. Cells were fixed in 
90% ethanol for 10 minutes and rinsed in TBS.  
 
2.3.3.2  Immunochemistry staining 
 
Fixed cells were blocked for 1 hour in 1% block (1% (w/v) BSA in TBS) then incubated 
overnight with diluted primary His-Tag Antibody 1:800 in 1% block at 4oC. Slides were 
washed in TBS for 15 minutes. Two drops of peroxidise block were applied per slide for 
15 minutes followed by a brief rinse in TBS. The secondary antibody, goat anti-mouse 
HRP diluted 1:200 in 1% block was applied for 1 hour and rinsed twice with TBS. Slides 
were developed with DAB (3,3'-diaminobenzidine) (1ml DAB buffer with two drops of 
DAB reagent) for 30 minutes then briefly rinsed with water. Cells were counterstained for 
20 seconds with Mayer’s Hematoxylin then rinsed with water, air-dried and mounted with 
Pertex mounting media. 
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Table 2.8 Biochemical consumables 
PRODUCT SUPPLIER CATALOG # 
Cell Stimulations 
Aprotinin Roche Biochemicals, Burgess Hill, UK 236624 
Bromophenol blue BD electran 44305 
Bradford Reagent Bio-Rad 500-006 
Glasgow’s Modified Eagle 
medium 
Invitrogen 21710-025 
200mM Glutamine Invitrogen 25030-024 
Glycerol Sigma G5150 
1M HEPES Invitrogen 15630-056 
Leupeptin Sigma L8511 
Nonidet P40 VWR, Leicestershire, UK 560092-L 
Pertussis toxin Calbiochem  
Pepstatin Sigma P5318 
Phosphate buffered saline 
(PBS) 
Invitrogen 18912-014 
PMSF Sigma H0891 
Sodium Chloride Sigma S7653 
SDS VWR 442444-H 
Sodium Fluoride Sigma S6521 
Sodium Molybdate VWR 102542-Q 
Sodium Vanadate Sigma S6508 
Soybean Trypsin Inhibitor Sigma T9003 
Trizma (Tris) base Sigma T8404 
Protein Resolution and Immunoblotting 
30% 
Acrylamide/bisacrylamide 
Bio-Rad 161-0158 
Ammonium Persulphate Sigma A7460 
Bovine Serum Albumin 
(BSA) 
Roche Biochemicals 735-108 
ECL Amersham/GE Healthcare, 
Buckinghamshire, UK 
RPN-2106 
ECL Advance Amersham/GE Healthcare RPN-2135 
Glycine Sigma G8790 
Hybond ECL Nitrocellulose 
membrane 
Amersham/GE Healthcare RPN203D 
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Ovalbumen Sigma A5378 
Ponceau S Sigma P7170 
Sodium azide Fisher Scientific S2380-48 
TEMED Sigma T9281 
3MM Whatman paper VWR 3030917 
Immunochemistry 
His-Tag Antibody Cell Signalling Technologies 2366 
Peroxidase Block Dako Cytomation 002428 
DAB Dako Cytomation K3465 
Mayer’s Hematoxylin BDH  
Pertex Mounting Media Cell Path SEA-0104-00A 
 
 
2.4 Functional assay techniques 
 
2.4.1 XTT dye reduction metabolism assay 
 
This technique was adapted from that used to assay for activated T cell and murine 
cytokine-dependent cell line viability and proliferation (Roehm et al., 1991, Scudiero et 
al., 1988). The assay relies on the cleavage of yellow tetrazolium salt XTT (sodium 3’-[1-
(phenylamino)-carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid 
hydrate) by mitochondrial dehydrogenases present in metabolically active cells, to 
produce an orange, water-soluble, formazan dye product. Optical density is measured at 
450nm and the bioreduction of XTT is potentiated by the addition of phenazine 
methosulfate (PMS), an electron coupling agent. 
 
2.4.1.1  XTT assays for BaF/3 cells 
 
BaF/3 cells were plated at 1x103 cells/well in NUNC flat bottomed 96 well plates in 
serum-free AIM-V media supplemented with recombinant mIL-3 to a final volume of 
100µl. Cells were incubated with inhibitors for 48-72 hours at 37oC. 
 
PMS-XTT solution was made by adding 5µl of 1.53mg/ml PMS in PBS to 1ml of 1mg/ml 
XTT in warmed medium. 25µl of PMS-XTT was added per well and incubated at 37oC 
for 4 hours. The soluble formazan product was measured at 450nm on a Versamax 
plate reader. 
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2.4.1.2  XTT assays for mESCs 
 
Murine ESCs were plated on a NUNC flat bottomed 96 well plate at 2.5x103 cells per 
well in GMEM plus 10% Hyclone serum supplemented with 1000U/ml LIF. Inhibitors 
were added after cells had adhered to give a final volume of 200µl. Plates were 
incubated for 24-48 hours at 37oC. 50µl of PMS-XTT solution was added per well. After 
4 hours incubation, the absorbance at 450nm was read on a Versamax microplate 
reader. 
 
2.4.1.3  Analysis of XTT assay 
 
The mean absorbance of wells containing GMEM, Hyclone and PMS-XTT solution but 
no cells was subtracted from the absorbance of each well containing cells. Data were 
analysed by a one-way ANOVA, with Dunnet’s post-hoc test where appropriate, to 
detect any effect of treatment on cell metabolism. 
 
2.4.2 Alkaline Phosphatase self-renewal assay 
 
Self-Renewal of mESCs was assessed by assaying for mESC surface alkaline 
phosphatase activity. Self-renewing mESCs express alkaline phosphatase, but cell-
surface expression is lost upon differentiation (Scutt and Bertram, 1999). 
 
E14tg2A or Mek* transfected mESCs were plated at 1.5x103 cells per well of 6 well 
NUNC-tissue culture plates coated with 0.1% (w/v) porcine gelatin in GMEM, or 
complete KO SR medium where stated, supplemented with 10% Hyclone serum (or 
10% Biosera serum) and 1000U/ml LIF (Chemicon). For some experiments, limited LIF 
concentrations were used, these are indicated accordingly. Where indicated, 500ng/ml 
tetracycline was added. Inhibitors were added after 4 hours when cells had adhered. 
Plates were incubated for 4-5 days at 37oC with 5% (v/v) CO2.  
 
Cells were washed twice with PBS and fixed with 100% methanol for 10 minutes. Plates 
were allowed to air-dry at room temperature. Staining was conducted by applying a 
solution of 0.1M Tris-HCl pH 9.2, 200µg/ml Napthol AS-MX and 1mg/ml Fast Red TR 
Salt, for 20 minutes. Wells were washed twice with milliQ® H2O and air-dried. 
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All colonies were counted in each well and scored according to the extent of staining 
and appearance. Pure self-renewing colonies stain bright red and are compact with a 
smooth outline. Self-renewing colonies stain strongly in the centre with a paler outer 
area and often have a rough perimeter to the colony. Differentiated cells stain weakly or 
do not stain at all and have a flattened, rough morphology. The number of pure self-
renewing colonies alone or total self-renewing colonies (the sum of pure self-renewing 
and self-renewing colonies) were expressed as a percentage of the total number of 
colonies in each well. The means plus S.E.M of a number of independent experiments 
are shown. Where a treatment was found to alter the total number of colonies, alkaline 
phosphatase assay data are represented graphically by the number of self-renewing 
colonies and the number of non-self-renewing colonies observed on the same graph, 
thus giving the total number of colonies for that treatment. Statistical significance of the 
results was determined using ANOVA and Dunnet’s post hoc test or a Student’s t-test 
where appropriate, where * indicates p<0.05, ** indicates p<0.01 and *** indicates 
p<0.001. 
 
2.4.3 Cell Viability Counts 
 
 
E14tg2A mESCs were plated at 2 x 104 cells per 60mm tissue culture dish and 
incubated with 103 U/ml LIF in the presence of vehicle (DMSO), LY294002, Compound 
15e or PIK-75, in triplicate, for 1-4 days. At 24 hour time points, adherent cells were 
harvested by dissociation using trypsin/EDTA. Live cells were determined using the vital 
dye trypan blue. Cells were counted using a haemocytometer in triplicate and data 
represented graphically with standard deviations. 
 
2.4.4 Analysis of apoptosis using DiOC6 staining 
 
Mitochondrial membrane integrity was assessed by DiOC6 (3,3’ –
dihexyloxacarbocyanide iodide) staining. Used at low concentrations DiOC6 is a cell-
permeable, green fluorescent dye that preferentially stains the mitochondria of live cells. 
Inner mitochondrial membrane impermeability aids the maintenance of a proton 
gradient, essential for oxidative phosphorylation. Mitochondrial membrane 
permeabilisation is both a marker of and an irreversible point in programmed cell death 
(Petit et al., 1995, Rottenberg and Wu, 1998). Mitochondrial membrane permeabilisation 
causes dissipation of the proton gradient, dissipation of mitochondrial membrane 
potential and functional failure of the mitochondria. DiOC6 dye is lipophilic and 
accumulates in the mitochondrial matrix of live cells with intact inner mitochondrial 
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membranes. A decrease in DiOC6 staining and a corresponding decrease in FL1 
fluorescence measured by flow cytometry are indicative of reduced mitochondrial 
membrane potential and apoptosis. 
 
Cells were treated with vehicle (DMSO), LY294002, Compound 15e or PIK-75 for 16 
hours. Media was collected from each treatment dish to ensure that cells that may have 
detached from a colony or the tissue culture dish surface were collected. Cells were 
dissociated using trypsin/EDTA and resuspended in the corresponding media. Cells 
were washed twice in PBS and resuspended at 1x106 cells in 1ml PBS. As a positive 
control, a sample of vehicle treated cells were pre-treated with 100µM carbonyl cyanide 
m-chlorophenyl hydrazone (CCCP) for 20 minutes. CCCP is a mitochondrial-uncoupling 
agent that induces mitochondrial membrane permeability and apoptosis.  
 
CCCP treated and inhibitor treated cells were treated with 1nM DiOC6 (in DMSO). A 
sample of unstained control cells was also retained. All cell samples were incubated in 
the dark at room temperature for 30 minutes. Cells were washed three times with PBS 
and resuspended in 1ml PBS. Fluorescence was measured using a FACS Canto on 
parameter FL1 (Galluzzi et al., 2007, Metivier et al., 1998). DiOC6 staining data were 
analysed using Cell Quest flow cytometry software (BD). 
 
  
Table 2.9 Functional analysis technique consumables 
PRODUCT SUPPLIER CATALOG # 
XTT Dye Reduction Assay 
XTT Salt Sigma X4626 
Phenazine methosulfate 
(PMS) 
Sigma P5812 
AIM-V Media Gibco (Fisher Scientific) 31035 
Self-Renewal Assay 
Napthol-AS MX Sigma N4875 
Fast Red TR Salt Sigma F2768 
DiOC6 Staining 
DiOC6 Calbiochem 305110 
CCCP Calbiochem 215911 
 
 
 
 
 
Chapter 2: Materials and Methods 
89 
2.5 Molecular techniques 
 
2.5.1 Virtual northern expression data 
 
Expression information for Pik3ca, Pik3cb, Pik3cd, Pik3cg and LPA/S1P receptors was 
gained from virtual Northern data available from the NCBI Unigene database 
(http://www.ncbi.nlm.nih.gov/unigene). Searches were made for genes of interest and 
the data available scrutinised for expression during mouse embryo development. Details 
of this information are referenced in the text and the date the database was accessed is 
also given. 
 
2.5.2 Expression analysis 
 
Cells were incubated with appropriate inhibitors for 3-7 days as indicated. Expression of 
self-renewal and early lineage marker mRNA was assessed to determine the fate of 
mESCs. Expression of PI3K catalytic subunit isoform mRNA was used to confirm a 
decrease in expression following siRNA-mediated knockdown. 
 
2.5.2.1  RNA isolation 
 
Cells were washed twice with PBS, resuspended at 1ml Trizol per 1x106 cells and 
transferred to sterile RNase-free 1.5ml Eppendorf tubes. After 5 minutes, 200µl 
chloroform was added and tubes were shaken vigorously. The two phases were allowed 
to separate for 2-3 minutes at room temperature followed by centrifugation at 10000 rpm 
for 15 minutes at 4oC. The aqueous upper phase was transferred to sterile 1.5ml tubes 
and 500µl isopropanol added to precipitate RNA. After 10 minutes, tubes were 
centrifuged as before to pellet the RNA. The supernatant was discarded and the pellet 
washed with ice-cold 70% ethanol. Tubes were centrifuged at 10000 rpm for 5 minutes 
at 4oC. The ethanol was aspirated and pellets allowed to air dry briefly. The RNA pellet 
was resuspended in 10-30µl RNase-free water. To denature secondary structures and 
aid solubilisation, tubes were incubated at 55oC for 5 minutes. RNA was stored at -80oC. 
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2.5.2.2  RNA quantification 
 
RNA was quantified by measuring the absorption of light at 260nm. Protein absorbs light 
at 280nm, therefore measuring the absorption at both 260nm and 280nm allows 
quantification of RNA and assessment of protein contamination.  
 
RNA was diluted 1:100 in milliQ® H2O and absorbance measured using a GeneQuant II 
spectrophotometer. 
 
RNA concentration was calculated using Beer’s law: 
 
A260 = ε Cl 
 
Where A260 is the absorbance at 260nm, ε is the RNA extinction coefficient (25µg/µl/cm), 
C is the concentration of the diluted sample and l is the path length (1cm for the cuvette 
used). 
 
Ideally the ratio of absorption A260/A280 should be close to 2. However, this ratio is pH 
sensitive so values of 1.6-2.0 were accepted since milliQ® H2O was used to dilute 
samples prior to quantification. If purity was questionable, (A260/A280 <1.6) a sample of 
RNA was separated by agarose gel electrophoresis. Electrophoresis equipment was 
made RNAse free by washing in 3% H2O2. Non-degraded RNA produces two bands 
corresponding to 28s and 16s rRNA with the latter being approximately half as intense 
as the former. 
 
2.5.2.3  Reverse transcription polymerase chain reaction  
 
Reverse transcription was used to make cDNA for expressional analysis from mRNA. 
Contaminating genomic DNA was removed by DNase treating RNA. 1µg RNA was 
incubated with 0.5µl of 10x DNase buffer, 1µl of DNase and an appropriate volume of 
RNase-free water to give a final volume of 5µl at 37oC, for 30 minutes. 1µl of DNase 
Stop Solution (0.5M EDTA, pH 8.0) was added and tubes were incubated at 65oC for 10 
minutes to denature DNase enzymes. 0.5µl RNasin Plus and 0.5µl Oligo dT was added 
and incubated for a further 5 minutes at 65oC. A reverse transcription master mix was 
made with 6µl RNase-free water, 4µl First Strand sample buffer, 5mM DTT, and 50µM 
dNTPs (dATP, dTTP dGTP and dCTP) per sample. Samples were incubated on ice for 
2-3 minutes then 13µl of reverse transcription master mix was added to each sample 
tube. Finally 1µl Superscript Reverse Transcriptase III was added to each sample. 
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Duplicate negative control samples were set up in the absence of reverse transcriptase 
enzyme. The reverse transcription reaction was performed by incubating tubes for 50 
minutes at 50oC followed by 15 minutes at 70oC in a Techne Touchgene gradient PCR 
machine. The resulting cDNA products were stored at -20oC. 
 
2.5.2.4  Primer design 
 
Primers were designed to detect expression of PI3K catalytic isoform subunits p110α, 
p110β and p110δ. Where possible, sense (S) and antisense (A) primers (Table 2.10) 
were designed according to the following guidelines (Innis et la., 1990). Primers should 
be 17-28 base pairs in length with 3’ terminal bases G, C, GC or CG. GC content should 
be 50-60% to produce a melting temperature of 55-80oC but runs of 3 or more G’s or C’s 
are undesirable. 3’ complementarity or internal self complementarity should also be 
avoided. 
 
Melting temperature was calculated according to the base content of primers (Rychlik 
and Rhoads, 1989): 
 
Tm = 4(G+C) + 2(A+T) 
 
Possible primer sequences were checked for the potential formation of dimers and 
hairpins using Net Primer, an online tool by Premier Biosoft 
(http://www.premierbiosoft.com/netprimer/) 
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Table 2.10 Primers 
MARKER 
GENE PRIMER SEQUENCES 
ANNEALING 
TEMP oC CYCLES SOURCE 
Self-Renewal Markers 
Nanog S: 5'-CTCTTCAAGGCAGCCCTGAT-3' A: 5'-CCATTGCTAGTCTTCAACCAC-3' 60 25-30 
Paling, N 
(designed in 
house) 
Rex1 S: 5'-CGTGTAACATACACCATCCG-3' A: 5'-GAAATCCTCTTCCAGAATGG-3' 55 25-30 
(Faloon et 
al., 2000, 
Lacaud et al., 
2004) 
Oct4 S: 5’-GCGTTCTCTTTGGAAAGGTGTTC-3’ A: 5’-CTCGAACCACATCCTTCTCT-3’ 58 25-30 
Paling, N. 
(Designed in 
house) 
Early Lineage Markers 
GATA1 S: 5’-ACTCGTCATACCACTAAG-3’ A: 5’-AGTGTCTGTAGGCCTCAG-3’ 56 30 
(Ogawa et 
al., 1999) 
GATA6 S: 5’-GCAATGCATGCGGTCTCTAC-3’ A: 5’-CTCTTGGTAGCACCAGCTCA-3’ 56 30 
(Fujikura et 
al., 2002) 
Pax6 S: 5’-CGGAGAAGACTCGGATGAAG-3’ A: 5’-GGCCCTTCGATTAGAAAACC-3’ 56 30 
(Yoshida-
Koide et al., 
2004) 
Nodal S: 5’-ACGTTCACCGTCATTCCTTC-3’ A: 5’-TCAGCTTCCCAAAGCAAAGT-3’ 62 30 
(Yoshida-
Koide et al., 
2004) 
FGF 5 S: 5’-AAAGTCAATGGCTCCCACGAA-3’ A: 5’-CTTCAGTCTGTACTTCACTGG-3 62 30 
(Cartwright et 
al., 2005, 
Oka et al., 
2002) 
PI3K Catalytic Isoforms 
p110α S: 5'-AAATGGCGACGACTTACG-3' A: 5'-TTGTTCTTGTCCTTGAGC-3' 54 30 
Kingham, E. 
Designed 
according to 
guidelines 
(Section 
2.5.2.4) 
p110β S: 5'-TAATGTGTCAAGTCGTGG-3' A: 5'-CAGCCTACAGCGTATTCC-3' 58 30 
p110δ S: 5'-CTGGACCTGAGGATGACG-3' A: 5-GGCTCAAGTCCAAGAACC-3' 58 30 
Loading Markers/House-Keeping 
β-actin S: 5'-TAGGCACCAGGGTGTGATGG-3' A: 5'-CATGGCTGGGGTGTTGAAGG-3' 62 25 
Storm, M. 
(designed in 
house) 
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2.5.2.5 Quantitative polymerase chain reaction 
 
PCR exponentially amplifies DNA enzymatically using GoTaq, a modified form of Taq 
DNA polymerase lacking 5’ 3’ exonuclease activity. PCR was conducted by combining 
10µl 5X Green GoTaq Flexi buffer or colourless GoTaq Flexi buffer, 2mM MgCl2, 250µl 
dNTPs, 5pmol sense primers, 5pmol antisense primers and 0.5U GoTaq DNA 
polymerase. 2µl of DNA from the reverse transcription reaction was added to give a final 
volume of 20µl. Reactions were performed using a Techne Touchgene gradient PCR 
machine. 
 
Table 2.11 PCR program for expression analysis 
STAGE TEMPERATURE  DURATION  CYCLES 
Initial Elongation 94oC 5 min 
 
Denaturation 94oC 30 s 
Annealing Primer Dependent 30 s 
25-30 
Primer Dependent 
Elongation 72oC 60 s 
Final Elongation 72 oC 5 min 
Hold 4 oC   
 
2.5.2.6  Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used to separate DNA in order to visualise PCR 
products. Typically, 2% Agarose gels were used to resolve linear DNA of 0.05-1.5kb. 
Agarose was dissolved in Tris-acetate EDTA (TAE) buffer (50x TAE buffer: 2M Tris, 
50mM Na2 EDTA (pH8.0) adding glacial acetic acid (to pH 7.6)) by boiling. Once cooled, 
the agarose solution was poured into a pre-assembled agarose gel casting support with 
a well forming comb inserted. Once set, the gel was placed into an electrophoresis tank 
containing TAE. When Green GoTaq Flexi buffer was used in PCR reactions, no DNA 
loading buffer with dye was required, when colourless GoTaq Flexi buffer was used, 
DNA loading buffer (6x loading buffer: 30% (v/v) glycerol, 0.05% (w/v) bromophenol 
blue) was added to each PCR product tube. PCR products were loaded into individual 
wells and agarose gels run at 70-90V until sufficient separation was achieved. Agarose 
gels were submersed in 0.5µg/ml ethidium bromide in TAE for 15 minutes. Ethidium 
bromide intercalates DNA and can be visualised under UV light. Agarose gels were 
photographed in a Syngene UV transluminator using Genesnap software.  
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2.5.2.7  Real-time quantitative PCR 
 
Real time quantitative PCR (QPCR) was conducted using a 1X solution of reaction 
buffer containing 2.5mM MgCl2, 5pmol sense primers, 5pmol antisense primers and 1µl 
SYBR Green enzyme to a final volume of 8µl with PCR sterile H2O. 8µl of this reaction 
mix was added to glass LightCycler capillaries (Roche) and 2µl of 1:5 diluted sample 
cDNA from RT-PCR reactions as described in section 2.5.2.3. Capillaries were sealed 
with plastic caps and centrifuged at 4000 rpm for 20 seconds at 4oC.  
 
Capillaries were loaded into the carousel and placed into a Roche Molecular 
Biochemical LightCycler. LightCycler amplification using SYBR Green was performed for 
each sample in duplicate, together with a no-template negative control. The LightCycler 
program for acquiring real-time quantitative PCR data is detailed in Table 2.12. Briefly, 
samples were incubated at 95 oC for 10 minutes at the start of each run to activate Taq 
DNA polymerase. Real-time quantitative PCR utilises the double-stranded DNA 
intercalator SYBR Green. Fluorescence emitted by SYBR green intercalation during 
amplification of DNA was measured at 530nm during the elongation phase by the 
LightCycler. Increasing fluorescence, when amplification increases the amount of DNA 
present, was monitored over 40 PCR cycles. Annealing temperatures for primers are 
given in Table 2.13. 
 
Table 2.12 LightCycler program 
STAGE TEMPERATURE DURATION CYCLES 
Hot Start 95 oC 10 minutes 
 
Initial Denaturation 95 oC 30 seconds 
Denaturation 95 oC 10 seconds 
40 cycles Annealing 
Primer Dependent  
(Table 2.13) 5 seconds 
Elongation 72oC 16 seconds 
 
Melting Curve 65-95 oC  0.1 oC/sec  
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Table 2.13 QPCR annealing temperatures 
PRIMERS ANNEALING TEMPERATURE 
β-actin 60 oC 
P110α 54 oC 
P110β 60
 oC 
P110δ 58 oC 
Nanog 60 oC 
 
 
Following a run, melt curve analysis was performed to confirm the presence of only the 
desired PCR product. Melt curves were constructed by programming the LightCycler to 
slowly heat the PCR product from 65-95oC. This induces melting of the double-stranded 
DNA and a decrease in SYBR Green fluorescence, which was continuously monitored. 
Melt curve analysis produces melting peaks (examples of which are shown in Figure 
2.2) that are specific to particular DNA products. Where necessary, PCR products were 
subsequently analysed by agarose gel electrophoresis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Melting peaks are specific to particular DNA products 
The melting peaks shown here are specific to a particular DNA product. The presence of 
abnormal or additional peaks for samples may indicate contamination of the capillary 
samples or poor PCR primer design leading to the amplification of a non-specific region 
of the template DNA. Furthermore, melt curve analysis confirms the lack of PCR product 
in the no template negative control capillaries, represented here by the pink trace. 
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Variations in cDNA synthesis efficiency of samples, differences in the amount of starting 
cDNA, RNA degradation, pipetting errors and loading errors were corrected for by 
comparing the data accumulated for target genes (for example p110 isoform genes) with 
that of a reference gene (β-actin). Crossing point values were determined by the 
LightCycler Version 4.0 software (Roche, Idaho Technology Inc.) using data obtained by 
monitoring fluorescence intensity per PCR cycle. A crossing point value for a reaction is 
the cycle at which the fluorescent signal becomes detectable as greater than the 
threshold background signal (Figure 2.3). Thus, crossing point values are different for 
each sample depending on the amount of target gene in the starting reaction mix. 
Crossing point values appear within the logarithmic-linear phase where a logarithmic 
increase in fluorescence is detected (Figure 2.3). Furthermore, the cycle at which a 
crossing point occurs is presumed to be proportional to the amount of starting material 
of the target gene. Efficient PCR reactions are considered to have one replication of 
every PCR product every cycle. Within the logarithmic region, amplification efficiencies 
of each reaction are constant and can therefore be compared. Crossing points are 
assumed to be reliably proportional to the initial starting amount of target gene. 
Therefore, a target to reference ratio was calculated from the crossing point values 
derived. Measurements taken at the plateau phase do not provide information regarding 
the amount of starting material since reactions with low or high amounts of target gene 
or different efficiencies can reach the same plateau. 
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Figure 2.3 A typical amplification curve  
The fluorescence intensity versus the number of cycles of PCR are plotted to obtain an 
amplification curve. Here the blue trace represents a positive control where the DNA 
product is amplified from the template DNA and the green trace represents a no 
template negative control sample. The number of cycles where the fluorescent intensity 
of the target gene is distinguishable from the background fluorescent signal is described 
as the crossing point (indicated on the amplification curve) and occurs within the 
logarithmic linear phase.  
 
 
Duplicate calibrator cDNA samples were included for all real time QPCR runs. Calibrator 
cDNA from a single batch of RT-PCR cDNA product was diluted 1:5 and used for all 
LightCycler runs in this study. This allows the data for each run to be compensated to 
account for batch variations in SYBR Green and differing experimental sample RT-PCR 
efficiencies.  
 
Standard curves for target and reference genes were determined to allow relative 
quantification of the unknown samples. Serial dilutions (typically 1:5 1:50 1:500 etc.) of a 
standard template cDNA were used in triplicate to determine a standard curve for each 
gene used in the present study. Serial dilutions were set up in separate capillaries but 
within the same LightCycler run. The LightCycler software was used to generate 
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standard curves for each gene where the cycle number at the crossing point for each 
dilution of standard template was plotted versus the log concentration of starting cDNA 
material (Figure 2.4). Therefore, the crossing point value for any given sample, 
determined after a LightCycler run, allows the relative concentration of starting material 
to be determined. Furthermore, PCR efficiencies (E) are generated from the slope of the 
standard curve for each gene investigated using the formula: 
 
E = 10–1/slope 
 
Under optimal conditions, PCR efficiency E=2. However, most PCR reactions do not 
occur at maximum efficiency and, as a result, the error gets greater with increasing PCR 
cycles. In the example shown in Figure 2.4, E= 1.824 and can be corrected for by an 
efficiency algorithm, part of the LightCycler Version 4.0 software. 
 
 
 
 
 
 
 
 
 
Figure 2.4 Standard curves were plotted for all target and reference genes 
For each target gene and the reference gene, a standard curve was determined by 
plotting the crossing point versus the log concentration of serially diluted cDNA. From 
the slope of the standard curve, PCR efficiency values are derived and are used to 
correct data collected from unknown samples. Error values are also derived from the 
standard curve (mean squared error, Σ (∆x)2/n  where ∆x is the vertical distance 
between data points and the regression line and n the number of data points), indicating 
replicate variations such as pipetting errors between LightCycler capillary reactions. An 
error value ≤0.1 is acceptable. 
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2.5.2.7.1 QPCR relative quantification by calibrator normalisation and efficiency 
correction 
 
In the present study, QPCR data were analysed by relative quantification, where the 
target concentration is expressed as a ratio of target (p110) to reference gene (β-actin). 
Using the PCR efficiency and crossing point values allow quantification of both a target 
and a reference gene. To derive the QPCR values, expressed as histogram graphs in 
the present study, LightCycler software divides the ratio of target to reference gene 
relative concentrations by the calibrator relative concentration in order to normalise the 
data from each run: 
 
Normalised ratio =  concentration target sample        /     concentration target calibrator 
                               concentration reference sample     concentration reference calibrator 
 
 
This corrects variations in replicate samples within the same run and for different runs. 
Additionally, PCR efficiency correction is conducted to account for sub-maximal PCR 
efficiencies.  Finally the mean and standard deviation of corrected and normalised ratio 
values (in duplicate per run and two runs conducted per experiment) are used to plot 
histogram graphs representing the relative normalised amount of the target gene of 
interest. 
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2.5.3 Transient transfection 
2.5.3.1  Transfection of mESCs with siRNA 
 
 
Transient transfections were conducted using short interfering RNA (siRNA) to 
knockdown the expression of PI3K catalytic p110 subunit isoforms and Nanog. The 
method of conducting RNA interference (RNAi) using siRNAs was first identified by 
investigations into post-transcriptional gene silencing in plants (Hamilton and 
Baulcombe, 1999) and later adapted for use in mammalian cells (Elbashir et al., 2001). 
 
Briefly, double stranded RNAs enter a cell aided by a transfection reagent. This RNA is 
cleaved into fragments of 21-25 nucleotides of siRNA duplexes by Dicer (in drosophila), 
an RNAse III-like enzyme (Figure 2.5) (Bernstein et al., 2001, Elbashir et al., 2001). 
Following this, siRNAs are incorporated into the RNA induced silencing complex (RISC) 
in an ATP-dependent manner (Nykänen et al., 2001). When siRNAs become single 
stranded, the antisense strand remains bound to RISC and activates the complex. The 
activated complex then binds to the complementary endogenous mRNA sequence. 
Once bound, mRNA is cleaved by Slicer (in drosophila), a component of RISC and 
targeted for degradation by nucleases therefore, preventing translation into functional 
protein (Martinez et al., 2002).  
 
For the transfection of mESCs with siRNA, 5nmol siRNA (Dharmacon or Ambion) was 
resuspended in RNase-free siRNA buffer (20mM KCl, 6mM HEPES pH7.5 and 0.2mM 
MgCl2) to a working concentration of 20µM. Aliquots were stored at -80oC.  
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Figure 2.5 Gene silencing with siRNA 
Double stranded RNA is cleaved by Dicer to form siRNAs. These subsequently bind to 
RISC and unwind. Antisense siRNA bound to RISC binds to complementary mRNA. 
Slicer, a member of RISC, cleaves mRNA rendering it unsuitable for translation. 
 
 
Lipofectamine transfection reagent was incubated with Knockout DMEM (lacking 
Knockout Serum Replacement) (3.1µl lipofectamine per 50µl Knockout DMEM) for 5 
minutes at room temperature. In individual tubes, 2.5, 5.0 or 7.5µl siRNA was diluted 
with Knockout DMEM to a total volume of 50µl. Next 50µl of lipofectamine/Knockout 
DMEM solution was added to tubes containing siRNA and incubated at room 
temperature for 20 minutes. Meanwhile, mESCs were washed and resuspended at 
8.9x104 cells/ml in KO complete media. Following incubation, 900µl of cell suspension 
(8x104 cells) was added to 100µl lipofectamine/siRNA solution and plated onto 6 well 
NUNC plates coated with 0.1% gelatine. 1ml of KO complete media was added to each 
well to give a final volume of 2ml and a final dilution of lipofectamine of 1:650. Plates 
were incubated at 37oC with 5% (v/v) CO2.  
 
 
Dicer
dsRNA
siRNAs
RISC
Antisense siRNA
mRNA
ATP
ADP
mRNA Cleavage
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For transfection with Dharmacon smartpool siRNA targeting Pik3ca, Pik3cb, Pik3cd and 
Nanog, and non-targeting siRNA, final concentrations of 25, 50 and 75nM siRNA were 
used. Cells were initially transfected for 48 hours followed by re-transfection. For re-
transfection, lipofectamine and siRNA were incubated in Knockout DMEM as before. 
Cell media was replaced with fresh KO complete media plus 100µl of 
lipofectamine/siRNA solution. Plates were incubated at 37oC with 5% (v/v) CO2 for 24 
hours after re-transfection then harvested for use. Harvested cells were either used to 
set up self-renewal assays, which were incubated for a further 4 days before fixing and 
staining colonies for alkaline phosphatase, lysed immediately with solubilisation buffer or 
resuspended immediately in TRIzol for RNA isolation. Knockdown of targeted genes 
was confirmed by quantitative and semi-quantitative PCR.  
 
Ambion siRNA (Applied Biosystems) was also used to target Pik3cb at two independent 
regions. Additionally Ambion siRNAs were selected to targeted regions different from 
those targeted by Dharmacon siRNA (Figure 2.6) For transfection with Ambion siRNA, 
Pik3cb targeting and negative control siRNA, a final siRNA concentration of 10nM was 
used. Cells were plated at 1x105 cells/well with lipofectamine/siRNA solution prepared 
as described above. For Ambion siRNA experiments, a 48h transfection period was 
sufficient to induce knockdown of target genes. Following this, cells were harvested then 
lysed immediately for protein analysis, resuspended immediately in TRIzol for RNA 
isolation or used for self-renewal assays, which were incubated for a further 4 days 
before fixing and staining colonies for alkaline phosphatase. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Pik3cb regions targeted by Dharmacon and Ambion siRNAs 
Dharmacon Smartpool siRNAs contain four individual siRNAs which target four different 
regions of Pik3cb at different exons (2 and 3) or different exon boundaries (7/8 and 
18/19). Two Ambion Silencer Select siRNAs were also used in this study; s93107 and 
s93108 which target exons 22 and 10 respectively. 
Pik3cb
Exons
Coding region
Dharmacon Smartpool siRNAs
Ambion Silencer Select siRNAs
18/19 7/8 3 2
22 10
s93107 s93108
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Table 2.14 Molecular techniques consumables 
PRODUCT SUPPLIER CATALOG # 
Expression Analysis 
Agarose Invitrogen 15510-027 
DNase Promega M6101 
dNTPs Invitrogen 10297-018 
Ethidium Bromide Bio-Rad 1610433 
Oligo (dT)15 Primer Promega C1101 
Primers Invitrogen Made to order 
RNase Free Eppendorfs Eppendorf 3810X 
RNasin Plus Promega N2611 
Superscript III reverse transcriptase 
(including RT buffer and DTT) 
Invitrogen 18080-044 
Taq Polymerase Promega M1661 
TRIzol Invitrogen 15596-018 
siRNA-Mediated Knockdown 
Lipofectamine 2000 Invitrogen 11668-019 
5X siRNA Buffer Dharmacon B-002000-UB 
siGENOME SMARTPool siRNA: 
Mouse Nanog siRNA Dharmacon NM-057004-00 
Mouse Pik3ca siRNA Dharmacon NM-008839-00 
Mouse Pik3cb siRNA Dharmacon NM-008840-00 
Mouse Pik3cd siRNA Dharmacon NM-029094-00 
Non-Targeting Control siRNA Dharmacon D-001206-13-20 
Silencer Select siRNA Pre-designed siRNA: 
Mouse Pik3cb Targeting siRNA 
s93107 
Ambion (Applied 
Biosystems) Warrington UK 
4390771 s93107 
Mouse Pik3cb Targeting siRNA 
s93108 
Ambion 4390771 s93108 
Negative Control siRNA Ambion 4390843 
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3 RESULTS: PI3K activation, regulation of 
the MAPK pathway and lineage 
commitment of mESCs 
Chapter 3: Results 
105 
3.1 Introduction and aims 
 
PI3Ks have been implicated in both the maintenance of self-renewal and in the 
promotion of proliferation of mESCs (Sections 1.3.6.1 and 1.3.6.2). Inhibition of PI3Ks 
leads to a decrease in alkaline phosphatase positive colonies and a reduction in Nanog 
expression demonstrating a loss of self-renewal (Paling et al. 2004, Storm et al., 2007). 
Faster growth rates are observed in mESCs lacking PTEN, the endogenous antagonist 
of PI3K activity (Sun et al., 1999), and enhanced growth rates were also observed 
following over-expression of ERas, a Ras isoform that activates PI3Ks in mESCs 
(Takahashi et al., 2003). 
 
A variety of external stimuli, particularly growth factors and cytokines, are known to 
activate pathways that facilitate the maintenance of self-renewal and other cellular 
functions. For example, LIF is known to promote the maintenance of self-renewal and 
pluripotency via activation of Signal Transducer and Activator of Transcription 3 (Stat3) 
(Niwa et al., 1998, Boeuf et al., 1997) and by the activation of PI3Ks (Paling et al., 
2004). However, in the absence of serum, in a chemically defined media, both LIF and 
BMP4 are required to maintain self-renewal (Ying et al., 2003a, Ying et al., 2003b). 
BMP4 maintains self-renewal by activation of Smad proteins and subsequent regulation 
of Id (Inhibitor of differentiation) gene expression (Hollnagel et al., 1999, Ying et al., 
2003b) and also prevents differentiation by the inhibition of Erk and p83 of the Mitogen 
Activated Protein Kinase (MAPK) pathway (Qi et al., 2004). Previously, only LIF has 
been shown to activate PI3Ks in mESCs thus the present investigation sought to identify 
other such factors. Of interest were factors that might be present in routine culture 
media or factors that are known to be secreted by mESCs, which could be involved in 
autocrine signalling.  
 
It has previously been reported that inhibition of PI3Ks with LY294002 in mESCs 
enhances basal Erk phosphorylation (Paling et al., 2004) and that inhibition of the MAPK 
pathway, by the inhibition of Mek (directly upstream of Erk) with PD098059, can promote 
self-renewal (Burdon et al., 1999). Conversely, the effect of activating the MAPK 
pathway, as observed following PI3K inhibition, was investigated in the present study. 
 
Self-renewal appears to be a balance of inhibition of differentiation and promotion of 
self-renewal. In some cases, particular signalling pathways direct differentiation towards 
a particular lineage. For example, BMP4, in the absence of LIF and serum, promotes the 
differentiation of mESCs towards non-neural cell types (Wiles and Johansson, 1999). 
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Although the activity of PI3Ks support self-renewal and inhibition of PI3Ks with the broad 
selectivity inhibitor LY294002 leads to a loss of self-renewal (Paling et al., 2004, Storm 
et al., 2007), the effect of inhibiting PI3Ks in terms of directed differentiation has not 
been assessed. Therefore, a role for PI3Ks in lineage commitment was also addressed. 
 
 
3.2 Stimulation of PI3Ks by factors present in culture medium 
 
3.2.1 Serum-free chemically defined media 
 
The use of complex, serum containing or serum-replacement media impedes the 
identification of factors that may activate signalling pathways of interest. The presence 
of a variety of factors in routine culture media can mask the effects of stimulating cells 
with individual factors. In order to identify factors that activate PI3Ks in mESCs a serum-
free, chemically defined media with known components was used. This media was 
initially described for the culture of a rat neuroblastoma cell line (Bottenstein and Sato, 
1979, Brewer and Cotman, 1989, Brewer, 1993) but refined for the culture of mESCs 
(Ying et al., 2003a, Ying et al., 2003b). Supplemented with N2 and B27 (the components 
of which are listed in Table 2.1), this media can be used for the long-term culture of 
mESCs in a self-renewing, pluripotent state (Ying et al., 2003a).  
 
3.2.1.1 LIF stimulation of mESCs in chemically defined media 
 
The signalling response of mESCs to stimulation with LIF following culture in chemically 
defined media was assessed. Activation of the Stat3 pathway by LIF is important for the 
maintenance of self-renewal (Boeuf et al., 1997, Niwa et al., 1998) and pluripotency 
(Raz et al., 1999). Stat3 is phosphorylated following the binding of LIF to a heterodimer 
of the LIF receptor and the cytokine receptor gp130, and regulates the expression of the 
transcription factor c-myc (Cartwright et al., 2005). Prior to stimulation, mESCs were 
cultured in chemically defined medium containing supplements (detailed in Section 
2.1.3.2) for at least 2 days then incubated for 4 hours in media lacking supplements. 
Unstimulated mESCs exhibited no detectable basal Stat3 phosphorylation on the 
activating tyrosine (Y705). LIF stimulation for 2, 10 and 20 minutes induced the 
phosphorylation of Stat3 at Y705 (Figure 3.1A). These observations are consistent with 
LIF stimulation of mESCs cultured in serum containing or serum-replacement media 
(Paling et al., 2004). 
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Figure 3.1 LIF stimulates Stat3 and Erk phosphorylation in mESCs cultured in 
chemically defined media   
Prior to stimulation, mESCs were cultured in chemically defined culture media 
supplemented with N2, B27, LIF and BMP4. Cells were incubated for 4 hours in the 
absence of N2, B27, LIF and BMP4 to decrease basal signalling. 1000U/ml LIF was 
applied for 2, 10 or 20 minutes, as indicated. Following stimulation, cells were lysed and 
analysed by SDS-PAGE and immunoblotting with antibodies detecting pStat3 (Tyr705) 
(A) and pErk (Thr202/Tyr204) (B). Immunoblots were stripped and reprobed using 
antibodies detecting total Stat3 and Erk protein to ascertain equal loading. The data 
presented here are representative of three independent experiments. 
 
 
In addition to activating the Stat3 pathway, LIF is reported to activate the MAPK 
pathway, inhibition of which enhances self-renewal (Burdon et al., 1999). Prior to 
stimulation, low basal levels of Erk2 phosphorylation were detectable but 
phosphorylated Erk1 protein was not detected. LIF stimulation for 2 minutes did not alter 
Erk1 or Erk2 phosphorylation at Thr202/Tyr204 from basal, unstimulated levels. 
Stimulation with LIF for 10 or 20 minutes induced phosphorylation of both Erk1 and Erk2 
(Figure 3.1B). 
 
The signalling response to LIF stimulation of mESCs cultured in chemically defined 
media was found to be similar to the reported signalling response to LIF in mESCs 
cultured in serum-containing media (Paling et al., 2004). Having ascertained that this 
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media was suitable for investigating signalling in mESCs, it was used to assess the 
activation of PI3K signalling following short-term cell stimulation experiments. 
 
 
3.2.1.2 BMP4 stimulation of mESCs cultured in chemically defined media 
stimulates signalling downstream of PI3K 
 
BMP4 contributes to the maintenance of mESC self-renewal by activation of Smad 
proteins and by inhibition of MAPK pathway activity (Qi et al., 2004, Ying et al., 2003a, 
Ying et al., 2003b, Suzuki et al., 2006). To ascertain if BMP4 could activate PI3Ks in 
mESCs, cells cultured in chemically defined medium were stimulated with BMP4 and 
signalling downstream of PI3Ks was assessed. 
 
Murine ESCs were cultured in chemically defined media and incubated for 4 hours in 
chemically defined media lacking N2 and B27 supplements, and lacking LIF and BMP4. 
Unstimulated cells exhibited basal phosphorylation of PKB at Ser473, a site of 
phosphorylation important for the activation of PKB (Hanada et al., 2004). Additionally, 
basal phosphorylation of S6 (Ser235/236) and Erk2 (Thr202/Tyr204) were also 
detectable (Figure 3.2A). When stimulated with BMP4, no change in PKB 
phosphorylation was observed, where as, phosphorylation of Erk1, Erk2 and S6 were 
enhanced with 10ng/ml BMP4. Interestingly, stimulation of mESCs with BMP4 enhances 
S6 phosphorylation but not PKB (Figure 3.2A). Evidence exists to support both PKB-
dependent and PKB-independent activation of S6K, upstream of S6, according to the 
membrane or cytosolic localisation of PKB respectively (Dufner et al., 1999). This may 
explain the observation of S6 phosphorylation in the absence of PKB phosphorylation, 
although further investigation would be required to confirm PKB localisation. 
 
Treatment of mESCs with the broad selectivity PI3K inhibitor LY294002 did not alter 
basal PKB phosphorylation but did reduce basal S6 phosphorylation (Figure 3.2A). The 
phosphorylation of both Erk1 and Erk2 was enhanced by LY294002 treatment, 
consistent with previous reports in this mESC line (Paling et al., 2004). When mESCs 
were stimulated with BMP4 following pre-treatment with LY294002, no effect on PKB 
phosphorylation at Ser473 was detected (Figure 3.2A). LY294002 enhanced BMP4-
stimulated Erk1 and Erk2 phosphorylation but inhibited BMP4-induced S6 
phosphorylation, consistent with the activation of S6 via PI3K. 
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An alternative broad spectrum PI3K inhibitor was also used to investigate BMP4 induced 
signalling. Wortmannin is an irreversible inhibitor of PI3Ks that is less stable than 
LY294002 but still suitable for short-term investigations (Wymann et al., 1996). Unlike 
LY294002, treatment of mESCs cultured in chemically defined media with wortmannin 
produced a decrease in Erk2 phosphorylation (Figure 3.2B). This disparity might be the 
result of different inhibitor profiles or the way in which these inhibitors bind to PI3Ks 
(discussed in Section 1.2.3). Consistent with LY294002 treatment, wortmannin reduced 
basal phosphorylation of S6 (Figure 3.2B). BMP4-induced Erk phosphorylation was 
slightly reduced in cells pre-treated with wortmannin. Inhibition of PI3Ks with wortmannin 
resulted in reduced BMP4-induced S6 phosphorylation, in a similar manner to that 
observed using LY294002. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Response of mESCs cultured in chemically defined media to BMP4 
stimulation 
Murine ESCs grown in chemically defined media were incubated for 4 hours in the 
absence of LIF, BMP4, N2 and B27 supplements. Where indicated, cells were pre-
incubated with 5µM LY294002 (A) or 100nM wortmannin (B) for 30 minutes prior to 
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stimulation. Cells were stimulated with 1, 2, 5 or 10ng/ml BMP4, where indicated, for 5 
minutes. Signalling downstream of PI3Ks was assessed by SDS-PAGE and 
immunoblotting with antibodies to detect phosphorylated PKB (Ser473), Erk 
(Thr202/Tyr204) and S6 (Ser235/236). Equal loading was assessed by stripping and 
reprobing immunoblots with antibodies detecting PKB, Erk and Shp-2. The stimulation 
experiment shown is representative of four independent experiments. 
 
 
3.2.1.3 Insulin stimulation of mESCs cultured in chemically defined media 
stimulates signalling downstream of PI3Ks 
 
Activity of PI3Ks is reported to be essential for glucose metabolism and the survival of 
blastocyst stage embryos (Riley et al., 2006). Furthermore, the expansion of ICM cell 
numbers in preimplantation mouse embryos was reported to require PI3K activity 
(Harvey and Kaye, 1990). Typically, the class IA PI3Ks are activated upon stimulation of 
the insulin receptor (Vanhaesebroeck et al., 2005, Roche et al., 1998, Knight et al., 
2006). It was this class of PI3Ks that were implicated in maintaining mESC self-renewal, 
since expression of ∆p85, a dominant negative mutant of class IA PI3K regulatory 
subunit, leads to a reduction in alkaline phosphatase stained mESC colonies, indicating 
a decrease in self-renewal (Paling et al., 2004). Therefore, the activation of PI3K 
signalling by insulin was investigated in mESCs cultured in chemically defined media. 
 
Following an incubation period in chemically defined media lacking LIF, BMP4, N2 and 
B27 supplements, stimulation of mESCs with insulin was conducted. Insulin stimulation 
induced phosphorylation of PKB at serine 473, which could be enhanced by increasing 
the concentration of insulin used to stimulate cells (Figure 3.3A). Insulin stimulation of 
mESCs also induced Erk1, Erk2 and S6 phosphorylation at Thr202/Tyr204 and 
Ser235/236 respectively. Enhancements in Erk1, Erk2 and S6 phosphorylation were 
prominent following stimulation with 10µg/ml insulin. Pre-treatment with LY294002, to 
inhibit PI3Ks, prevented insulin-induced PKB and S6 phosphorylation (Figure 3.3A). An 
enhancement in both basal and insulin stimulated Erk1 and Erk2 phosphorylation was 
observed following LY294002 pre-treatment. In contrast, pre-treatment with wortmannin 
did not alter insulin-induced Erk2 phosphorylation but did prevent insulin-induced S6 
phosphorylation (Figure 3.3B). 
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Figure 3.3 Response of mESCs cultured in chemically defined media to insulin 
stimulation 
Murine ESCs grown in chemically defined media supplemented with LIF and BMP4 
were incubated for 4 hours in the absence of LIF, BMP4, N2 and B27 supplements. 
Where indicated, cells were incubated with 5µM LY294002 (A) or 100nM wortmannin 
(B) for 30 minutes prior to stimulation. Stimulations were conducted using 1, 2, 5 or 10 
µg/ml insulin for 5 minutes. Signalling downstream of PI3Ks was assessed by SDS-
PAGE and immunoblotting with antibodies detecting phosphorylated PKB (Ser473), Erk 
(Thr202/Tyr204) and S6 (Ser235/236). Equal loading was assessed by stripping and 
reprobing immunoblots with antibodies detecting PKB, Erk and Shp-2. The stimulation 
experiment shown is representative of four independent experiments. 
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3.2.2 Stimulation of mESCs in knockout serum-replacement media 
 
Serum and serum-replacement media are used for the routine culture of mESCs and 
contain a cocktail of undefined components that may contribute to maintaining self-
renewal. Having identified BMP4 and insulin as activators of PI3K signalling in mESCs 
cultured in chemically defined N2B27 media, the effect of BMP4 and insulin stimulation 
on mESCs grown in complete Knockout serum-replacement media was assessed.  
 
Following a period of serum starvation, LIF stimulation of mESCs induced 
phosphorylation of Erk1 and Erk2 above basal levels and induced a small increase in S6 
phosphorylation (Figure 3.4). Stimulation of mESCs with 2 or 5ng/ml BMP4 resulted in 
enhanced phosphorylation of Erk1 and Erk2 from unstimulated levels (Figure 3.4A). In 
contrast, higher concentrations of 10 or 20ng/ml BMP4 induced a small decrease in 
Erk1 and Erk2 phosphorylation when compared to unstimulated levels. This BMP4-
induced decrease in Erk phosphorylation is consistent with reports indicating that BMP4 
signalling can inhibit the MAPK pathway in order to maintain self-renewal (Qi et al., 
2004, Yamaguchi et al., 1999). Similarly, the effects of BMP4 stimulation on S6 
phosphorylation were only observed at higher concentrations, where an increase in S6 
phosphorylation was observed (Figure 3.4A). 
 
In mESCs cultured in complete Knockout serum replacement media, serum starved then 
stimulated with insulin, only the highest concentration of insulin used induced an 
enhancement in Erk phosphorylation (Figure 3.4B). High levels of basal S6 
phosphorylation are often observed in cells cultured in serum-replacement media. 
Despite high basal S6 phosphorylation, an increase in phosphorylation was induced 
using 5µg/ml insulin (Figure 3.4B).  
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Figure 3.4 BMP4 and insulin stimulation of mESCs cultured in serum-replacement 
media 
Cells cultured in complete Knockout serum-replacement media were serum and LIF 
starved for 4h prior to stimulation. Cells were stimulated for 5 minutes with LIF, BMP4 or 
Insulin as indicated. Immunoblotting was used to detect Erk protein phosphorylated at 
Thr202/Tyr204. Immunoblots were stripped and reprobed with appropriate antibodies 
detecting phosphorylated S6 (Ser235/236) and with antibodies detecting Shp-2 to 
confirm equal loading. The data shown are representative of two independent 
experiments. 
 
 
3.2.3 BMP4 stimulated signalling in mESCs 
 
Smad1 is known to be directly phosphorylated by BMP type I receptors (Kretzschmar et 
al., 1997). In mESCs, reciprocal inhibition of BMP signalling and of signalling molecules 
of the MAPK pathway has been reported. For example, Erk is known to phosphorylate 
Smad1 and prevent nuclear accumulation (Fuentealba et al., 2007). Conversely, BMP4-
activated XIAP is known to inhibit p38 MAPK signalling (Yamaguchi et al., 1999). 
Furthermore, inhibitors of p38 or Mek, of the MAPK family, mimic the effect of BMP4 on 
self-renewal (Qi e al., 2004). In section 3.2.1.2, BMP4 was shown to activate signalling 
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downstream of PI3Ks via S6 but not via PKB. Given that LY294002 treatment of mESCs 
elicits an enhancement in Erk phosphorylation, the effect of inhibiting PI3Ks on Smad1 
activity was of interest.  
 
In order to assess the effect of inhibition of PI3Ks on Smad1 activity, mESCs were 
incubated in the presence or absence of LY294002 or wortmannin and Smad1 
phosphorylation detected by immunoblotting. High basal levels of Smad1 
phosphorylation were observed even after 4 hours incubation in the absence of BMP4, 
LIF, N2 and B27 supplements (Figure 3.5A). Stimulation of mESCs with BMP4 did not 
alter levels of Smad1 phosphorylation. Additionally, no effect on Smad1 phosphorylation 
was seen following pharmacological inhibition of PI3Ks with either LY294002 or 
wortmannin.  
 
These findings are inconsistent with Ying et al., (2003), who reported an induction in 
Smad1 phosphorylation in mESCs following addition of BMP4 for 15 minutes or 1 hour 
after an overnight incubation in the absence of BMP4. In mESCs incubated in the 
absence of BMP4, they detected no Smad1 phosphorylation (Ying et al., 2003b). In the 
present study, high basal levels of Smad1 phosphorylation were unchanged by BMP4 
stimulation. An experiment was set up to determine whether this high level of basal 
Smad1 phosphorylation could be reduced by BMP4 withdrawal over a longer period of 
time. No change in Smad1 phosphorylation was observed following BMP4 withdrawal 
(Figure 3.5B). Even after 24 hours incubation in the absence of BMP4, Smad1 
phosphorylation remained high. However, withdrawal of BMP4 enhanced S6 
phosphorylation, peaking at 1 hour after withdrawal and enhanced Erk phosphorylation 
maximally at 2 hours post-BMP4 withdrawal. Both of which are consistent with early 
triggers to induce differentiation and consistent with a report demonstrating BMP4-
induced inhibition of MAPK signalling (Qi et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Results 
115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Neither stimulation with BMP4 nor withdrawal of BMP4 alters Smad1 
phosphorylation 
A Following a 4 hour incubation in the absence of LIF, BMP4, N2 and B27 supplements, 
mESCs were stimulated with BMP4 for 5 minutes. Lysates were resolved by SDS-PAGE 
and immunoblotting with antibodies detecting phosphorylated Smad1 (Ser463/465). B A 
BMP4-withdrawal time-course was conducted by washing mESCs with PBS and 
incubating with media lacking BMP4. Lysates were prepared at the times indicated 
following BMP4 withdrawal and resolved by SDS-PAGE. Immunoblotting was conducted 
using antibodies detecting phosphorylated Smad1 (Ser463/465) or Erk (Thr202/Tyr204). 
Immunoblots were stripped and reprobed to allow detection of phosphorylated S6 
(Ser235/236) and Shp-2 to confirm equal loading. 
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3.3 Activation of the MAPK Pathway 
 
The maintenance of self-renewal and pluripotency is governed by activation of pathways 
that maintain self-renewal and inhibition of pathways that promote differentiation. Whilst 
activating the Stat3 pathway to promote self-renewal, LIF also activates the MAPK 
pathway and inhibition of the MAPK pathway is known to enhance self-renewal (Burdon 
et al., 1999). Furthermore, inhibition of Mek, of the MAPK pathway, reverses the effects 
of LY294002 inhibition of PI3Ks on self-renewal (Paling et al., 2004). In the present 
study, BMP4 was identified as a factor that activated PI3Ks in mESCs (Welham et al., 
2007) and reduced the activity of the MAPK pathway when applied to cells cultured in 
serum-replacement media, used for the routine culture of mESCs (Figure 3.4A). Thus, 
under normal culture conditions, given the right external stimuli such as BMP4 and LIF, 
PI3Ks may act to inhibit activity of the MAPK pathway. 
 
To further address the role of Mek in self-renewal, mESC clones that can be induced to 
express a constitutively active form of Mek1 (Mek*) were used. Mek* clones were 
generated by Prof. M. J. Welham (unpublished data). Briefly, constitutively active Mek1 
was created by substitution mutations within the catalytic domain. Serine 218 and serine 
222 were substituted for glutamic acid residues to mimic activating phosphorylation 
(Treinies et al., 1999) (Figure 3.6A). This activated form of Mek, referred to as Mek*, 
was histidine-tagged and inserted into a gene expression vector under the control of a 
tetracycline-off expression system (Era and Witte, 2000). The CAG promoter drives 
expression of the tetracycline-sensitive transactivator (tTA) containing a tetracycline 
response element. Mek* expression is driven by a tTA-dependent promoter. 
Tetracycline binds to tTA and prevents it from binding to the tTA-dependent promoter, 
resulting in no transcription of Mek*. In the absence of tetracycline, tTA binds the tTA-
dependent promoter to drive expression of exogenous Mek* (Figure 3.6B). Thus, under 
the tetracycline-off expression system, in the presence of tetracycline only endogenous 
Mek is expressed, while in the absence of tetracycline, both endogenous Mek and 
induced, exogenous Mek* are expressed. 
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Figure 3.6 Inducible expression of Mek* by the tetracycline-off expression system 
A Constitutively active Mek1 (Mek*) was generated by replacement of serine 218 and 
serine 222 with glutamic acid residues (E) within the catalytic domain of Mek1. B The 
tetracycline-sensitive transactivator (tTA) is expressed by a CAG promoter. In the 
absence of tetracycline, tTA binds the tTA-dependent promoter driving transcription of 
Mek*. However, in the presence of tetracycline, tTA is prevented from binding the tTA-
dependent promoter and Mek* is not transcribed. Adapted from Treinies et al., 1999, Era 
and Witte, 2000. 
 
 
The hypothesis that expression of constitutively active Mek would promote constitutive 
activation of the MAPK pathway leading to the loss of self-renewal and the promotion 
differentiation was tested using two independent Mek* clones, clone 28 and clone 34. 
 
A 
             
Mek1
E218 E222
Mek*
 
B 
+Tetracycline - Tetracycline
Mek* Mek*
CAG tTA
tTA
tTA
tTA
Transcription Transcription
Mek*
 
Chapter 3: Results 
118 
3.3.1 Assessment of Mek expression in cloned cells 
 
Expression of Mek was initially assessed in Mek* clones by immunoblotting (Figure 
3.7A). Cultured in the presence of tetracycline, clone 28 and 34 expressed moderate 
levels of phosphorylated and total Mek. Tetracycline withdrawal for 24 hours induced 
enhanced levels of phosphorylated and total Mek protein expression. However, this 
method of assessing Mek expression does not distinguish between endogenous Mek 
expression and induced Mek* expression since the antibodies used are capable of 
detecting both types of Mek1. 
 
Immunochemistry staining for histidine was used to assess expression of histidine-
tagged Mek* (Figure 3.7B). In the presence of tetracycline, histidine-tagged Mek* was 
detected in neither clone 28 nor clone 34. When tetracycline was removed for 24 hours, 
histidine-tagged Mek* could be detected in both clone 28 and clone 34. Murine ESCs 
have large nuclei, which were evident in stained cells (Figure 3.7B). Despite this, 
staining for histidine-tagged Mek* was observed in the cytosol of mESCs cultured in the 
absence of tetracycline (Figure 3.7B right hand panel). Clone 28 exhibited a mosaic 
expression pattern where not all cells stained positive for histidine-tagged Mek* 
expression. Clone 34 did not exhibit such a phenomenon, all clone 34 cells stained 
positively for histidine-tagged Mek* in the absence of tetracycline. 
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Figure 3.7 Expression of Mek in Mek* cloned mESCs 
Mek* clones 28 and 34 (Mek*28 and Mek*34 respectively) were harvested after 24 
hours incubation in the presence or absence of tetracycline. A Lysates were analysed 
by immunoblotting with antibodies that detect phosphorylated Mek (Ser217/221) (upper 
panel) and or total Mek protein (lower panel). The data shown are representative of two 
independent experiments. B Cytospin slides were prepared with fixed cells and 
incubated with an anti-histidine antibody. Transfected Mek* is histidine-tagged, thus 
positive cells stain brown. An enlarged image of stained cells demonstrates cytoplasmic 
staining, right hand panel. 
 
 
Having ascertained that histidine-tagged Mek* expression was induced following 
withdrawal from tetracycline and that the majority of the cells within each clone 
expressed Mek* following induction, signalling downstream of Mek* was investigated. In 
the absence of tetracycline, when Mek* and endogenous Mek are expressed, Erk 
phosphorylation was greater than that in the presence of tetracycline, when cells 
express endogenous Mek alone (Figure 3.8A). This indicated that Mek* was functionally 
active since expression of Mek* enhanced Erk phosphorylation, consistent with Erk 
being a direct target of the kinase activity of Mek. 
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LIF promotes self-renewal and maintenance of pluripotency via induction of Stat3 
phosphorylation but LIF also activates the MAPK pathway (Burdon et al., 1999, Niwa et 
al., 1998, Paling et al., 2004). Unstimulated Mek* clones cultured in the absence of 
tetracycline displayed elevated levels of phosphorylated Erk, consistent with expression 
of both endogenous Mek and induced Mek* (Figure 3.8B). Upon LIF stimulation, Erk 
phosphorylation was elevated above unstimulated levels. Erk phosphorylation was 
greater in cells expressing induced Mek* and endogenous Mek compared to cells 
expressing endogenous Mek alone. This indicates that Mek and Mek* are functionally 
active in mESC Mek* clones. Additionally, enhanced MAPK pathway activity is 
detectable and elevated in unstimulated and LIF-stimulated cells when Mek* is 
expressed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Mek* is functionally active and enhances MAPK pathway activation 
Mek* clones 28 and 34 (Mek*28 and Mek*34 respectively) were harvested after 24 
hours incubation in the presence or absence of tetracycline. A Lysates were analysed 
by immunoblotting with phosphorylated Erk antibodies. The data shown are 
representative of two independent experiments. B Mek* clones incubated for 24 hours in 
the presence or absence of tetracycline were serum starved for 4 hours prior to 
stimulation. Stimulations were conducted for 10mins with vehicle (DMSO), 500 and 
1000U/ml LIF. Cell lysates were analysed by SDS-PAGE separation and immunoblotting 
with antibodies detecting phosphorylated Erk (Thr202/Tyr204). Immunoblots were 
stripped and reprobed using antibodies detecting phosphorylated Stat3 (Tyr705) and 
Shp-2. Mek* clone 34 data presented here are representative of two independent 
experiments for each Mek* clone. 
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LIF-induced Stat3 phosphorylation at Tyr705 is essential for dimerisation and nuclear 
translocation (Zhong et al., 1994). Stat3 phosphorylation at Tyr705 appeared unchanged 
by the presence of tetracycline (Figure 3.8B). However, on closer inspection a small 
change in the migration of the band corresponding to pStat3 was observed. Phospho-
Stat3 protein bands detected by immunoblotting following SDS-PAGE separation of 
protein lysates appeared to correlate with protein of a greater size in the absence of 
tetracycline. 
 
 
Migration of proteins through a polyacrylamide gel is dependent on the size of the 
protein. Retarded migration is often due to molecular weight variation as a result of 
additional phosphorylation. The molecular weight of Stat3 appeared to be altered 
following expression of Mek*, which might be explained by phosphorylation at another 
site, potentially mediated by activated Mek*. Therefore, the phosphorylation of Stat3 at 
alternative sites was investigated. Phosphorylation at Tyr705 is required for the 
dimerisation and nuclear translocation of Stat3 (Zhong et al., 1994) but phosphorylation 
at a second site, Ser727, is critical for optimal induction of transcriptional activity of Stat3 
(Wen et al., 1995). Basal phosphorylation of Ser727 was similar in cells cultured with 
and without tetracycline (Figure 3.9). Therefore, the expression of Mek* does not appear 
to alter basal Ser727 phosphorylation of Stat3. Furthermore, LIF stimulation did not 
change Ser727 phosphorylation for Mek* clones 28 and 34 (Figure 3.9). Similarly, basal 
phosphorylation of Ser668, of unknown function, remained unchanged regardless of the 
presence of tetracycline or LIF stimulation for either clone.  
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Figure 3.9 LIF stimulation of Mek* clones does not elicit phosphorylation of Stat3 
at alternative phosphorylation sites 
Mek* clones, incubated for 24 hours in the presence or absence of tetracycline, were 
serum starved for 4 hours prior to stimulation with LIF. Stimulations were conducted for 
10mins with vehicle (DMSO), 500 or 1000U/ml LIF. Cell lysates were analysed by SDS-
PAGE separation and immunoblotting with antibodies detecting phosphorylation sites at 
Ser727 and Ser668 of Stat3, loading was assessed by stripping and reprobing 
immunoblots with antibodies detecting all Stat3 proteins. Data are representative of two 
independent experiments for each Mek* clone. 
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3.3.2 Effect of constitutively active Mek expression on self-renewal 
 
Self-renewal of ESCs is important to maintain pluripotency, the ability of ESCs to 
differentiate into any adult cell type of the organism from which they were derived, and 
to maintain the undifferentiated state of ESCs in culture. However, self-renewal and 
differentiation involve a number of signalling pathways. Previously LIF was 
demonstrated to stimulate signalling of the Stat3, PI3K and MAPK pathways in mESCs 
(Niwa et al., 1998, Boeuf et al., 1997, Paling et al., 2004). Interestingly, inhibition of 
PI3Ks with LY294002 was shown to enhance MAPK pathway signalling (Paling et al., 
2004) (Figure 3.2 and 3.3) demonstrating cross-talk between the pathways activated by 
LIF. However, inhibition of the MAPK pathway, via pharmacological inhibition of Mek, is 
reported to enhance mESC self-renewal (Burdon et al., 1999) and reverse the effects of 
LY294002 inhibition of PI3Ks on self-renewal (Paling et al., 2004). Therefore, the effect 
of enhanced MAPK pathway activation on mESC self-renewal was of interest. In order 
to address the effect of enhanced MAPK pathway activity on mESC fate, mESC Mek* 
clones were induced to express Mek* and the effect on self-renewal assessed by 
alkaline phosphatase assay. Alkaline phosphatase is a hydrolase enzyme responsible 
for dephosphorylating molecules such as nucleotides, proteins, and alkaloids under 
alkaline conditions. It is expressed on the surface of pluripotent, self-renewing mESCs 
but surface expression is lost upon the initiation of differentiation (Scutt and Bertram, 
1999, Pease et al., 1990). The alkaline phosphatase assay was used to assess self-
renewal of mESC Mek* clones expressing endogenous Mek alone and both 
endogenous Mek and exogenous Mek*. 
 
Mek* clones were cultured at clonal density for 4 days in the presence or absence of 
tetracycline then assayed for alkaline phosphatase activity (Figure 3.10A). In the 
presence of LIF and tetracycline, 80 to 90% of colonies were alkaline phosphatase 
positive. Most colonies stained bright red with a smooth rounded morphology (an 
example is depicted in Figure 3.10Bi), indicative of highly self-renewing, undifferentiated 
colonies. Other colonies stained strongly in the centre and were surrounded by pale or 
unstained cells (Figure 3.10Bii), classed as self-renewing or mixed colonies. In the 
absence of tetracycline, but in the presence of LIF, 70 to 85% of colonies were self-
renewing and exhibited a similar morphology to colonies incubated with tetracycline. 
Statistically, there was no difference in the proportion of self-renewing colonies observed 
in the presence or absence of tetracycline when LIF was present, although a small but 
consistent decrease in self-renewal was noted in the absence of tetracycline. In the 
absence of LIF, the ability of cells to form self-renewing colonies was significantly 
reduced, consistent with the requirement of LIF to maintain self-renewal (Smith and 
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Hooper, 1987, Boeuf et al., 1997, Niwa et al., 1998, Raz et al., 1999, Cartwright et al., 
2005). In the absence of LIF, colonies either stained pale pink (Figure 3.10Biii) or 
remained unstained (Figure 3.10Biv) and displayed an asymmetrical, flattened 
appearance with rough colony edges, indicative of differentiated colonies. In the 
absence of LIF, colonies expressing Mek* exhibited a moderate decrease in self-
renewal compared to colonies expressing endogenous Mek alone (Figure 3.10A) but 
this was not statistically significant. 
 
To confirm that induced cells were expressing Mek* at the time of harvesting the alkaline 
phosphatase assay, protein lysates were analysed for Mek protein expression after 4 
days incubation in the presence or absence of tetracycline (Figure 3.10C). In the 
absence of tetracycline, higher Mek protein levels were detected in Mek* clones 28 and 
34 on day 4, indicating expression of induced Mek* and endogenous Mek protein was 
maintained.  
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Figure 3.10 Expression of Mek* does not significantly reduce alkaline 
phosphatase staining 
Mek* mESC clones were cultured in supplemented GMEM plus 10% (v/v) serum, in the 
presence or absence of 500ng/ml tetracycline for 4 days. A Self-renewal was quantified 
by staining for alkaline phosphatase activity, a cell-surface marker of undifferentiated 
self-renewing mESCs. Two independent Mek* mESC clones were used (Mek* 28 and 
Mek* 34). The mean data from three experimental repeats are shown with Standard 
Error of Mean (S.E.M.). Statistical significance was assessed using a Student’s T-test 
where *** represents p<0.001. In the presence of LIF, no significant difference was 
found in the level of alkaline phosphatase staining of colonies cultured in the presence 
or absence of tetracycline (Mek* 28 p=0.64, Mek* 34 p=0.61). B Representative 
colonies are shown following alkaline phosphatase staining. Bi depicts a pure self-
A 
        
0
10
20
30
40
50
60
70
80
90
100
%
 
al
ka
lin
e 
ph
os
ph
at
as
e
 
po
si
tiv
e
 
c
ol
on
ie
s
+ Tetracycline
- Tetracycline
+ +-- 1000U/ml LIF
Mek* 28 Mek* 34
***
***
***
***
 
B 
          
i ii iii iv
 
C 
                    
Mek1
Shp-2α-Shp-2
α-Mek1
Mek*28   Mek*34
-+-+500ng/ml Tet
←
←
 
Chapter 3: Results 
126 
renewing colony. Colonies with morphology and staining similar to Bii are also scored 
as self-renewing. Biii and Biv are representative of non-self-renewing, differentiated 
colony types. C After 4 days incubation in the presence or absence of tetracycline, cell 
lysates were prepared and resolved by SDS-PAGE. Mek1 was detected by 
immunoblotting with Mek1 antibody and Shp-2 used to confirm equal loading. 
 
 
Expression of constitutively active Mek*, which activates the MAPK pathway 
downstream of Mek, produced a trend towards decreased alkaline phosphatase staining 
that was not found to be statistically significant. The assessment of self-renewal by 
alkaline phosphatase assay was conducted in the presence of 1000U/ml LIF. This 
concentration is used for the routine culture of mESCs but might be considered to be in 
excess of the concentration required to maintain self-renewal. In order to address this 
matter, the level of self-renewal of mESC Mek* clones was assessed in the presence 
and absence of tetracycline, and under reduced, limiting LIF concentrations. 
Additionally, if excess LIF was supporting self-renewal upon constitutive activation of 
MAPK signalling then limiting LIF concentrations might reveal a decrease in self-renewal 
upon activation of the MAPK pathway.  
 
Mek* clones were plated at clonal density in the presence or absence of tetracycline, 
and in limiting LIF conditions then assayed for alkaline phosphatase assay after 4 days. 
Both Mek* clone 28 and clone 34 colonies exhibited reduced alkaline phosphatase 
staining when incubated with 10 and 20U/ml LIF compared to incubation with 1000U/ml 
(Figure 3.11). Moreover, in the absence of tetracycline, when Mek* is expressed, a 
further decrease in the proportion of alkaline phosphatase positive colonies was 
observed compared to colonies incubated in the presence of tetracycline, although 
again this was found not to be statistically significant. This trend towards decreased 
alkaline phosphatase activity when Mek* was expressed and mESCs cultured in low 
concentrations of LIF was particularly noticeable for clone 28. 
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Figure 3.11 A decrease in self-renewal is observed upon expression of Mek* in 
low LIF concentrations 
Mek* mESC clones were cultured in supplemented GMEM plus 10% (v/v) serum in the 
presence or absence of 500ng/ml tetracycline for 4 days and in the presence of 0, 10, 
20 or 1000U/ml LIF. Self-renewal was quantified by staining for alkaline phosphatase 
activity. The mean data from three independent experiments are shown with S.E.M. The 
data were analysed statistically, using a Student’s T-test to compare the presence or 
absence of tetracycline at each LIF concentration. No statistical significance was found 
despite a trend towards decreased alkaline phosphatase staining upon expression of 
Mek* in low LIF concentrations. 
 
 
Self-renewal of Mek* mESC clones was also assessed using Knockout serum 
replacement (KO SR) media (used for the routine culture of mESCs) supplemented with 
10% (v/v) serum to support the growth of differentiated cells (Figure 3.12). In this media 
and in the presence of LIF, alkaline phosphatase staining in the presence of tetracycline 
was indistinguishable from staining observed in the absence of tetracycline. In the 
absence of LIF, alkaline phosphatase staining was significantly reduced compared to 
the presence of LIF. In the absence of LIF, no consistent trend correlating with the 
presence or absence of tetracycline was observed (Figure 3.12). 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 1000 0 10 20 1000
%
 
al
ka
lin
e 
ph
os
ph
at
as
e 
po
si
tiv
e 
co
lo
ni
es
+ Tetracycline
- Tetracycline
U/ml LIF
Mek* 28 Mek* 34
 
Chapter 3: Results 
128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 The trend towards decreased alkaline phosphatase staining when the 
MAPK pathway is activated is not observed when clones are cultured in complete 
KO SR media 
Mek* mESC clones were cultured in complete KO SR media with 10% serum in the 
presence or absence of 500ng/ml tetracycline and in the presence or absence of 
1000U/ml LIF for 4 days. Self-renewal was quantified by staining for alkaline 
phosphatase activity. The mean data from three experimental repeats are shown with 
S.E.M. Statistical significance was assessed using a Student’s T-test where *** 
represents p<0.001. Alkaline phosphatase staining in the presence of LIF and 
tetracycline was not significantly different from staining in the presence of LIF and 
absence of tetracycline (Mek* 28 p= 0.954, Mek* 34 p=0.953). 
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3.4 Inhibition of PI3K and lineage commitment 
 
LIF promotes self-renewal allowing mESCs to retain their pluripotency, therefore mESCs 
cultured with LIF remain largely undifferentiated. Conversely, culture in the absence of 
LIF causes spontaneous differentiation towards multiple lineages. While LIF maintains 
self-renewal and its withdrawal triggers differentiation, other factors direct commitment 
to particular cell lineages. For example, BMP4 promotes self-renewal by blocking neural 
differentiation (Ying et al., 2003b) and promoting non-neural differentiation (Ying et al., 
2003b, Xu et al., 2002). PI3K inhibition, even in the presence of LIF, results in a loss of 
self-renewal with mESCs adopting a differentiated morphology, reduced alkaline 
phosphatase staining and a reduction in Nanog expression (Paling et al., 2004, Storm et 
al., 2007). However, whether inhibition of PI3Ks results in differentiation towards specific 
lineages is unknown.  
 
To ascertain whether or not PI3K inhibition directs differentiation towards a particular 
lineage in adherent 2D monolayer culture, mESCs were incubated in the presence of 
the PI3K inhibitor LY294002. Usually, mESCs are replated every two days to maintain a 
sub-confluent cell density suitable for self-renewal and are cultured in a media suitable 
for the maintenance of undifferentiated cells. However, at higher densities, mESCs 
undergo spontaneous differentiation. For this experiment cells were plated on day 0 in 
media containing serum to support the growth of both undifferentiated and differentiated 
cells. RNA was isolated on days 3-7 without passaging cells in between. Additionally, 
cells were cultured in the presence or absence of LIF to demonstrate differentiation that 
is not restricted to a particular lineage. Primers detecting early lineage marker genes, 
GATA1, GATA6, Pax6, Nodal and FGF5, were used to determine the effects of these 
treatments on the differentiation potential of mESCs following inhibition of PI3K 
signalling (Figure 3.13). GATA1 belongs to the sub-family of haematopoietic GATA 
transcription factors, which are predominantly expressed in cells of the haematopoietic 
system (Ferreira et al., 2005). GATA1 is reported to be a suitable marker of mesodermal 
differentiation of ESCs (Robertson et al., 2000, Fujimoto et al., 2001) and is expressed 
by ES-derived cells undergoing mesodermal differentiation to haematopoietic and 
endothelial lineages (Robertson et al., 2000). In contrast, GATA6 belongs to the non-
haematopoietic subfamily of GATA transcription factors and its expression correlates 
with its indispensability in the development of heart, lung and gastrointestinal tract 
tissues (reviewed by Maeda et al., 2005). With the exception of GATA6 expression in 
the heart, GATA6 is frequently used as a marker of endodermal lineage cells (Natira et 
al., 1997). Pax6 is a homeobox transcription factor that regulates the expression of 
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proteins important for the development of the central nervous system, eye, and 
endocrine glands. Thus, Pax6 expression can be used to detect the presence of 
neuroectodermal cell types (Yoshida-Koide et al., 2004). Nodal is a transforming growth 
factor β (TGFβ) related gene, which is detected at E5.5 in primitive streak ectoderm of 
developing mouse embryos, where its expression is required for mesoderm induction 
(Conlon et al., 1994). During implantation (E4.5) nodal expression is also detectable in 
the ICM and primitive endoderm (Mesnard et al., 2006). Therefore, nodal can be used 
as a marker for embryonic ectoderm and primitive endoderm (Leahy et al., 1999, 
Yoshida-Koide et al., 2004). Fibroblast growth factor 5 (FGF5) belongs to the FGF family 
of mitogens, which have a variety of roles in developmental processes (Goldfarb, 1990). 
FGF5 is important in embryogenesis and expressed in the epiblast and visceral 
endoderm at E5.25-7.5 during the development of the mouse embryo (Haub and 
Goldfarb, 1991). Thus FGF5 expression is frequently used as a marker of primitive 
ectoderm in the early stages of ESC differentiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: PI3K inhibition results in differentiation towards all lineages 
Murine ESCs were cultured in the presence or absence of 1000U/ml LIF and in the 
presence or absence of 5µM LY294002. RNA was isolated daily from day 3 to day 7. 
Reverse-transcription was conducted to produce cDNA. Primers that mark early lineage 
differentiation were used in PCR reactions to determine cell fate. A typical expression 
profile, representative of three independent experiments, is depicted. The expression of 
β-Actin was used as a control and remained unchanged at different time points and 
regardless of treatment. 
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GATA1 expression, an indication of mesodermal differentiation, appeared to remain 
constant in the presence of LIF between days 4 and 7 (Figure 3.13). In the absence of 
LIF, GATA1 expression was low on days 3 and 4 but increased towards day 7. 
Treatment with LY294002 yielded low GATA1 expression with a notable peak on day 5. 
The GATA1 expression pattern for LY294002 treatment is similar to the pattern 
observed in the absence of LIF, indicating no change in spontaneous differentiation.  
 
In all experimental repeats, GATA6, a marker of visceral and definitive endoderm (Narita 
et al., 1997), showed highest expression with LIF alone and a peak in expression at 
days 4 and 7 (Figure 3.13). Expression of GATA6 was detected for each treatment 
suggesting a degree of endodermal differentiation. RNA isolated from cells incubated 
without LIF exhibited constant GATA6 expression throughout the time course of the 
experiment. Treatment with both LIF and LY294002 showed lower GATA6 expression 
on days 3 and 4 but similar expression to cells differentiating in the absence of LIF on 
days 5-7. This pattern suggests that the time-course involved in differentiation towards 
endodermal lineages is altered but not prevented by PI3K inhibition. 
 
Pax6 exhibited high expression in the presence of LIF particularly on day 4 (Figure 
3.13). In contrast, Pax6 was detected but expression was lower in the absence of LIF or 
in the presence of LIF and LY294002 compared to presence of LIF alone. Interestingly, 
PI3K inhibition did not alter the observed increase in Pax6 expression on day 4 from 
levels detected on day 3. However, in the presence of LY294002, expression levels of 
Pax6 were consistently lower. 
 
Nodal, a marker of embryonic ectoderm and primitive endoderm, showed an almost 
constant expression profile for each treatment, with one exception: Expression on day 3 
in cells treated with LY294002 was consistently lower than that observed for the other 
two treatments (Figure 3.13). Small dips in nodal expression were observed in different 
treatments from day 5 onwards but the temporal nature of these varied across 
experimental repeats. These differences may represent slight variations in the 
differentiation of cells populating a particular culture dish.  
 
In both humans and mice, two splice variants of FGF5 are known to be expressed 
(Ozawa et al., 1998), both mouse splice variants were detected by the primers used in 
the present study (Figure 3.13). FGF5 expression was similar to that of nodal, an 
alternative primitive ectoderm marker. FGF5 was undetectable or detectable at very low 
levels in cells treated with LY294002 at the day 3 time point (Figure 3.13). As with nodal 
expression, small fluctuations were observed on days 6 and 7 but these varied across 
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experimental repeats. Expression remained fairly constant between days 3 and 7 for 
cells incubated in the presence of LIF. A consistent elevation in FGF5 expression was 
observed in the absence of LIF on days 4 and 5. 
 
Overall, markers representing mesoderm, endoderm, neuroectoderm and ectoderm 
were detected in each of the treatments indicating differentiation along these lineages 
(Figure 3.13). Differentiation in the presence of LIF can be explained by a number of 
factors including spontaneous differentiation exhibited by ESCs, the presence of 
differentiation-inducing serum and differentiation induced by the high density of mESCs 
following a number of days without passage. Differentiation in the presence of LIF 
appeared to be more towards neuroectodermal lineages but other lineages were 
represented. Differentiation in the absence of LIF resulted in the formation of cells 
representing all lineages. Importantly, inhibition of PI3Ks with LY294002 did not appear 
to favour differentiation towards any particular lineage since the expression of markers 
from all lineages were detectable. Furthermore, marker expression patterns in the 
presence of LY294002 were notably similar to those observed in the absence of LIF, 
suggesting that differentiation potential is not altered by inhibition of PI3Ks. 
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3.5 Summary and discussion: Identification of factors activating PI3K in 
mESCs  
 
In the present study, a chemically defined media was used to determine factors that 
activate PI3K signalling in mESCs. The effects of BMP4 and insulin stimulation on 
mESCs are summarised in Table 3.1.  
 
Table 3.1 Responses to stimulations conducted in N2B27-defined media 
 INHIBITOR 
PHOSPHORYLATION RESPONSE 
PKB S6 Erk 
Control 
Control  High basal levels Low basal levels 
LY294002 No change 
Decreased basal 
levels 
Enhanced basal 
levels 
Wortmannin  
Decreased basal 
levels 
Negligible 
decrease 
Insulin 
Control 
Concentration-
response 
Enhanced 
Enhanced from 
basal 
LY294002 Inhibition Inhibition Further enhanced 
Wortmannin  Inhibition No change 
BMP4 
Control No change 
Concentration-
response 
Concentration-
response 
LY294002 No change Inhibition Further enhanced 
Wortmannin  Inhibition No change 
 
 
BMP4 stimulation of mESCs resulted in enhanced S6 phosphorylation but no change in 
PKB phosphorylation. Furthermore, BMP4-induced S6 phosphorylation was inhibited 
with either LY294002 or wortmannin. Insulin stimulation of mESCs induced PKB and S6 
phosphorylation, which was inhibited by either LY294002 or wortmannin. Insulin is 
present in both the N2 and B27 supplements, used in chemically defined media, and is 
likely to be present in undefined serum and serum-replacement. BMP4 is added to 
chemically defined media in order to maintain self-renewal alongside LIF, but may also 
be present in undefined serum-containing or serum-replacement media. Insulin and 
BMP4 were shown to stimulate PI3K signalling in mESCs.  
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Murine ESCs lacking endogenous BMP4 exhibit reduced Erk phosphorylation upon the 
addition of exogenous BMP4 (Qi et al., 2004). In contrast, LIF stimulation activates the 
MAPK pathway, yet both LIF and BMP4 are required in serum-free media to maintain 
self-renewal (Ying et al., 2003b). In the present study, and in a previous report (Paling et 
al., 2004), inhibition of PI3K with LY294002 enhanced basal Erk phosphorylation. 
Furthermore, in the present study, LY294002 enhanced BMP4-induced Erk 
phosphorylation. Taken together these results suggest that PI3K may exert a 
dampening effect on the MAPK pathway. It is unclear why wortmannin does not exert 
the same enhancement in Erk phosphorylation as observed with LY294002, but could 
be due to the different modes of action of these inhibitors. A handful of reports have 
noted the phenomenon of PI3K inhibition enhancing Erk phosphorylation in a number of 
cell types. In a pituitary gonadotroph cell line, treatment with either LY294002 or 
wortmannin enhanced Erk phosphorylation and enhanced the expression and promoter 
activity of the α subunit of gonadotrophins. Interestingly, inhibition of PKB did not 
enhance Erk phosphorylation and no change was observed in expression of promoter 
activity, suggesting that PI3K mediated this inhibitory action on the MAPK pathway 
(Kanasaki et al., 2008). LY294002 was also shown to enhance Erk phosphorylation in 
differentiating Caco-2/15 cells (an intestinal cell line) but not in undifferentiated Caco-
2/15 cells (Laprise et al., 2004). The mechanism by which PI3K might exert the inhibition 
of MAPK signalling is still unclear. Laprise et al., demonstrated that PI3K inhibition can 
enhance Mek activity (Laprise et al., 2004). In a different study, using pituitary cells, 
inhibition of PI3Ks resulted in enhanced Raf-1 kinase and Rap-1 activity, both of which 
are upstream of Mek and Erk (Romano et al., 2006).  
 
Insulin was also demonstrated to enhance Erk phosphorylation. Consistent with this 
observation, insulin has been shown to induce Erk phosphorylation via activation of type 
1 insulin-like growth factor (IGF-1) receptors in mESCs (Nguyen et al., 2007). 
Stimulation of insulin receptors or IGF-1 receptors results in activation of insulin receptor 
substrate-1 (IRS-1), which contains PH and SH2 domains. IRS-1 expression and 
activation have been reported to be required for mESC self-renewal since targeting  
IRS-1 with siRNA led to a decrease in alkaline phosphatase staining, a decrease in Oct4 
expression and a decrease in PKB phosphorylation indicating signalling via PI3K (Rubin 
et al., 2007). Interestingly, in cell types other than mESCs, the actions of IRS-1 are 
reported to be mediated through PI3K, PKB and p70S6K/mTOR pathways to regulate 
the expression of Id genes. Furthermore, IRS-1 is best known to be phosphorylated by 
insulin, IGF-1 and LIF (Argetsinger et al., 1995, Belletti et al., 2001). The mechanism by 
which IRS-1 is phosphorylated and aids the maintenance of self-renewal in mESCs is 
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yet to be defined. In the present study, insulin is demonstrated to activate both PKB and 
S6, downstream of PI3K in mESC, consistent with the signalling pathways defined by 
previous reports. Also, in agreement with the present study, in mouse R- fibroblasts 
(lacking IGF-1 receptors) LY294002 enhanced insulin-induced Erk phosphorylation. 
However, unlike the present study, LY294002 did not enhance Erk phosphorylation in 
unstimulated mouse R- fibroblasts cells (Choi and Sung, 2004). 
 
High levels of phosphorylated Smad1 were detected in mESCs. Smad1 phosphorylation 
was unchanged by stimulation with BMP4 or withdrawal of BMP4 for up to 24 hours. 
These results are inconsistent with those reported by Ying et al., where over-night 
incubation in the absence of BMP4 resulted in undetectable Smad1 phosphorylation in 
unstimulated cells and Smad1 phosphorylation in BMP4-stimulated cells (Ying et al., 
2003b). However this discrepancy might be explained by the use of a different mESC 
line. In the present study, the E14tg2A mESC line was used and cells were cultured in 
chemically defined media for at least 2 days prior to being used for experiments. 
However Ying et al., derived ESCs from blastocysts and cultured these cells directly in 
chemically defined media (Ying et al., 2003b). The different results may reflect the 
adaptation of mESCs to their routine culture media. Furthermore, Smad1, Smad5 and 
Smad8 are known to couple to BMP4 induced activation of the type 1 BMP receptor, 
BmprIa and type II receptor, BmprII, both of which are expressed in mESCs (Qi et al., 
2004, Kishigami and Mishina, 2005). Since only antibodies detecting Smad1 were used 
in the present study, it is possible that Smad5 and/or Smad8 mediate the response to 
BMP4 in this mESC line. 
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3.6 Summary and discussion: The effect constitutively activating MAPK 
pathway signalling 
 
Burdon et al., demonstrated that inhibition of MAPK pathway activity using the Mek 
inhibitor PD098059 resulted in enhanced self-renewal of mESCs and inhibition of 
differentiation in embryoid bodies (Burdon et al., 1999). Additionally, Kunath et al., have 
reported that FGF4-induced Erk activity was responsible for lineage commitment 
towards neural and mesodermal lineages although mESCs lacking FGF4-induced 
MAPK activity were still capable of undergoing differentiation (Kunath et al., 2007). The 
present study used mESC clones expressing constitutively active Mek to mimic the 
effect of activating the MAPK pathway.  
 
The expression of constitutively active Mek* was confirmed upon withdrawal of 
tetracycline from 24h to 4 days. Furthermore, activation of the MAPK pathway was 
observed by induced expression of Mek*, in that Erk phosphorylation was enhanced. 
LIF-induced activation of Stat3 appeared normal when Mek* was expressed.  
 
Constitutive activation of the MAPK pathway was not sufficient to induce a significant 
reduction in mESC self-renewal. A trend towards decreased alkaline phosphatase 
positive colonies was observed in the absence of tetracycline, when Mek* is expressed. 
Additionally, culture in the presence of excessive concentrations of LIF was not masking 
the effects of enhanced MAPK pathway activity. At sub-optimal LIF concentrations, 
colonies expressing Mek* exhibited a small, non-significant, but consistent reduction in 
alkaline phosphatase staining.  
 
The media used for alkaline phosphatase assays supports the growth of both 
differentiated and undifferentiated cells when LIF is present. Culture in the absence of 
LIF or with low concentrations of LIF induced a reduction in alkaline phosphatase 
staining. Even in the presence of low concentrations of LIF, only a small decrease in 
self-renewal was observed when Mek* was expressed compared to cells expressing 
endogenous Mek alone. Taken together these results suggest that activation of the 
MAPK pathway can be overcome by compensatory mechanisms. Consistent with this 
notion, culture in routine mESC culture medium, optimised for self-renewal and 
undifferentiated growth of mESCs but supplemented with serum that allows the 
differentiation of mESCs, overcame these small decreases in alkaline phosphatase 
staining observed in the absence of tetracycline using typical alkaline phosphatase 
assay media. This indicates that factors present in routine culture medium can 
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overcome the small functional effects induced by enhanced MAPK pathway activity, in 
order to maintain self-renewal.  The culture of Mek* mESC clones in chemically defined 
media may reveal more about the effect of factors present in culture media and the 
mechanisms involved in maintaining mESC self-renewal when the activity of the MAPK 
pathway is enhanced.   
 
In conclusion, artificially activating the MAPK pathway leads to a minimal decrease in 
self-renewal. The effect of constitutive activation of the MAPK pathway might be 
overcome by compensatory mechanisms, possibly activated by factors present in serum 
or serum-replacement.  
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3.7 Summary and discussion: Inhibition of PI3K does not regulate lineage 
commitment 
 
The present study has investigated the differentiation of mESCs in 2D monolayer culture 
when PI3Ks are inhibited. Inhibition of PI3Ks with LY294002 led to the differentiation of 
mESCs to cells types expressing a panel of markers representing all lineages. 
Previously the differentiation of mESCs in the form of 3D embryoid bodies had been 
described (Bone et al., 2007). Embryoid bodies have considerable morphological and 
gene expression pattern similarities to early embryos and therefore provide a useful 3D 
developmental model of early embryogenesis (Keller, 1995, Desbaillets et al., 2000). 
Treatment with the broad selectivity PI3K inhibitor LY294002 did not affect the number 
of embryoid bodies formed (Bone et al., 2007). However, embryoid bodies formed in the 
presence of LY294002 were found to be smaller compared to untreated embryoid 
bodies. A similar effect on embryoid body formation was observed in PDK-1 knockout 
mESCs (Bone et al., 2007). In terms of PI3K regulating differentiation towards a 
particular lineage, no difference was observed in the temporal expression of a number of 
early lineage marker genes in embryoid bodies formed from wild-type mESCs in the 
presence of LY294002 or in embryoid bodies formed from PDK-1 null mESCs. 
Quantitative expression analysis revealed a small enhancement in haematopoietic 
marker gene expression in embryoid bodies formed in the presence of LY294002, 
correlating to enhanced production of haematopoietic cell colonies. PDK-1 deficient cells 
were reported to form smaller colonies and fewer haematopoietic colony types, leading 
to the conclusion that PI3K was required for the proliferation of cells in order to form 
haematopoietic-type colonies as opposed to a restriction on differentiation (Bone et al., 
2007). In contrast, the present study has demonstrated that differentiation of mESCs in 
2D monolayer culture in the presence of LY294002 leads to a similar pattern of lineage 
marker expression to that observed in the absence of LIF. 
 
Increased expression of GATA1 was observed on day 5 both in the absence of LIF and 
in the presence of LY294002, which is reminiscent of the up-regulation of GATA1 
expression on days 4 and 5 with increasing expression towards day 6, observed in 
previous reports (Fujimoto et al., 2001, Robertson et al., 2000). In the presence of 
LY294002 and LIF, GATA6 expression was lower on days 3 and 4 compared to the 
presence of LIF alone, but comparable on days 5-7. This pattern suggests that the time-
course involved in differentiation towards endodermal lineages is altered but not 
prevented by PI3K inhibition. Heterozygote GATA6/lacZ mouse embryos were used to 
demonstrate a double wave pattern of GATA6 expression during mouse embryo 
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development (Koutsourakis et al., 1999). The first wave of GATA6 expression was 
detected in blastocyst stage embryos (E3.5), specifically in the ICM and in the 
trophectoderm lining of the blastocoel cavity. The second wave of expression was 
detected at E7.0-E9.5 in parietal endoderm (derived from primitive endoderm, Figure 
1.7), embryonic endoderm that forms the gut and embryonic mesoderm that forms the 
heart (Koutsourakis et al., 1999).  If this same expression pattern is observed in mESC 
differentiation in vitro, cells entered into the protocol, used in the present study, on day 0 
could be considered to represent E3.5. Therefore, cells differentiating in the presence of 
LIF appear to undergo this second wave of expression at day 6-7 correlating to E8.5-
E9.5, consistent with Koutsourakis et al.,. Additionally, endoderm formation in the early 
stages of embryoid body differentiation was demonstrated to require GATA6 expression 
downstream of FGF signalling (Li et al., 2004). The altered expression pattern of GATA6 
in differentiating mESCs in the presence of LY294002 observed here might be explained 
by the inhibition of PI3Ks preventing FGF signalling. Reduced FGF signalling may lead 
to a delay in the first wave of expression explaining the low expression of GATA6 on 
days 3 and 4 (Figure 3.13). Further investigation, covering more time-points, would be 
required to ascertain the normal expression pattern of GATA6 in differentiating mESCs 
in order to confirm a delay in expression when PI3K is inhibited and to investigate if this 
expression pattern was FGF-dependent. 
 
Expression of Pax6 was detected in mESCs grown on feeder cells and in feeder-free 
culture conditions (Wiles and Johansson, 1999, Gordeeva et al., 2003). However, Pax6 
expression was elevated in embryoid bodies compared to levels detected in mESCs 
(Gordeeva et al., 2003). Thus the expression of Pax6 in self-renewing mESCs after 3 
days in the presence of LIF, as well as expression in differentiated cells after a number 
of days culture in the absence of LIF, or in the presence of LIF and LY294002, observed 
in the present study is consistent with previously reported expression patterns. 
Furthermore, the high levels of Pax6 expression might be explained by the positive 
autoregulation of Pax6 expression by Pax6 (Pinson et al., 2006). 
 
In the ESC field, neural differentiation has often been predicted to be the default mode 
of differentiation of mESCs in the absence of cues directing differentiation towards other 
lineages or suppressing differentiation. It was reported that, in chemically defined serum, 
mESCs freely formed neural precursor cells in the absence of LIF, regardless of the 
presence or absence of N2 or B27 factors (Ying et al., 2003b). However, neural 
differentiation in chemically defined medium was reported to be dependent on 
endogenous FGF-induced signalling (Bouhon et al., 2005). FGF-induced PI3K/PKB 
signalling is dispensable for neural induction in mESC differentiation (Stavridis et al., 
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2007). Therefore, inhibition of FGF signalling by PI3K inhibition with LY294002 does not 
explain reduced Pax6 expression observed in the present study. 
 
Nodal expression, an indication of embryonic ectodermal and primitive endodermal 
lineages, was observed to be consistently reduced in the presence of LY294002 on day 
3, which may also reflect a delay in expression as a result of PI3K inhibition. Nodal 
expression was reported to be detectable in embryoid bodies from day 2 onwards 
(Leahy et al., 1999), consistent with expression observed from day 3 onwards in the 
present study. Furthermore, FGF5, a marker of primitive ectoderm, was demonstrated to 
have a similar expression pattern to that observed for Nodal in differentiating mESCs, 
with low or undetectable expression in the presence of LY294002 on day 3. This 
provides further evidence for a short delay in differentiation towards ectodermal lineages 
when PI3K is inhibited. Consistent with the present findings, FGF5 was reported to have 
lower expression following 24, 48 and 72 hours incubation in the presence of LY294002 
compared to the absence of LY294002 (Storm et al., 2009). Despite this apparent delay 
in expression, LY294002 treatment did not prevent or greatly enhance ectoderm marker 
expression compared to the presence or absence of LIF. 
 
A consistent elevation in FGF5 expression was observed in the absence of LIF on days 
4 and 5. Consistent with this, FGF5 expression is reported to be detectable in day 5 
embryoid bodies but not detectable at day 10 and not detectable in self-renewing ESCs 
(other time points were not published) (Oka et al., 2002). However, FGF5 was 
detectable at very low levels in mESCs investigated in a separate study, nevertheless 
expression increased in embryoid bodies formed from aggregates of these cells 
(Cartwright et al., 2005). Moreover, FGF5 was detected from day 1 to day 10, with a 
peak in expression between days 2-5, in embryoid bodies formed by LIF withdrawal and 
culture in differentiation medium (Leahy et al., 1999). In a separate study, expression of 
FGF5 increased upon formation of embryoid bodies with a peak in expression on day 3 
(Cartwright et al., 2005), slightly earlier than demonstrated in the present study.  
 
In summary, mesodermal and endodermal differentiation, assessed with GATA1 and 
GATA6 respectively, was similar in cells incubated in the absence of LIF and cells 
treated with LY294002. However, inhibition of PI3K signalling appeared to cause a 
change in the expression of the ectodermal markers nodal and FGF5. Furthermore, an 
altered temporal expression pattern was observed for the neuroectoderm marker Pax6. 
Taken together, PI3K signalling does not appear to prevent or promote differentiation 
towards a specific lineage but does alter the temporal expression pattern of some 
lineage-associated markers. 
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4 Results: The role of Class I PI3K catalytic 
subunit isoforms in mESC self-renewal 
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4.1 Introduction and Aims 
 
PI3Ks have been implicated in the regulation of both ESC proliferation and self-renewal 
(discussed in detail in Section 1.2.6). Indeed, class IA PI3Ks were specifically implicated 
in maintaining mESC self-renewal (Paling et al., 2004) and interestingly, this class of 
PI3Ks are known to be expressed from the one cell stage of mammalian embryo 
development (Riley et al., 2005, Riley et al., 2006).  
 
One of the aims of this study was to investigate whether individual class IA PI3K catalytic 
subunit isoforms are responsible for regulating distinct aspects of mESC fate. In 
particular, regulation of self-renewal by PI3K catalytic subunit isoforms was of interest. 
Recently, a number of cell-permeable, small molecule inhibitors have been 
characterised regarding their selectivity for the class I PI3K family (the structures of 
these compounds are detailed in Table 2.3). Using a range of small molecule isoform 
specific inhibitors, complemented with gene silencing of individual isoforms, the roles of 
class IA PI3K catalytic subunit isoforms in regulating mESC self-renewal was assessed. 
 
It has previously been reported that treatment of mESCs with the broad selectivity PI3K 
inhibitor LY294002, known to inhibit class I PI3Ks (Vlahos et al., 1994), reduces their 
capacity to self-renew (Paling et al, 2004). Recently, a new class I PI3K inhibitor, 
ZSTK474, has been described, which has fewer reported off-target effects on PI3K-
related kinases (Kong and Yamori, 2007, Yaguchi et al., 2006) (for ZSTK474 structure 
see Table 2.3). The effect of this inhibitor was compared to the effects observed with 
LY294002 and results are presented in this chapter. 
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4.2 ZSTK474 induces a loss of mESC self-renewal 
 
ZSTK474 is an s-triazine derivative that exhibits inhibition of tumour cell proliferation and 
is described as being more potent than wortmannin or LY294002 as an anti-tumour 
compound (Yaguchi et al., 2006). Ex vivo, ZSTK474 is reported to inhibit class IA PI3Ks 
in the nM range (Yaguchi et al., 2006) and to inhibit all isoforms of this class with similar 
selectivity (Kong and Yamori, 2007). It was the selectivity for class I PI3K isoforms, the 
class previously implicated in regulating mESC self-renewal (Paling et al., 2004), that 
warranted an investigation into the effect of treatment of mESCs with ZSTK474. Any 
affect of ZSTK474 on mESC self-renewal markers, such as alkaline phosphatase 
staining and Nanog expression, in comparison to the effects observed using LY294002 
were of particular interest.  
 
Self-renewing mESCs were treated for 4 days with vehicle, LY294002 or ZSTK474 and 
self-renewal assessed by alkaline phosphatase staining using a clonal assay. Treatment 
with vehicle, DMSO, did not alter the level of alkaline phosphatase staining when 
compared to untreated cells (Figure 4.1A). Treatment with the broad selectivity PI3K 
inhibitor LY294002 induced a significant reduction in the percentage of alkaline 
phosphatase positive, self-renewing mESC colonies, consistent with previous reports 
(Paling et al., 2004). Following four days incubation in the presence of ZSTK474, 
concentrations of 1µM or greater induced a significant decrease in the proportion of 
alkaline phosphatase positive colonies, indicating a loss of self-renewal. Considering the 
inhibition of class I PI3Ks by both ZSTK474 and LY294002, this similar reduction in the 
percentage of alkaline phosphatase positive colonies was predicted (Figure 4.1A). 
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Figure 4.1 ZSTK474 induces a loss of mESC self-renewal 
After 4 days incubation with the inhibitors indicated, colonies were stained for alkaline 
phosphatase activity (n=3) (A) or harvested for analysis of protein expression with the 
antibodies indicated (representative of two independent experiments) (B). Alkaline 
phosphatase positive colonies are represented as a percentage of all colonies for each 
treatment. Data were analysed by ANOVA and Dunnet’s post hoc test, where * indicates 
p<0.05. Antibodies detecting Nanog, phosphorylated PKB (Ser473), S6 (Ser235/236) 
and Gsk-3 (Ser21/9) were used initially. Immunoblots were stripped and reprobed with 
antibodies detecting PKB, Shp-2 and Gsk-3 to assess equal loading. 
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In order to assess the expression of the self-renewal marker Nanog, mESCs were 
treated for 4 days with ZSTK474, and then harvested for protein analysis by 
immunoblotting. Expression of Nanog protein was reduced in cells treated with 
ZSTK474 compared to levels observed in control cells after 4 days incubation, 
consistent with decreased alkaline phosphatase staining and a loss of self-renewal 
(Figure 4.1B). Furthermore, the activity of ZSTK474 was maintained for up to 4 days of 
incubation, judged by assessment of the phosphorylation states of signalling molecules 
downstream of PI3K. Phosphorylation of PKB, at Ser473, and S6, at Ser235/236, were 
both reduced in cells treated with ZSTK474 (Figure 4.1B). Typically, Gsk-3 activity is 
inhibited by PI3K-induced PKB activity (Cross et al., 1995), which involves 
phosphorylation at Ser21 and Ser9 of Gsk-3α and Gsk-3β respectively. Treatment of 
mESCs with ZSTK474 induced a reduction in Gsk-3 phosphorylation at these sites 
(Figure 4.1B), indicating reduced negative regulation of Gsk-3 and consistent with the 
observed reduction in PKB phosphorylation at sites important for PKB activity 
(Balendran et al., 1999, Williams et al., 2000). 
 
 
As observed in the previous experiment, treatment with DMSO does not significantly 
alter the level of alkaline phosphatase staining when compared to untreated colonies 
(Figure 4.1A). Figures depicting alkaline phosphatase assay data from here on in will 
only show vehicle (DMSO) treatment, since DMSO is a suitable control. 
 
 
Signalling downstream of PI3K was also investigated after 24 and 48 hours incubation in 
the presence of ZSTK474 or LY294002. Both inhibitors induced a decrease in levels of 
phosphorylated PKB at Ser473 but this was more pronounced in cells treated with 
ZSTK474 (Figure 4.2A). This may reflect the more potent inhibition of growth of tumour 
cells by ZSTK474 (Yaguchi et al., 2006) since growth and insulin signalling are often 
mediated via PI3K/PKB signalling. Consistent with this, a similar pattern of Gsk-3 
phosphorylation at Ser9/21 was observed to that of PKB when LY294002 and ZSTK474 
were compared. Unlike PKB and Gsk-3, the decrease observed in S6 phosphorylation 
was similar for both inhibitors at both time points (Figure 4.2A). At 24 hours, no 
alterations in the phosphorylation of Erk1 or Erk2 at Thr202/Tyr204 were observed with 
either inhibitor. At 48 hours a small enhancement in Erk2 phosphorylation was evident 
for LY294002 but not for ZSTK474. Enhancements in Erk phosphorylation by LY294002 
are best observed following a period of serum starvation, whereas this experiment was 
designed to assess the effects on signalling during typical culture and incubation of 
mESCs. 
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A notable feature of decreased Nanog expression induced by LY294002 is the time-
course for which Nanog protein expression is decreased. Nanog expression was shown 
to be decreased as early as 8 hours after application of LY294002 to mESCs, with a 
significant decrease reported at 24 and 48 hours (Storm et al., 2007). In the present 
study, small decreases in Nanog protein expression were observed at 24 and 48 hours 
for both LY294002 and ZSTK474 (Figure 4.2B) consistent with the early down-
regulation of protein expression upon PI3K inhibition. During differentiation of mESCs, 
Oct4 protein expression typically takes longer to decrease than Nanog. Indeed Oct4 
expression has been reported to be detected in differentiating mESCs up to 5 days after 
withdrawal from LIF (Sauter et al., 2005) and Oct4 protein and RNA levels were reported 
to not change significantly following PI3K inhibition with LY294002 (Storm et al., 2007). 
Consistent with these reports, treatment of mESCs with either LY294002 or ZSTK474 
did not alter Oct4 expression at 24 or 48 hours (Figure 4.2B), although later time points 
were not investigated. 
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Figure 4.2 Changes in signalling downstream of PI3Ks are similar following 
treatment with LY294002 or ZSTK474 
Murine ESCs were incubated for 24 or 48 hours with vehicle (DMSO), LY294002 or 
ZSTK474 and harvested for protein analysis by SDS-PAGE and immunoblotting. 
Antibodies detecting phosphorylated PKB (Ser473), S6 (Ser235/236), Erk1/2 
(Thr202/Tyr204) and Gsk-3 (Ser21/9) were used to assess signalling (A) and antibodies 
detecting the self-renewal markers Nanog and Oct4 were used to assess self-renewal 
(B). Immunoblots were stripped and reprobed with the antibodies indicated to confirm 
equal loading. The data shown are representative of three independent experiments. 
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In addition to assessing the loss of self-renewal induced by ZSTK474 in comparison with 
LY294002, the effects of ZSTK474 on LIF-induced PI3K signalling were also compared 
to the effects seen using LY294002. In the absence of PI3K inhibitors, LIF stimulation 
induced an enhancement in PKB and S6 phosphorylation, at Ser473 and Ser235/236 
respectively, and an increase in Erk1 phosphorylation (Figure 4.3). Inhibition of PI3Ks 
with LY294002 or ZSTK474, prior to LIF stimulation, resulted in reduced basal PKB and 
S6 phosphorylation. A decrease in LIF-induced PKB and S6 phosphorylation resulted 
following pre-treatment with LY294002. However, ZSTK474 pre-treatment resulted in a 
considerable inhibition of LIF-induced PKB and S6 phosphorylation. These differences 
in PKB and S6 phosphorylation observed with LY294002 and ZSTK474 upon LIF 
stimulation are similar to those observed when mESCs are incubated in the presence of 
these inhibitors alone (i.e. no prior serum starvation and no specific stimulation, as 
shown in Figure 4.2). A small enhancement in Erk2 phosphorylation was observed in 
LIF stimulated cells following LY294002 treatment. This enhancement in Erk 
phosphorylation with LY294002 is consistent with that demonstrated in mESCs cultured 
in chemically defined media using LY294002 and stimulation with LIF or BMP4 (Figure 
3.2) and with previous reports (Paling et al., 2004). In contrast, ZSTK474 did not result 
in the enhancement of basal or LIF-stimulated Erk phosphorylation.  
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Figure 4.3 Inhibition of PI3Ks with ZSTK474 prevents LIF-induced signalling 
downstream of PI3Ks 
Murine ESCs were serum and LIF starved for 4 hours and pre-treated with vehicle 
(DMSO), LY294002 or ZSTK474 for 30 minutes prior to stimulation. Stimulations were 
conducted with 103 U/ml LIF for 10 minutes. Protein lysates were separated by SDS-
PAGE and proteins detected by immunoblotting using the antibodies detecting 
phosphorylated PKB (Ser473), S6 (Ser235/236) and Erk1/2 (Thr202/Tyr204) as 
indicated. Immunoblots were stripped and reprobed with antibodies detecting PKB, Shp-
2 and Erk to assess equal loading. The data shown are representative of two 
independent experiments. 
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4.3 PI3K isoform specific inhibitors are active in BaF/3 cells 
 
Recently, small molecule inhibitors that display specificity over particular PI3K catalytic 
subunit isoforms have been synthesised and characterised. These selective inhibitors 
are useful tools, in comparison to the broad selectivity PI3K inhibitors, for dissecting the 
physiological processes that individual isoforms are involved in. BaF/3 cells, an 
immortalised murine bone marrow derived pro-B cell line with interleukin-3 (IL-3)-
dependent proliferation (Palacios and Steinmetz, 1985), were used to assess the effect 
of a panel of selective and broad spectrum PI3K inhibitors on mouse cells known to 
express all class IA PI3K isoforms (Vanhaesebroeck et al., 1997).  
 
In unstimulated BaF/3 cells, low basal levels of PKB phosphorylated at Ser473 were 
enhanced by stimulation with IL-3. The broad spectrum PI3K inhibitors, LY294002, 
wortmannin and ZSTK474, all inhibited IL-3-induced PKB phosphorylation (Figure 4.4A). 
BaF/3 cells are known to express all class I catalytic isoforms (Vanhaesebroeck et al., 
1997). Accordingly, inhibitors with selectivity for p110α, p110β, p110δ (Figure 4.4B) and 
p110γ (Figure 4.4A) resulted in reduced IL-3-induced PKB phosphorylation compared to 
vehicle treated cells.  
 
Selective inhibition of PI3K isoforms did not alter basal, unstimulated levels of PKB 
phosphorylation at Ser473 compared to vehicle pre-treatment alone (Figure 4.4B). 
Interestingly, the broad spectrum PI3K inhibitors induced a small enhancement in basal 
PKB phosphorylation (Figure 4.4A). In Drosophila and mammalian cell types, evidence 
exists demonstrating that the rictor-mTOR complex is capable of phosphorylating PKB 
at Ser473 (Radimerski et al., 2002, Sarbassov et al., 2005). Furthermore, knockdown of 
S6K activity has been shown to enhance rictor-mTOR-dependent PKB phosphorylation 
at this site (Harrington et al., 2004, Sarbassov et al., 2005). Thus, enhanced PKB 
phosphorylation, observed in the present study, might be the result of inhibition of PI3Ks 
and reduced downstream activation of S6K, leading to enhanced PKB phosphorylation 
via rictor/mTOR. Further investigation would be required to explore this possibility.  
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Figure 4.4 Broad range and isoform selective inhibitors are active in BaF/3 cells 
BaF/3 cells were washed and resuspended in serum-free media in the absence of IL-3. 
Cells were pre-treated for 30 minutes with each of a panel of inhibitors. A PI3K broad 
spectrum inhibitors (LY294002, Wortmannin and ZSTK474), dual p110α and mTOR 
inhibitor (PI-103) and PI3K class IB p110γ selective inhibitor (AS605340). B PI3K class IA 
catalytic subunit isoform inhibitors selective for p110α (PIK-75 and compound 15e), 
p110β (TGX-221 and TGX-121) and p110δ (IC87114). Following pre-treatment with 
inhibitors, BaF/3 cells were stimulated with 20ng/ml IL-3 for 10 minutes. Cell lysates 
were resolved by SDS-PAGE and signalling downstream of PI3Ks assessed by 
immunoblotting using antibodies detecting PKB protein phosphorylated at Ser473. Blots 
were stripped and reprobed with antibodies detecting PKB to assess equal loading. The 
data shown are representative of three independent experiments. 
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4.4 Investigating which p110 isoforms contribute to self-renewal 
4.4.1 The role of p110β in mESC fate 
 
The role of the PI3K catalytic subunit isoform p110β in mESCs was of particular interest 
since mouse embryos homozygous for a partial deletion of Pik3cb, the gene encoding 
the p110β subunit, exhibit early embryonic lethality at E3.5 and ESC lines cannot be 
derived from these blastocysts (Bi et al., 2001). Of note here is that isolation of mESCs 
is achieved from wild-type blastocysts at E3.5 (Evans and Kaufman, 1981) the same 
time point at which embryonic lethality was reported in mice deficient in functional p110β 
(Bi et al., 2001). Both pharmacological inhibition and gene silencing techniques were 
used to determine if this isoform is involved in mESC self-renewal. 
 
4.4.1.1 Pharmacological inhibition of p110β leads to a loss of self-renewal 
 
In order to address the contribution of p110β to the maintenance of self-renewal, two 
isoform selective inhibitors of p110β, TGX-221 and TGX-121, the synthesis of which 
have been previously described (Jackson et al., 2004, Robertson et al., 2001), were 
used. TGX-221 is the more potent of these two p110β inhibitors and has been used 
effectively to assess p110β signalling and cellular function (Jackson et al., 2005). 
 
Murine ESCs incubated in the presence of vehicle for 4 days formed rounded colonies 
with smooth defined edges which stained strongly for alkaline phosphatase activity 
(Figure 4.5A). Treatment with LY294002 resulted in flattened colonies with rough 
borders which had weak staining or did not stain for alkaline phosphatase. This effect of 
broad spectrum inhibition of PI3Ks resulting in a loss of the self-renewal marker alkaline 
phosphatase is consistent with previous reports (Paling et al., 2004, Storm et al., 2007). 
Treatment of mESCs with the p110β selective inhibitor TGX-221 induced colonies to 
adopt a more differentiated morphology similar to colonies incubated with LY294002 
(Figure 4.5A). Incubation in the absence of LIF resulted in a decrease in Nanog 
expression compared to the presence of LIF, on both day 2 and day 4, indicating a loss 
of self-renewal (Figure 4.5B). Murine ESCs incubated in the presence of TGX-221 and 
LIF expressed slightly lower levels of Nanog protein compared to cells incubated in the 
presence of LIF alone on day 2 (Figure 4.5B). When colonies were scored for alkaline 
phosphatase staining and results represented graphically, treatment with LY294002 
typically reduced the percentage of alkaline phosphatase stained colonies to 
approximately 30% of all colonies present on a tissue culture dish, consistent with a 
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decrease in self-renewal. A significant reduction in alkaline phosphatase staining, to a 
level comparable with that attained in the presence of LY294002, was observed in the 
presence of 50nM TGX-221 (Figure 4.5C). Typically TGX-221 is used at 100nM, 
treatment of mESCs with 100nM or 1µM TGX-221 did not further reduce alkaline 
phosphatase staining compared to 50nM TGX-221 (Figure 4.5D). The less potent p110β 
selective inhibitor, TGX-121, also decreased alkaline phosphatase staining with a 
significant reduction in staining observed at concentrations greater than 5µM (Figure 
4.5E). 
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Figure 4.5 Pharmacological inhibition of p110β leads to a decrease in self-renewal 
of mESCs 
Murine ESCs were treated for 4 days with LY294002, TGX-221 or TGX-121 at the doses 
shown or with vehicle alone (DMSO). Self-renewal was assessed by staining for alkaline 
phosphatase activity. A Representative colonies are shown following treatment with 
LY294002 or TGX-221, scale bars=100µm. B Following incubation for 2 or 4 days in the 
presence or absence of LIF, or in the presence of LIF and TGX-221, mESCs were 
harvested and protein lysates analysed for the expression of Nanog by immunoblotting. 
Immunoblots were stripped and reprobed for Shp-2 to confirm equal loading. The 
average percentage of alkaline phosphatase positive, self-renewing colonies in each 
condition are shown with S.E.M. for TGX-221 treatment (n=3) C and (n=4) D and TGX-
121 treatment (n=4) E. For each, ANOVA with Dunnet's post-hoc test was applied, 
where * indicates p<0.05 and ** indicates p<0.01.  
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The density at which mESCs are cultured is important for maintaining optimal self-
renewal and for survival. It has previously been reported that mESCs display a 
dependency on autocrine signalling, thus fewer colonies may affect their ability to 
maintain self-renewal (Guo et al., 2006, Singla et al., 2008, Welham et al 2007). In order 
to verify that inhibition of p110β did not alter the number of colonies which may indirectly 
alter self-renewal, the total number of colonies per tissue culture dish for each treatment 
is represented graphically (Figure 4.6). Statistical analysis revealed that after 4 days 
incubation with neither TGX-121 (Figure 4.6A), nor treatment with TGX-221 (Figure 
4.6B and C), gave a significant difference in the number of colonies per dish when 
compared with the number of colonies on vehicle treated dishes. Only LY294002 
caused a decrease in the number of colonies when compared to vehicle treated colony 
numbers (Figure 4.6). This was only significant in panels A and B, but not panel C and 
might be explained by the inhibition of p110α by LY294002 (see Sections 4.4.5.3 and 
Figure 4.25) (Kingham and Welham, In Press). 
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Figure 4.6 Inhibition of p110β does not alter colony number 
The data obtained for Figure 4.5 is represented as the average number of colonies per 
dish shown with S.E.M. for TGX-121 (n=4) (A), TGX-221 (n=3) (B) and TGX-221 (n=4) 
(C). Statistical analysis using ANOVA and Dunnet’s post hoc test were used to 
determine which treatments caused a significant change in the number of colonies 
compared to the number of colonies counted on vehicle (DMSO) treated control dishes. 
 
The use of these two, structurally similar p110β isoform inhibitors has provided evidence 
which indicates that p110β activity is required in order to maintain optimal self-renewal.  
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4.4.1.2 siRNA-mediated knockdown of p110β expression leads to a loss of self-
renewal 
 
To further characterise mESC self-renewal regulation by p110β, and to support findings 
obtained by pharmacological inhibition of this isoform, short-interfering RNAs (siRNAs) 
were used to target Pik3cb, the gene encoding p110β.  
 
Targeting of Pik3cb, was conducted using two different commercially available siRNA 
products. Smartpool siRNA, supplied by Dharmacon, is a pool of four single siRNAs 
whereas Silencer Select siRNAs, supplied by Ambion, are individual siRNAs, two of 
which were used independently to knockdown the expression of p110β. Care was taken 
when choosing siRNA products so that in each case, siRNAs targeting different exons or 
exon boundaries were selected. The regions of Pik3cb targeted by Dharmacon 
Smartpool siRNAs and Ambion Silencer Select siRNAs are depicted in Figure 2.6. Off-
target effects of using siRNAs include the binding of siRNA to mRNA with incomplete 
complementarity and subsequent silencing of non-target genes, which provides false 
data. Selecting siRNAs that have independent target regions within Pik3cb allowed such 
data to be more easily identified. In addition, the appropriate controls of non-targeting 
Dharmacon siRNA or negative control Ambion siRNA were selected and allowed siRNA 
toxicity effects, those not associated specifically with Pik3cb silencing, to be taken into 
account. The use of a pooled siRNA product, such as Dharmacon Smartpool siRNA, 
ensures efficient knock-down of the target gene. As a positive control, siRNAs targeting 
Nanog, the homeodomain transcription factor and key regulator of self-renewal 
(Chambers et al., 2003, Mitsui et al., 2003), were used.  
 
4.4.1.2.1 siRNA-mediated knockdown of p110β using Dharmacon Smartpool siRNA 
commercially available products 
 
Using Dharmacon Smartpool siRNAs, which contain 4 specific gene targeting siRNAs, 
the effect of knockdown of Pik3cb, the gene encoding p110β, on self-renewal was 
assessed. Nanog targeting siRNA was used as a positive control. Quantitative PCR 
(QPCR) revealed a significant knock-down of Pik3cb RNA when using Dharmacon 
Smartpool Pik3cb targeting siRNAs (Figure 4.7A). Typically a 50-60% decrease in 
expression was achieved. No change in expression of Pik3cb was detected using 
Nanog siRNAs. On assessment of self-renewal, by alkaline phosphatase assay, 
knockdown of Pik3cb led to a reduction of approximately 50% in the proportion of 
alkaline phosphatase positive colonies (Figure 4.7B). A significant decrease in alkaline 
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phosphatase staining was observed following transfection with 50nM Pik3cb targeting 
siRNA. Transfection with Nanog targeting siRNAs decreased alkaline phosphatase 
staining, consistent with the requirement for Nanog protein expression to maintain self-
renewal (Mitsui et al., 2003). Furthermore, a significant reduction in the proportion of 
pure self-renewing alkaline phosphatase colonies was observed with either Nanog or 
Pik3cb targeting siRNAs compared to non-targeting siRNAs (Figure 4.7C). Importantly, 
levels of self-renewal following siRNA-mediated knockdown of Pik3cb were comparable 
to pharmacological inhibition of p110β with TGX-221 (Figure 4.5) and with siRNA-
mediated knockdown of Nanog (Figure 4.7B). Transfection with Pik3cb targeting siRNA 
did not significantly change the total number of colonies when compared to non-
targeting control colony numbers (Figure 4.7D). Interestingly transfection with Nanog 
targeting siRNA induced a significant increase in the number of colonies per dish. 
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Figure 4.7 Expression of p110β is required to maintain self-renewal 
Murine ESCs were transfected with Dharmacon Pik3cb or Nanog targeting siRNAs or 
non-targeting (NT) siRNAs. A QPCR was conducted in quadruplicate using samples of 
cDNA obtained by reverse transcribing RNA isolated from transfected cells. QPCR was 
used to measure knockdown of Pik3cb RNA, which was normalised relative to levels of 
β-actin RNA. A representative experiment of 4 independent experiments is shown with 
standard deviations. B Following transfection, cells were plated for 4 days and self-
renewal assessed by alkaline phosphatase staining. The average percentage of alkaline 
phosphatase positive, self-renewing colonies in each condition is shown with S.E.M 
(n=4). C Assessment of self-renewal by alkaline phosphatase staining is depicted by the 
percentage of pure alkaline phosphatase positive colonies (colonies that appear 
compact, round and stain bright red) of all colonies shown with S.E.M. (n=4). D From the 
self-renewal assay data, the total number of colonies per dish are shown with S.E.M. 
Statistical analysis was conducted using a Student’s t-test to compare targeting siRNA 
data to non-targeting siRNA data, where * indicates p<0.05 and ** indicates p<0.01.  
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In addition to alkaline phosphatase staining, expression of Nanog protein and RNA is 
typically reduced following the induction of differentiation (Mitsui et al., 2003, Storm et 
al., 2007). As expected, a significant decrease in Nanog expression was observed 
following siRNA-mediated knockdown of Nanog, when assessed by QPCR (Figure 
4.8A). A decrease in Nanog expression was also detected following transfection with 
Pik3cb targeting siRNAs, consistent with a decrease in alkaline phosphatase staining 
and indicating a loss of self-renewal. Semi-quantitative assessment of self-renewal 
markers, Nanog and Rex1 was also conducted (Figure 4.8B). Knockdown of Pik3cb 
expression resulted in a modest decrease in Nanog expression and a very small 
decrease in Rex1 expression. Knockdown of Nanog expression did not decrease Pik3cb 
expression and did not appear to alter Rex1 expression. Consistent with a decrease in 
Nanog RNA, Nanog protein levels were reduced by knockdown of either Nanog or 
Pik3cb genes (Figure 4.8C). Levels of Oct4 protein expression appeared unchanged 
with 25nM Pik3cb siRNA when compared to 25nM non-targeting siRNA, however, a 
small decrease in Oct4 expression was observed with 50nM Pik3cb siRNA when 
compared to 50nM non-targeting siRNA. 
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Figure 4.8 Nanog expression is reduced following Pik3cb gene silencing 
A Following transfection with Pik3cb, Nanog or non-targeting (NT) siRNAs, QPCR was 
conducted on quadruplicate samples to measure knockdown of Nanog RNA. Nanog 
RNA levels were normalised relative to levels of β-actin RNA. The normalised ratio of 
Nanog expression is shown with standard deviations. A Student’s t-test was conducted 
to compare gene targeting samples to non-targeting samples, where * indicates p<0.05 
and ** indicates p<0.01. B Semi-quantitative PCR was conducted using primers 
detecting Pik3cb, Nanog, Rex1 and β-actin. C Protein lysates were made from siRNA 
transfected cells and immunoblotting conducted using antibodies detecting Nanog and 
Oct4. Antibodies detecting Shp-2 were used to assess equal loading. In each case, the 
data shown are representative of four independent experiments. 
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4.4.1.2.2 siRNA-mediated knockdown of p110β using Ambion Silencer Select siRNA 
commercially available products 
 
Two Ambion Silencer Select siRNAs, termed Pik3cb s93107 and Pik3cb s93108, were 
used independently to knockdown Pik3cb by targeting different regions of the gene to 
those targeted by Dharmacon Smartpool siRNAs (see Figure 2.6 for siRNA targeting 
regions of Pik3cb).  
 
Using Ambion Silencer Select siRNAs to target Pik3cb resulted in a 40-60% knockdown 
of Pik3cb RNA expression (Figure 4.9A). Knockdown of Pik3cb significantly reduced the 
proportion of alkaline phosphatase positive colonies compared to negative control 
siRNA transfection (Figure 4.9B). The average number of colonies per dish was not 
significantly different for cells transfected with Pik3cb targeting siRNA compared to 
transfection with negative control siRNA (Figure 4.9C). Consistent with Dharmacon 
smartpool siRNA products, Ambion Silencer Select resulted in a similar level of Pik3cb 
knockdown, which in turn induced a reduction in alkaline phosphatase staining but did 
not affect colony number. 
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Figure 4.9 siRNA-mediated knockdown of Pik3cb results in reduced self-renewal 
Murine ESCs were transfected with 10nM Ambion Silencer Select Pik3cb targeting 
siRNAs (s93107 or s93108) or with 10nM negative control Silencer Select siRNAs. A 
Following transfection, cells were plated for 4 days then RNA isolated and reverse 
transcribed. QPCR was conducted to detect knockdown of Pik3cb RNA normalised 
relative to levels of β-actin RNA. Representative data with standard deviations for 
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quadruplicate QPCR samples are shown. B Following transfection, cells were plated for 
4 days and self-renewal assessed by alkaline phosphatase staining. The average 
percentage of alkaline phosphatase positive colonies are shown (n=4), with S.E.M. C 
From the alkaline phosphatase data obtained, the average number of colonies per dish 
was plotted for each treatment with S.E.M. Statistical analysis was conducted using a 
Student’s t-test to compare data for Pik3cb targeting siRNA compared to data for 
negative control siRNA where * indicates p<0.05 and ** indicates p<0.01. No significant 
difference was found in the number of colonies per dish for Pik3cb s093107 (p=0.677) or 
Pik3cb s093108 (p=0.921) siRNA treatment compared to Negative siRNA treatment. 
 
 
 
Nanog RNA expression was reduced in cells transfected with either Pik3cb s93107 or 
Pik3cb s93108 compared to cells transfected with negative control siRNA (Figure 
4.10A). On assessment of Nanog protein, targeting Pik3cb reduced Nanog protein 
expression when compared to Nanog protein in cells transfected with negative control 
siRNA (Figure 4.10B). Only modest decreases in Oct4 protein levels were observed 
following Pik3cb knockdown with Pik3cb s93107 or Pik3cb s93108 compared to 
negative control siRNA. Decreases in Nanog and Oct4 protein, along with a reduction in 
alkaline phosphatase staining are all consistent with a decrease in self-renewal of cells 
following knockdown of Pik3cb. 
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Figure 4.10 Knockdown of Pik3cb RNA results in decreased Nanog RNA and 
protein expression 
Following transfection with 10nM Pik3cb targeting siRNAs (s93107 or s93108) or with 
negative control Silencer select siRNA, cells were plated for 4 days then harvested for 
RNA and protein expression analysis. A QPCR was conducted to detect Nanog RNA 
expression. Nanog RNA levels were normalised relative to levels of β-actin RNA. 
Representative data with standard deviations for quadruplicate QPCR samples are 
shown. A Student’s t-test was conducted where * indicates p<0.05. B Immunoblotting 
was conducted using antibodies detecting Nanog and Oct4. Equal loading was 
assessed by stripping and reprobing immunoblots using antibodies detecting Shp-2. 
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In some instances, altering the expression of p110 isoforms has been shown to alter the 
expression of the regulatory subunit p85 or the expression of other p110 isoforms (Bi et 
al., 1999, Clayton et al., 2002, Fruman et al., 1999, Jou et al., 2002). In order to address 
this, p85 protein expression was assessed by immunoblotting and the expression of 
Pik3ca and Pik3cd, the genes encoding the catalytic subunit isoforms p110α and p110δ 
respectively, were investigated by QPCR. A combination of a low protein yield following 
siRNA-mediated gene silencing of mESCs and the low specificity and poor sensitivity of 
the antibodies available that detect p110α and p110δ meant that analysis of protein 
levels by immunoblotting could not be achieved for these isoforms. Following 
knockdown of Pik3cb by Dharmacon Smartpool siRNAs (Figure 4.11A) or by Ambion 
Silencer Select siRNAs (Figure 4.11B), p85 protein expression remained unchanged. 
Following knockdown of Pik3cb by Dharmacon Smartpool siRNAs, no significant or 
consistent change in the expression of either Pik3ca (Figure 4.11C) or Pik3cd (Figure 
4.11D) were detected. Consistent with the data obtained using Dharmacon siRNAs, no 
significant changes in the expression of Pik3ca (Figure 4.11E) or Pik3cd (Figure 4.11F) 
were found following Ambion Silencer Select siRNA-mediated knockdown of Pik3cb. 
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Figure 4.11 Expression of other PI3K isoforms following p110β knockdown 
Immunoblotting was conducted using antibodies detecting p85 to assess protein 
expression following transfection with Dharmcon (A) or Ambion (B) siRNAs. 
Immunoblots were stripped and reprobed using antibodies detecting Shp-2 in order to 
assess equal loading. Samples were assessed in quadruplicate by QPCR for the 
expression of Pik3ca (C) and Pik3cd (D) following transfection with Dharmacon siRNA 
and expression of Pik3ca (E) and Pik3cd (F) following transfection with Ambion siRNA, 
normalised to relative levels of β-actin. All graphs show standard deviation and are 
representative of all experimental repeats (n=4). 
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4.4.2 Addressing the signalling mediated by p110β in mESCs 
 
Signalling mediated by p110β following LIF stimulation was investigated using the 
p110β selective inhibitors, TGX-121 and TGX-221 (Figure 4.12). Basal and LIF-
stimulated levels of PKB phosphorylation at Ser473, Gsk-3α/β phosphorylation at 
Ser20/9 and S6 phosphorylation at Ser235/236 were all unaffected by 5 or 10µM TGX-
121 and 100, 200 or 1000nM TGX-221 (Figure 4.12). However, at the highest 
concentration of TGX-121 used, 20µM, a small decrease in LIF-induced PKB, S6 and 
Gsk-3 phosphorylation was observed. The selectivity of 20µM TGX-121 for targeting 
p110β alone could be questionable. 
 
LIF-stimulated phosphorylation of Erk1 and Erk2 were also unaffected by pre-treatment 
with these p110β inhibitors although, basal Erk2 phosphorylation was modestly 
enhanced in unstimulated cells following incubation with either TGX-121 or TGX-221. 
This observation was noteworthy since an enhancement in Erk phosphorylation has 
been observed with LY294002 in mESCs (Paling et al., 2004) and was also observed in 
mESCs cultured and treated with LY294002 in chemically defined media (Figure 3.2). It 
appears that this phenomenon of inhibition of MAPK pathway activity by PI3K might be 
mediated by the p110β isoform since selective inhibition of p110β by either TGX-121, or 
the more potent TGX-221, enhanced basal Erk phosphorylation (Figure 4.12).  
 
No alteration LIF-stimulated signalling was observed following treatment with typical 
doses of two p110β inhibitors despite the activity and expression of p110β being 
required for mESCs to maintain self-renewal (Figures 4.5, 4.7 and 4.9). This observation 
was surprising since LIF is the major extrinsic ligand known to promote mESCs self-
renewal (Bard and Ross, 1991, Gough et al., 1998, Smith et al., 1988, Williams et al., 
1988). 
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Figure 4.12 LIF-induced signalling is not mediated by p110β 
Murine ESCs were treated with TGX-121 (A) or TGX-221 (B) for 30min prior to 
stimulation with 103 U/ml LIF for 10min. Cell lysates were resolved by SDS-PAGE and 
immunoblotting carried out using the antibodies indicated to detect signalling 
downstream of PI3Ks. Equal loading was assessed by stripping and reprobing 
immunoblots with appropriate antibodies as indicated. The data shown are 
representative of three independent experiments. 
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4.4.2.1 Investigating the activation of p110β by GPCR agonists in mESCs 
 
The activation of p110β by G proteins, the intracellular mediators of G protein coupled 
receptors (GPCRs), has been reported in a number of cell types (discussed in Section 
1.1.2.1) (Ciraolo et al., 2008, Guillermet-Guibert et al., 2008, Maier et al., 1999, Murga et 
al., 2000, Roche et al., 1998). GPCR agonists are present in the serum and serum-
replacement products used for the routine culture of mESCs. To investigate the 
possibility of these agonists activating p110β in mESCs, stimulation experiments were 
conducted using GPCR agonists following pre-treatment of mESCs with vehicle or 
p110β isoform inhibitors, TGX-121 and TGX-221. Serum contains a cocktail of ligands 
that can potentially activate a wide variety of receptors. However, boiling serum destroys 
many of these ligands with the exception of heat stable lysophospholipids, which 
typically activate GPCRs (personal communication Bart Vanhaesebroeck).  
 
Knock-out Serum Replacement (KO SR) is used for the routine culture of mESCs and is 
optimised by the manufacturer for the culture of self-renewing mESCs. However, the 
components of this product are proprietary to the manufacturer, Invitrogen. Stimulation 
of mESCs with 10% (v/v) KO SR in GMEM would be expected to stimulate a variety of 
signalling pathways. Indeed 10% (v/v) KO SR in GMEM induced the phosphorylation of 
PKB at Ser473, Gsk3 at Ser20/9 and Erk1/2 at Thr202/Tyr204 (Figure 4.13). When 
boiled to denature heat unstable components, boiled 10% (v/v) KO SR in GMEM 
induced the phosphorylation of PKB and Gsk3 when compared to phosphorylated levels 
detected following stimulation with boiled GMEM alone. In addition, a small 
enhancement in Erk1/2 phosphorylation was also observed following stimulation with 
boiled 10% (v/v) KO SR in GMEM. In the presence of TGX-121 or TGX-221, no change 
in the phosphorylation states of PKB, Gsk3 or Erk1/2 was observed following stimulation 
with 10% (v/v) KO SR in GMEM. Interestingly, boiled 10% KO SR (v/v) in GMEM-
induced stimulation of PKB phosphorylation was reduced following pre-treatment with 
either TGX-121 or TGX-221 (Figure 4.13). Additionally TGX-221 pre-treatment reduced 
the phosphorylation of Gsk3α/β and Erk1/2 induced by stimulation with boiled 10% (v/v) 
KO SR in GMEM. The results presented in Figure 4.13 indicate that components of KO 
SR, that are not denatured by boiling, stimulate signalling downstream of PI3Ks and that 
this is mediated, at least in part, by the p110β catalytic subunit isoform of PI3Ks. The 
activation of PKB following stimulation of GPCRs is consistent with a previous study 
which investigated the mechanism involved and demonstrated that activation of PKB in 
this manner occurred via interaction of p85 SH2 domains with tyrosine phosphorylated 
proteins and also required p85 interaction with p110β (Kubo et al., 2005). 
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Figure 4.13 Stimulation of GPCRs activated PKB via p110β in mESCs 
Murine ESCs were serum and LIF starved for 4 hours and pre-treated for 30 minutes 
with TGX-121 or TGX-221 where indicated. Stimulations were conducted for 5 minutes 
with boiled GMEM, 10% (v/v) Knock-out Serum Replacement (KO SR) in GMEM or 
boiled 10% (v/v) KO SR in GMEM. Boiling of GMEM and 10% (v/v) KO SR in GMEM 
was conducted for 5 minutes and the media was allowed to cool to room temperature 
prior to applying to mESCs. Protein lysates were analysed by immunoblotting using the 
antibodies indicated. Immunoblots were stripped and reprobed using appropriate 
antibodies, as indicated, to assess equal loading. The data presented here are 
representative of two independent experiments. 
 
 
Two agonists in particular, lysophosphatidic acid (LPA) and sphingosine-1-phosphate 
(S1P), are reported to activate PKB via p110β (Guillermet-Guibert et al., 2008, Roche et 
al., 1998, Yart et al., 2002). LPA and S1P receptors typically couple to heterotrimeric G 
proteins, including members of the Gi, Go, Gs, G12/13 and Gq families of G proteins. 
Furthermore, LPA and S1P-induced signalling has been linked to cellular functions 
including cell migration, proliferation, cell-cell contacts and implantation (Meyer zu 
Heringdorf and Jakobs, 2007). Interestingly, S1P was reported to aid the maintenance of 
self renewal of human ESCs (hESCs) in the presence of mitomycin-treated mouse 
embryonic fibroblasts (MEFs) (feeder layer for the culture of undifferentiated hESCs) 
and platelet-derived growth factor (PDGF) (Pébay et al., 2005). The expression of G-
protein-coupled lysophospholipid receptors in ESCs has not been fully investigated but 
reports do exist demonstrating the expression of LPA receptor LPA5 and S1P receptors 
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S1P3 receptors in hESCs (Inniss and Moore, 2006, Kleger et al., 2007, Lee et al., 2006, 
Pébay et al., 2005). Additionally information gained from the NCBI database 
(http://www.ncbi.nlm.nih.gov/unigene accessed 04.12.08) suggests that LPA1, S1P2 and 
S1P5 are expressed at the blastocyst stage of mouse embryo development. 
Furthermore, microarray data (Storm et al., 2009) from the mESC line used in the 
present study (E14tg2A, clone R63) indicates that LPA2, LPA3, S1P2, S1P3 and S1P5 
receptor expression is detectable in these cells (Storm and Welham, unpublished data). 
It was therefore, of interest to examine the signalling induced following stimulation of 
these receptors with their agonists LPA and S1P. 
 
 
LPA and S1P agonists of the GPCRs were used to stimulate mESCs and signalling 
downstream of PI3Ks, specifically mediated via the p110β isoform, was investigated. 
Pertussis toxin, an exotoxin produced by the bacterium Bordetella pertussis, which 
catalyses ADP ribosylation of Gα subunit of heterotrimeric G proteins Gi, Go, and Gt, 
preventing these G proteins from interaction with GPCRs (Burns, 1988) was also used 
to assess GPCR coupling in mESCs. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Stimulation of mESCs with LPA and S1P 
Murine ESCs were serum and LIF starved for 4 hours and pre-treated for 30 minutes 
with TGX-221, or treated overnight with pertussis toxin (PTX). Stimulations were 
conducted for 5 minutes with lysophosphatidic acid (LPA) and sphingosine-1-phosphate 
(S1P) (n=1). Protein lysates were analysed by immunoblotting using antibodies 
detecting phosphorylated PKB (Ser473) and Erk (Thr202/Tyr204). Immunoblots were 
stripped and reprobed with antibodies detecting PKB and Erk to assess equal loading. 
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Stimulation of mESCs with LPA or S1P for 5 minutes failed to induce a change in the 
phosphorylation of PKB at Ser473 (Figure 4.14). However, GPCRs are known to be 
rapidly desensitised following stimulation, a process involving phosphorylation of 
activated receptors by GPCR kinases, subsequent arrestin binding and internalisation, 
which inhibits downstream signalling (Krupnick and Benovic, 1998, Zhang et al., 1997). 
Therefore, further investigation implementing shorter stimulation periods of mESCs with 
LPA or S1P might reveal GPCR-induced PKB phosphorylation. Levels of PKB 
phosphorylation were unaltered by the treatment of mESCs with pertussis toxin (Figure 
4.14). Enhanced levels of basal Erk2 phosphorylation were observed following pre-
treatment with TGX-221, as previously demonstrated (Figure 4.12), and also following 
pre-treatment with pertussis toxin (Figure 4.14). Stimulation with either LPA or S1P 
induced the phosphorylation of Erk2 when compared to basal, unstimulated levels 
(Figure 4.14). Pre-treatment with either TGX-221 or pertussis toxin appeared to further 
enhance LPA-induced Erk2 phosphorylation. Conversely, pre-treatment with either TGX-
221 or pertussis toxin inhibited S1P-induced Erk2 phosphorylation. 
 
 
The stimulation of Erk phosphorylation by LPA and S1P is consistent with the activation 
of ERK by S1P1-4 and LPA1-3 receptors (reviewed by Meyer zu Heringdorf and Jakobs 
2007, Pébay et al., 2007). Furthermore, the use of pertussis toxin has implicated Gi, Go 
and
 
Gt G protein types, consistent with the coupling of LPA and S1P receptors to Gi and 
Go G proteins (Meter zu Heringdorf and Jakobs, 2007, Pébay et al., 2005, Rosen and 
Goetzl, 2005). However, further investigation is required in order to determine if PI3K 
signalling is activated upon stimulation of mESCs with LPA or S1P. 
 
 
Chapter 4: Results 
 174 
4.4.3 p110δ and the control of mESC fate 
 
In contrast to p110β, mice deficient in active p110δ are viable and fertile but are subject 
to impaired immune responses (Clayton et al., 2002, Jou et al., 2002). These reports are 
consistent with the expression of p110δ being largely restricted to cells of the immune 
system and a major role for p110δ in the lymphohaemopoietic system (Okkenhaug et 
al., 2002, Vanhaesebroeck et al., 1997). As with p110β, a role for p110δ in mESC self-
renewal was investigated by both pharmacological inhibition and gene silencing 
techniques. 
 
The isoform selective p110δ inhibitor, IC87114 (Sadhu et al., 2001) has been shown to 
inhibit p110δ in cells at doses of 5-10µM (Sadhu et al., 2003). To test the potential role 
of p110δ in mESCs, self-renewing cells were incubated with IC87114 for 4 days and the 
effects on self-renewal assessed by alkaline phosphatase assay.  
 
Treatment of mESCs with 2 or 5µM IC87114 did not significantly reduce alkaline 
phosphatase staining (Figure 4.15A). However, treatment with 10µM IC87114 did 
induce a significant reduction in the percentage of alkaline phosphatase positive 
colonies when compared to control colonies. This decrease was not as great as that 
observed with the broad spectrum PI3K inhibitor LY294002 (Figure 4.15A) or that 
observed with the p110β inhibitors TGX-121 or TGX-221 (Figure 4.5C, D and E). 
Incubation of mESCs with IC87114 did not significantly alter the number of colonies on 
each dish compared to incubation with DMSO alone (Figure 4.15B). 
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Figure 4.15 Pharmacological inhibition of p110δ results in a modest decrease in 
alkaline phosphatase staining only at high doses 
Murine ESCs were incubated with the p110δ inhibitor IC87114 or LY294002 for 4 days. 
Self-renewal was assessed by staining for alkaline phosphatase activity. Data are 
represented as the average percentage of alkaline phosphatase positive, self-renewing 
colonies in each condition (A) or as the average total number of colonies per dish for 
each treatment (B) both with S.E.M. (n=4). Data were analysed using ANOVA and, 
where significant, Dunnet’s post hoc test was applied. * indicates p<0.05. 
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The role of p110δ in mESC self-renewal was further investigated using Dharmacon 
Smartpool siRNA targeting Pik3cd (Figure 4.16). When expression of Pik3cd RNA was 
assessed following siRNA-mediated knockdown, 50 and 75nM siRNA induced a 39% 
and 77% knockdown in Pik3cd expression respectively, when compared to non-
targeting siRNA (Figure 4.16A). This knockdown followed a consistent trend, although 
not statistically significant. Following transfection, cells were plated for 4 days and self-
renewal assessed by alkaline phosphatase staining. No significant change in the 
proportion of cells staining positive for alkaline phosphatase activity was found (Figure 
4.16B). The total number of colonies on dishes containing cells transfected with Pik3cd 
targeting siRNA was slightly greater than on dishes containing cells transfected with 
non-targeting siRNA, although this difference was not statistically significant (Figure 
4.16C). 
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Figure 4.16 Gene silencing of Pik3cd does not alter alkaline phosphatase staining  
Murine ESCs were transfected with Dharmacon Pik3cd targeting siRNAs or non-
targeting (NT) siRNAs. A QPCR was conducted in quadruplicate to assess knockdown 
of Pik3cd RNA which was normalised relative to levels of β-actin RNA. A representative 
experiment of 4 independent experiments is shown with standard deviations. A 
Student’s t-test was conducted to compare levels of Pik3cd expression following 
treatment with Pik3cd targeting siRNA and non-targeting (NT) siRNA. Although a 
consistent trend of reduced Pik3cd expression was detected with Pik3cd targeting 
siRNA, this decrease was not statistically significant. B Following transfection, cells were 
plated for 4 days and self-renewal assessed by alkaline phosphatase staining. The 
average percentage of alkaline phosphatase positive, self-renewing colonies in each 
condition is shown with S.E.M (n=4). A Student’s t-test revealed no statistical 
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significance. C The average total number of colonies per dish is shown with S.E.M. 
(n=4) and was analysed using a Student’s t-test to confirm no statistical significance 
between the number of colonies on dishes incubated with Pik3cd targeting siRNA 
compared to dishes treated with non-targeting siRNA. 
 
 
Consistent with no change in alkaline phosphatase activity, Nanog expression was not 
reduced by knockdown of Pik3cd (Figure 4.17A). In fact, expression of Nanog RNA 
appeared slightly enhanced in cells transfected with Pik3cd targeting siRNA compared 
to cells transfected with non-targeting siRNA. This enhancement in Nanog expression 
following gene silencing of Pik3cd was particularly noticeable using 50nM siRNA. 
Correlating with enhanced Nanog RNA expression, Nanog protein levels were also 
elevated following knockdown of Pik3cd (Figure 4.17B). Importantly, this enhancement 
in Nanog expression was not sufficient to alter alkaline phosphatase staining.  
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Figure 4.17 Expression of Nanog RNA and protein is enhanced following 
knockdown of Pik3cd 
A QPCR was conducted on samples from Pik3cd siRNA or non-targeting siRNA 
transfected cells for the expression of Nanog and normalised to relative levels of β-actin 
RNA. The data shown are representative of four independent experiments and is shown 
with standard deviations. B Protein lysates were analysed for the expression of Nanog 
and immunoblots were stripped and reprobed for Shp-2 to assess equal loading. The 
data shown are representative of four independent experiments. 
 
  
The expression of p85 and other p110 isoforms were assessed following knockdown of 
Pik3cd. No change in the class IA PI3K regulatory subunit p85 protein expression was 
detected (Figure 4.18A). QPCR was used to assess the RNA expression of Pik3ca and 
Pik3cb, the genes encoding p110α and p110β respectively. Comparing 50nM Pik3cd 
targeting siRNA to 50nM non-targeting siRNA, no change in Pik3ca expression was 
observed (Figure 4.18B). At 75nM siRNA concentrations, Pik3ca expression was 
reduced although not significantly. This may reflect the high concentration of siRNA 
used since expression of Pik3ca was also decreased for 75nM non-targeting siRNA 
compared to 50nM non-targeting siRNA. No change in Pik3cb expression was detected 
using either 50 or 75nM Pik3cd targeting siRNA when compared to 50 or 75nM non-
targeting siRNA respectively (Figure 4.18C).  
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Figure 4.18 Expression of other p110 isoform genes following knockdown of 
Pik3cd  
A Protein lysates were obtained from cells following transfection with Dharmacon Pik3cd 
targeting siRNA. Immunoblotting was conducted and antibodies detecting p85 and Shp-
2. Samples were assessed in quadruplicate by QPCR for the expression of Pik3ca (B) 
and Pik3cb (C) normalised to relative levels of β-actin. The data shown are 
representative of four independent experiments. 
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The incongruent results obtained by pharmacological inhibition of p110δ and siRNA-
mediated knockdown of Pik3cd, the gene encoding p110δ, might reflect the fact that 
IC87114 shows some inhibition of p110β. In vitro assays demonstrated that inhibition of 
p110β by IC87114 occurs with an IC50 of 16µM (Knight et al., 2006). Therefore, it is 
likely that, doses of 10µM IC87114 could inhibit p110β as well as p110δ. This certainly 
seems plausible given that knockdown of Pik3cd did not alter the expression of other 
isoforms and did not induce a decrease in self-renewal. Additionally, these decreases in 
alkaline phosphatase staining observed following pharmacological inhibition or gene 
silencing of p110β (Figures 4.5-4.10) were greater than those observed with IC87114 at 
the highest concentrations used. Therefore, changes in alkaline phosphatase staining 
with IC87114 may not be directly attributable to the inhibition of p110δ but could be the 
result of inhibition of p110β by IC87114. To investigate this possibility, IC87114 and 
TGX-121 or TGX-221 were applied simultaneously and self-renewal analysed by 
alkaline phosphatase assay. 
 
 
As demonstrated previously, treatment of mESCs with 5µM LY294002 for 4 days results 
in a significant reduction in the percentage of alkaline phosphatase positive, self-
renewing mESC colonies compared to vehicle treatment (Figure 4.19) (Paling et al., 
2004, Storm et al., 2007). In the presence of 5µM IC87114, a small but not significant 
decrease in alkaline phosphatase positive colonies was also observed. Treatment with 5 
or 10µM TGX-221 resulted in a significant reduction in stained colonies compared to 
vehicle treatment (Figure 4.19), consistent with data presented previously (Figures 4.5 
and 4.15). Incubation in the presence of both 5µM TGX-121 and 5µM IC87114 resulted 
in fewer alkaline phosphatase positive colonies when compared with 5µM TGX-121 
alone or 5µM IC87114 alone, although this reduction was not significant. Interestingly, 
10µM TGX-121 and 5µM IC87114 resulted in a smaller decrease when compared to 
10µM TGX-121 alone. Therefore, a plateau is reached at the highest concentration of 
TGX-121 used, where the addition of IC87114 can not further reduce alkaline 
phosphatase staining. If both p110β and p110δ regulated self-renewal, then a further 
decrease in alkaline phosphatase staining would be expected when both p110β and 
p110δ were inhibited compared to inhibition of p110β alone. Additionally, IC87114 
induces a significant decrease in alkaline phosphatase staining only at the highest 
concentrations used (Figure 4.15A). Taken together, these results indicate that IC87114 
may exhibit inhibition of p110β, which would account for a small decrease in self-
renewal following treatment with IC87114.  
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Figure 4.19 Simultaneous inhibition of p110β and p110δ  
Murine ESCs were incubated in the presence or absence of IC87114 and TGX-121 and 
self-renewal was assessed by alkaline phosphatase staining after 4 days. Data are 
represented as the mean percentage of alkaline phosphatase positive colonies with 
S.E.M. (n=3). Data were analysed by ANOVA and Fisher’s post hoc test applied 
comparing the percentage of alkaline phosphatase positive colonies for each treatment, 
where *** indicates p<0.005 when compared to DMSO control and ns (not significant) 
indicates no significant difference between the treatments indicated. 
 
 
4.4.4 Treatment with p110γ selective inhibitor does not alter self-renewal 
 
The expression of p110γ in blastocyst stage mouse embryos is undetectable (NCBI 
virtual Northern http://www.ncbi.nlm.nih.gov/unigene accessed 25.05.07) and microarray 
data obtained from samples of the mESC line used in the present study indicates that 
p110γ expression is extremely low if present at all (Storm and Welham, unpublished 
data). Regardless of reported undetectable expression, and for completeness of the 
investigation into class I PI3K isoforms in the regulation of mESC self-renewal, any 
contribution of this isoform towards maintaining self-renewal was explored using a 
selective inhibitor, AS605240. This inhibitor has been shown to target the p110γ isoform 
with sufficient selectivity in mouse models to inhibit rheumatoid arthritis joint 
inflammation and to prolong the survival of mice with systemic lupus erythematosus 
(Barber et al., 2005, Camps et al., 2005). 
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When mESCs were treated with AS605240 for 4 days, no changes in the percentage of 
alkaline phosphatase positive colonies were detected (Figure 4.20A). For this 
experiment, AS605240 was used at 0.3-10µM, sufficient to cause inhibition of p110γ 
(Camps et al., 2005). Additionally, treatment with AS605240 did not alter the number of 
colonies present compared to control colony counts (Figure 4.20B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20 The p110γ inhibitor AS605240 does not alter alkaline phosphatase 
staining  
Murine ESCs were plated at clonal density and treated for 4 days with vehicle (DMSO) 
or AS605240, a selective p110γ isoform inhibitor. Self-renewal was assessed by alkaline 
phosphatase staining. The percentage of alkaline phosphatase positive colonies (A) and 
the total number of colonies per treatment dish (B) are shown (n=1). 
 
 
Having found no change in alkaline phosphatase staining and observed no effect of 
AS605240 on colony morphology or number, in addition to reported undetectable 
expression of p110γ in mESCs, a role for p110γ in mESC fate was not further 
investigated. 
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4.4.5 p110α does not regulate mESC self-renewal 
 
To investigate if mESCs require the activity or expression of p110α in order to maintain 
self-renewal, both pharmacological inhibition, with two structurally different inhibitors, 
and siRNA gene silencing approaches were implemented. 
 
 
4.4.5.1 siRNA-mediated knockdown of p110α does not alter self-renewal 
 
To investigate a role for PI3K p110α in maintaining mESC self-renewal, Dharmacon 
Smartpool siRNAs targeting Pik3ca, the gene encoding p110α, were used.  
 
Targeting Pik3ca with siRNA led to a significant reduction in the expression of Pik3ca, 
typically 88% reduction in Pik3ca expression was achieved (Figure 4.21A). Despite such 
a high level of knockdown, on assessment of self-renewal by alkaline phosphatase 
staining, no change in the percentage of alkaline phosphatase positive colonies was 
found in cells treated with Pik3ca targeting siRNAs compared to cells treated with non-
targeting siRNAs (Figure 4.21B). Cells transfected with Pik3ca targeting siRNAs formed 
similar colony numbers to those transfected with non-targeting siRNAs (Figure 4.21C). 
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Figure 4.21 Expression of Pik3ca is not required to maintain mESC self-renewal 
Murine ESCs were transfected with Pik3ca or non-targeting Dharmacon Smartpool 
siRNAs. A QPCR of quadruplicate samples was conducted to detect knockdown of 
Pik3ca RNA. Mean values are given with standard deviation and are representative of 
four independent experiments. B Following transfection cells were plated for 4 days and 
self-renewal assessed by alkaline phosphatase staining (n=4). The average percentage 
of alkaline phosphatase positive, self-renewing colonies in each condition are shown 
with S.E.M. No statistical significance was found. C The average total number of 
colonies on each dish is shown with S.E.M. A Student’s t-test was conducted comparing 
non-targeting and Pik3ca targeting and no statistical significance was found. 
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Having observed no change in alkaline phosphatase staining following gene silencing of 
Pik3ca, the expression of other self-renewal markers were investigated. Using QPCR to 
detect Nanog expression revealed that expression was slightly elevated following Pik3ca 
knockdown compared to levels in control, non-targeting siRNA treated cells (Figure 
4.22A). However, statistically, there was no significant difference in Nanog RNA 
expression following treatment with Pik3ca targeting siRNAs compared to non-targeting 
siRNAs. Importantly, despite the changes observed in Nanog expression, Nanog protein 
levels appeared unchanged following Pik3ca knockdown (Figure 4.22B). Consistent with 
QPCR data (Figure 4.21A), semi-quantitative PCR using primers detecting Pik3ca 
demonstrated a notable knockdown of expression following the use of Pik3ca targeting 
siRNAs compared to non-targeting siRNAs (Figure 4.22C). Consistent with no change in 
alkaline phosphatase staining, no detectable change in the expression of the self-
renewal markers Nanog or Rex1 was found upon semi-quantitative PCR analysis 
(Figure 4.22C). These data, assessing a number of self-renewal markers, strongly 
indicate that expression of Pik3ca, the gene encoding p110α, is not required in order for 
mESCs to self-renew. 
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Figure 4.22 p110α does not regulate mESC self-renewal 
RNA was isolated from mESCs transfected with Pik3ca targeting or non targeting 
siRNAs and reverse transcribed. The data presented here are representative of four 
independent experiments. A QPCR was used to assess changes in Nanog expression. 
Samples were assessed in quadruplicate. The mean expression is shown normalised to 
β-actin expression, with standard deviations. B Nanog protein expression was assessed 
by immunoblotting. Immunoblots were stripped and reprobed with antibodies detecting 
Shp-2 in order to assess equal loading, then reprobed with antibodies detecting p85 to 
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detect levels of expression. C Semi-quantitative PCR was conducted using primers 
indicated to assess knockdown of Pik3ca and expression of Nanog and Rex1 self-
renewal markers. The data shown are representative of 4 independent experiments. 
 
 
In order to confirm that knockdown of Pik3ca by siRNA did not affect the expression of 
p85 or the expression of other p110 isoforms, immunoblotting and QPCR was 
conducted (Figure 4.23). Following knockdown of Pik3ca, mESCs exhibited similar 
levels of p85 protein when compared to cells treated with non-targeting siRNA (Figure 
4.23A). Pik3cb, encoding p110β, showed no significant change in expression following 
knockdown of Pik3ca (Figure 4.23B). Additionally, expression of Pik3cd, encoding 
p110δ, was also unaffected by knockdown of Pik3ca (Figure 4.23C). 
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Figure 4.23 Expression of Pik3cb and Pik3cd remains unchanged by Pik3ca 
knockdown  
Following siRNA-mediated knockdown of Pik3ca, p85 protein levels were assessed by 
immunoblotting using antibodies detecting p85. Blots were stripped and reprobed using 
antibodies detecting Shp-2 to assess equal loading. The effect of siRNA knockdown of 
Pik3ca on the expression of Pik3cb (A) and Pik3cd (B) was assessed by QPCR. 
Expression of Pik3cb or Pik3cd was assessed in quadruplicate and expression was 
normalised to β-actin expression. Mean data are shown with standard deviations. A 
representative experiment from four independent experiments is shown.  
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4.4.5.2 Pharmacological inhibition of p110α does not lead to a loss of self-
renewal 
 
Two structurally distinct p110α inhibitors were also employed to investigate a possible 
role for p110α in the regulation of mESC self-renewal and to complement the studies 
performed with siRNA-mediated gene silencing of this isoform. Following its synthesis 
(Hayakawa et al., 2001a) PIK-75 has been fully characterised as a selective p110α 
inhibitor. In kinase assays, PIK-75 was reported to inhibit p110α with an IC50 of 5.8nM 
(Knight et al., 2006). Additionally, IC50 values for the inhibition of mTORC1 and mTORC2 
by PIK-75 were 1 and 10µM respectively, indicating that at concentrations of PIK-75 
selective for p110α inhibition, mTOR is unlikely to be targeted. Another selective p110α 
inhibitor, compound 15e, was synthesised and identified as a potential anti-tumour 
compound since it was effective at inhibiting A375 cell proliferation with an IC50 of 
580nM (Hayakawa et al., 2006). The inhibition of mTOR or other PI3K related kinases 
by compound 15e has not yet been described. 
 
Treatment of mESCs with compound 15e resulted in no significant change in the levels 
of alkaline phosphatase staining (Figure 4.24A). Similarly, treatment with PIK-75 did not 
alter the percentage of alkaline phosphatase positive colonies when compared to 
control, vehicle treated colonies (Figure 4.24B). Therefore, inhibition of p110α with either 
compound 15e or PIK-75 did not result in a change in alkaline phosphatase staining, 
which is consistent with the effects observed following knockdown of Pik3ca, where no 
loss of self-renewal was evident (Figures 4.21 and 4.22). In each case, LY294002 was 
used as a positive control to demonstrate a significant reduction in alkaline phosphatase 
staining, representative of a loss of self-renewal (Figure 4.24). 
 
Following incubation with p110α inhibitors for 4 days, the expression of Nanog was 
assessed. In the absence of LIF, Nanog protein expression was decreased consistent 
with a loss of self-renewal (Figure 4.24C). Treatment of mESCs with PIK-75 in the 
presence of LIF did not alter the level of Nanog expression when compared with mESCs 
incubated in the presence of LIF alone (Figure 4.24C). In the presence of LIF and 
compound 15e, Nanog levels appeared to be enhanced compared to the presence of 
LIF alone. This slight enhancement in Nanog expression did not increase alkaline 
phosphatase staining (Figure 4.24A and Figure 4.24B) and is similar to the enhanced 
expression of Nanog RNA observed following knockdown of Pik3ca by siRNA (Figure 
4.22A and B), which also did not enhance alkaline phosphatase staining (Figure 4.21B). 
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Figure 4.24 Pharmacological inhibition of p110α with two structurally distinct 
inhibitors does not alter self-renewal 
Murine ESCs were incubated with vehicle (DMSO), LY294002, compound 15e (A) or 
PIK-75 (B) for 4 days. Self-renewal was assessed by staining for alkaline phosphatase 
activity. Colonies were scored for alkaline phosphatase staining and alkaline 
phosphatase positive colonies represented as average percentage of total colonies 
present on a culture dish, n=5 for compound 15e, n=3 for PIK-75. Statistical analysis 
using ANOVA was conducted and Dunnet’s post hoc test applied to compare inhibitor 
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treatments with vehicle treatment, where * indicates p<0.05 and *** indicates p<0.005. C 
Following 4 days incubation in the absence of LIF or in the presence of LIF with vehicle 
(DMSO), PIK-75 or 15e mESCs were harvested and protein lysates analysed for the 
expression of Nanog and Shp-2 using appropriate antibodies. 
 
 
4.4.5.3 Incubation with selective p110α inhibitors produces smaller and fewer 
mESC colonies 
 
Although alkaline phosphatase staining was unchanged following treatment with p110α 
inhibitors, it was observed that colonies treated with these inhibitors were smaller in 
diameter compared to vehicle treated colonies (Figure 4.25A). In addition, fewer 
colonies were present after 4 days treatment with compound 15e (Figure 4.25B). 
Increasing the dose of PIK-75 produced fewer colonies after 4 days (Figure 4.25C). 
Importantly, the proportion of alkaline phosphatase positive colonies (represented by 
dark bars) of the total number of colonies remained unchanged by pharmacological 
inhibition of p110α with either compound 15e or PIK-75 (Figure 4.25B and C). 
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Figure 4.25 Inhibition of p110α results in smaller and fewer colonies 
Murine ESCs were treated with DMSO, LY294002, compound 15e or PIK-75 for 4 days 
as described in Figure 4.24. Representative colonies are depicted following staining for 
alkaline phosphatase activity (scale bar = 100 µm) (A). Data obtained from scoring 
alkaline phosphatase staining of mESC colonies are represented as the average 
number of self-renewing alkaline phosphatase positive colonies (black histogram bars) 
and the average number of non-self-renewing, alkaline phosphatase negative colonies 
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(grey histogram bars) with S.E.M. for treatment with compound 15e (n=5) (B) and PIK-
75 (n=3) (C). Statistical analysis was conducted using ANOVA and Dunnet’s post hoc 
test, where * indicates p<0.05. 
 
 
A reduction in colony size and number is indicative of either reduced proliferation or 
enhanced apoptosis. Subsequently, the regulation of mESC proliferation and 
metabolism by PI3K catalytic subunit isoforms, particularly by p110α, was investigated 
and is reported and discussed in detail in Chapter 5. Furthermore, a direct method of 
assessing apoptosis was employed to address this matter following mESC treatment 
with p110α inhibitors (Section 5.22). 
 
 
4.4.5.4 Inhibition of p110α does not prevent differentiation 
 
Inhibition of p110α does not appear to lead to a decrease in mESC self-renewal 
suggesting that p110α does not regulate self-renewal. Alternatively, inhibition of p110α 
could aid the maintenance of self-renewal which might explain the lack of a reduction in 
self-renewal following inhibition. Another possibility is that since p110α is reported to be 
important for proliferation and insulin signalling (Bi et al., 1999, Foukas et al., 2006, 
Knight et al., 2006), inhibition of this isoform could result in apoptosis of differentiated 
cells, which may explain reduced colony numbers following treatment with p110α 
inhibitors.  
 
In order to investigate whether inhibition of p110α affects mESC differentiation or leads 
to apoptosis of differentiated derivatives, mESCs were treated with compound 15e or 
PIK-75 and incubated in the presence or absence of LIF. LIF is required to maintain self-
renewal of mESCs in culture, therefore incubation in the absence of LIF results in 
spontaneous differentiation to precursors of multiple cell lineages (Boeuf et al., 1997, 
Cartwright et al., 2005, Niwa et al., 2000), resulting in a significant reduction in the 
proportion of alkaline phosphatase positive colonies (Figure 4.26A). Colonies formed 
from mESCs incubated in the absence of LIF, but in the presence of PIK-75 or 
compound 15e, formed differentiated colonies that were negative for alkaline 
phosphatase activity (Figure 4.26A). These results suggest that in the absence of LIF 
inhibition of p110α cannot maintain self-renewal and also that inhibition of p110α does 
not prevent the spontaneous differentiation of mESCs observed upon LIF withdrawal. 
However, treatment with compound 15e or PIK-75 resulted in the formation of fewer 
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colonies following 4 days incubation (Figure 4.26B). In the absence of LIF, but presence 
of p110α inhibitors, the majority of colonies were differentiated, arguing against the 
selective apoptosis of differentiated colonies when p110α is inhibited. However, it is 
important to investigate apoptosis in a more direct manner; this was conducted and is 
reported in Section 5.2.2.  
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Figure 4.26 Inhibition of p110α does not prevent differentiation 
Murine ESCs were treated with p110α inhibitors compound 15e or PIK-75 for 4 days, at 
the doses indicated, in the presence or absence of LIF. Self-renewal was assessed by 
alkaline phosphatase staining (n=3). Data are represented as the average percentage of 
self-renewing colonies of the total number of colonies on each culture dish (A) or as the 
average number of self-renewing, alkaline phosphatase positive colonies (black 
histogram bars) and the average number of non-self-renewing alkaline phosphatase 
negative colonies (grey histogram bars) (B) with S.E.M.. Statistical analysis was 
conducted using ANOVA and Fisher’s post hoc test where *** indicates p<0.005. 
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4.5 Summary and discussion: Comparison of LY294002 and ZSTK474 
induced loss of self-renewal in mESCs 
 
Inhibition of PI3Ks with the broad selectivity PI3K inhibitor LY294002 has been shown to 
induce a loss of mESC self-renewal, indicated by a decrease in alkaline phosphatase 
staining and a reduction in Nanog protein and RNA expression (Paling et al., 2004, 
Storm et al., 2007). The effects mediated by LY294002 were compared to those induced 
by the recently described class I selective PI3K inhibitor ZSTK474 (Kong and Yamori, 
2007, Yaguchi et al., 2006). 
 
ZSTK474 was demonstrated to induce a reduction in alkaline phosphatase staining, to a 
level similar to that induced by incubation of mESCs with LY294002. In addition, 
ZSTK474 produced similar temporal changes in Nanog protein expression to those 
observed with LY294002 after 24 hours and 48 hours incubation, and up to 4 days 
incubation (Figures 4.2 and 4.1 respectively). Interestingly, ZSTK474 did not induce an 
enhancement in basal or stimulated Erk phosphorylation as is often observed with 
LY294002. Maybe subtle differences in the inhibition of PI3K classes, or related protein 
kinases (discussed in Sections 1.1.3 and 4.2) can account for the observed disparity in 
Erk phosphorylation. It is still unknown how PI3Ks might exert a dampening effect on 
MAPK signalling but this phenomenon has been reported in other cell types (discussed 
in Section 3.2.4) (Kanasaki et al., 2008, Laprise et al., 2004, Romano et al., 2006). 
 
Taken together, these results suggest that inhibition of PI3Ks by LY29402 or by 
ZSTK474 result in similar responses despite the differences in inhibitor profiles. 
Furthermore, the use of an alternative inhibitor to LY294002, one which selectively 
inhibits class I PI3Ks (Kong and Yamori, 2007, Yaguchi et al., 2006), confirms the 
involvement of this class of PI3Ks in maintaining mESC self-renewal (Paling et al., 
2004). 
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4.6 Summary and discussion: The roles of PI3K class I isoforms in the 
regulation of mESC self-renewal 
 
The activity of broad spectrum and isoform selective PI3K inhibitors used in this study 
were first confirmed in BaF/3 pro-B cell line. The broad spectrum PI3K inhibitors, 
LY294002, wortmannin and ZSTK474, inhibited IL-3-induced PKB phosphorylation in 
BaF/3 cells. Additionally, selective inhibitors of p110α, PIK-75 and compound 15e, 
p110β, TGX-121 and TGX-221, p110δ, IC87114, and p110γ, AS605240, reduced IL-3-
induced PKB phosphorylation. These results verified the activity of these inhibitors in a 
mouse cell line which is known to express all class I PI3K isoforms (Vanhaesebroeck et 
al., 1997). Subsequently, these inhibitors were used to investigate the roles of PI3K 
catalytic isoforms in regulating mESC self-renewal. 
 
Using siRNA-mediated knockdown and pharmacological inhibitors, the expression of 
Pik3cb and the activity of the protein encoded by this gene, p110β, were demonstrated 
to be required for mESCs to maintain optimal self-renewal. Importantly, consistent 
results implicating p110β in mESC self-renewal were obtained using two different p110β 
inhibitors and three different siRNAs. Interestingly, levels of self-renewal following p110β 
inhibition or Pik3cb knockdown were comparable to levels observed with LY294002 
treatment or Nanog knockdown. These observations suggest that p110β is the 
predominant isoform implicated in maintaining mESC self-renewal. 
 
The time-course with which inhibition of p110β induces a reduction in Nanog protein 
expression is similar to that previously reported for LY294002 (Paling et al., 2004), in 
that expression of Nanog is reduced early, by 48 hours for TGX-221 (Figure 4.5), and 
before a change in colony morphology is observed. Therefore, reduced Nanog 
expression is likely to be a more direct result of inhibition of p110β, rather than a 
secondary response that follows inhibition of p110β inducing a loss of self-renewal. 
 
The principle role of p110β in maintaining self-renewal of mESCs, defined in the present 
study, is consistent with, and supports the requirement for, the expression of p110β in 
blastocyst stage mouse embryos (Bi et al., 2001). In the ICM, self-renewal of cells is 
important for the establishment and development of the embryo proper (Figure 1.6 and 
Figure 1.7) thus explaining the requirement of p110β activity for the survival of embryos 
beyond the blastocyst stage (Bi et al., 2001). Interestingly, the incomplete penetrance of 
embryonic lethality reported in mice expressing a catalytically inactive knock-in of p110β 
(Ciraolo et al., 2008, Guillermet-Guibert et al., 2008) was proposed to be the result of 
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non-catalytic functions mediated by p110β (Christoforidis et al., 1999, Ciraolo et al., 
2008). This reasoning also explains the embryonic lethality of mouse embryos 
completely lacking p110β expression (Bi et al., 2001). In mESCs the requirement for 
both expression and activity of p110β was demonstrated to maintain optimal self-
renewal, suggesting that a non-catalytic role for p110β in maintaining self-renewal was 
not essential. However, a non-catalytic role for p110β in mESC fate cannot be 
disregarded based on the results presented in the present study alone. 
 
In mESCs, p110β did not appear to be activated by LIF stimulation, certainly inhibition of 
p110β did not alter LIF-induced signalling downstream of PI3Ks. This was surprising 
given that LIF is an important extrinsic factor necessary for the maintenance of mESC 
self-renewal in culture (Bard and Ross, 1991, Gough et al., 1989, Smith et al., 1988, 
Williams et al., 1988). A number of reports indicate the activation of p110β via G 
proteins following the activation of GPCRs (Ciraolo et al., 2008, Guillermet-Guibert et al., 
2008, Kubo et al., 2005, Maier et al., 1999, Murga et al., 2000, Roche et al., 1998) 
(discussed in Section 1.1.2.1). The activation of p110β by GPCRs in mESCs is certainly 
plausible given the low or undetectable levels of expression of p110γ in mESCs (Storm 
and Welham, unpublished data) and the lack of effect on alkaline phosphatase staining 
observed using AS605240, a selective p110γ inhibitor, leaving p110β as the only PI3K 
isoform capable of coupling to GPCRs in mESCs. The crude method of boiling serum to 
denature ligands other than heat stable lysophospholipids, agonists of GPCRs, followed 
by stimulation of mESCs, revealed enhanced PKB phosphorylation that could be 
inhibited with TGX-121 or TGX-221, inhibitors of p110β. This indicates that p110β may 
well couple to GPCRs and G proteins in mESCs, as reported previously in other cell 
types (Ciraolo et al., 2008, Guillermet-Guibert et al., 2008). However, the physiological 
relevance of this coupling requires further investigation.  
 
In contrast to the results observed with boiled serum, neither LPA nor S1P induced the 
same response in terms of PKB phosphorylation. LPA and S1P did stimulate Erk 
phosphorylation which, following the inhibition of p110β by TGX-221 or inhibition of Gi or 
Go G proteins by pertussis toxin, could be enhanced for LPA and decreased for S1P. 
These results are consistent with an enhancement in Erk phosphorylation known to be 
induced by activation of LPA and S1P receptors via Gi (Meyer zu Heringdorf and 
Jakobs, 2007, Pébay et al., 2005, Rosen and Goetzl, 2005). Furthermore, activation of 
the MAPK pathway, known to promote differentiation (Kunath et al., 2007, Stavridis et 
al., 2007), by LPA and S1P is consistent with reports indicating that lysophospholipids 
can induce differentiation. Indeed, S1P is reported to induce cardiac differentiation in 
embryoid bodies formed from mESCs (Sachinidis et al., 2003) and 
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sphingosylphosphorylcholine, which can stimulate S1P receptors as well as specific 
receptors such as GPR4 expressed in mESCs, was shown to induce cardiac and neural 
differentiation of mESCs (Kleger et al., 2007). As with GPCR activation coupling to PI3K 
signalling, further investigation would be required to fully characterise GPCR agonist-
induced differentiation and the signalling pathways underlying this cellular response. 
 
 
The enhancement in Erk phosphorylation, often observed following mESC incubation 
with LY294002 (Paling et al., 2004) (Figure 3.2), was also observed with TGX-121 and 
TGX-221 (Figure 4.12), thereby implicating p110β in the dampening effect exerted by 
PI3Ks on MAPK pathway activity under normal mESC culture conditions. A number of 
reports demonstrate this effect in other cell types (Kanasaki et al., 2008, Laprise et al., 
2004, Romano et al., 2006) and suggest that this phenomenon could be mediated by 
the regulation of Raf-1 phosphorylation by PKB (Rommel et al., 1999) but these reports 
did not link this observation to a specific PI3K isoform. Interestingly, an enhancement in 
Erk phosphorylation was observed in MEFs derived from p110β kinase-dead knock-in 
mice (Ciraolo et al., 2008), consistent with the implication of this isoform in regulating 
MAPK pathway activity in mESCs, demonstrated in the present study (Kingham and 
Welham, In Press). Furthermore, cross-talk between PI3K and MAPK signalling may 
provide another mechanism for p110β to contribute to the maintenance of mESC self-
renewal, since it has previously been reported that inhibition of the MAPK pathway 
enhances self-renewal (Burdon et al., 1999). In chapter 3, it was demonstrated that an 
enhancement in MAPK pathway activity induced only a small decrease in the capacity of 
mESCs to maintain self-renewal. Inhibition of p110β induced an enhancement in Erk 
phosphorylation, indicating an enhancement in the activity of the MAPK pathway, but the 
loss of self-renewal following p110β inhibition (Figure 4.5) was much more pronounced 
than that observed following induction of enhanced MAPK pathway activation (Figure 
3.10). Thus, the differentiation of mESCs induced by p110β inhibition might be aided by, 
but can not be fully accounted for, by enhanced MAPK pathway activation and is 
therefore likely to involve other pathways.  
 
Based on the studies reported here, a working model to explain how p110β controls self-
renewal is presented in Figure 4.27. Activation of p110β may occur via typical tyrosine 
kinase receptor activation or via GPCR activation by factors present in serum or serum 
replacement used for routine culture. Following activation, p110β may contribute to the 
maintenance of self-renewal through an undefined pathway involving the preservation of 
expression of the master regulator of self-renewal, Nanog. Additionally, p110β may 
Chapter 4: Results 
 201 
regulate MAPK pathway signalling upstream of Erk, preventing differentiation induced by 
MAPK activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27 Model of the regulation of mESC self-renewal by p110β 
Evidence presented in the present study indicates that PI3K p110β is the predominant 
isoform to maintain mESC self-renewal and might do so by inhibiting the activity of the 
MAPK pathway and supporting the maintenance of Nanog expression, a master 
regulator of self-renewal. Additionally, other pathways involving p110β, including non-
catalytic functions, may contribute to maintaining an undifferentiated state.  
 
 
The expression levels of markers of self-renewal are used to assess the self-renewal 
state of ESCs for investigation purposes. In the present study alkaline phosphatase and 
Nanog markers were used. In the stem cell field, Oct4 expression is frequently 
presented in conjunction with Nanog expression data. Little or no change in Oct4 
expression was observed during the present study, even when significant changes were 
observed for Nanog and alkaline phosphatase expression, consistent with the 
observations of others in our research group (Paling et al., 2004, Storm et al., 2007). 
Interestingly, Oct 4 expression levels in self-renewing mESCs cultured on a feeder layer, 
self-renewing mESCs in feeder-free culture and in embryoid bodies have been 
described to be ‘indistinguishable’ (Gordeeva et al., 2003). In support of this, the time-
course for a decrease in Oct4 expression following the induction of differentiation is 
somewhat delayed in comparison to Nanog. Oct4 is reported to be detected in day 5 
embryoid bodies at similar levels to those detected in ESCs used to form such embryoid 
bodies (Oka et al., 2002). Furthermore, a different research group report Oct4 
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expression to be maintained in mESCs cultured in the absence of LIF for up to 5 days 
(no longer time points were published) and in embryoid bodies up to day 16 (no longer 
time points were published) (Sauter et al., 2005). These reports indicate that Oct4 
expression may not best represent the self-renewal state of mESCs, particularly when 
early differentiation or triggers of loss of self-renewal are of interest, as in the present 
study. In the present study, Rex1 expression was used to demonstrate a loss of self-
renewal induced by knockdown of Pik3cb. Rex1 is expressed specifically in 
preimplantation embryos, trophoblast and spermatocytes but importantly, expression in 
mESCs is reduced following induction of differentiation (Rogers et al., 1991). Rex1 
expression is reported to be detectable in mESCs but undetectable in day 5 embryoid 
bodies (Oka et al., 2002) and was notably reduced in embryoid bodies by day 3.25 
(Robertson et al., 2000) making it a suitable marker for self-renewal and a loss of 
expression was detectable when mESCs are in the early stages of differentiation. 
 
No role for p110α in the maintenance of self-renewal was observed following 
pharmacological inhibition with two structurally distinct selective inhibitors or by siRNA-
mediated knockdown of Pik3ca, the gene encoding p110α. These findings suggest that 
neither the expression nor the activity of p110α is required in order for mESC self-
renewal to be maintained. Furthermore, inhibition of p110α was demonstrated not to 
prevent mESC differentiation and not to induce cell death, which would have resulted in 
a lack of differentiated colony types following a period of incubation in the absence of 
LIF. Furthermore, an enhancement in Nanog expression was observed at a 
transcriptional level only following Pik3ca knockdown but was enhanced at a protein 
level following inhibition of p110α with compound 15e. Importantly, this small 
enhancement in Nanog expression was not sufficient to enhance alkaline phosphatase 
staining in the presence of LIF and did not prevent differentiation in the absence of LIF. 
Furthermore, enhanced Nanog protein was not observed following gene silencing of 
Pik3ca or following inhibition of p110α by PIK-75. Smaller colonies, which were fewer in 
number, were observed following incubation of mESCs with p110α inhibitors, indicating 
an effect on mESC proliferation. This was further investigated and is reported and 
discussed in detail in chapter 5.  
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Knockdown of p110δ had no effect on self-renewal and the reduction in self-renewal 
observed using the highest concentrations of the p110δ inhibitor, IC87114, are best 
explained by the inhibition of p110β, which would be predicted at these concentrations 
(Knight et al., 2006). Interestingly, knockdown of Pik3cd, encoding p110δ, led to 
enhanced expression of Nanog protein and RNA. In microarray data from samples 
comparing self-renewing mESCs to those undergoing differentiation, the expression of 
Pik3cd was enhanced following induction of differentiation (Storm and Welham, 
unpublished data). One explanation for enhanced Nanog expression is that by knocking 
down expression of Pik3cd, under a protocol where transfection is conducted over a 
period of 3 days, cells may be restricted from differentiating. Consistent with this, 
mESCs transfected with non-targeting siRNA would continue to undergo low levels of 
spontaneous differentiation, a feature of ESCs (Cheng et al., 1998, Ying et al., 2003a, 
Ying et al., 2003b) and would result in lower Nanog expression when compared to 
mESCs transfected with Pik3cd siRNA, which might be subject to restricted 
spontaneous differentiation and therefore maintain the Nanog expression levels 
possessed on commencement of the transfection protocol. 
 
In summary, p110β is the predominant class IA PI3K catalytic isoform that regulates 
mESC self-renewal, whereas p110α or p110δ do not directly or independently regulate 
self-renewal. 
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5 Results: The regulation of mESC 
proliferation by PI3K catalytic subunit 
p110α and a link between proliferation and 
the regulation of self-renewal 
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5.1 Introduction and Aims 
 
ESCs exhibit a continual proliferative capacity, which has been likened to the perpetual 
proliferation of tumour cells. PI3Ks have been implicated in regulating ESC growth and 
proliferation in a number of published reports. In mESCs, deletion or pharmacological 
inhibition of mammalian target of rapamycin (mTOR), a downstream effector of PI3K 
signalling, results in proliferative defects (Murakami et al., 2004). Experiments involving 
the broad selectivity PI3K inhibitor LY294002 give disparate results largely owing to the 
concentrations used. For example, doses of 10µM LY294002 or above were reported to 
inhibit the proliferation of mESCs but lower doses, that did not affect cell viability or 
proliferation, induced differentiation (Paling et al., 2004). In agreement with this, 20-
40µM LY294002 led to a reduction in cell growth after 48 hours (Lianguzova et al., 2007)  
and 25µM LY294002 led to an increase in the number of mESCs in G1 phase after 24 
hours, with a dramatic reduction in cell growth being reported after 4 days (Jirmanova et 
al., 2002). However, inhibition of mTOR is possible at 1-30µM LY294002 (Brunn et al., 
1996) and, since mTOR is also reported to be important for mESC proliferation 
(Murakami et al., 2004), the effects seen with LY294002 might reflect inhibition of mTOR 
rather than PI3K directly. 
 
In chapter 4, an assessment was made as to which class I PI3K isoforms contribute to 
the regulation of self-renewal of mESCs (Section 4.4). The catalytic p110β isoform was 
implicated as the major contributor to the maintenance of mESC self-renewal (Kingham 
and Welham, In Press). However, when catalytic isoform p110α was targeted by the 
selective inhibitors compound 15e and PIK-75, colonies were smaller and fewer in 
number. These observations suggested that p110α might regulate mESC growth or 
proliferation. In order to realise the aim of identifying how p110 catalytic isoforms 
contribute to mESC fate, p110α, p110β and p110δ, were investigated for their 
participation in proliferation, metabolism and insulin signalling.  
 
Self-renewal is often defined as the proliferation of ESCs whilst suppressing 
differentiation (Burdon et al., 2002, Burdon et al., 1999, Savatier et al., 1994, Smith, 
2001). Having identified which PI3K catalytic isoforms regulate the cellular functions of 
self-renewal and proliferation, the possibility that these two features are in someway 
linked in ESCs was explored. 
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5.2 p110α regulates mESC proliferation 
 
When the effect of inhibition of p110α on self-renewal was assessed, treatment with 
selective inhibitors for 4 days produced smaller colonies that were fewer in number 
(Figure 4.25). In fact, with PIK-75 at concentrations greater than 25nM, few colonies 
were visible after 4 days incubation and were too small to score for alkaline 
phosphatase staining. To demonstrate the change in size of colonies following treatment 
with p110α inhibitors, compound 15e and PIK-75, the diameters of fixed and alkaline 
phosphatase stained colonies were measured using a graticule. Treatment with 200nM 
compound 15e induced a significant reduction in colony diameter and 800nM compound 
15e resulted in colonies that were approximately half the diameter of colonies formed 
from cells incubated in the absence of inhibitor (Figure 5.1A). Treatment with 5nM PIK-
75 or greater concentrations also led to significantly smaller colonies after 4 days 
incubation (Figure 5.1B). Indeed 25nM PIK-75 produced colonies that were 
approximately one third the diameter of colonies formed from cells incubated in the 
absence of PIK-75. 
Chapter 5: Results 
 207 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Compound 15e and PIK-75 lead to the formation of smaller mESC 
colonies 
Murine ESCs were plated at clonal density and incubated for 4 days with compound 15 
(A) or PIK-75 (B) at the doses indicated. Colonies were fixed and stained for alkaline 
phosphatase. Under a microscope, colony diameters were measured (n=30), for each 
treatment. The graphs shown represent the average colony diameter for each treatment 
with standard deviations. Statistical analysis was conducted using ANOVA and Dunnet’s 
post hoc test, where *** indicates p<0.001 A representative experiment from n=5 and 
n=3 independent experiments for compound 15e and PIK-75 respectively, was chosen 
for quantitative assessment of colony diameters. 
 
 
The smaller colony sizes observed following inhibition of p110α could be explained by 
reduced cell proliferation which would lead to reduced colony growth. Alternatively, 
inhibition of p110α could lead to the induction of programmed cell death. To explore 
these two possibilities, cell counts to assess cell proliferation and an investigation into 
the early stages of apoptosis were both conducted. 
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5.2.1 Incubation with p110α inhibitors results in reduced cell numbers 
 
To assess cell proliferation, mESCs were incubated with LY294002, compound 15e or 
PIK-75 and harvested after 1-4 days. Harvested cells were counted using the vital dye, 
trypan blue, in order to assess proliferation. After 24 and 48 hours incubation with 
LY294002, numbers of cells retrieved from LY294002 treatment dishes were similar to 
numbers of cells harvested from vehicle treatment dishes (Figure 5.2), consistent with a 
previous report from this research group (Paling et al., 2004). However, in the present 
study, fewer cells were counted from dishes treated with LY294002 on days 3 and 4 
when compared to vehicle treatments at these time points. This observation might be 
explained by differentiated cells, which would be present at this later time point, 
becoming sensitive to LY294002 resulting in reduced proliferation and therefore a 
reduction in the number of cells retrieved. After 24 hours of incubation in the presence of 
compound 15e or PIK-75, a similar number of cells were retrieved from these plates as 
those counted from dishes treated with vehicle (DMSO) alone (Figure 5.2). In the 
presence of compound 15e, dramatically fewer cells were retrieved on days 2-4 than 
those counted from vehicle treated plates. Furthermore, PIK-75 treatment also resulted 
in much lower numbers of cells being retrieved from dishes incubated with this inhibitor 
compared to vehicle alone on days 2-4 (Figure 5.2). Incubation of mESCs with 
compound 15e or PIK-75 resulted in fewer cells being harvested in comparison to the 
number of cells harvested following incubation with LY294002. 
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Figure 5.2 p110α is coupled to mESC proliferation 
To assess cell proliferation, viable cell numbers were determined at 24 hour intervals for 
up to 4 days. Murine ESCs were treated with vehicle (DMSO), 5µM LY294002, 10nM 
PIK-75, 25nM PIK-75 or 600nM 15e, dishes were set up in triplicate for each treatment. 
The average number of cells harvested from each culture dish (counted in triplicate, 
using a haemocytometer) is shown with standard deviations. The experiment shown is 
representative of three independent experiments. 
 
 
A viable cell count following a period of incubation is one way of assessing cell 
proliferation. However, since this method only takes into account viable, adherent cells, 
it is possible that reduced cell numbers are the result of apoptosis rather than reduced 
proliferation. 
 
 
5.2.2 Inhibitors of p110α do not induce apoptosis 
 
The reduction in cell number observed following incubation with p110α inhibition could 
arise due to apoptosis, rather than a reduction in proliferation. To investigate this 
possibility directly, mitochondrial membrane permeability transition, a hallmark of and an 
irreversible point in programmed cell death (Rottenberg and Wu, 1998), was examined 
following inhibition of PI3Ks. The green fluorescent dye, 3,3’–dihexyloxacarbocyanide 
iodide (DiOC6), stains the mitochondrial membrane of live cells but not mitochondria that 
have become permeabilised, a feature of apoptotic cells (explained in more detail in 
Section 2.4.3). DiOC6 fluorescence can be measured by flow cytometry, therefore it was 
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important to first establish that p110α inhibitors do not exhibit fluorescence. The 
fluorescence intensity profiles of cells treated with DMSO, LY294002, compound 15e 
and PIK-75 (green histogram traces) were similar to that for untreated cells (purple 
histogram) (Figure 5.3) indicating that these inhibitors are not fluorescent and, therefore, 
are suitable for use with this method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Inhibitors of p110α do not exhibit fluorescence 
Murine ESCs were incubated for 18h in the absence of any treatment or in the presence 
of vehicle (DMSO), LY294002, compound 15e or PIK-75 at the concentrations indicated. 
Data are represented as a histogram of cell counts vs. fluorescence intensity, where 
untreated cells are represented by a purple trace and inhibitor treatments overlaid in 
green.  
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An example of the fluorescence profile exhibited by untreated control mESCs is 
represented by the purple trace in Figure 5.4A. When mESCs are stained with DiOC6, a 
positive shift in fluorescence intensity is observed (green trace) (Figure 5.4A). During 
the early stages of apoptosis, the mitochondrial membrane becomes permeable and the 
proton gradient is lost (Petit et al., 1995, Rottenberg and Wu, 1998), thus cells 
undergoing apoptosis exhibit reduced fluorescence, evident by a negative shift of the 
histogram trace. It is known that DiOC6 stains the mitochondrial membrane of live cells, 
but at higher concentrations, non-specific staining of the endoplasmic reticulum also 
occurs (Terasaki, 1989). Since staining of the endoplasmic reticulum is unaffected in the 
early stages of apoptosis, non-specific staining can mask the detection of loss of 
mitochondrial membrane integrity by keeping fluorescence high. Therefore care was 
taken to select a dose where only specific staining occurred. In most cell types, less 
than 10nM DiOC6 typically gives specific mitochondrial membrane staining, for mESCs, 
1nM DiOC6 was found to be suitable. As a positive control, carbonyl cyanide m-
chlorophenyl hydrazone (CCCP), a mitochondrial uncoupling agent, was used to induce 
apoptosis. DMSO treated cells were used as a negative control (purple trace) to 
compare the fluorescence profiles of cells treated with inhibitors (Figure 5.4B). When 
mESCs were treated with CCCP (green trace) prior to DiOC6 staining, a negative shift in 
fluorescence intensity was observed compared to DMSO treated cells (purple trace). 
This negative shift indicates reduced DiOC6 staining consistent with the presence of 
apoptotic cells. An alternative way of analysing this flow cytometry data is to assess the 
percentage of cells with lower fluorescence intensity in each treatment. In DMSO treated 
cells, 32.8% of cells were unstained (Figure 5.4) whereas treatment of mESCs with 
CCCP induced apoptosis so that 77.3% of cells were found to have lower fluorescence 
intensity. This confirmed that 1nM DiOC6 was suitable for detecting apoptotic cells and 
that CCCP was a satisfactory positive control.  
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When comparing treatment of mESCs with 5µM LY294002 (green trace) and treatment 
with DMSO alone (purple trace), no change in fluorescence was visible indicating that 
cells were not apoptotic (Figure 5.4B). A small enhancement in the percentage of 
unstained cells (of 7%) was observed with LY294002, similar to that observed previously 
in similar conditions (Paling et al., 2004). At 600nM compound 15e, fluorescence was 
similar to that of DMSO treated cells. However, 800nM compound 15e induced a small 
shift in fluorescence with 45% of cells adopting lower fluorescence intensity, an increase 
of ~12% when compared to DMSO treated cells. This indicates that at this concentration 
of compound 15e, a proportion of cells enter the early stages of apoptosis. Importantly, 
at 600nM compound 15e, viable cell counts were reduced compared to DMSO 
treatment (Figure 5.2) but this dose did not induce apoptosis (Figure 5.4) therefore the 
alteration in viable cell counts is most likely to arise predominantly from reduced cell 
division. Treatment of mESCs with 10 or 25nM PIK-75 failed to alter DiOC6 staining 
compared to treatment of mESCs with DMSO alone (Figure 5.4) indicating that 
apoptosis is not induced by PIK-75 at these concentrations. Reduced cell numbers were 
detected following incubation with 10 or 25nM PIK-75 (Figure 5.2), which is not due to 
apoptosis but likely due to reduced cell division.  
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Figure 5.4 DiOC6 staining of mESCs following p110α inhibitor treatment 
Murine ESCs were incubated for 18h in the absence of any treatment or in the presence 
of vehicle (DMSO), LY294002, compound 15e or PIK-75 at the concentrations indicated. 
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Data are represented as a histogram of cell counts vs. fluorescence intensity. A 
Untreated cells were divided into two samples. One sample was treated with 1nM DiOC6 
for 30 minutes in dark conditions. Both samples were analysed by flow cytometry. 
Unstained cells are represented by a purple trace and DiOC6 stained cells shown by an 
overlaid green trace. B A sample of untreated cells were incubated with 100µM CCCP 
for 20 minutes and used as a positive control. Samples were treated with 1nM DiOC6 for 
30 minutes in dark conditions and fluorescence measured by flow cytometry. DMSO 
treated cells were used as a representative negative control shown by a purple trace 
and inhibitor treatments represented as a green trace. DiOC6 staining data were 
analysed using Cell Quest flow cytometry software (BD). The percentage of cells 
exhibiting lower fluorescence intensity (cells potentially in early apoptosis) for each 
treatment is indicated. 
 
 
 
Taking into account the results of viable cell counts and DiOC6 staining following 
inhibition of p110α with selective inhibitors, the reduction in mESC cell numbers 
observed following inhibition of p110α PI3Ks appears most likely to arise as a result of 
reduced cell division, rather than a significant increase in apoptosis. Therefore, these 
studies support a role for p110α coupled to mESC proliferation, consistent with previous 
reports highlighting a proliferative defect and embryonic lethality, but no abnormal 
apoptosis, in p110α knock-out mouse embryos (Bi et al., 1999).  
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5.3 p110α is implicated in insulin and LIF signal transduction in mESCs 
 
Insulin was shown to activate signalling downstream of PI3Ks in mESCs cultured in a 
chemically defined media (Figure 3.3) (Welham et al., 2007). This media, of known 
components, contains the supplements N2 and B27, both of which contain insulin (Table 
2.1) and insulin is also a likely component of undefined serum replacement, used for the 
routine culture of mESCs. PI3K activity is reported to be essential for glucose 
metabolism and the survival of blastocyst stage embryos (Riley et al., 2006). Since 
mESCs are derived from blastocysts, identification of the isoform or isoforms mediating 
insulin signalling in mESCs was of interest.  
 
Insulin target tissues typically express p110α and p110β as a result of their ubiquitous 
expression, whereas the expression of p110δ is largely restricted to cells of the immune 
system (Vanhaesebroeck et al., 1997). Predictably, both p110α and p110β have been 
implicated in insulin signalling. Studies of knock-in mice expressing a catalytically 
inactive form of p110α and investigations using selective p110α inhibitors have mapped 
out a predominant role in insulin signalling and in functional responses to insulin for 
p110α (Foukas et al., 2006, Knight et al., 2006). However, p110β has also been 
reported to mediate insulin signalling in certain cell types (Asano et al., 2000, 
Hooshmand-Rad et al., 2000, Roche et al., 1994). 
  
Selective p110 inhibitors were used to identify which isoform or isoforms participate in 
insulin-induced signalling in mESCs. In vehicle (DMSO) pre-treated cells, incubation 
with insulin led to enhanced PKB phosphorylation at Ser473 (Figure 5.5A), consistent 
with the activation of the PI3K-PKB pathway by insulin in other cell types (Cross et al., 
1995) and in mESCs (Figure 3.3) (Welham et al., 2007). Basal PKB phosphorylation 
was decreased by pre-treatment with the broad selectivity PI3K inhibitors LY294002 and 
wortmannin, and by the dual p110α/mTOR inhibitor PI-103. Inhibition of insulin-induced 
PKB phosphorylation by PI-103 is consistent with observed effects of this inhibitor in 
Chinese hamster ovary cells expressing human insulin receptor (CHO-IR cells) 
(Chaussade et al., 2007). Insulin-stimulated PKB phosphorylation was not visibly 
prevented by pre-treatment with LY294002, TGX-121 or IC87114, indicating that p110β 
and p110δ are unlikely to be involved in insulin signalling in mESCs. Conversely, pre-
treatment with PI-103 the dual p110α/mTOR inhibitor revealed a decrease in insulin-
induced PKB phosphorylation (Figure 5.5A). 
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The involvement of p110α in insulin-induced signalling was further investigated using the 
selective p110α inhibitors, compound 15e and PIK-75. Treatment with compound 15e 
reduced basal PKB phosphorylation at Ser473 in unstimulated cells (Figure 5.5B). 
Compound 15e pre-treated cells also had reduced levels of PKB phosphorylation 
following insulin stimulation compared to vehicle pre-treated insulin-stimulated cells. 
Furthermore, increasing concentrations of compound 15e resulted in decreasing insulin-
stimulated PKB phosphorylation. Similarly, both basal and insulin-induced S6 
phosphorylation were reduced by compound 15e pre-treatment (Figure 5.5B). PIK-75 
pre-treatment induced a concentration-dependent decrease in basal levels of PKB 
phosphorylation in unstimulated cells (Figure 5.5C). A pronounced decrease in insulin-
induced PKB phosphorylation was observed in cells pre-treated with PIK-75. As with 
compound 15e, an inverse relationship between PIK-75 concentration and levels of 
insulin-induced PKB phosphorylation were observed. Additionally, both basal and 
insulin-stimulated S6 phosphorylation were reduced by PIK-75 pre-treatment. The 
present findings are consistent with reports of the involvement of p110α in insulin signal 
transduction in other cell types (Foukas et al., 2006, Knight et al., 2006). 
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Figure 5.5 p110α mediated insulin induced signalling 
Murine ESCs were pre-treated with vehicle (DMSO), LY294002, Wortmannin, PI-103, 
TGX-121 or IC87114 (A), compound 15e (B) or PIK-75 (C) at the concentrations 
indicated. Following pre-treatment, mESCs were stimulated with 10µg/ml insulin for 5 
min. The signalling downstream of PI3Ks was assessed using the antibodies indicated 
and equal loading was assessed by stripping and reprobing blots with appropriate 
antibodies. The data shown are representative of three independent experiments for 
each panel.  
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More recently, redundant functionality for PI3K catalytic isoforms has been reported. 
Knockdown of p110α or p110β with short-hairpin RNA in CHO-IR cells did not affect 
insulin-induced PKB phosphorylation (Kubo et al., 2005). Additionally, in a report using 
selective isoform inhibitors, independent inhibition of p110α, p110β or p110δ had little 
effect on insulin-induced PKB phosphorylation in a human hepatoma (HepG2) cell line 
(Chaussade et al., 2007). However, inhibition of p110α and p110β or p110α and p110δ 
simultaneously resulted in a significant attenuation in insulin signalling via PKB, 
suggesting functional redundancy of these isoforms (Chaussade et al., 2007). Of 
interest, neither p110α (p110α+/-) nor p110β (p110β+/-) heterozygote mice are insulin 
resistant but combined heterozygote mice (p110α+/- p110β+/-) exhibit slight glucose 
intolerance (Brachmann et al., 2005). It has been suggested that these findings 
demonstrate functional redundancy in vivo, however, a ~50% reduction in p85 
expression was reported in insulin-sensitive tissues of p110α+/- p110β+/- mice 
(Brachmann et al., 2005), which could explain the observed phenotype. 
 
Having already demonstrated the participation of p110α in mESC insulin signalling, the 
possibility of functional redundancy of p110β and p110δ in insulin signalling of mESCs 
was explored.  
 
In mESCs pre-treated with the p110β inhibitors, TGX-121 or TGX-221, alone or the 
p110δ inhibitor, IC87114, alone, insulin-induced PKB phosphorylation at Ser473 was 
unaffected compared to untreated cells (Figure 5.6). When p110β and p110δ were 
inhibited simultaneously, no change in PKB phosphorylation was observed suggesting 
that p110β and p110δ do not exhibit redundancy in terms of insulin signalling and 
confirming that these isoforms do not participate in insulin signalling in mESCs.  
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Figure 5.6 p110β and p110δ do not exhibit functional redundancy in mESC insulin 
signalling 
Murine ESCs were pre-treated with 5µM TGX-121, 100nM TGX-221 or 5µM IC87114 
alone and in combination as indicated. Cells were stimulated with 10µg/ml insulin for 5 
min. Following SDS-PAGE and immunoblotting, PKB phosphorylation at Ser473 was 
detected with appropriate antibodies. Immunoblots were stripped and reprobed using 
antibodies detecting PKB to assess equal loading. The example shown is representative 
of two independent experiments. 
 
 
5.3.1 LIF-induced activation of signalling downstream of PI3K is mediated by 
p110α 
 
LIF-mediated signalling was shown to be unperturbed by the inhibition of p110β (Figure 
4.12) despite a major role for this isoform in regulating self-renewal of mESCs. To that 
end, evidence presented in the previous chapter suggests that p110β might be activated 
via GPCRs (Figure 4.13). However, LIF was shown to activate signalling downstream of 
PI3Ks in mESCs (Paling et al., 2004) (also see section 3.2). To test if p110α mediates 
LIF-induced signalling the selective inhibitors compound 15e and PIK-75 were used.  
 
In the absence of inhibitors, LIF stimulation of mESCs induced an enhancement in the 
phosphorylation of PKB at Ser473 and S6 at Ser235/236 (Figure 5.7A and B) Following 
pre-treatment with compound 15e (Figure 5.7A) or PIK-75 (Figure 5.7B), basal 
unstimulated levels of PKB and S6 phosphorylation were reduced when compared to 
unstimulated, vehicle pre-treatment alone. Pre-treatment with compound 15e resulted in 
the inhibition of LIF-induced PKB phosphorylation but only a small reduction in S6 
phosphorylation (Figure 5.7A). Similarly, pre-treatment with PIK-75 prevented LIF-
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induced PKB phosphorylation but no change in LIF-induced S6 phosphorylation (Figure 
5.7B). This observation is interesting since LIF is the predominant extrinsic factor known 
to promote self-renewal and is required to maintain undifferentiated mESCs in culture 
(Bard and Ross, 1991, Gough et al., 1989, Smith et al., 1988, Williams et al., 1988) but 
p110α was demonstrated not to couple to the maintenance of self-renewal (Section 
4.4.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Inhibition of p110α prevents LIF-mediated signalling 
Murine ESCs were treated with compound 15e (A) or PIK-75 (B) for 30min prior to 
stimulation with 103 U/ml LIF for 10min. Cell lysates were resolved by SDS-PAGE and 
immunoblotting carried out using the antibodies indicated to detect signalling 
downstream of PI3K. 
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5.4 p110α-mediated signalling regulates mESC metabolism 
 
Having identified a role for p110α in proliferation and insulin signalling in mESCs, it 
seemed plausible that p110α may also couple to the regulation of mESC metabolism. 
An assessment of mESC metabolism was made following incubation with selective p110 
isoform inhibitors. 
 
An XTT-based metabolism assay relies on the cleavage of the yellow tetrazolium salt 
XTT by mitochondrial dehydrogenases, present in metabolically active cells, to produce 
an orange, water-soluble, formazan dye product (Roehm et al., 1991, Scudiero et al., 
1988). The bioreduction of XTT is potentiated by the addition of PMS, an electron 
coupling agent. When the assay has developed, over a period of 4 hours, optical density 
is measured at 450nm. Lower absorbance at 450nm, when compared to vehicle 
treatment, indicates a reduced amount of mitochondrial dehydrogenase activity 
consistent with reduced metabolic activity. 
 
Initially, the effect of a number of p110 selective inhibitors on metabolic activity was 
assessed using the mouse pro-B cell line, BaF/3. Following 48 hour incubation with PI-
103, BaF/3 cells displayed reduced absorbance at 450nm indicating a reduced level of 
metabolic activity compared to vehicle treated BaF/3 cells (Figure 5.8A). A statistically 
significant reduction in metabolic activity was detected using 500nM PI-103. In contrast 
to PI-103, neither TGX-121 (Figure 5.8B) nor IC87114 (Figure 5.8C) altered relative 
metabolic activity of BaF/3 cells. 
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Figure 5.8 Effect of selective isoform inhibitors on the metabolism of BaF/3 cells  
BaF/3 cells were plated in 96 well plates and vehicle (DMSO), PI-103, TGX-121 or 
IC87114 added at the concentrations indicated. After 48 hours incubation, XTT-PMS 
solution was added to each well and incubated for a further 4 hours. Plates were read 
for the absorbance of light at a wavelength of 450nm. Data are the average of six 
replicates for each treatment. Data were analysed by ANOVA and Dunnet’s post-hoc 
test applied, where * indicates p<0.05. Experiments shown are representative of two 
independent experiments. 
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Next, the effect of the selective p110α isoform inhibitors on the metabolic activity of 
mESCs was investigated by XTT assay. Following 48 hours incubation in the presence 
of 50 or 100nM PI-103, absorbance at 450nm was similar to that for vehicle treated 
cells, indicating no change in relative metabolic activity (Figure 5.9A). At 500nM PI-103 
produced a significant decrease in relative metabolic activity compared to vehicle 
treated mESCs, similar to that found with BaF/3 cells (Figure 5.8). No significant 
reduction in relative metabolic activity of mESCs was detected following 48 hours 
incubation with 100nM PIK-75 (Figure 5.9B). PIK-75 is known to inhibit mTOR at higher 
concentrations, but not in the range of selective inhibition of p110α (5-10nM) used for 
these studies (Knight et al., 2006). Therefore a significant reduction in metabolic activity 
of mESCs at 150nM could arise as the result of mTOR inhibition. Interestingly, the 
concentrations of PI-103 or PIK-75 that induce a significant reduction in relative 
metabolic activity are higher than concentrations typically used and higher than 
concentrations required to inhibit PI3K activity (Fan et al., 2006, Knight et al., 2006). The 
effects of compound 15e on mTOR have not been reported but compound 15e is 
typically used at 600nM in the present study, a concentration shown to inhibit insulin 
signalling via p110α (Figure 5.5C). Treatment of mESCs with compound 15e produced a 
significant reduction in metabolic activity at 500nM and above (Figure 5.9C). 
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Figure 5.9 Effect of p110α isoform inhibitors on the metabolism of mESCs 
Murine ESCs were plated in 96 well plates and vehicle (DMSO), PI-103 (A), PIK-75 (B) 
or compound 15e (C) added at the concentrations indicated. After 48 hours incubation, 
XTT-PMS solution was added to each well and incubated for a further 4 hours. Plates 
were read for the absorbance of light at a wavelength of 450nm. Data are the average of 
six replicates for each treatment and was analysed by ANOVA and Dunnet’s post-hoc 
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test, where * indicates p<0.05. Experiments shown are representative of three 
independent experiments. 
 
 
These three inhibitors, with selectivity for p110α, appear to produce conflicting results. It 
is known that mTOR is important for the proliferation of mESCs (Murakami et al., 2004) 
and that PIK-75 displays off-target inhibition of mTOR at µM concentrations. However, if 
off-target inhibition was suspected, only higher concentrations of PIK-75 would induce a 
significant decrease in metabolic activity. Additionally, given the dual inhibition of mTOR 
and p110α by PI-103 (Fan et al., 2006, Knight et al., 2006) a decrease in metabolic 
activity would have been predicted at nM concentrations, previously shown to inhibit 
signalling downstream of mTOR (Fan et al., 2006). Thus, typical doses of PI-103 and 
PIK-75 did not induce reduced metabolic activity. In contrast, compound 15e reduced 
metabolic activity at concentrations typically used (600nM) although no evidence exits 
for the inhibition of mTOR by compound 15e, this may explain a decrease in metabolic 
activity. In any case, the implications of mTOR inhibition on mESC fate cannot be 
ignored and are addressed in Sections 5.5.1 and 5.5.2. 
 
 
The effect of inhibition of p110β and p110δ on mESC metabolic activity was also 
investigated. Treatment of mESCs with the less potent p110β inhibitor, TGX-121, gave 
no change in relative metabolic activity compared to vehicle treated cells (Figure 5.10A). 
Importantly the concentrations used to assess metabolic activity, 5 and 10µM, do cause 
a notable and statistically significant reduction in self-renewal (Figure 4.5). Consistent 
with these findings, the more potent p110β inhibitor, TGX-221, produced no change in 
relative metabolic activity up to 500nM (Figure 5.10B), whereas 100nM TGX-221 
produces a significant decrease in self-renewal (Figure 4.5). IC87114, the selective 
p110δ inhibitor, also failed to induce a change in metabolic activity of mESCs when 
compared to vehicle treated mESCs (Figure 5.10C). 
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Figure 5.10 Inhibition of p110β and p110δ does not decrease mESC metabolic 
activity 
Murine ESCs were plated in 96 well plates and vehicle (DMSO), TGX-121 (A), TGX-221 
(B) or IC87114 (C) added at the concentrations indicated. After 48 hours incubation, 
XTT-PMS solution was added to each well and incubated for a further 4 hours. Plates 
were read for the absorbance of light at a wavelength of 450nm. Data are the average of 
six replicates for each treatment and was analysed by ANOVA and no statistical 
significance found. Experiments shown are representative of three independent 
experiments. 
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For completeness, the effect of ZSTK474, a selective class I PI3K inhibitor (Dan et al., 
2008, Kong and Yamori, 2007, Yaguchi et al., 2006), on mESC metabolic activity was 
also addressed by XTT assay. ZSTK474 induced a decrease in the absorbance of light 
of wavelength 450nm, indicating a decrease in metabolic activity of mESCs (Figure 
5.11). Concentrations of 1µM ZSTK474 induced a significant decrease in relative 
metabolic activity when compared to vehicle-treated control cells (Figure 5.11). 
LY294002 was not shown to result in reduced metabolic activity of mESCs following 48 
hours incubation, measured by XTT assay (Paling et al., 2004). This difference in 
ZSTK474 and LY294002 is likely the result of different inhibitor profiles and possibly due 
to the inhibition of other classes of PI3K by LY294002. Incidentally, the decreased 
metabolism detected in mESCs following incubation with ZSTK474 is consistent with 
previous findings demonstrating reduced growth and proliferation of tumour cells in mice 
following ZSTK474 administration (Yaguchi et al., 2006) and with reduced proliferation, 
but not apoptosis, of human cancer xenografts (Dan et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 ZSTK474 induces a reduced metabolic activity of mESCs 
Murine ESCs were plated in a 96 well plate in the presence of vehicle (DMSO) or 
ZSTK474 at the concentrations indicated. After 48 hours incubation, XTT-PMS solution 
was added to each well and incubated for a further 4 hours. The plate was read for the 
absorbance of light at a wavelength of 450nm. Data are the average of six replicates for 
each treatment and was analysed by ANOVA and Dunnet’s post-hoc test, where * 
indicates p<0.05. The experiment shown is representative of two independent 
experiments. 
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5.5 Are proliferation and self-renewal linked? 
 
Self-renewal is frequently defined as proliferation with the suppression of differentiation. 
However, no reports exist that investigate these two cellular processes as a linked 
function in mESCs. The present study has defined distinct roles for p110α in regulating 
mESC proliferation and insulin signalling and p110β in maintaining mESC self-renewal. 
Furthermore, at concentrations of the selective p110β inhibitors, TGX-121 and TGX-221, 
which induce a loss of self-renewal (Figure 4.5), no significant alterations in metabolic 
activity are detected (Figure 5.10A and B) indicating that differentiation can occur 
without detectable and significant changes in metabolism. Conversely, inhibition of 
p110α reduces mESC proliferation (Figure 5.2), metabolism (Figure 5.9B and C) and 
insulin signalling (Figure 5.5B and C), with no change in self-renewal (Figure 4.25), 
although differentiation is not restricted in mESCs with reduced proliferation (Figure 
4.26), indicating that these events are likely to be regulated independently.  
 
 
5.5.1 Inhibition of mTOR and p110α by PI-103 results in a decrease in self-
renewal 
 
The notion that proliferation and self-renewal are linked was initially explored using PI-
103, an inhibitor that is commonly described as a dual mTOR and p110α inhibitor (Fan 
et al., 2006, Hayakawa et al., 2001, Knight et al., 2006). As demonstrated previously, 
treatment of mESCs with vehicle does not significantly alter alkaline phosphatase 
staining, indicating no change in self-renewal (Figure 5.12A). Treatment with LY294002 
results in a significant decrease in alkaline phosphatase staining, typically reduced to 
approximately 30% alkaline phosphatase positive colonies of all colonies present after 4 
days incubation. Incubation of cells with PI-103 also resulted in a decrease in alkaline 
phosphatase staining (Figure 5.12A). At 100nM PI-103, a significant decrease in 
alkaline phosphatase positive colonies was observed. Furthermore, at 50nM PI-103, no 
change in Nanog expression was observed (Figure 5.12B). However, 100nM PI-103 
induced a decrease in the expression of Nanog after 4 days incubation, which was 
comparable to the expression of Nanog in mESCs incubated in the absence of LIF 
(Figure 5.12B). A decrease in alkaline phosphatase staining and a reduction in Nanog 
expression are symptomatic of a loss of self-renewal but only occur at the highest 
concentration of PI-103 used in the present study. 
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Figure 5.12 PI-103 induces a reduction in self-renewal 
A Murine ESCs were plated at clonal density and incubated in the presence of PI-103. 
After 4 days self-renewal was assessed by alkaline phosphatase staining and colonies 
were scored for staining and colony morphology. Data are represented as the mean 
percentage of alkaline phosphatase positive, self-renewing colonies with S.E.M. (n=6). 
Data were analysed by ANOVA and Dunnet’s post hoc test used to determine which 
treatments were significant compared to vehicle treatment. B mESCs were incubated in 
the presence or absence of LIF and in the presence of LIF plus PI-103 at the 
concentrations indicated for 4 days. Protein lysates were analysed for the expression of 
Nanog immunoblotting with the antibodies indicated. Immunoblots were stripped and 
reprobed using antibodies detecting Shp-2 to assess equal loading. 
 
 
PI-103 is reported to inhibit p110α with an IC50 value of 8nM and rapamycin-sensitive 
mTORC1 and rapamycin-insensitive mTORC2 with IC50 values of 20 and 83nM 
respectively (Knight et al., 2006). However, PI-103 is only slightly more selective for 
p110α than the other p110 isoforms which are reported to have IC50 values of 88, 48, 
150nM for p110β, p110δ and p110γ respectively (Knight et al., 2006). Additionally, in 
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Chapter 4, it was demonstrated that selective inhibition or knockdown of p110α did not 
alter self-renewal where as, a predominant role for p110β in regulating mESC self-
renewal was defined (Kingham and Welham, In Press). Therefore, the loss in self-
renewal exhibited by mESCs following incubation with PI-103 is likely to arise as a result 
of inhibition of p110β and is certainly plausible given the inhibition profile of PI-103 and 
the concentrations used to induce this effect. However, it is difficult to compare 
functional effects with IC50 values obtained from in vitro assays since factors such as cell 
permeability, stability of inhibitors under culture conditions and incubation periods can 
alter the concentration of inhibitor available to inhibit target proteins. 
 
 
5.5.2 Partial inhibition of mTOR reveals a synergistic relationship between self-
renewal and proliferation 
 
As a point of interest, inhibition of PI3Ks with LY294002 decreases mESC alkaline 
phosphatase staining to a similar, but consistently lower, level than that observed using 
inhibitors of p110β. One explanation for this might be the simultaneous inhibition of 
PI3Ks and mTOR, since LY294002 is reported to also target mTOR (Brunn et al., 1996, 
Knight et al., 2006) and mTOR activity and expression is reported to be required for 
mESC proliferation (Murakami et al., 2004), symptomatic of a synergistic relationship 
between self-renewal and proliferation. 
 
In order to investigate possible synergy between self-renewal and proliferation, it was 
necessary to be able to manipulate proliferation in a manner that allowed a loss of self-
renewal to be induced and subsequently quantified. It has previously been reported that 
mTOR activity is an important regulator of mESC proliferation in studies which involved 
the use of the specific mTORC1 inhibitor, rapamycin, amongst other methods 
(Murakami et al., 2004). Therefore, a range of concentrations of rapamycin were tested 
to find a suitable concentration that resulted in partial inhibition of mTOR and a 
reduction, but not complete suppression, of proliferation. After 24 hours incubation, 
analysis of S6 phosphorylation, downstream of mTOR, indicated that 1nM rapamycin 
inhibited mTOR sufficiently to reduce S6 phosphorylation (Figure 5.13A). In contrast, no 
change in S6 phosphorylation, compared to vehicle treated mESCs, was detected using 
0.01 or 0.02nM rapamycin (Figure 5.13A). This indicates that a suitable, partial inhibition 
of mTOR can be achieved between 0.1 and 0.2nM. In addition, no change in Nanog 
expression was detected using rapamycin. Following 48 hours incubation with 
rapamycin, an XTT assay was used to assess relative metabolic activity of mESCs. As 
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expected, rapamycin decreased relative metabolic activity (Figure 5.13B), consistent 
with a reported role for mTOR in mESC proliferation (Murakami et al., 2004). At 
concentrations of 0.25nM and greater, the decrease in relative metabolic activity 
induced by rapamycin was significantly different from vehicle treated mESCs (Figure 
5.13B). Therefore, 0.1nM appeared to be a suitable concentration of rapamycin to use 
to assess a possible relationship between proliferation and self-renewal since it resulted 
in partial inhibition of signalling downstream of mTOR and reduced metabolic activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 Identifying a concentration of rapamycin that partially inhibits mTOR 
Murine ESCs were incubated with vehicle (DMSO), LY294002 or rapamycin at the 
concentrations indicated. A After 24 hours cells were harvested. Protein lysates were 
analysed for S6 phosphorylation by immunoblotting. Immunoblots were stripped and 
reprobed to assess Nanog expression, and to assess equal loading, antibodies 
detecting Shp-2 were used. The data shown are representative of two independent 
experiments. B After 48 hours an XTT assay was conducted to assess relative 
metabolic activity (see Sections 2.4.1 and 5.4 for details). Mean absorbance at 450nm of 
6 replicates is shown with standard deviations (n=1). Statistical analysis was conducted 
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using AVOVA and Dunnet’s post hoc test to compare each concentration of rapamycin 
to vehicle treatment, where * indicates p<0.05. 
 
 
To test the hypothesis that proliferation and self-renewal were linked, mESCs with 
reduced proliferation, due to partial mTOR inhibition, were induced to differentiate, by 
inhibition of p110β, and changes in self-renewal assessed by alkaline phosphatase 
assay. Treatment with 0.1nM rapamycin did not significantly alter the percentage of 
alkaline phosphatase positive colonies after 4 days incubation when compared to control 
colonies (Figure 5.14A). As demonstrated previously (Figure 4.5E), treatment with TGX-
121 induces a significant reduction in alkaline phosphatase positive colonies at 
concentrations of 5 and 10µM. Addition of 0.1nM rapamycin in conjunction with TGX-
121 further decreased the percentage of alkaline phosphatase positive colonies 
compared to TGX-121 treatment alone (Figure 5.14A). In particular, addition of 
rapamycin in the presence of 2 and 5µM TGX-121 induced a significant decrease in the 
percentage of alkaline phosphatase positive colonies compared to 2 and 5µM TGX-121 
alone. Using 10µM TGX-121, addition of rapamycin did not significantly decrease 
alkaline phosphatase staining compared to 10µM TGX-121 alone. This apparent plateau 
was reached at 36%, similar to the level of self-renewal observed following incubation 
with LY294002 (Figure 5.12). These results indicate that a minor reduction in 
proliferation can potentiate a loss of self-renewal but does not induce a loss of self-
renewal alone. TGX-121 treatment did not alter the number of colonies per tissue culture 
dish (Figure 5.14B). Additionally, since a low dose of rapamycin had been used, no 
alteration in colony number was observed with 0.1nM rapamycin treatment compared to 
vehicle treatment. Furthermore, treatment with both TGX-121 and rapamycin did not 
significantly alter the number of colonies per treatment dish when compared to vehicle 
treatment or to TGX-121 treatment alone (Figure 5.14B). 
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Figure 5.14 Partial inhibition of mTOR potentiates the loss in self-renewal 
observed upon inhibition of p110β 
Murine ESCs were incubated in the presence or absence of 0.1nM rapamycin and TGX-
121 at the concentrations indicated. After 4 days colonies were fixed and stained for 
alkaline phosphatase. Data are represented as the mean percentage of alkaline 
phosphatase colonies (A) or as the average number of colonies per tissue culture dish 
(B) with S.E.M (n=3). Statistical analysis was conducted using AVOVA and Fisher’s post 
hoc test to compare each treatment, where * indicates p<0.05 and ** indicates p<0.01 
and ns indicates not significantly different. 
 
 
At the highest concentration of TGX-121 used, a level of self-renewal similar to that 
observed with LY294002 is attained. Presumably, the loss of self-renewal induced by 
LY294002 is the result of combined inhibition of p110α and p110β and possibly mTOR. 
To confirm that inhibition of p110α and mTOR does not induce a loss of self-renewal, 
mESCs were incubated in the presence or absence of 0.1nM rapamycin and compound 
15e. As previously demonstrated (Figure 4.24 and Figure 5.14), incubation with 
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compound 15e alone or with rapamycin alone does not alter the level of alkaline 
phosphatase exhibited by mESCs compared to cells treated with vehicle (Figure 5.15A). 
Furthermore, incubation in the presence of both rapamycin and compound 15e did not 
induce a reduction in alkaline phosphatase staining, consistent with no change in the 
level of self-renewal of mESCs (Figure 5.15A). Therefore, inhibition of both p110α and 
mTOR does not perturb self-renewal and, in order to potentiate a loss of self-renewal, 
inhibition of p110β appears to be required. Furthermore, this data suggests that 
decreased self-renewal, induced by incubation of mESCs with PI-103, is not attributable 
to the inhibition of mTOR and p110α but more likely the result of inhibition of mTOR, 
p110α and p110β. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15 Inhibition of p110α and mTOR does not induce a loss of self-renewal 
Murine ESCs were incubated in the presence or absence of compound 15e and 
rapamycin at the concentrations indicated. After 4 days, mESC colonies were fixed and 
stained for alkaline phosphatase. Data are represented as the percentage of alkaline 
phosphatase positive colonies of all the colonies present (A) or as the number of 
colonies per culture dish (B) (n=1). 
 
 
A 
0
10
20
30
40
50
60
70
80
90
100
DMSO 600nM 15e 700nM 15e
%
 
Al
ka
lin
e 
ph
os
ph
at
as
e 
po
si
tiv
e
 
co
lo
ni
e
s
0nM Rapamycin
0.1nM Rapamycin
 
B 
0
50
100
150
200
250
300
DMSO 600nM 15e 700nM 15eN
u
m
be
r 
o
f c
o
lo
n
ie
s 
pe
r 
di
sh 0nM Rapamycin
0.1nM Rapamycin
 
Chapter 5: Results 
 235 
Treatment of mESCs with compound 15e was previously shown to reduce the number 
of colonies present after 4 days incubation compared to vehicle treatment (Figures 
4.25B and 4.26B). Predictably, treatment of mESCs with both compound 15e and 
rapamycin potentiated the reduction in colony number observed in the presence of 
compound 15e alone (Figure 5.15B). 
 
 
5.5.3 Simultaneous inhibition of p110α and p110β potentiates a loss of self-
renewal 
 
Given that reduced proliferation leads to a greater decline in mESC self-renewal upon 
the induction of differentiation by p110β inhibition, the effects observed with LY294002 
could well be explained by inhibition of p110β, to induce differentiation, promoted by 
reduced proliferation by either inhibition of mTOR or p110α. Figure 5.14 demonstrates 
this potentiation in the loss of self-renewal using rapamycin to induce a partial decrease 
in proliferation. It has also been demonstrated that inhibition of p110α induces a 
decrease in mESC proliferation (Figure 5.2). Therefore, reduced proliferation induced by 
inhibition of p110α could further enhance a loss of self-renewal induced by inhibition of 
p110β. 
 
Compound 15e was used to reduce mESC proliferation and TGX-121 and TGX-221 
used to induce a loss of self-renewal. As demonstrated in the present study, incubation 
of mESCs with compound 15e does not induce a significant alteration in mESC self-
renewal assessed by alkaline phosphatase staining (Figure 5.16A and B) or expression 
of Nanog (Figure 5.16C). In the presence of TGX-121 or TGX-221 alone, a significant 
decrease in alkaline phosphatase staining of mESC colonies was observed (Figure 
5.16A and B). Furthermore, this decrease in alkaline phosphatase staining was 
enhanced in the presence of both TGX-121 and compound 15e (Figure 5.16A) or TGX-
221 and compound 15e (Figure 5.16B). Consistent with this reduction in alkaline 
phosphatase staining, the presence of inhibitors of p110β and p110α induced a large 
decrease in the expression of Nanog, indicating a greater loss of self-renewal compared 
to the presence of p110β or p110α inhibitors alone (Figure 5.16C). 
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Figure 5.16 Inhibition of p110α and p110β enhances the loss of self-renewal 
observed with inhibition of p110β alone 
Murine ESCs were incubated for 4 days in the presence or absence of compound 15e 
and in the presence or absence of TGX-121 (A) or TGX-221 (B). Self-renewal was 
assessed by staining for alkaline phosphatase. Data are represented as the percentage 
of alkaline phosphatase positive colonies with S.E.M. (TGX-121 n=4 and TGX=221 
n=4). C After 4 days, mESCs were harvested and protein lysates analysed by 
immunoblotting with antibodies detecting Nanog and Shp-2. 
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5.6 Summary and discussion: Involvement of p110 isoforms in regulating 
mESC proliferation 
 
In the previous chapter it was demonstrated that mESCs required neither full expression 
of p110α nor activity of p110α in order to maintain optimal self-renewal (Figures 4.21, 
4.22, 4.24 and 4.25). However, mESCs were shown to display indications of limited 
growth and proliferation in the presence of selective inhibitors of p110α in that the 
colonies formed from mESCs incubated in the presence of PIK-75 and compound 15e 
were smaller and fewer in number compared to untreated or vehicle treated mESC 
colonies (Figure 4.25). Consistent with this observed reduction in colony size, 
significantly fewer mESCs were harvested from culture dishes incubated in the presence 
of inhibitors of p110α (Figure 5.1). This feature could be attributed to a loss of cells 
through programmed cell death, apoptosis, however this possibility was disproved. 
Following incubation with inhibitors of p110α, mESCs did not in general display a loss of 
mitochondrial membrane integrity, indicating that cells were not in the early stages of 
apoptosis (Figure 5.4). However, the long-term effects of p110α inhibition were not 
addressed and therefore further investigation would be required to confirm that 
apoptosis was not induced following 4 days incubation with p110α inhibitors, the same 
time point used for alkaline phosphatase assay to assess self-renewal. Additionally, only 
one method of assessing apoptosis was employed, other techniques suitable for mESCs 
include, detection of p53 translocation to the mitochondria (Han et al., 2008, Mihara et 
al., 2003), annexin V and propidium iodide staining analysed by flow cytometry and 
detection of cleaved Caspase 3 by immunoblotting (Duval et al., 2006). 
 
In light of reports indicating a role for p110α in regulating insulin signalling, proliferation 
and growth of many cell types (Bi et al., 1999, Fan et al., 1999, Foukas et al., 2006, 
Hooshmand-Rad et al., 2000, Knight et al., 2006, Roche et al., 1994, Vanhaesebroeck 
and Waterfield, 1999), the present study sought to investigate the role of this isoform in 
mESCs. Indeed, p110α was found to couple to insulin signal transduction in mESCs 
(Figure 5.5), but functional redundancy with other p110 isoforms in insulin signalling, 
reported in other cell types (Chaussade et al., 2007), was not found in mESCs. Neither 
p110β nor p110δ were found to be involved in mESC insulin signal transduction to any 
detectable extent (Figure 5.6), which presumably allows p110β to couple effectively to 
maintenance of self-renewal, as demonstrated in chapter 4. 
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When the regulation of proliferation and metabolism by p110α were assessed, doses of 
PI-103 and PIK-75 that affected mESC proliferation, evidenced by reduced cell 
numbers, did not appear to affect cellular metabolism over a period of 48 hours. Only 
higher doses of PIK-75, in the range that is likely to inhibit mTOR, induced reduced 
metabolic activity to a detectable extent. When an alternative p110α inhibitor, compound 
15e was used, a reduction in metabolic activity was observed at more typical 
concentrations of 500nM and above. It is possible that compound 15e also inhibits 
mTOR, which may explain this reduction in metabolic activity, although this has not yet 
been reported. 
 
This defined and selective role for p110α in regulating mESC proliferation and insulin 
signalling is in support of previous studies reporting proliferative effects or glucose 
metabolism deficiency in mESCs following inhibition of PI3Ks with LY294002 (Jirmanova 
et al., 2002, Lianguzova et al., 2007, Riley et al., 2005) or disruption of up and 
downstream signalling molecules of PI3K pathways (Murakami et al., 2004, Stiles et al., 
2002, Sun et al., 1999). Furthermore, the present study has identified the PI3K catalytic 
isoform that mediates these cellular functions and these results are consistent with the 
over-expression of p110α being able to rescue knockout of ERas mESCs and the 
subsequent proliferative defects (Takahashi et al., 2003) and consistent with the plasma 
membrane localisation and interaction with PI3K featured by ERas (Takahashi et al., 
2005). Additionally, the embryonic lethality resulting from proliferative defects in mouse 
embryos deficient for p110α expression is consistent with the regulation of proliferation 
and insulin signalling of mESCs, isolated from blastocyst stage embryos. 
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5.7 Summary and discussion: Possible synergy of proliferation and self-
renewal 
 
The present study has defined roles for p110α in mESC proliferation and insulin 
signalling and a role for p110β in maintenance of self-renewal (summarised in Figure 
5.17). Interestingly, these investigations have found that the rate of proliferation and 
metabolic activity of mESCs can be reduced without perturbing self-renewal (Figures 
5.2, 5.9B and C, 4.24 and 4.25), while alterations in proliferation without effects on self-
renewal has been previously reported (Murakami et al., 2004, Takashi et al., 2003). The 
contrary is also true; self-renewal can be lost without a change in metabolism in the first 
48 hours (Figure 4.5, 5.10A and B). Additionally, LIF-induced signalling downstream of 
PI3K does not appear to be regulated by p110β (Figure 4.12) as might be expected 
given the predominant role of this isoform in regulating self-renewal (Section 4.4.2) and 
the importance of LIF for maintaining undifferentiated mESCs (Bard and Ross, 1991, 
Gough et al., 1988, Smith et al., 1988, Williams et al., 1988). 
 
The definition of self-renewal as the proliferation of ESCs whilst suppressing 
differentiation (Burdon et al., 2002) implies that both of these functions are required in 
order to satisfy self-renewal. The hypothesis that these functions are linked 
cooperatively is supported by results generated in the present study. In order to further 
enhance differentiation induced by inhibition of p110β, inhibition of p110α was also 
required. Importantly, the possibility that p110α might be functionally redundant in 
regulating self-renewal, whereby its contribution would only be observed when p110β 
was also inhibited, was disproved since mTOR inhibition in conjunction with p110β 
inhibition produced the same effect as inhibition of p110α and p110β. Furthermore, the 
inhibition of mTOR alone did not alter self-renewal in the present study. In a previous 
report from our group, 20nM rapamycin was shown to induce a reduction in the 
expression of Nanog after 48 hours, later than the decrease observed with LY294002 
(Storm et al., 2007). In the present study, only partial inhibition of mTOR was required in 
order to reduce, but not completely suppress, proliferation. Therefore, in this study, only 
0.1nM rapamycin was used and at this concentration, no change in Nanog expression 
was observed after 24 hours (Figure 5.13) and no change in alkaline phosphatase was 
detected after 4 days incubation with 0.1nM rapamycin alone (Figure 5.14). Additionally, 
inhibition of mTOR and p110α simultaneously did not perturb self-renewal indicating that 
inhibition of mTOR and any PI3K isoform is not sufficient to induce a loss of self-
renewal, confirming that reduced self-renewal observed with PI-103 must be the result 
of inhibition of p110β in conjunction with p110α and mTOR as opposed to inhibition of 
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simply p110α and mTOR. Figure 5.17 details the findings of the present study in terms 
of the regulation of mESC behaviour by p110α and mTOR. 
  
The present study supports the existence of cross-talk of pathways regulating 
proliferation and self-renewal, by the coupling to distinct PI3K catalytic isoforms. 
Evidence for this has been highlighted in other cell types and involving different cellular 
functions. For example, p110β was demonstrated to set a threshold for p110α in insulin 
signalling (Chaussade et al., 2007, Knight et al., 2006) and p110γ was reported to be 
activated in the first phase, prior to second phase p110δ activation, in the neutrophil 
respiratory bust (Condliffe et al., 2005). It is therefore feasible that p110α activity, 
possibly regulated by LIF, and proliferation rate regulated by p110α, might set a 
threshold which sensitises mESCs to changes in the level of activity of p110β. A model 
demonstrating how PI3K isoforms might regulate mESC behaviour is shown in Figure 
5.17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17 Model of the regulation of mESC fate by p110α and potentiation of 
loss of self-renewal by reduced proliferation 
PI3K p110α has been implicated in mESC proliferation, metabolism and insulin 
signalling but does not directly regulate self-renewal. However, a partial reduction in 
proliferation, achieved by inhibition of either p110α or mTOR, potentiates a loss of self-
renewal induced by inhibition of p110β, therefore, linking proliferation rate to the 
regulation of self-renewal. 
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6.1 General Discussion and future directions 
 
Self-renewal of ESCs is essential for the maintenance of pluripotency, a feature of ESCs 
defined as the ability to differentiate into any specialised cell type of the adult organism. 
The regulation of ESC self-renewal and maintenance of pluripotency involves the 
coordination of a number of signalling pathways including activation by extrinsic factors, 
cross-talk of pathways and regulation of core transcriptional components (Boiani and 
Scholer, 2005, Niwa, 2007). A well defined understanding of the mechanisms which 
regulate self-renewal and proliferation will enable the therapeutic potential of ESCs to be 
fully realised. The class IA PI3K family of lipid kinases have been previously implicated in 
regulating mESC self-renewal (Paling et al., 2004, Storm et al., 2007) and the activity of 
PI3Ks and downstream signalling is reported to be important for maintaining 
undifferentiated mESCs (Bone et al., 2009, Pritsker et al., 2006, Sato et al., 2004, 
Williams et al., 2000). Furthermore, a role for PI3Ks in regulating hESC self-renewal is 
also beginning to be defined (Armstrong et al., 2006, Pyle et al., 2006). An alternate role 
for PI3Ks in regulating mESC proliferation has also been well reported (Jirmanova et al., 
2002, Lianguzova et al., 2007, Murakami et al., 2004, Sun et al., 1999).  
 
The hypothesis that maintenance of self-renewal and the regulation of proliferation might 
be coordinated by PI3Ks via coupling to different PI3K catalytic subunits was tested. 
Additionally, the present study sought to identify factors, present in routine culture 
media, which activate PI3Ks. Lineage commitment, often reported to be influenced by a 
particular pathway, was also investigated under conditions where PI3K activity was 
inhibited. Finally, cross-talk between the pathways regulating mESC self-renewal and 
proliferation was investigated. 
 
In realising the aims of this project (defined in Section 1.4), a number of new questions 
regarding the regulation of mESC fate by PI3Ks have come to light. These future 
directions will be discussed in the present chapter. Ultimately, it is hoped that a clear 
understanding of the mechanisms and signalling pathways underlying ESC fate will 
further the potential for the use of ESCs as a model system of embryonic development, 
for drug toxicity screens and for regenerative medicine since understanding the 
regulation of proliferation and self-renewal are important for exploitation in these 
systems. 
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6.1.1 Inhibition of PI3Ks does not influence lineage commitment of mESCs 
 
Inhibition of PI3K activity was previously reported to lead to a reduction in mESC self-
renewal (Paling et al., 2004, Storm et al., 2007). However, the effect of inhibiting PI3Ks 
on early lineage commitment of mESCs in 2D culture had not previously been 
investigated. The present study determined that upon inhibition of PI3Ks with the broad 
selectivity PI3K inhibitor LY294002, differentiation towards all lineages was neither 
restricted nor promoted. Although small alterations in the temporal expression of 
neuroectodermal and ectodermal markers were observed, generally, markers of 
mesoderm, endoderm, primitive ectoderm and neuroectoderm were detectable in cells 
incubated in both the presence and absence of LY294002. Most importantly, mESCs 
incubated in the presence of LY294002 exhibited a differentiation potential comparable 
to that observed for mESCs undergoing spontaneous differentiation induced by LIF 
withdrawal.  
 
The concept of the activity of a particular pathway promoting differentiation towards a 
particular lineage, counteracted by an independent pathway in order to maintain an 
undifferentiated state is best exemplified by the balance of LIF and BMP4-induced 
signalling (described in Section 1.3.4.4 and Figure 1.14). Interestingly, the findings 
presented here demonstrate that PI3Ks regulate and integrate proliferation and self-
renewal of mESCs by coupling to independent class IA PI3K isoforms. Therefore, it is 
feasible that, independently, PI3K isoforms might regulate lineage commitment and 
could be studied in more detail using small molecule, isoform selective inhibitors. The 
present study implicated p110β in self-renewal, a process whereby the undifferentiated 
state of mESCs is maintained. Selective inhibition or siRNA-mediated knockdown of 
p110β and subsequent analysis of expression of lineage marker genes may reveal a 
role for this isoform in maintaining pluripotency by inhibition of differentiation towards a 
particular lineage or lineages. In a similar manner, using LY294002 to inhibit PI3Ks, the 
role of PI3Ks in the formation and differentiation of embryoid bodies, a 3D model system 
of embryonic development, has previously been described (Bone and Welham, 2007), 
whereas the present study investigated differentiation of mESCs in 2D monolayer 
cultures. Thus, the requirement for the activity of different PI3K isoforms during different 
stages of embryoid body formation and differentiation might be of interest 
developmentally. Microarray data mapping the temporal expression of PI3Ks isoforms in 
differentiating mESCs, indicate that the expression of p110β decreases upon 
differentiation while expression of p110δ increases (Storm and Welham, unpublished 
data). Therefore, different isoforms may regulate different stages of differentiation, 
lineage commitment and development. Addition of selective isoform inhibitors at 
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different stages of embryoid body formation and analysis of marker gene expression will 
allow this possibility to be investigated.  
 
 
6.1.2 Cross-talk between PI3K and MAPK pathways 
 
Inhibition of MAPK pathway activity has previously been reported to enhance mESC 
self-renewal (Burdon et al., 1999, Kunath et al., 2007) and inhibition of PI3Ks was 
reported to enhance Erk phosphorylation (Paling et al., 2004). Hence, the effect of 
activating the MAPK pathway on self-renewal and the dampening effect exerted by 
PI3Ks on the MAPK pathway in mESCs warranted investigation. 
 
Using mESC clones that inducibly express a constitutively active form of Mek1 (Mek*) 
(generated by Prof. M. J. Welham, unpublished data) the MAPK pathway could be 
artificially and constitutively activated. Colonies formed from mESC clones induced to 
express Mek* displayed alkaline phosphatase staining that was not significantly different 
from clones expressing endogenous Mek alone. However, a trend towards fewer 
alkaline phosphatase colonies was observed following induction of Mek* expression. 
These results indicated that enhancing MAPK pathway activity causes only a minimal 
drop in self-renewal suggesting that the balance of self-renewal promoting signals and 
differentiation promoting signals was not sufficiently tipped towards differentiation. 
Additionally, the activity of other pathways might be modulated to compensate for an 
enhancement in MAPK pathway activity, in order to maintain self-renewal. The present 
study demonstrated that basal and LIF-induced Stat3 phosphorylation was normal in 
Mek* clones incubated in the presence or absence of tetracycline although the activation 
of other pathways was not addressed. An assessment of the phosphorylation states of 
signalling molecules, implicated in the regulation self-renewal of mESCs, in Mek* clones 
in the presence or absence of tetracycline may reveal alterations in the activity of other 
pathways. 
 
The hypothesis that activated MAPK pathway activity was compensated by excess LIF 
concentrations, used for routine culture, was disproved since limiting LIF conditions 
supported the trend of a non-significant drop in alkaline phosphatase positive colonies 
when Mek* was expressed. Furthermore, this trend was abolished when mESC clones 
expressing Mek* were cultured in routine culture media containing serum replacement, 
indicating that factors present in this serum were capable of overcoming differentiation 
promoting signals that might be induced by constitutive activation of the MAPK pathway. 
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Thus, the fate of Mek* mESC clones in chemically defined, serum-free media would be 
of interest given that serum-free, chemically defined media is thought to contain the 
minimum requirements for maintaining mESCs in an undifferentiated state. Culture of 
Mek* clones in this media would therefore provide a more stringent environment to 
assess the effect of activation of MAPK pathway signalling on mESC fate. Furthermore, 
self-renewal of these clones was assessed by alkaline phosphatase staining alone and 
only at the 4 day time point. A greater insight into the survival and fate of these clones 
might be gained from detecting other markers of self-renewal, Nanog and Rex1, and 
assessing their expression from induction of Mek* expression to the time point at which 
alkaline phosphatase staining is conducted. Additionally, the survival and ability of these 
clones to maintain self-renewal over longer periods of culture is of interest.  
 
It has frequently been observed within our research group that inhibition of PI3Ks with 
LY294002 in mESCs induces an enhancement in Erk phosphorylation (Paling et al., 
2004). Indeed, this phenomenon was also observed in mESCs cultured in chemically 
defined media in the presence of LY294002. Furthermore, in chemically defined media, 
LY294002 treatment not only enhanced basal Erk phosphorylation but also enhanced 
BMP4 and insulin-induced Erk phosphorylation. Although there are reports describing an 
inhibitory effect of PI3K activity on MAPK pathway activity in other cell types (Kanasaki 
et al., 2008, Laprise et al., 2004, Romano et al., 2006), the isoforms that might mediate 
this effect have not previously been described. The present study demonstrated that an 
enhancement in basal Erk phosphorylation was induced by selective inhibition of class IA 
PI3K catalytic subunit p110β, implicating this isoform in cross-talk with the MAPK 
pathway. Consistent with the present study, an enhancement in Erk2 phosphorylation 
was reported in MEFs derived from p110β kinase-dead knock-in mice (Ciraolo et al., 
2008). In pituitary cells, inhibition of PI3Ks is reported to enhance Raf-1 kinase and  
Rap-1 activity, both of which are upstream of Mek and Erk (Romano et al., 2006). 
However, the exact mechanism of how p110β might mediate effects on MAPK signalling 
in mESCs requires further investigation. In previous studies, inhibition of PKB with the 
selective inhibitors Akt I and PIA6 lead to enhanced Erk phosphorylation (Romano et al., 
2006) while LY294002 was demonstrated to enhance Mek phosphorylation, directly 
upstream of Erk (Laprise et al., 2004). Similar approaches using inhibitors of PKB and 
antibodies detecting phosphorylated Mek could be used in mESCs to determine the 
level of cross talk of these two pathways. Additionally kinase assays detecting Raf-1 
kinase activity following treatment with LY294002 or the p110β selective inhibitors TGX-
121 or TGX-221 may clarify the involvement of Raf-1 in PI3K/MAPK pathway cross talk 
in mESCs. 
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6.1.3 The roles of PI3K subunit isoforms in mESC fate 
 
Prior to the commencement of this project, PI3Ks had been implicated in both 
proliferation and self-renewal of mESCs (discussed in detail in Section 1.2.6). In other 
cell types, emerging roles for independent PI3K isoforms in regulating different cellular 
functions were beginning to arise due to the availability of new, isoform selective small 
molecule inhibitors (Chaussade et al., 2007, Condliffe et al., 2005, Hennessy et al., 
2005, Jackson et al., 2005, Knight et al., 2006) and genetic targeting in mice (Bi et al., 
2001, Bi et al., 1999, Ciraolo et al., 2008, Clayton et al., 2002, Foukas et al., 2006, 
Fruman et al., 1999, Hirsch et al., 1999, Jou et al., 2002, Okkenhaugh et al., 2002, 
Patrucco et al., 2004, Terauchi et al., 1999). Therefore, the present study sought to test 
the hypothesis that PI3Ks might regulate both proliferation and self-renewal by coupling 
to different PI3K class I isoforms. In particular, the class IA catalytic isoforms of PI3Ks 
were of interest since they had previously been identified as having an involvement in 
regulating mESC self-renewal (Paling et al., 2004). 
 
6.1.3.1 Regulation of mESC self-renewal by PI3K p110β 
 
Pharmacological inhibition and siRNA-mediated knockdown approaches were used to 
assess the involvement of each class I PI3K isoform in turn, in the regulation of mESC 
self-renewal.  
 
Evidence for the predominant role of p110β in self-renewal was demonstrated by the 
requirement of p110β activity and expression in order for mESCs to maintain optimal 
self-renewal. When the activity of p110β was reduced by selective pharmacological 
inhibition of this isoform, mESCs exhibited colony morphologies akin to differentiated 
colony types, reduced alkaline phosphatase staining and decreased Nanog protein 
expression, all features that indicate a loss of self-renewal (Kingham and Welham, In 
Press). Consistent with a requirement for p110β activity, reduced expression of this 
isoform, using three different siRNAs, also led to fewer alkaline phosphatase positive 
colonies, reduced Nanog protein and RNA expression and led to small decreases in 
Rex1 and Oct4 expression. Importantly, no significant alterations in p85 or other 
catalytic subunit isoform expression was found following knockdown of p110β 
expression, an issue that has plagued the usefulness of knockout mice in such 
investigations (Bi et al., 1999, Clayton et al., 2002, Jou et al., 2002). This lack of change 
in the expression of other isoforms indicates that the effects observed are likely to be the 
direct result of reduced p110β expression as opposed to alterations in the expression of 
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other isoforms, which might arise as a compensation mechanism (Vanhaesebroeck et 
al., 2005).  
 
The implication of p110β in maintaining self-renewal marries well with investigations in 
knockout mice, where mouse embryos homozygous for a partial deletion of Pik3cb 
exhibit early embryonic lethality at E3.5 and cells cannot be derived from these 
blastocysts (Bi et al., 2001). Isolation of mESCs from blastocysts is typically conducted 
at E3.5 (Evans and Kaufman, 1981), the same time point at which embryonic lethality is 
reported to occur in mice deficient in functional p110β (Bi et al., 2001). Therefore, taken 
together with the present findings, embryonic lethality might be the result of an inability 
of cells of the ICM to self-renew sufficiently, a process required at this stage to maintain 
the ICM prior to differentiation and further embryonic development. However, in a 
previous study, the expression of a catalytically inactive form of p110β led to embryonic 
lethality with incomplete penetrance (Ciraolo et al., 2008). Surviving mice exhibited 
some growth retardation but were viable to adulthood, which led the authors to suggest 
that kinase-independent functions of p110β were sufficient to allow embryonic 
development and viability to adulthood. In the present study it was demonstrated that 
pharmacological inhibition of p110β induced a loss of self-renewal indicating that kinase-
independent functions are not sufficient to maintain mESC self-renewal although they 
might be important for other aspects of mESC fate. The functional relevance of kinase-
independent functions of p110β in mESC fate could be investigated using mESCs 
isolated from these mutant mice or transfection of mESCs with the catalytically inactive 
form of p110β (Ciraolo et al., 2008). An alternate approach could include the use of a 
site specific recombination system, such as the Cre-loxP system (Sauer, 1993). This 
could be designed to allow inducible expression of kinase-dead mutant form of p110β or 
provide an inducible p110β knockout mESC line. This method would allow a more 
detailed analysis and comparison of both kinase-dependent and kinase-independent 
functions in mESCs. The association of p110β with Rab5, a small GTPase, has 
previously been reported linking p110β to clathrin-coated vesicle formation and growth 
factor receptor endocytosis (Christoforidis et al., 1999, Ciraolo et al., 2008). This p110β 
kinase-independent function could be investigated in mESCs initially by detecting 
clathrin positive vesicles following knockdown of Pik3cb compared to full expression of 
p110β. 
 
To further the investigation of kinase-dependent functions of p110β in mESCs, it would 
be interesting to test the hypothesis that over-expression of p110β or inducible 
expression of a constitutively active form of p110β, previously described (Hu et al., 
1995, Logan et al., 1997), would enhance mESC self-renewal. Furthermore, over-
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expression of p110β or expression of constitutively active p110β might support self-
renewal of mESCs even in the absence of LIF. In contrast, inducible short-hairpin (sh) 
RNA targeting Pik3cb would allow fine regulation over reduced expression of p110β 
compared to siRNA used in the present study. Following induction of shRNA targeting 
Pik3cb, the expression of self-renewal markers and other gene targets of p110β could 
be investigated using mircoarray analysis over a number of time-points to determine 
how p110β regulates self-renewal on a genetic level. 
 
Unexpectedly, LIF-induced signalling downstream of PI3K was not perturbed by 
inhibition of p110β, indicating that LIF does not engage and activate this isoform to any 
appreciable extent. Although p110γ is typically activated by G proteins following GPCR 
stimulation (Brock et al., 2003, Krugmann et al., 1999, Maier et al., 1999, Stephens et 
al., 1997), a number of reports suggest that in some cell types, p110β can be activated 
by stimulation of GPCRs particularly in the absence of p110γ or when p110γ is 
expressed at low levels (Ciraolo et al., 2008, Guillermet-Guibert et al., 2008, Kubo et al., 
2005, Maier et al., 1999, Murga et al., 2000, Roche et al., 1998). Since the mESC line 
used in the present study is known to express GPCRs and very low levels of p110γ 
(Storm and Welham, unpublished data), the possibility that p110β could be activated by 
GPCR agonists was explored. Stimulation of mESCs with heat stable lysophospholipids 
present in serum replacement induced the activation of signalling downstream of PI3Ks, 
namely PKB and Gsk-3 and this activation was demonstrated to be sensitive to inhibition 
of p110β. Furthermore, stimulation of mESCs with known GPCR agonists, LPA and 
S1P, induced the phosphorylation of Erk, which could be ameliorated by pertussis toxin, 
implicating heterotrimeric G proteins Gi, Go, and Gt in this process, and altered by the 
inhibition of p110β, suggesting coupling to this PI3K isoform. Further investigation into 
GPCR agonist-induced activation of p110β might explore a time-course of agonist 
stimulation and assessment of a broader panel of signalling molecules downstream of 
PI3Ks, in addition to the use of other agonists of GPCRs known to be expressed in 
mESCs. 
 
Although the present study demonstrated activation of p110β in mESCs by undefined, 
heat stable lysophospholipids and by the lysophospholipids LPA and S1P, the functional 
relevance of this in self-renewing mESCs is unknown. Previous reports indicate that in 
hESCs, S1P can contribute to the maintenance of the undifferentiated state (Pébay et 
al., 2005). In contrast, sphingosylphosphorylcholine is reported to induce mESCs to 
differentiate towards cardiac and neural lineages (Kleger et al., 2007) and in embryoid 
bodies formed from mESCs, S1P promoted cardiac differentiation (Sachinidis et al., 
2003). Therefore, it is possible that the coupling of GPCR activation to p110β activity 
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might promote differentiation towards these lineages but in self-renewing cells, this push 
towards particular lineages might be counteracted by other signalling pathways. 
Incubation of mESCs with LPA, S1P or other GPCR agonists in the presence or 
absence of pertussis toxin, TGX-121 or TGX-221 and subsequent assessment of 
markers of self-renewal and differentiation would determine if GPCR-induced activation 
of p110β regulates self-renewal or lineage commitment. 
 
6.1.3.2 Regulation of mESC self-renewal by other p110 isoforms and other PI3Ks 
 
When other class I catalytic isoforms were independently assessed for a role in mESC 
self-renewal, no contribution of p110α to maintenance of mESC self-renewal was 
identified. Pharmacological inhibition, using two structurally distinct selective p110α 
inhibitors, and siRNA-mediated knockdown of 88%, failed to alter the proportion of 
alkaline phosphatase positive colonies, Nanog and Rex1 RNA expression and Nanog 
protein expression, indicating no change in self-renewal. Furthermore, no significant 
change in the levels of expression of p110β or p110δ were found following knockdown 
of Pik3ca, indicating that a lack of effect of Pik3ca knockdown on self-renewal was not 
the result of up-regulated expression of the other isoforms. Additionally, inhibition of 
p110α did not restrict the differentiation of mESCs, induced by withdrawal from LIF. As 
expected, given the low or undetectable expression of p110γ, incubation of mESCs with 
a selective inhibitor of this isoform did not alter levels of alkaline phosphatase positive 
colonies. Pharmacological inhibition of p110δ led to a modest decrease in alkaline 
phosphatase positive colonies whereas siRNA-mediated knockdown did not alter the 
proportion of alkaline phosphatase positive colonies. The discrepancy in the results 
obtained from two different approaches was resolved on investigation of the inhibitory 
profile of the p110δ isoform inhibitor IC87114 (Knight et al., 2006). Only at higher 
concentrations of IC87114 was a decrease in alkaline phosphatase positive colonies 
observed, a concentration that could be considered high enough to also inhibit p110β. 
Given that p110β was already implicated in maintaining mESC self-renewal and that 
application of both IC87114 and inhibitors of p110β did not induce a further decrease in 
self-renewal, p110δ is unlikely to contribute to the maintenance of self-renewal and does 
not appear to exhibit functional redundancy in regulating this cellular function. 
Interestingly, siRNA-mediated knockdown of p110δ resulted in enhanced Nanog 
expression which might be explained by the observation that Pik3cd expression is 
enhanced following induction of differentiation (Storm and Welham, unpublished data). 
Therefore, knockdown of the expression of this isoform in self-renewing mESCs might 
restrict spontaneous differentiation and prevent a reduction in Nanog expression. 
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Furthermore, these findings suggest that p110δ might be important for differentiation 
following an initial induction of loss of self-renewal. Defining a role for p110δ later in the 
differentiation process requires further investigation using embryoid bodies formed from 
mESCs and incubated in the presence of IC87114 to inhibit p110δ, followed by 
detection of lineage marker genes. 
 
The regulation of mESC fate by class II and III PI3Ks was beyond the scope of this 
project but would make for a complete analysis of PI3Ks in mESCs. Much the same as 
the class I PI3Ks were investigated in this study, roles for class II and class III PI3Ks 
could be investigated using selective pharmacological inhibitors, where available, and 
complimented by gene targeting of specific isoforms, assessing mESC fate in terms of 
self-renewal, differentiation, pluripotency and proliferation. Additionally, the PH domain 
containing GTP/GDP exchange factors (GEFs) that are specific for the Rho family of 
GTPases, namely Rho, Rac and cdc42, interact with PIP3 (Vanhaesebroeck and 
Waterfield, 1999) and are yet to be investigated in mESCs. 
 
6.1.3.3 Regulation of mESC proliferation by p110α 
 
Whilst investigating the involvement of p110α in regulating mESC self-renewal, it was 
observed that inhibition of this isoform gave rise to smaller colonies that were fewer in 
number. These observations indicated that this isoform might be involved in proliferation 
and cell growth, cellular functions already reported to be coupled with p110α activity in 
other cell types (Foukas et al., 2006, Knight et al., 2006). Indeed, selective inhibition of 
p110α led to the generation of reduced numbers of mESCs but no apparent 
enhancement in the proportion of apoptotic cells, at least at early time points, indicating 
reduced proliferation was most likely responsible for the reduction in cell numbers 
observed (Kingham and Welham, In Press). This defined role for p110α in regulating 
mESC proliferation is consistent with embryonic lethality resulting from proliferative 
defects observed in homozygous p110α knockout mouse embryos (Bi et al., 1999) and 
consistent with a report describing the ability of over-expression of p110α to be sufficient 
to rescue proliferative defects observed in ERas null ESCs (Takahashi et al., 2003). The 
involvement of p110α in signalling and mESC fate is summarised in Figure 6.1. 
 
Areas of possible further investigation into the regulation of mESC fate by p110α, 
predominantly identifying signalling downstream of p110α, are depicted in Figure 6.1. 
Incubation of mESCs with inhibitors of Gsk-3 produces small, rounded, self-renewing 
colonies (Bone et al., 2009, Sato et al., 2004) similar to the smaller colonies observed 
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following inhibition of p110α. Furthermore, Gsk-3 is known to regulate cyclin D1 and GS 
activity, important for cell cycle regulation and glycogen synthesis respectively 
(Eisenmann, 2005, Kestler and Kühl, 2008). Thus, determining if Gsk-3 is downstream 
of p110α in mESCs might help to further define the regulation of proliferation by p110α. 
This could be addressed by immunoblotting using antibodies detecting Gsk-3 
phosphorylation sites following both long and short-term incubation with inhibitors of 
p110α. Protein synthesis requires the binding of mRNA to the small ribosomal subunit, a 
process aided by the eukaryotic initiation factor (eIF4) family. The translation repressor 
proteins, eIF4E-binding proteins (4E-BPs) bind eIF4E and prevent its association with 
an eIF4 complex, inhibiting translation (Beretta et al., 1996). 4E-BP1 is reported to be 
phosphorylated and inactivated by mTOR in a wortmannin-sensitive and rapamycin-
sensitive manner (Brunn et al., 1997) but can also be phosphorylated and inactivated 
downstream of PKB in a manner that also relies on mTOR activity (Gingras et al., 1998). 
This PKB/mTOR/4E-BP pathway might also regulate mESC growth and proliferation by 
activation downstream of p110α and could be analysed following p110α inhibition by 
immunoblotting with antibodies to detect phosphorylation of 4E-BP at mTOR and PKB-
dependent sites. Furthermore, alterations in proliferation were assessed in the present 
study following pharmacological inhibition of p110α but proliferation could not be 
investigated in mESCs transfected with Pik3ca targeting siRNA due to the nature of the 
siRNA transfection protocol and the effect of siRNA transfection on mESCs. However, 
inducible shRNA targeting Pik3ca may make assessment of proliferation following 
knockdown of this isoform feasible and could be investigated to compliment the findings 
of this study using pharmacological inhibition of p110α. 
 
 
 
 
 
 
Chapter 6: General Discussion and Conclusions 
252 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 The role of p110α in mESC fate and avenues of further investigation 
The PI3K isoform p110α was demonstrated, in the present study, to be activated by 
mESC stimulation with LIF and insulin. Additionally, following stimulation with either of 
these factors, enhancements in PKB and S6 phosphorylation were observed. This 
isoform was also demonstrated to mediate mESC growth and proliferation. Potential 
future investigation into the regulation of mESC fate and signalling mediated by p110α 
are indicated with dashed arrows. 
 
 
 
6.1.4 Cross-talk between pathways regulating mESC proliferation and self-
renewal 
 
The present study investigated self-renewal and proliferation independently and led to 
the observation that self-renewal can be lost without an apparent change in proliferation. 
Also, reduced proliferation did not appear to alter the expression of markers of self-
renewal, although a change in self-renewal would not necessarily be expected if the 
typical definition of self-renewal, as the maintenance of pluripotency with continuous 
proliferation, is true. Interestingly, when these two features were investigated together, 
reducing the rate of proliferation of mESCs enhanced a loss of self-renewal. This 
reduced rate of proliferation was achieved by the inhibition of mTOR or p110α and a 
loss of self-renewal induced by the inhibition of p110β.  
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Interestingly, LIF-induced signalling downstream of PI3K was unaltered by p110β 
inhibition, the isoform highlighted as a regulator of self-renewal, but prevented by the 
inhibition of p110α, which appeared to have no independent role in regulating self-
renewal. Evidence from other systems indicates that the signalling of one PI3K isoform 
might be regulated by another isoform (Chaussade et al., 2007, Condliffe et al., 2005, 
Knight et al., 2006). Therefore, a model that might explain the findings of the present 
study encompasses a threshold being set by p110α for the activity of p110β. This 
proposed model, taking into account the present findings is depicted in Figure 6.2. In 
this model, a reduction in the rate of proliferation governed by p110α activity might make 
mESC self-renewal more sensitive to a reduction in p110β activity. Furthermore, this 
threshold might be set by LIF or insulin-induced stimulation of p110α, as opposed to 
p110β. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Proposed model of the regulation of mESC proliferation and self-
renewal by coupling to different PI3K class IA isoforms 
The activation of p110α and p110β by extrinsic factors allows the regulation of mESC 
fate in terms of inhibition of differentiation, promotion of self-renewal and regulation of 
proliferation and metabolism. However, these pathways appear to work both 
independently and to display cross-talk. This proposed model explains how the rate of 
proliferation and signalling via p110α might set a threshold for the activity of p110β to 
regulate self-renewal where a reduction in proliferation sensitises mESCs to alterations 
in signalling inducing a loss of self-renewal and further potentiates the induction of 
differentiation and loss of self-renewal. 
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6.1.4.1 Rate of proliferation and the implications on differentiation potential 
 
While the rate of proliferation and the level of self-renewal can be altered independently, 
a reduction in the rate of proliferation was demonstrated to potentiate an induced loss of 
self-renewal. The complexities of two cellular events being linked, in addition to the 
regulation of both by isoforms of PI3Ks makes further investigation somewhat 
problematic. Although, if the rate of proliferation does set a threshold for sensitivity to 
p110β activity and loss of self-renewal, then the implications of the rate of proliferation at 
the time of differentiation induction and also the mode of inducing differentiation and the 
impact this has on differentiation potential might be worthy of investigation. At the outset, 
proliferation rates could be crudely controlled using a range of rapamycin concentrations 
and assessment of self-renewal markers conducted following induction of differentiation. 
However, analysing loss of self-renewal in a manner employed by the present study 
provides information about a whole population of mESCs. Recently the technique of 
laser scanning cytometry has been described that allows investigation of molecular and 
cellular events on an individual cell basis using imaging and quantitative analysis 
(Harnett, 2007). Using this technique to detect self-renewal markers and activation of 
signalling pathways alongside indications of cell cycle or proliferation might reveal a 
correlation between proliferation rate and differentiation kinetics. 
  
6.1.5 Regulation of hESCs by PI3K isoforms 
 
While a number of differences in the regulation of self-renewal in mESCs and hESCs 
have been reported, there are some common signalling pathways. As in mESCs, the 
inhibition of PI3Ks with LY294002 in hESCs is reported to reduce alkaline phosphatase 
staining, indicative of a loss of self-renewal of hESCs (Pyle et al., 2006). Additionally 
genes of PI3K-PKB pathway signalling molecules, in particular PIK3CB, which encodes 
p110β in human cells, were highlighted as being important for the maintenance of 
pluripotency of hESCs (Armstrong et al., 2006). The contribution of individual PI3K 
isoforms in the regulation of hESC fate remains to be investigated. A similar approach 
using selective isoform inhibitors complemented by siRNA-mediated knockdown of 
individual isoforms might reveal if the maintenance of self-renewal by p110β in mESCs 
is conserved in hESCs. 
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6.2 Conclusions 
 
The present study has further defined the regulation of mESC fate by PI3Ks. PI3Ks do 
not appear to direct the differentiation of mESCs towards particular lineages but rather 
allow differentiation towards cell types expressing markers of each of the three 
embryonic germ layers; endoderm, mesoderm, ectoderm. In mESCs PI3Ks are 
activated by LIF, insulin, BMP4 and lysophospholipids but differential coupling to class I 
PI3K isoforms, dependent on extrinsic factor stimulation, is exhibited. It was established 
that PI3Ks regulate mESC self-renewal and proliferation by differential coupling to the 
PI3K catalytic subunit isoforms p110β and p110α respectively. Furthermore, cross-talk 
between p110β signalling and the MAPK pathway, in addition to cross-talk between 
pathways regulating self-renewal and proliferation was demonstrated. Thus activity of 
PI3Ks act to coordinate both self-renewal and proliferation of mESCs. 
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Abstract
ES (embryonic stem) cell lines are derived from the epiblast of pre-implantation embryos and like the inner
cell mass cells from which they are derived exhibit the remarkable property of pluripotency, namely the
ability to differentiate into all cell lineages comprising the adult organism. ES cells and their differentiated
progeny offer tremendous potential to regenerative medicine, particularly as cellular therapies for the
treatment of a wide variety of chronic disorders, such as Type 1 diabetes, Parkinson’s disease and retinal
degeneration. In order for this potential to be realized, a detailed understanding of the molecular mech-
anisms regulating the fundamental properties of ES cells, i.e. pluripotency, proliferation and differentiation,
is required. In the present paper, we review the evidence that PI3K (phosphoinositide 3-kinase)-dependent
signalling plays a role in regulation of both ES cell pluripotency and proliferation.
ES (embryonic stem) cells
ES cell lines exhibit the unique property of pluripotency, i.e.
the ability to differentiate into all cell lineages comprising the
adult organism [1,2]. Pluripotency is underpinned by ES cell
self-renewal, the term given to the symmetrical division of ES
cells to generate two identical, undifferentiated daughter cells.
In essence, self-renewal is proliferation that is accompanied
by the suppression of differentiation. Regulation of ES cell
self-renewal is of great interest because the ability to maintain
and expand pluripotent ES cells is essential if the therapeutic
potential offered by ES cell-derived progeny to regenerative
medicine is to be realized.
Regulation of murine ES cell pluripotency
Pluripotency of mES (murine ES) cells is regulated by a
complex network of extrinsic factors, signalling pathways
and transcription factors. LIF (leukaemia inhibitory factor)
was the first cytokine shown to play a role in maintenance of
pluripotency [2], via activation of STAT3 (signal transducer
and activator of transcription 3) and induction of c-Myc [3–5].
However, like many cytokines, LIF also activates the ERKs
(extracellular-signal-regulated kinases) ERK1 and ERK2,
which appear to promote differentiation [6], leading to the
suggestion that the balance between STAT3 and ERK signals
is important in determining ES cell fate [7]. More recently
it has been demonstrated that BMPs (bone morphogenetic
proteins) BMP2 and BMP4 collaborate with LIF to facilitate
Key words: bone morphogenetic protein (BMP), embryonic stem cell (ES cell), phosphoinositide
3-kinase (PI3K), pluripotency, self-renewal.
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mES cell self-renewal, via BMP2/BMP4 activation of Smad4,
inducing expression of the Id transcriptional repressors,
which actively suppress neuronal differentiation [8]. Wnt
signalling has also been implicated, largely as a result of the
use of the small molecule BIO [6-bromo-indirubin 3′-oxime;
an inhibitor of GSK-3 (glycogen synthase kinase 3)] that
facilitates activation of the canonical Wnt signalling pathway
[9]. The Src tyrosine kinase also appears to play a role in
maintenance of self-renewal of mES cells [10].
Among the transcriptional regulators, Oct-4 (octamer-
binding protein-4), Sox-2 and Nanog have all been implicated
in the maintenance of mES cell pluripotency [11]. Oct-4 is
expressed by undifferentiated mES and hES (human ES) cells,
its expression being lost upon differentiation [11]. Nanog
(from the Norse Tir nan Og meaning ‘ever young’) was
identified by expression cloning [12] and in silico analyses [13]
as a homeodomain protein that can maintain pluripotency of
mES cells independently of LIF. Recent large-scale screening
studies have mapped promoters co-bound by Nanog, Oct-
4 and Sox-2 in hES cells [14] and Nanog/Oct-4 co-bound
promoters in murine ES cells [15], demonstrating that Oct-
4 and Nanog target some of the same genes in ES cells.
Ivanova et al. [16] have identified a further five genes, Tcl1,
Tbx3, Esrrb, Dppa4 and Unigene Mm.343880, whose down-
regulation leads to loss of pluripotency of mES cells. Further
evidence suggests that epigenetic mechanisms also play a part
in determining ES cell fate [17]. Thus it is increasingly clear
that a network of transcription factors and other regulators
influence and control the fate of both mES and hES cells [11].
Regulation of ES cell proliferation
Studies of murine and Rhesus monkey ES cells have
demonstrated that the cell cycle of ES cells is not subject to
the same regulatory checkpoints as the cell cycle of somatic
cells [18–20]. mES cells transit through the cell cycle very
rapidly (∼8 h), spending as little as 1–2 h in G1-phase and as a
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consequence approx. 50% of ES cells in a growing population
are in S-phase [18,19]. The unorthodox cell cycle of mES cells,
which shows no periodicity in cyclin E expression and no
retinoblastoma restriction point [18,19], has made it a chal-
lenge to define the molecular mechanisms that regulate ES cell
proliferation and the relationship between the signals regu-
lating proliferation and pluripotency is still relatively poorly
understood. Recent data have demonstrated that an ES-cell-
specific Ras-family member, termed ERas (ES cell-expressed
Ras), plays a role in controlling proliferation of mES cells
[21] as does mTOR (mammalian target of rapamycin) [22,23].
Both of these pathways involve PI3K (phosphoinositide 3-
kinase)-dependent signalling.
PI3Ks
The PI3Ks are a family of lipid kinases, comprising three
subclasses and it is typically the class IA subgroup that is activ-
ated in response to growth factor and cytokine signalling
[24]. Class IA PI3Ks are heterodimers, consisting of a regula-
tory subunit (for which there are three genes, generating
five isoforms, p85α, p55α, p50α, p85β and p55γ ) and a
catalytic subunit, of which there are three isoforms, p110α,
p110β and p110δ, each encoded by a separate gene. The
primary product of class IA PI3K action is the phosphoinos-
itide PI(3,4,5)P3 (phosphatidylinositol 3,4,5-trisphosphate),
which recruits PH domain (pleckstrin homology domain)-
containing proteins to the plasma membrane, facilitating
activation of a range of downstream signalling cascades
[25]. Functionally, PI3Ks have been implicated in a wide
array of physiological processes including proliferation,
development, growth and migration [25]. Accumulating
evidence from mice that have the activity of a selected class IA
catalytic or regulatory isoform ablated have demonstrated
that specific isoforms play selective roles both during
development and in the function of somatic cells. For
example, p110δ plays a key role in T-, B- and mast-cell bio-
logy [24,26], p110γ in inflammatory cells [24] and p110α in
insulin signalling [27,28]. Interestingly, ablation of the p110β
isoform leads to lethality at the pre-implantation stage and
although the molecular basis of this lethality is unknown,
this observation suggests that PI3K signalling plays a critical
role during early embryogenesis [29]. One caveat to the gene-
targeted mice that completely lack a specific class IA PI3K
isoform is the observation that expression of other subunits
can also be affected, complicating interpretation of the data
in some studies. For a more detailed discussion see [24].
PI3K signalling and ES cell proliferation
A role for PI3Ks in control of mES cell proliferation was first
suggested when it was discovered that ES cells deficient in
PTEN [phosphatase and tensin homologue deleted on chro-
mosome 10; a lipid phosphatase that dephosphorylates the
3′ position of the inositol ring, thereby reducing PI(3,4,5)P3
levels and acting as a negative regulator of PI3K signalling]
displayed a 5–10% decrease in the time taken to complete
a cell division cycle [30]. Interestingly, PTEN-null ES cells
also show decreased dependency on serum for division, rais-
ing the possibility that serum-containing factors play an im-
portant role in activation of PI3Ks in ES cells. Ablation of the
ES cell-specific form of Ras, ERas, also results in decreased ES
cell proliferation, while expression of an active form of p110α
in ERas-deficient ES cells restores proliferation to levels
similar to those of wild-type ES cells [21]. However, ERas
cannot be the only activator of class IA PI3Ks in ES cells, since
PKB (protein kinase B) activity (PKB is a critical downstream
mediator of PI3K signals) is still observed in ERas-null
ES cells [21], although significantly decreased. Hence, the
evidence from these essentially gain-of-function approaches
suggest that an elevation in PI(3,4,5)P3 levels can enhance
proliferation of ES cells. Further data support a role for PI3Ks
in regulation of ES cell proliferation since inhibition of
PI3Ks with 25 µM of the broad specificity inhibitor
LY294002 decreases ES cell proliferation, cells accumulating
in G1-phase of the cell cycle [20]. mTOR signalling plays a key
role in regulation of mES cell proliferation, since inducible
deletion of mTOR in mES cells or treatment with rapamycin
leads to dramatic decreases in ES cell proliferation [22,23].
In contrast however, knockout of the pik3r1 gene (which
produces the p85α, p55α and p50α regulatory subunits) leads
to only a modest decrease in ES cell proliferation, whereas
ES cells deficient in PDK1 (phosphoinositide-dependent
kinase 1), one of the key downstream targets of class IA PI3K
signalling, have no reported proliferative phenotype [31].
One caveat to these latter two studies is that compensatory
changes could have arisen during selection of the ES cell
clones derived and used for these studies such that alternative
pathways controlling proliferation are up-regulated in these
clones. While this important possibility should be taken
into consideration, current evidence collectively suggests that
PI3K-dependent signalling does play a role in controlling
ES cell proliferation [23], similar to the role of PI3Ks in
somatic cells [24].
PI3K signalling and ES cell self-renewal
In contrast with the reports implicating PI3K signalling in
regulation of ES cell proliferation, our group has reported that
PI3K-dependent signals are required for optimal maintenance
of self-renewal, since inhibition of PI3K signalling (with
either 5 µM LY294002 or upon expression of a dominant-
negative class IA PI3K mutant) in the presence of LIF led to
loss of self-renewal [32], with cells under going multi-lineage
differentiation (E. Kingham and M. J. Welham, unpublished
work). Our findings have recently been supported by
the work of other groups. For example, expression of a
myristoylated form of PKB maintains pluripotency of murine
ES cells in the absence of LIF and also maintains self-renewal
of monkey ES cells [33]. In addition, PKB was identified in an
RNA interference-based screen for positive regulators of ES
cell self-renewal [34]. Importantly, a role for PI3K signalling
in maintenance of hES cell pluripotency and survival has been
reported [35,36]. To date there has been little commonality
demonstrated between the signals regulating murine versus
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hES cell pluripotency, so the demonstration that PI3K
signalling plays a role in maintenance of pluripotency in both
cell types is significant.
Mechanistically, our group has identified a potential role
for activation of ERK signalling upon inhibition of PI3Ks in
promoting the loss of self-renewal observed [32]. In further
studies, we have found that PI3K inhibition leads to down-
regulation of the intrinsic regulator, Nanog, at both the RNA
and protein levels. We have also revealed a role for GSK-
3 in PI3K-dependent regulation of self-renewal and Nanog
expression. Significantly, activation of an inducible form of
Nanog prevents the loss of self-renewal observed in the
presence of PI3K inhibitors, consistent with the relation-
ship between PI3K signalling and maintenance of Nanog
expression being a functional one [37].
Recent progress
We have taken a number of approaches to further investigate
the molecular mechanisms whereby PI3Ks regulate ES cell
fate. Using Affymetrix microarray expression analyses we
have defined the PI3K-dependent transcriptome in ES cells
generating a dataset of genes whose expression is altered
upon inhibition of PI3K signalling in ES cells. We have also
investigated the ability of other growth factors and cytokines
to activate PI3K signalling in ES cells. Our previous work
has shown that LIF can stimulate PI3K signalling in ES
cells, while LIF or serum treatment facilitates co-precipitation
of the p85 PI3K regulatory subunits with phosphotyrosine
proteins, indicative of recruitment/activation of class IA
PI3Ks [32]. To investigate which extracellular factors may
further contribute to activation of PI3Ks in ES cells we have
used serum-free conditions to cultivate ES cells, as described
in [8]. Using this system, we have found that LIF, BMP4 and
insulin can all activate PI3K signalling, judged in part by their
ability to induce phosphorylation of S6 ribosomal protein at
serine residues Ser235/Ser236. In each case, S6 phosphorylation
can be inhibited by wortmannin (see Figure 1). These results
confirm that multiple upstream factors can activate PI3Ks in
ES cells and, in view of the observation that PTEN-null ES
cells exhibit decreased dependence on serum for their growth,
suggest that PI3Ks are normally activated by multiple signals
in ES cells.
Interestingly, under the serum-free conditions used, ES
cells needed to be maintained at densities of more than ∼1.5 ×
104 cells/cm2 in order to retain viability, leading us to consider
a contribution from either cell–cell contact or autocrine
factors in maintenance of ES cells. To study this, conditioned
medium was collected from ES cells for 24 h (either in the
presence or absence of LIF) and then used to treat naı¨ve ES
cells. Expression of Nanog was monitored by quantitative
PCR, as a measure of the ability to maintain expression
of pluripotency genes, and the effects were compared with
those of fresh medium ± LIF. Our results (Figure 2) suggest
that ES cells can produce autocrine factors that co-operate
with LIF to ensure maximal expression of Nanog. We
have also studied the effects of PDK1 (phosphoinositide-
dependent kinase 1) deficiency on ES cell pluripotency. In
Figure 1 Induction of PI3K signalling by BMP4 and insulin in ES
cells cultured under serum-free conditions
ES cells were cultured under serum-free conditions in the presence of
LIF and BMP4, as described by Ying et al. [8]. ES cells were plated at 5×
105 cells per 50 mm diameter gelatin-coated Nunc tissue culture plate,
cultured for 48 h, washed three times with PBS and then deprived of
LIF and BMP4 for 4 h. Samples were pre-treated with either 100 nM
wortmannin for 30 min or DMSO, as a control. Stimulations with BMP4 or
insulin were carried out for 5 min at the doses indicated. Immunoblotting
was performed with an antibody that detects S6 phosphorylation
at Ser235 and Ser236 (α-pS6, Cell Signaling Technology). The same im-
munoblots were stripped and reprobed with anti-SHP-2 (Src homology 2
domain-containing protein tyrosine phosphatase 2) antibodies (α-SHP-2;
Santa Cruz Biotechnology) to demonstrate equivalent loading.
contrast with the initial report [31], we find that pdk-1-
null ES cells exhibit enhanced proliferation compared with
parental ES cells and while self-renewal of pdk1-null ES
cells is decreased at low doses of LIF, this is not apparent
at optimal doses of LIF (H. K. Bone and M. J. Welham,
unpublished work). Most surprisingly, we discovered that
pdk-1 ES cells exhibit elevated levels of Nanog mRNA
and protein (H. K. Bone and M. J. Welham, unpublished
work). These observations suggest the pdk1-null ES cells
may have undergone compensatory alterations during either
their initial derivation and/or subsequent culture and these
findings highlight to us the difficulty in comparing ES lines
with targeted homozygous disruption of specific genes.
Summary
How can the evidence supporting a role for PI3Ks in regu-
lation of both mES cell proliferation and regulation of pluri-
potency be rationalized? We have observed that doses of
LY294002 greater than 10 µM decrease ES cell proliferation
[32], while others have shown similar effects with 25 µM
LY294002 [20]. At lower doses, LY294002 perturbs self-
renewal [32]. mTOR is a key regulator of ES cell proliferation
[22,23] and can also be inhibited by LY294002, but in
general this requires higher doses of LY294002 than the
dose that inhibits class IA PI3K isoforms β and δ [28].
Hence, it is possible that the effects of higher doses of
LY294002 on proliferation result from additional inhibition
of mTOR. Taking these findings into consideration we
propose two models that may explain the involvement of
PI3Ks in the control of both proliferation and self-renewal
of ES cells. In model 1, distinct PI3K isoforms could couple
selectively with either ERas or mTOR, to regulate ES cell
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Figure 2 Regulation of Nanog expression by autocrine factors
Conditioned medium (CM) was harvested from ES cells cultured for 24 h
in knockout (KO) DMEM (Dulbecco’s modiﬁed Eagle’s medium) alone
(CM− LIF) or with LIF (CM+ LIF). Aliquots of CM were placed on to fresh
ES cultures, with or without addition of LIF. As controls, fresh cultures of
ES cells were also treated with fresh medium to which LIF was added
(KO+ LIF) or not (KO− LIF). RNA was harvested following 48 h and
Nanog expression, normalized to β-actin, determined by quantitative
PCR. ES cells cultured in CM+ LIF exhibited a 2-fold increase in Nanog
RNA expression compared with ES cells cultured in fresh medium sup-
plemented with LIF (KO+ LIF). Incubation with conditioned medium
generated in the absence of LIF, to which fresh LIF was then added
(CM−/+LIF), also led to enhanced expression of Nanog compared
with KO+ LIF. Results are the means± S.D. for quadruplicate samples,
representative of four independent experiments.
proliferation, while other isoforms couple specifically with
GSK-3/Nanog pathways, thereby contributing to regulation
of self-renewal. In an alternative model, the PI3K-dependent
pathways controlling pluripotency and proliferation could
be regulated by different threshold levels of PI(3,4,5)P3. A
modest reduction in PI(3,4,5)P3 levels could perturb PI3K-
dependent signals involved in regulation of self-renewal,
while proliferation is not affected. A more significant reduc-
tion in PI(3,4,5)P3 levels could lead to a decline in the
PI3K-dependent signals regulating proliferation, resulting in
decreased ES cell proliferation. Future investigations will
help delineate the mechanisms by which PI3Ks contribute
to regulation of ES cell fate.
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